

PROTEIN-PROTEIN INTERACTIONS
Between *Shigella flexneri* polypeptides And Mammalian Polypeptides

PRIORITY

[0001] This application claims priority on the basis of United States Provisional Application No. 60/261,130, filed January 12, 2001, the contents of which are hereby incorporated by reference.

BACKGROUND OF THE INVENTION

[0002] Most biological processes involve specific protein-protein interactions. Protein-protein interactions enable two or more proteins to associate. A large number of non-covalent bonds form between the proteins when two protein surfaces are precisely matched. These bonds account for the specificity of recognition. Thus, protein-protein interactions are involved, for example, in the assembly of enzyme subunits, in antibody-antigen recognition, in the formation of biochemical complexes, in the correct folding of proteins, in the metabolism of proteins, in the transport of proteins, in the localization of proteins, in protein turnover, in first translation modifications, in the core structures of viruses and in signal transduction.

[0003] General methodologies to identify interacting proteins or to study these interactions have been developed. Among these methods are the two-hybrid system originally developed by Fields and co-workers and described, for example, in U.S. Patent Nos. 5,283,173, 5,468,614 and 5,667,973, which are hereby incorporated by reference.

[0004] The earliest and simplest two-hybrid system, which acted as basis for development of other versions, is an *in vivo* assay between two specifically constructed proteins. The first protein, known in the art as the "bait protein" is a chimeric protein which binds to a site on DNA upstream of a reporter gene by means of a DNA-binding domain or BD. Commonly, the binding domain is the DNA-binding domain from either Gal4 or native *E. coli* LexA and the sites placed upstream of the reporter are Gal4 binding sites or LexA operators, respectively.

[0005] The second protein is also a chimeric protein known as the "prey" in the art. This second chimeric protein carries an activation domain or AD. This activation domain is typically derived from Gal4, from VP16 or from B42.

[0006] Besides the two hybrid systems, other improved systems have been developed to detected protein-protein interactions. For example, a two-hybrid plus one system was developed that allows the use of two proteins as bait to screen available cDNA libraries to detect a third partner. This method permits the detection between proteins that are part of a larger protein complex such as the RNA polymerase II holoenzyme and the TFIID or TFIID complexes. Therefore, this method, in general, permits the detection of ternary complex

formation as well as inhibitors preventing the interaction between the two previously defined fused proteins.

[0007] Another advantage of the two-hybrid plus one system is that it allows or prevents the formation of the transcriptional activator since the third partner can be expressed from a conditional promoter such as the methionine-repressed Met25 promoter which is positively regulated in medium lacking methionine. The presence of the methionine-regulated promoter provides an excellent control to evaluate the activation or inhibition properties of the third partner due to its "on" and "off" switch for the formation of the transcriptional activator. The three-hybrid method is described, for example in Tirode et al., *The Journal of Biological Chemistry*, **272**, No. 37 pp. 22995-22999 (1997). incorporated herein by reference.

[0008] Besides the two and two-hybrid plus one systems, yet another variant is that described in Vidal et al, *Proc. Natl. Sci.* 93 pgs. 10315-10320 called the reverse two- and one-hybrid systems where a collection of molecules can be screened that inhibit a specific protein-protein or protein/DNA interactions, respectively.

[0009] A summary of the available methodologies for detecting protein-protein interactions is described in Vidal and Legrain, *Nucleic Acids Research* Vol. 27, No. 4 pgs.919-929 (1999) and Legrain and Selig, *FEBS Letters* 480 pgs. 32-36 (2000) which references are incorporated herein by reference.

[0010] However, the above conventionally used approaches and especially the commonly used two-hybrid methods have their drawbacks. For example, it is known in the art that, more often than not, false positives and false negatives exist in the screening method. In fact, a doctrine has been developed in this field for interpreting the results and in common practice an additional technique such as co-immunoprecipitation or gradient sedimentation of the putative interactors from the appropriate cell or tissue type are generally performed. The methods used for interpreting the results are described by Brent and Finley, Jr. in *Ann. Rev. Genet.*, 31 pgs. 663-704 (1997). Thus, the data interpretation is very questionable using the conventional systems.

[0011] One method to overcome the difficulties encountered with the methods in the prior art is described in WO 99/42612, incorporated herein by reference. This method is similar to the two-hybrid system described in the prior art in that it also uses bait and prey polypeptides. However, the difference with this method is that a step of mating at least one first haploid recombinant yeast cell containing the prey polypeptide to be assayed with a second haploid recombinant yeast cell containing the bait polynucleotide is performed. Of course the person skilled in the art would appreciate that either the first recombinant yeast cell or the second recombinant yeast cell also contains at least one detectable reporter gene that is activated by a polypeptide including a transcriptional activation domain.

[0012] The method described in WO 99/42612 permits the screening of more prey polynucleotides with a given bait polynucleotide in a single step than in the prior art systems due to the cell to cell mating strategy between haploid yeast cells. Furthermore, this method is more thorough and reproducible, as well as sensitive. Thus, the presence of false negatives and/or false positives is extremely minimal as compared to the conventional prior art methods.

[0013] The genus *Shigella* includes four species (major serogroups): *S. dysenteriae* (Grp. A), *S. flexneri* (Grp. B), *S. boydii* (Grp. C) and *S. sonnei* (Grp. D) as classified in Bergey's Manual for Systematic Bacteriology (N. R. Krieg, ed., pp. 423-427 (1984)). The genera *Shigella* and *Escherichia* are phylogenetically closely related. Brenner and others have suggested that the two are more correctly considered sibling species based on DNA/DNA reassociation studies (D. J. Brenner et al., International J. Systematic Bacteriology, 23:1-7 (1973)). These studies showed that *Shigella* species are on average 80-89% related to *E. coli* at the DNA level. Also, the degree of relatedness between *Shigella* species is on average 80-89%.

[0014] The genus *Shigella* is pathogenic in humans; it causes bacillary dysentery at levels of infection of 10 to 100 organisms.

[0015] Shigellosis or bacillary dysentery is a disease that is endemic throughout the world. The disease presents a particularly serious public health problem in tropical regions and developing countries where *Shigella dysenteriae* and *S. flexneri* predominate. In industrialized countries, the principal etiologic agent is *S. sonnei* although sporadic cases of shigellosis are encountered due to *S. flexneri*, *S. boydii* and certain entero-invasive *Escherichia coli*.

[0016] The primary step in the pathogenesis of bacillary dysentery is invasion of the human colonic mucosa by *Shigella* (Labrec, E. H., H. Schneider, T. J. Magnani, and S. B. Formal. 1964. Epithelial cell penetration as an essential step in the pathogenesis of bacillary dysentery. J. Bacteriol. 88:1503). Mucosal invasion encompasses several steps which include penetration of the bacteria into epithelial cells, intracellular multiplication, killing of host cells, and final spreading to adjacent cells and to connective tissue (Formal, S. B., T. L. Hale, and P. J. Sansonetti. 1983. Invasive enteric pathogens. Rev. Infect. Dis. 5:S702, Rout, W. R., S. B. Formal, R. A. Giannella, and G. J. Dammin. 1975. The pathophysiology of *Shigella* diarrhea in the Rhesus monkey; intestinal transport, morphology and bacteriological studies. Gastroenterology 68:270, Takeuchi, A., H. Spring, E. H. LaBrec, and S. B. Formal. 1965. Experimental acute colitis in the Rhesus monkey following peroral infection with *Shigella flexneri*. Am. J. Pathol. 52:503, Takeuchi, A. 1967. Electron microscope studies of experimental *Salmonella* infection. I. Penetration into cells of the intestinal epithelium by *Salmonella typhimurium*. Am. J. Pathol. 47:1011). The overall process which is usually

limited to the mucosal surface leads to a strong inflammatory reaction which is responsible for abscesses and ulcerations (Labrec, E. H., H. Schneider, T. J. Magnani, and S. B. Formal. 1964. Epithelial cell penetration as an essential step in the pathogenesis of bacillary dysentery. *J. Bacteriol.* 88:1503., Rout, W. R., S. B. Formal, R. A. Giannella, and G. J. Dammin. 1975. The pathophysiology of *Shigella* diarrhea in the Rhesus monkey; intestinal transport, morphology and bacteriological studies. *Gastroenterology* 68:270, Takeuchi, A., H. Spring, E. H. LaBrec, and S. B. Formal. 1965. Experimental acute colitis in the Rhesus monkey following peroral infection with *Shigella flexneri*. *Am. J. Pathol.* 52:503).

[0017] Even though dysentery is characteristic of shigellosis, it may be preceded by watery diarrhea. Diarrhea appears to be the result of disturbances in colonic reabsorption and increased jejunal secretion whereas dysentery is a purely colonic process (Kinsey, M. D., S. B. Formal, G. J. Dammin, and R. A. Giannella. 1976. Fluid and electrolyte transport in Rhesus monkeys challenged intracecally with *Shigella flexneri* 2a. *Infect. Immun.* 14:368). These include toxic megacolon, leukemoid reactions and hemolytic-uremic syndrome ("HUS"). The latter is a major cause of mortality from shigellosis in developing areas (Gianantonio, C., H. Vitacco, F. Mendilaharsu, A. Rutty, and J. Mendilaharsu. 1964. The hemolytic-uremic syndrome. *J. Pediatr.* 64:478, Koster, F., J. Levin, L. Walker, K. S. K. Tung, R. H. Gilman, M. M. Rajaman, M. A. Majid, S. Islam, and R. C. Williams Jr. 1977. Hemolyticuremic syndrome after shigellosis. Relation to endotoxin and circulating immune complexes. *N. Engl. J. Med.* 298:927).

[0018] The role of Shiga-toxin produced at high level by *S. dysenteriae* 1 (Conradi, H., 1903. Ueber loshlishe, durch aseptische Autolyse, erhaltene Giftstoffe von Ruhr--un Typhus bazillen. *Dtsch. Med. Wochenschr.* 29:26) and Shiga-like toxins ("SLT") produced at low level by *S. flexneri* and *S. sonnei* (Keusch, G. T., and M. Jacewicz. 1977. The pathogenesis of *Shigella* diarrhea. VI. Toxin and antitoxin in *Shigella flexneri* and *Shigella sonnei* infections in humans. *J. Infect. Dis.* 135:552) in the four major stages of shigellosis (i.e., invasion of individual epithelial cells, tissue invasion, diarrhea and systemic symptoms) is not well understood. For review see O'Brien and Holmes (O'Brien, A. D., and R. K. Holmes. 1987. Shiga and Shiga-like toxins. *Microbiol. Rev.* 51:206). Plasmids of 180-220 kilobases ("kb") are essential in all *Shigella* species for invasion of individual epithelial cells (Rout, W. R., S. B. Formal, R. A. Giannella, and G. J. Dammin. 1975. The pathophysiology of *Shigella* diarrhea in the Rhesus monkey; intestinal transport, morphology and bacteriological studies. *Gastroenterology* 68:270, Sansonetti, P. J., D. J. Kopecko, and S. B. Formal. 1981. *Shigella sonnei* plasmids: evidence that a large plasmid is necessary for virulence. *Infect. Immun.* 34:75, Sansonetti, P. J., T. L. Hale, G. I. Dammin, C. Kapper, H. H. Collins Jr., and S. B. Formal. 1983. Alterations in the pathogenesis of *Escherichia coli* K12 after transfer of plasmids and chromosomal genes from *Shigella flexneri*. *Infect. Immun.* 39:1392). This

includes entry, intracellular multiplication and early killing of host cells (Clerc, P., A. Ryter, J. Mounier, and P. J. Sansonetti. 1987. Plasmid-mediated early killing of eucaryotic cells by *Shigella flexneri* as studied by infection of J774 macrophages. *Infect. Immun.* 55:521, Clerc, P., and P. J. Sansonetti. 1987. Entry of *Shigella flexneri* into HeLa cells: Evidence for directed phagocytosis involving actin polymerization and myosin accumulation. *Infect. Immun.* 55:2681). The role of Shiga-toxin and SLT at this stage is unclear.

[0019] Recent evidence indicates that Shiga-toxin is cytotoxic for primary cultures of human colonic cells (Moyer, M. P., P. S. Dixon, S. W. Rothman, and J. E. Brown. 1987. Cytotoxicity of Shiga toxin for human colonic and ileal epithelial cells. *Infect. Immun.* 55:1533). Tissue invasion requires additional chromosomally encoded products among which are smooth lipopolysaccharides ("LPS") (Sansonetti, P. J., T. L. Hale, G. I. Dammin, C. Kapper, H. H. Collins Jr., and S. B. Formal. 1983. Alterations in the pathogenesis of *Escherichia coli* K12 after transfer of plasmids and chromosomal genes from *Shigella flexneri*. *Infect. Immun.* 39:1392), the non-characterized product of the Kcp locus, and aerobactin. A region of the *S. flexneri* chromosome necessary for fluid production in rabbit ileal loops has been localized to the rha-mt1 regions and near the lysine decarboxylase locus (Sansonetti, P. J., T. L. Hale, G. I. Dammin, C. Kapper, H. H. Collins Jr., and S. B. Formal. 1983. Alterations in the pathogenesis of *Escherichia coli* K12 after transfer of plasmids and chromosomal genes from *Shigella flexneri*. *Infect. Immun.* 39:1392). However, no evidence has been adduced to show that the ability to cause fluid accumulation is due to the SLT of *S. flexneri*. Thus, the role of Shiga-toxin in causing the systemic complications of shigellosis is still hypothetical. However, Shiga-toxin can mediate vascular damage since capillary lesions observed in HUS resemble those observed in cerebral vessels of animals injected with this toxin (Bridgewater, F. A. I., R. S. Morgan, K. E. K. Rowson, and G. P. Wright. 1955. the neurotoxin of *Shigella shigae*. Morphological and functional lesions produced in the central nervous system of rabbits. *Br. J. Exp. Pathol.* 36: 447, Cavanagh, J. B., J. G. Howard, and J. L. Whitby. 1956. The neurotoxin of *Shigella shigae*. A comparative study of the effects produced in various laboratory animals. *Br. J. Exp. Med.* 37:272).

[0020] As described before, the genera of *Shigella* and *Escherichia* are phylogenetically closely related. Furthermore, the pathogenesis of enteroinvasive *E. coli* is very similar to that of *Shigella*. In both, dysentery results from invasion of the colonic epithelial cells followed by intracellular multiplication which leads to bloody, mucous discharge with scanty diarrhea.

[0021] Pathogenic *E. coli* serotypes are collectively referred to as Enterovirulent *E. coli* (EVEC) (J. R. Lupski, et al., *J. Infectious Diseases*, 157:1120-1123 (1988); M. M. Levine, *J. Infectious Diseases*, 155:377-389 (1987); M. A. Karmali, *Clinical Microbiology Reviews*, 2:15-38 (1989)). This group includes at least 5 subclasses of *E. coli*, each having a

characteristic pathogenesis pathway resulting in diarrheal disease. The subclasses include Enterotoxigenic *E. coli* (ETEC), Verotoxin-Producing *E. coli* (VTEC), Enteropathogenic *E. coli* (EPEC), Enteroadherent *E. coli* (EAEC) and Enteroinvasive *E. coli* (EIEC). The VTEC include Enterohemorrhagic *E. coli* (EHEC) since these produce verotoxins.

[0022] Thus, detection of *Shigella* and EIEC is important in various medical contexts. For example, the presence of either *Shigella* or EIEC in stool samples is indicative of gastroenteritis, and the ability to screen for their presence is useful in treating and controlling that disease. Detection of *Shigella* or EIEC in any possible transmission vehicle such as food is also important to avoid spread of gastroenteritis.

[0023] That is why there is a great need to construct Protein Interaction Map between *Shigella* polypeptides and human polypeptides in order to understand mechanisms of *Shigella* pathogenesis and to identify drug target to treat *Shigella* associated diseases and *Shigella* detection means.

SUMMARY OF THE PRESENT INVENTION

[0024] Thus, it is an object of the present invention to identify protein-protein interactions between *Shigella* polypeptides and mammalian, preferably human, polypeptides.

[0025] It is another object of the present invention to identify protein-protein interactions between *Shigella* polypeptides and mammalian, preferably human, polypeptides for the development of more effective and better targeted therapeutic applications.

[0026] It is yet another object of the present invention to identify complexes of polypeptides or polynucleotides encoding the polypeptides and fragments of the polypeptides of *Shigella* genus and polypeptides and fragments of the polypeptides of mammals, preferably human.

[0027] It is yet another object of the present invention to identify antibodies to these complexes of polypeptides or polynucleotides encoding the polypeptides and fragments of the polypeptides of *Shigella* genus and mammals, preferably human, including polyclonal, as well as monoclonal antibodies that are used for detection.

[0028] It is still another object of the present invention to identify selected interacting domains of the polypeptides, called SID® polypeptides.

[0029] It is still another object of the present invention to identify selected interacting domains of the polynucleotides, called SID® polynucleotides.

[0030] It is another object of the present invention to generate protein-protein interactions maps called PIM®s.

[0031] It is yet another object of the present invention to provide a method for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions between *Shigella* polypeptides and mammalian, preferably human, polypeptides.

[0032] It is another object to administer the nucleic acids of the present invention via gene therapy.

[0033] It is yet another object of the present invention to provide protein chips or protein microarrays.

[0034] It is yet another object of the present invention to provide a report in, for example paper, electronic and/or digital forms, concerning the protein-protein interactions, the modulating compounds and the like as well as a PIM®.

[0035] Thus the present invention, in one aspect thereof, relates to a protein complex between a *Shigella* polypeptide and a mammalian polypeptide. In another embodiment, the *Shigella* and the mammalian polypeptides are polypeptides set forth on columns 1 and 3 respectively of Table II.

[0036] Furthermore, the present invention provides SID® polynucleotides and SID® polypeptides of Table III, as well as a PIM® between *Shigella* polypeptides and mammalian, preferably human, polypeptides.

[0037] The present invention also provides antibodies to the protein-protein complexes between *Shigella* polypeptides and mammal, preferably human, polypeptides.

[0038] In another embodiment the present invention provides a method for screening drugs for agents that modulate the protein-protein interactions and pharmaceutical compositions that are capable of modulating protein-protein interactions.

[0039] In another embodiment the present invention provides protein chips or protein microarrays.

[0040] In yet another embodiment the present invention provides a report in, for example, paper, electronic and/or digital forms.

BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Fig. 1 is a schematic representation of the pB1 plasmid.

[0042] Fig. 2 is a schematic representation of the pB5 plasmid.

[0043] Fig. 3 is a schematic representation of the pB6 plasmid.

[0044] Fig. 4 is a schematic representation of the pB13 plasmid.

[0045] Fig. 5 is a schematic representation of the pB14 plasmid.

[0046] Fig. 6 is a schematic representation of the pB20 plasmid.

[0047] Fig. 7 is a schematic representation of the pP1 plasmid.

[0048] Fig. 8 is a schematic representation of the pP2 plasmid.

[0049] Fig. 9 is a schematic representation of the pP3 plasmid.

[0050] Fig. 10 is a schematic representation of the pP6 plasmid.

[0051] Fig. 11 is a schematic representation of the pP7 plasmid.

[0052] Fig. 12 is a schematic representation of vectors expressing the T25 fragment.

[0053] Fig. 13 is a schematic representation of vectors expressing the T18 fragment.

[0054] Fig. 14 is a schematic representation of various vectors of pCmAHL1, pT25 and pT18.

[0055] Fig. 15 is a schematic representation of identification of SID®. In this figure the "Full-length prey protein" is the Open Reading Frame (ORF) or coding sequence (CDS) where the identified prey polypeptides are included. The Selected Interaction Domain (SID®) is determined by the commonly shared polypeptide domain of every selected prey fragment.

[0056] Fig. 16 is a protein map (PIM®).

DETAILED DESCRIPTION OF THE INVENTION

[0057] As used herein the terms "polynucleotides", "nucleic acids" and "oligonucleotides" are used interchangeably and include, but are not limited to RNA, DNA, RNA/DNA sequences of more than one nucleotide in either single chain or duplex form. The polynucleotide sequences of the present invention may be prepared from any known method including, but not limited to, any synthetic method, any recombinant method, any *ex vivo* generation method and the like, as well as combinations thereof.

[0058] The term "polypeptide" means herein a polymer of amino acids having no specific length. Thus, peptides, oligopeptides and proteins are included in the definition of "polypeptide" and these terms are used interchangeably throughout the specification, as well as in the claims. The term "polypeptide" does not exclude post-translational modifications such as polypeptides having covalent attachment of glycosyl groups, acetetyl groups, phosphate groups, lipid groups and the like. Also encompassed by this definition of "polypeptide" are homologs thereof.

[0059] By the term "homologs" is meant structurally similar genes contained within a given species, orthologs are functionally equivalent genes from a given species or strain, as determined for example, in a standard complementation assay. Thus, a polypeptide of interest can be used not only as a model for identifying similar genes in given strains, but also to identify homologs and orthologs of the polypeptide of interest in other species. The orthologs, for example, can also be identified in a conventional complementation assay. In addition or alternatively, such orthologs can be expected to exist in bacteria (or other kind of cells) in the same branch of the phylogenetic tree, as set forth, for example, at <ftp://ftp.cme.msu.edu/pub/rdp/SSU-rRNA/SSU/Prok.phylo>.

[0060] As used herein the term "prey polynucleotide" means a chimeric polynucleotide encoding a polypeptide comprising (i) a specific domain; and (ii) a polypeptide that is to be tested for interaction with a bait polypeptide. The specific domain is preferably a transcriptional activating domain.

[0061] As used herein, a "bait polynucleotide" is a chimeric polynucleotide encoding a chimeric polypeptide comprising (i) a complementary domain; and (ii) a polypeptide that is to

be tested for interaction with at least one prey polypeptide. The complementary domain is preferably a DNA-binding domain that recognizes a binding site that is further detected and is contained in the host organism.

[0062] As used herein "complementary domain" is meant a functional constitution of the activity when bait and prey are interacting; for example, enzymatic activity.

[0063] As used herein "specific domain" is meant a functional interacting activation domain that may work through different mechanisms by interacting directly or indirectly through intermediary proteins with RNA polymerase II or III-associated proteins in the vicinity of the transcription start site.

[0064] As used herein the term "complementary" means that, for example, each base of a first polynucleotide is paired with the complementary base of a second polynucleotide whose orientation is reversed. The complementary bases are A and T (or A and U) or C and G.

[0065] The term "sequence identity" refers to the identity between two peptides or between two nucleic acids. Identity between sequences can be determined by comparing a position in each of the sequences which may be aligned for the purposes of comparison. When a position in the compared sequences is occupied by the same base or amino acid, then the sequences are identical at that position. A degree of sequence identity between nucleic acid sequences is a function of the number of identical nucleotides at positions shared by these sequences. A degree of identity between amino acid sequences is a function of the number of identical amino acid sequences that are shared between these sequences. Since two polypeptides may each (i) comprise a sequence (i.e., a portion of a complete polynucleotide sequence) that is similar between two polynucleotides, and (ii) may further comprise a sequence that is divergent between two polynucleotides, sequence identity comparisons between two or more polynucleotides over a "comparison window" refers to the conceptual segment of at least 20 contiguous nucleotide positions wherein a polynucleotide sequence may be compared to a reference nucleotide sequence of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.

[0066] To determine the percent identity of two amino acids sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison. For example, gaps can be introduced in the sequence of a first amino acid sequence or a first nucleic acid sequence for optimal alignment with the second amino acid sequence or second nucleic acid sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied

by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position.

[0067] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences. Hence % identity = number of identical positions / total number of overlapping positions X 100.

[0068] In this comparison the sequences can be the same length or may be different in length. Optimal alignment of sequences for determining a comparison window may be conducted by the local homology algorithm of Smith and Waterman (*J. Theor. Biol.*, 91 (2) pgs. 370-380 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.*, 48(3) pgs. 443-453 (1972), by the search for similarity via the method of Pearson and Lipman, *PNAS, USA*, 85(5) pgs. 2444-2448 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetic Computer Group, 575, Science Drive, Madison, Wisconsin) or by inspection.

[0069] The best alignment (i.e., resulting in the highest percentage of identity over the comparison window) generated by the various methods is selected.

[0070] The term "sequence identity" means that two polynucleotide sequences are identical (i.e., on a nucleotide by nucleotide basis) over the window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size) and multiplying the result by 100 to yield the percentage of sequence identity. The same process can be applied to polypeptide sequences.

[0071] The percentage of sequence identity of a nucleic acid sequence or an amino acid sequence can also be calculated using BLAST software (Version 2.06 of September 1998) with the default or user defined parameter.

[0072] The term "sequence similarity" means that amino acids can be modified while retaining the same function. It is known that amino acids are classified according to the nature of their side groups and some amino acids such as the basic amino acids can be interchanged for one another while their basic function is maintained.

[0073] The term "isolated" as used herein means that a biological material such as a nucleic acid or protein has been removed from its original environment in which it is naturally present. For example, a polynucleotide present in a plant, mammal or animal is present in its natural state and is not considered to be isolated. The same polynucleotide separated

from the adjacent nucleic acid sequences in which it is naturally inserted in the genome of the plant or animal is considered as being "isolated."

[0074] The term "isolated" is not meant to exclude artificial or synthetic mixtures with other compounds, or the presence of impurities which do not interfere with the biological activity and which may be present, for example, due to incomplete purification, addition of stabilizers or mixtures with pharmaceutically acceptable excipients and the like.

[0075] "Isolated polypeptide" or "isolated protein" as used herein means a polypeptide or protein which is substantially free of those compounds that are normally associated with the polypeptide or protein in a naturally state such as other proteins or polypeptides, nucleic acids, carbohydrates, lipids and the like.

[0076] The term "purified" as used herein means at least one order of magnitude of purification is achieved, preferably two or three orders of magnitude, most preferably four or five orders of magnitude of purification of the starting material or of the natural material. Thus, the term "purified" as utilized herein does not mean that the material is 100% purified and thus excludes any other material.

[0077] The term "variants" when referring to, for example, polynucleotides encoding a polypeptide variant of a given reference polypeptide are polynucleotides that differ from the reference polypeptide but generally maintain their functional characteristics of the reference polypeptide. A variant of a polynucleotide may be a naturally occurring allelic variant or it may be a variant that is known naturally not to occur. Such non-naturally occurring variants of the reference polynucleotide can be made by, for example, mutagenesis techniques, including those mutagenesis techniques that are applied to polynucleotides, cells or organisms.

[0078] Generally, differences are limited so that the nucleotide sequences of the reference and variant are closely similar overall and, in many regions identical.

[0079] Variants of polynucleotides according to the present invention include, but are not limited to, nucleotide sequences which are at least 95% identical after alignment to the reference polynucleotide encoding the reference polypeptide. These variants can also have 96%, 97%, 98% and 99.999% sequence identity to the reference polynucleotide.

[0080] Nucleotide changes present in a variant polynucleotide may be silent, which means that these changes do not alter the amino acid sequences encoded by the reference polynucleotide.

[0081] Substitutions, additions and/or deletions can involve one or more nucleic acids. Alterations can produce conservative or non-conservative amino acid substitutions, deletions and/or additions.

[0082] Variants of a prey or a SID® polypeptide encoded by a variant polynucleotide can possess a higher affinity of binding and/or a higher specificity of binding to its protein or

polypeptide counterpart, against which it has been initially selected. In another context, variants can also lose their ability to bind to their protein or polypeptide counterpart.

[0083] By "anabolic pathway" is meant a reaction or series of reactions in a metabolic pathway that synthesize complex molecules from simpler ones, usually requiring the input of energy. An anabolic pathway is the opposite of a catabolic pathway.

[0084] As used herein, a "catabolic pathway" is a series of reactions in a metabolic pathway that break down complex compounds into simpler ones, usually releasing energy in the process. A catabolic pathway is the opposite of an anabolic pathway.

[0085] As used herein, "drug metabolism" is meant the study of how drugs are processed and broken down by the body. Drug metabolism can involve the study of enzymes that break down drugs, the study of how different drugs interact within the body and how diet and other ingested compounds affect the way the body processes drugs.

[0086] As used herein, "metabolism" means the sum of all of the enzyme-catalyzed reactions in living cells that transform organic molecules.

[0087] By "secondary metabolism" is meant pathways producing specialized metabolic products that are not found in every cell.

[0088] As used herein, "SID®" means a Selected Interacting Domain and is identified as follows: for each bait polypeptide screened, selected prey polypeptides are compared. Overlapping fragments in the same ORF or CDS define the selected interacting domain.

[0089] As used herein the term "PIM®" means a protein-protein interaction map. This map is obtained from data acquired from a number of separate screens using different bait polypeptides and is designed to map out all of the interactions between the polypeptides.

[0090] The term "affinity of binding", as used herein, can be defined as the affinity constant K_a when a given SID® polypeptide of the present invention which binds to a polypeptide and is the following mathematical relationship:

[0091] $[\text{SID®/polypeptide complex}]$

[0092] $K_a = \frac{[\text{SID®/polypeptide complex}]}{[\text{free SID®}][\text{free polypeptide}]}$

[0093] $[\text{free SID®}][\text{free polypeptide}]$

[0094] wherein $[\text{free SID®}]$, $[\text{free polypeptide}]$ and $[\text{SID®/polypeptide complex}]$ consist of the concentrations at equilibrium respectively of the free SID® polypeptide, of the free polypeptide onto which the SID® polypeptide binds and of the complex formed between SID® polypeptide and the polypeptide onto which said SID® polypeptide specifically binds.

[0095] The affinity of a SID® polypeptide of the present invention or a variant thereof for its polypeptide counterpart can be assessed, for example, on a Biacore™ apparatus marketed by Amersham Pharmacia Biotech Company such as described by Szabo et al *Curr*

10043437, 011102

Opin Struct Biol 5 pgs. 699-705 (1995) and by Edwards and Leartherbarrow, *Anal. Biochem* 246 pgs. 1-6 (1997).

[0096] As used herein the phrase "at least the same affinity" with respect to the binding affinity between a SID® polypeptide of the present invention to another polypeptide means that the K_a is identical or can be at least two-fold, at least three-fold or at least five fold greater than the K_a value of reference.

[0097] As used herein, the term "modulating compound" means a compound that inhibits or stimulates or can act on another protein which can inhibit or stimulate the protein-protein interaction of a complex of two polypeptides or the protein-protein interaction of two polypeptides.

[0098] More specifically, the present invention comprises complexes of polypeptides or polynucleotides encoding the polypeptides composed of a bait polypeptide, or a bait polynucleotide encoding a bait polypeptide and a prey polypeptide or a prey polynucleotide encoding a prey polypeptide. The prey polypeptide or prey polynucleotide encoding the prey polypeptide is capable of interacting with a bait polypeptide of interest in various hybrid systems.

[0099] As described in the Background of the present invention there are various methods known in the art to identify prey polypeptides that interact with bait polypeptides of interest. These methods, include, but are not limited to, generic two-hybrid systems as described by Fields et al in *Nature*, 340:245-246 (1989) and more specifically in U.S. Patent Nos. 5,283,173, 5,468,614 and 5,667,973, which are hereby incorporated by reference; the reverse two-hybrid system described by Vidal et al, *supra*; the two plus one hybrid method described, for example, in Tirode et al, *supra*; the yeast forward and reverse 'n'-hybrid systems as described in Vidal and Legrain, *supra*; the method described in WO 99/42612; those methods described in Legrain et al *FEBS Letters* 480 pgs. 32-36 (2000) and the like.

[0100] The present invention is not limited to the type of method utilized to detect protein-protein interactions and therefore any method known in the art and variants thereof can be used. It is however better to use the method described in WO 99/42612 or WO 00/66722, both references incorporated herein by reference due to the methods' sensitivity, reproducibility and reliability.

[0101] Protein-protein interactions can also be detected using complementation assays such as those described by Pelletier et al. at <http://www.abrf.org/JBT/Articles/JBT0012/jbt0012.html>, WO 00/07038 and WO98/34120.

[0102] Although the above methods are described for applications in the yeast system, the present invention is not limited to detecting protein-protein interactions using yeast, but also includes similar methods that can be used in detecting protein-protein interactions in, for example, mammalian systems as described, for example in Takacs et al., *Proc. Natl. Acad.*

Sci., USA, 90 (21):10375-79 (1993) and Vasavada et al., *Proc. Natl. Acad. Sci., USA*, 88 (23):10686-90 (1991), as well as a bacterial two-hybrid system as described in Karimova et al (1998), WO99/28746, WO 00/66722 and Legrain et al *FEBS Letters*, 480 pgs. 32-36 (2000).

[0103] The above-described methods are limited to the use of yeast, mammalian cells and *Escherichia coli* cells, the present invention is not limited in this manner. Consequently, mammalian and typically human cells, as well as bacterial, yeast, fungus, insect, nematode and plant cells are encompassed by the present invention and may be transfected by the nucleic acid or recombinant vector as defined herein.

[0104] Examples of suitable cells include, but are not limited to, VERO cells, HELA cells such as ATCC No. CCL2, CHO cell lines such as ATCC No. CCL61, COS cells such as COS-7 cells and ATCC No. CRL 1650 cells, W138, BHK, HepG2, 3T3 such as ATCC No. CRL6361, A549, PC12, K562 cells, 293 cells, Sf9 cells such as ATCC No. CRL1711 and Cv1 cells such as ATCC No. CCL70.

[0105] Other suitable cells that can be used in the present invention include, but are not limited to, prokaryotic host cells strains such as *Escherichia coli*, (e.g., strain DH5- α), *Bacillus subtilis*, *Salmonella typhimurium*, or strains of the genera of *Pseudomonas*, *Streptomyces* and *Staphylococcus*.

[0106] Further suitable cells that can be used in the present invention include yeast cells such as those of *Saccharomyces* such as *Saccharomyces cerevisiae*.

[0107] The bait polynucleotide, as well as the prey polynucleotide can be prepared according to the methods known in the art such as those described above in the publications and patents reciting the known method *per se*.

[0108] The bait polynucleotide of the present invention is obtained from *Shigella flexneri* (see Table I). The prey polynucleotide is obtained from a human placenta cDNA or variants thereof and fragments from the genome or transcriptome of human placenta ranging from about 12 to about 5,000, or about 12 to about 10,000 or from about 12 to about 20,000. The prey polynucleotide is then selected, sequenced and identified.

[0109] A human placenta cDNA prey library is prepared from global human placenta and constructed in the specially designed prey vector pP6 as shown in Figure 10 after ligation of suitable linkers such that every cDNA fragment insert is fused to a nucleotide sequence in the vector that encodes the transcription activation domain of a reporter gene. Any transcription activation domain can be used in the present invention. Examples include, but are not limited to, Gal4, YP16, B42, His and the like. Toxic reporter genes, such as CAT^R, CYH2, CYH1, URA3, bacterial and fungi toxins and the like can be used in reverse two-hybrid systems.

[0110] The polypeptides encoded by the nucleotide inserts of the human placenta cDNA prey library thus prepared are termed "prey polypeptides" in the context of the presently described selection method of the prey polynucleotides.

[0111] The bait polynucleotide can be inserted in bait plasmid pB6 or pB20 as illustrated in Figure 3 or 6 respectively. The bait polynucleotide insert is fused to a polynucleotide encoding the binding domain of, for example, the Gal4 DNA binding domain and the shuttle expression vector is used to transform cells. The bait polynucleotides used in the present invention are described in Table I. As stated above, any cells can be utilized in transforming the bait and prey polynucleotides of the present invention including mammalian cells, bacterial cells, yeast cells, insect cells and the like.

[0112] In an embodiment, the present invention identifies protein-protein interactions in yeast. In using known methods a prey positive clone is identified containing a vector which comprises a nucleic acid insert encoding a prey polypeptide which binds to a bait polypeptide of interest. The method in which protein-protein interactions are identified comprises the following steps:

[0113] mating at least one first haploid recombinant yeast cell clone from a recombinant yeast cell clone library that has been transformed with a plasmid containing the prey polynucleotide to be assayed with a second haploid recombinant yeast cell clone transformed with a plasmid containing a bait polynucleotide encoding for the bait polypeptide;

[0114] cultivating diploid cell clones obtained in step i) on a selective medium; and

[0115] selecting recombinant cell clones which grow on the selective medium.

[0116] This method may further comprise the step of:

[0117] iv) characterizing the prey polynucleotide contained in each recombinant cell clone which is selected in step iii).

[0118] In yet another embodiment of the present invention, *in lieu* of yeast, *Escherichia coli* is used in a bacterial two-hybrid system, which encompasses a similar principle to that described above for yeast, but does not involve mating for characterizing the prey polynucleotide.

[0119] In yet another embodiment of the present invention, mammalian cells and a method similar to that described above for yeast for characterizing the prey polynucleotide are used.

[0120] By performing the yeast, bacterial or mammalian two-hybrid system it is possible to identify for one particular bait an interacting prey polypeptide. The prey polypeptide that has been selected by testing the library of preys in a screen using the two-hybrid, two plus one hybrid methods and the like, encodes the polypeptide interacting with the protein of interest.

[0121] The present invention is also directed, in a general aspect, to a complex of polypeptides, polynucleotides encoding the polypeptides composed of a bait polypeptide or bait polynucleotide encoding the bait polypeptide and a prey polypeptide or prey polynucleotide encoding the prey polypeptide capable of interacting with the bait polypeptide of interest. These complexes are identified in Table II, as the bait amino acid sequences and the prey amino acid sequences, as well as the bait and prey nucleic acid sequences.

[0122] In another aspect, the present invention relates to a complex of polynucleotides consisting of a first polynucleotide, or a fragment thereof, encoding a prey polypeptide that interacts with a bait polypeptide and a second polynucleotide or a fragment thereof. This fragment has at least 12 consecutive nucleotides, but can have between 12 and 5,000 consecutive nucleotides, or between 12 and 10,000 consecutive nucleotides or between 12 and 20,000 consecutive nucleotides.

[0123] The polypeptides of column 1 and 3 from Table II according to the present invention and the complexes of these two polypeptides also form part of the present invention. More specifically, the polypeptides of SEQ ID NOS. 1 to 7 are part of the present invention and their complexes with the polypeptides of Column 3, Table II.

[0124] In yet another embodiment, the present invention relates to an isolated complex of at least two polypeptides encoded by two polynucleotides wherein said two polypeptides are associated in the complex by affinity binding and are depicted in columns 1 and 3 of Table II.

[0125] In yet another embodiment, the present invention relates to an isolated complex comprising at least a polypeptide as described in column 1 of Table II and a polypeptide as described in column 3 of Table II. The present invention is not limited to these polypeptide complexes alone but also includes the isolated complex of the two polypeptides in which fragments and/or homologous polypeptides exhibiting at least 95% sequence identity, as well as from 96% sequence identity to 99.999% sequence identity.

[0126] Also encompassed in another embodiment of the present invention is an isolated complex in which SID® of the prey polypeptides encoded by SEQ ID Nos. 15 to 215 in Table III form the isolated complex.

[0127] Besides the isolated complexes described above, nucleic acids coding for a Selected Interacting Domain (SID®) polypeptide or a variant thereof or any of the nucleic acids set forth in Table III can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Such transcription elements include a regulatory region and a promoter. Thus, the nucleic acid which may encode a marker compound of the present invention is operably linked to a promoter in the expression vector. The expression vector may also include a replication origin.

[0128] A wide variety of host/expression vector combinations are employed in expressing the nucleic acids of the present invention. Useful expression vectors that can be used include, for example, segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include, but are not limited to, derivatives of SV40 and pcDNA and known bacterial plasmids such as col EI, pCR1, pBR322, pMal-C2, pET, pGEX as described by Smith et al [need cite 1988], pMB9 and derivatives thereof, plasmids such as RP4, phage DNAs such as the numerous derivatives of phage λ such as NM989, as well as other phage DNA such as M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2 micron plasmid or derivatives of the 2m plasmid, as well as centomeric and integrative yeast shuttle vectors; vectors useful in eukaryotic cells such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or the expression control sequences; and the like.

[0129] For example in a baculovirus expression system, both non-fusion transfer vectors, such as, but not limited to pVL941 (*Bam*HI cloning site Summers, pVL1393 (*Bam*HI, *Sma*I, *Xba*I, *Eco*RI, *Not*I, *Xma*II, *Bgl*II and *Pst*I cloning sites; Invitrogen) pVL1392 (*Bgl*II, *Pst*I, *Not*I, *Xma*II, *Eco*RI, *Xba*I, *Sma*I and *Bam*HI cloning site; Summers and Invitrogen) and pBlueBacII (*Bam*HI, *Bgl*II, *Pst*I, *Nco*I and *Hind*III cloning site, with blue/white recombinant screening, Invitrogen), and fusion transfer vectors such as, but not limited to, pAc700(*Bam*HI and *Kpn*I cloning sites, in which the *Bam*HI recognition site begins with the initiation codon; Summers), pAc701 and pAc70-2 (same as pAc700, with different reading frames), pAc360 (*Bam*HI cloning site 36 base pairs downstream of a polyhedrin initiation codon; Invitrogen (195)) and pBlueBacHisA, B, C (three different reading frames with *Bam*HI, *Bgl*II, *Pst*I, *Nco*I and *Hind*III cloning site, an N-terminal peptide for ProBond purification and blue/white recombinant screening of plaques; Invitrogen (220) can be used.

[0130] Mammalian expression vectors contemplated for use in the invention include vectors with inducible promoters, such as the dihydrofolate reductase promoters, any expression vector with a DHFR expression cassette or a DHFR/methotrexate co-amplification vector such as pED (*Pst*I, *Sal*I, *Sba*I, *Sma*I and *Eco*RI cloning sites, with the vector expressing both the cloned gene and DHFR; Kaufman, 1991). Alternatively a glutamine synthetase/methionine sulfoximine co-amplification vector, such as pEE14 (*Hind*III, *Xba*I, *Sma*I, *Sba*I, *Eco*RI and *Bcl*I cloning sites in which the vector expresses glutamine synthetase and the cloned gene; Celltech). A vector that directs episomal expression under the control of the Epstein Barr Virus (EBV) or nuclear antigen (EBNA) can be used such as pREP4 (*Bam*HI, *Sfi*I, *Xho*I, *Not*I, *Nhe*I, *Hind*III, *Nhe*I, *Pvu*II and *Kpn*I cloning sites, constitutive RSV-LTR promoter, hygromycin selectable marker; Invitrogen) pCEP4 (*Bam*HI, *Sfi*I, *Xho*I, *Not*I, *Nhe*I, *Hind*III, *Nhe*I, *Pvu*II and *Kpn*I cloning sites, constitutive hCMV

immediate early gene promoter, hygromycin selectable marker; Invitrogen), pMEP4 (*KpnI*, *PvuI*, *NheI*, *HindIII*, *NotI*, *XhoI*, *SfiI*, *BamHI* cloning sites, inducible methallothionein IIa gene promoter, hygromycin selectable marker, Invitrogen), pREP8 (*BamHI*, *XhoI*, *NotI*, *HindIII*, *NheI* and *KpnI* cloning sites, RSV-LTR promoter, histidinol selectable marker; Invitrogen), pREP9 (*KpnI*, *NheI*, *HindIII*, *NotI*, *XhoI*, *SfiI*, *BamHI* cloning sites, RSV-LTR promoter, G418 selectable marker; Invitrogen), and pEBVHis (RSV-LTR promoter, hygromycin selectable marker, N-terminal peptide purifiable via ProBond resin and cleaved by enterokinase; Invitrogen).

[0131] Selectable mammalian expression vectors for use in the invention include, but are not limited to, pRc/CMV (*HindIII*, *BstXI*, *NotI*, *SbaI* and *Apal* cloning sites, G418 selection, Invitrogen), pRc/RSV (*HindIII*, *SpeI*, *BstXI*, *NotI*, *XbaI* cloning sites, G418 selection, Invitrogen) and the like. Vaccinia virus mammalian expression vectors (see, for example Kaufman 1991 that can be used in the present invention include, but are not limited to, pSC11 (*SmaI* cloning site, TK- and β -gal selection), pMJ601 (*SaI*, *SmaI*, *AflI*, *NarI*, *BspMI*, *BamHI*, *Apal*, *NheI*, *SacI*, *KpnI* and *HindIII* cloning sites; TK- and β -gal selection), pTKgptF1S (*EcoRI*, *PstI*, *SaII*, *AccI*, *HindI*, *SbaI*, *BamHI* and *HpaI* cloning sites, TK or XPRT selection) and the like.

[0132] Yeast expression systems that can also be used in the present include, but are not limited to, the non-fusion pYES2 vector (*XbaI*, *SphI*, *ShoI*, *NotI*, *GstXI*, *EcoRI*, *BstXI*, *BamHI*, *SacI*, *KpnI* and *HindIII* cloning sites, Invitrogen), the fusion pYESHisA, B, C (*XbaI*, *SphI*, *ShoI*, *NotI*, *BstXI*, *EcoRI*, *BamHI*, *SacI*, *KpnI* and *HindIII* cloning sites, N-terminal peptide purified with ProBond resin and cleaved with enterokinase; Invitrogen), pRS vectors and the like.

[0133] Consequently, mammalian and typically human cells, as well as bacterial, yeast, fungi, insect, nematode and plant cells are used in the present invention and may be transfected by the nucleic acid or recombinant vector as defined herein.

[0134] Examples of suitable cells include, but are not limited to, VERO cells, HELA cells such as ATCC No. CCL2, CHO cell lines such as ATCC No. CCL61, COS cells such as COS-7 cells and ATCC No. CRL 1650 cells, W138, BHK, HepG2, 3T3 such as ATCC No. CRL6361, A549, PC12, K562 cells, 293 cells, Sf9 cells such as ATCC No. CRL1711 and Cv1 cells such as ATCC No. CCL70.

[0135] Other suitable cells that can be used in the present invention include, but are not limited to, prokaryotic host cells strains such as *Escherichia coli*, (e.g., strain DH5- α), *Bacillus subtilis*, *Salmonella typhimurium*, or strains of the genera of *Pseudomonas*, *Streptomyces* and *Staphylococcus*.

[0136] Further suitable cells that can be used in the present invention include yeast cells such as those of *Saccharomyces* such as *Saccharomyces cerevisiae*.

[0137] Besides the specific isolated complexes, as described above, the present invention relates to and also encompasses SID® polynucleotides. As explained above, for each bait polypeptide, several prey polypeptides may be identified by comparing and selecting the intersection of every isolated fragment that are included in the same polypeptide. Thus the SID® polynucleotides of the present invention are represented by the shared nucleic acid sequences of SEQ ID Nos. 15 to 215 encoding the SID® polypeptides of SEQ ID Nos. 216 to 416 in columns 5 and 7 of Table III, respectively.

[0138] The present invention is not limited to the SID® sequences as described in the above paragraph, but also includes fragments of these sequences having at least 12 consecutive nucleic acids, between 12 and 5,000 consecutive nucleic acids and between 12 and 10,000 consecutive nucleic acids and between 12 and 20,000 consecutive nucleic acids, as well as variants thereof. The fragments or variants of the SID® sequences possess at least the same affinity of binding to its protein or polypeptide counterpart, against which it has been initially selected. Moreover this variant and/or fragments of the SID® sequences alternatively can have between 95% and 99.999% sequence identity to its protein or polypeptide counterpart.

[0139] According to the present invention the variants can be created by known mutagenesis techniques either *in vitro* or *in vivo*. Such a variant can be created such that it has altered binding characteristics with respect to the target protein and more specifically that the variant binds the target sequence with either higher or lower affinity.

[0140] Polynucleotides that are complementary to the above sequences which include the polynucleotides of the SID®'s, their fragments, variants and those that have specific sequence identity are also included in the present invention.

[0141] The polynucleotide encoding the SID® polypeptide, fragment or variant thereof can also be inserted into recombinant vectors which are described in detail above.

[0142] The present invention also relates to a composition comprising the above-mentioned recombinant vectors containing the SID® polypeptides in Table III, fragments or variants thereof, as well as recombinant host cells transformed by the vectors. The recombinant host cells that can be used in the present invention were discussed in greater detail above.

[0143] The compositions comprising the recombinant vectors can contain physiological acceptable carriers such as diluents, adjuvants, excipients and any vehicle in which this composition can be delivered therapeutically and can include, but is are not limited to sterile liquids such as water and oils.

[0144] In yet another embodiment, the present invention relates to a method of selecting modulating compounds, as well as the modulating molecules or compounds themselves which may be used in a pharmaceutical composition. These modulating compounds may

act as a cofactor, as an inhibitor, as antibodies, as tags, as a competitive inhibitor, as an activator or alternatively have agonistic or antagonistic activity on the protein-protein interactions.

[0145] The activity of the modulating compound does not necessarily, for example, have to be 100% activation or inhibition. Indeed, even partial activation or inhibition can be achieved that is of pharmaceutical interest.

[0146] The modulating compound can be selected according to a method which comprises:

[0147] cultivating a recombinant host cell with a modulating compound on a selective medium and a reporter gene the expression of which is toxic for said recombinant host cell wherein said recombinant host cell is transformed with two vectors:

[0148] wherein said first vector comprises a polynucleotide encoding a first hybrid polypeptide having a DNA binding domain;

[0149] wherein said second vector comprises a polynucleotide encoding a second hybrid polypeptide having a transcriptional activating domain that activates said toxic reporter gene when the first and second hybrid polypeptides interact;

[0150] selecting said modulating compound which inhibits or permits the growth of said recombinant host cell.

[0151] Thus, the present invention relates to a modulating compound that inhibits the protein-protein interactions between *Shigella flexneri* polypeptide and human placenta polypeptide of columns 1 and 3 of Table II, respectively. The present invention also relates to a modulating compound that activates the protein-protein interactions between *Shigella flexneri* polypeptide and human placenta polypeptide of columns 1 and 3 of Table II, respectively.

[0152] In yet another embodiment, the present invention relates to a method of selecting a modulating compound, which modulating compound inhibits the interaction between *Shigella flexneri* polypeptide and human placenta polypeptide of columns 1 and 3 of Table II, respectively. This method comprises:

(a) cultivating a recombinant host cell with a modulating compound on a selective medium and a reporter gene the expression of which is toxic for said recombinant host cell wherein said recombinant host cell is transformed with two vectors:

(i) wherein said first vector comprises a polynucleotide encoding a first hybrid polypeptide having a first domain of an enzyme;

(ii) wherein said second vector comprises a polynucleotide encoding a second hybrid polypeptide having an enzymatic transcriptional activating domain that activates said toxic reporter gene when the first and second hybrid polypeptides interact;

(b) selecting said modulating compound which inhibits or permits the growth of said recombinant host cell.

[0153] In the two methods described above any toxic reporter gene can be utilized including those reporter genes that can be used for negative selection including the URA3 gene, the CYH1 gene, the CYH2 gene and the like.

[0154] In yet another embodiment, the present invention provides a kit for screening a modulating compound. This kit comprises a recombinant host cell which comprises a reporter gene the expression of which is toxic for the recombinant host cell. The host cell is transformed with two vectors. The first vector comprises a polynucleotide encoding a first hybrid polypeptide having a DNA binding domain; and a second vector comprises a polynucleotide encoding a second hybrid polypeptide having a transcriptional activating domain that activates said toxic reporter gene when the first and second hybrid polypeptides interact.

[0155] In yet another embodiment a kit is provided for screening a modulating compound by providing a recombinant host cell, as described in the paragraph above, but instead of a DNA binding domain, the first vector comprises a first hybrid polypeptide containing a first domain of a protein. The second vector comprises a second polypeptide containing a second part of a complementary domain of a protein that activates the toxic reporter gene when the first and second hybrid polypeptides interact.

[0156] In the selection methods described above, the activating domain can be p42 Gal 4, YP16 (HSV) and the DNA-binding domain can be derived from Gal4 or Lex A. The protein or enzyme can be adenylate cyclase, guanylate cyclase, DHFR and the like.

[0157] Examples of modulating compounds are set forth in Table III.

[0158] In yet another embodiment, the present invention relates to a pharmaceutical composition comprising the modulating compounds for preventing or treating bacillary dysentery in a human or animal, most preferably in a mammal.

[0159] This pharmaceutical composition comprises a pharmaceutically acceptable amount of the modulating compound. The pharmaceutically acceptable amount can be estimated from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes or encompasses a concentration point or range having the desired effect in an *in vitro* system. This information can thus be used to accurately determine the doses in other mammals, including humans and animals.

[0160] The therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or in experimental animals. For example, the LD50 (the dose lethal to 50% of the population) as

well as the ED50 (the dose therapeutically effective in 50% of the population) can be determined using methods known in the art. The dose ratio between toxic and therapeutic effects is the therapeutic index which can be expressed as the ratio between LD 50 and ED50 compounds that exhibit high therapeutic indexes.

[0161] The data obtained from the cell culture and animal studies can be used in formulating a range of dosage of such compounds which lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.

[0162] The pharmaceutical composition can be administered via any route such as locally, orally, systemically, intravenously, intramuscularly, mucosally, using a patch and can be encapsulated in liposomes, microparticles, microcapsules, and the like. The pharmaceutical composition can be embedded in liposomes or even encapsulated.

[0163] Any pharmaceutically acceptable carrier or adjuvant can be used in the pharmaceutical composition. The modulating compound will be preferably in a soluble form combined with a pharmaceutically acceptable carrier. The techniques for formulating and administering these compounds can be found in "*Remington's Pharmaceutical Sciences*" Mack Publication Co., Easton, PA, latest edition.

[0164] The mode of administration optimum dosages and galenic forms can be determined by the criteria known in the art taken into account the seriousness of the general condition of the mammal, the tolerance of the treatment and the side effects.

[0165] The present invention also relates to a method of treating or preventing bacillary dysentery in a human or mammal in need of such treatment. This method comprises administering to a mammal in need of such treatment a pharmaceutically effective amount of a modulating compound which binds to a targeted Shigella protein. In a preferred embodiment, the modulating compound is a polynucleotide which may be placed under the control of a regulatory sequence which is functional in the mammal or human.

[0166] In yet another embodiment, the present invention relates to a pharmaceutical composition comprising a SID® polypeptide, a fragment or variant thereof. The SID® polypeptide, fragment or variant thereof can be used in a pharmaceutical composition provided that it is endowed with highly specific binding properties to a bait polypeptide of interest.

[0167] The original properties of the SID® polypeptide or variants thereof interfere with the naturally occurring interaction between a first protein and a second protein within the cells of the organism. Thus, the SID® polypeptide binds specifically to either the first polypeptide or the second polypeptide.

[0168] Therefore, the SID® polypeptides of the present invention or variants thereof interfere with protein-protein interactions between *Shigella* or *Escherichia* polypeptides or between a mammal polypeptide.

[0169] Thus, the present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable amount of a SID® polypeptide or variant thereof, provided that the variant has the above-mentioned two characteristics; i.e., that it is endowed with highly specific binding properties to a bait polypeptide of interest and is devoid of biological activity of the naturally occurring protein.

[0170] In yet another embodiment, the present invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of a polynucleotide encoding a SID® polypeptide or a variant thereof wherein the polynucleotide is placed under the control of an appropriate regulatory sequence. Appropriate regulatory sequences that are used are polynucleotide sequences derived from promoter elements and the like.

[0171] Polynucleotides that can be used in the pharmaceutical composition of the present invention include the nucleotide sequences of SID®s of SEQ ID Nos. 15 to 215.

[0172] Besides the SID® polypeptides and polynucleotides, the pharmaceutical composition of the present invention can also include a recombinant expression vector comprising the polynucleotide encoding the SID® polypeptide, fragment or variant thereof.

[0173] The above described pharmaceutical compositions can be administered by any route such as orally, systemically, intravenously, intramuscularly, intradermally, mucosally, encapsulated, using a patch and the like. Any pharmaceutically acceptable carrier or adjuvant can be used in this pharmaceutical composition.

[0174] The SID® polypeptides as active ingredients will be preferably in a soluble form combined with a pharmaceutically acceptable carrier. The techniques for formulating and administering these compounds can be found in "*Remington's Pharmaceutical Sciences*" *supra*.

[0175] The amount of pharmaceutically acceptable SID® polypeptides can be determined as described above for the modulating compounds using cell culture and animal models.

[0176] Such compounds can be used in a pharmaceutical composition to treat or prevent bacillary dysentery.

[0177] Thus, the present invention also relates to a method of preventing or treating bacillary dysentery in a mammal said method comprising the steps of administering to a

mammal in need of such treatment a pharmaceutically effective amount of a recombinant expression vector comprising a polynucleotide encoding a SID® polypeptide which binds to a either to a *Shigella flexneri* protein or to a human placenta protein involved in a protein-protein interaction between a *Shigella flexneri* protein and an human placenta protein. More specifically, the present invention relates to a method of preventing or treating bacillary dysentery in a mammal said method comprising the steps of administering to a mammal in need of such treatment a pharmaceutically effective amount of:

- (1) a SID® polypeptide of SEQ ID Nos. 216 to 416 or a variant thereof which binds to a targeted *Shigella flexneri* protein or human placenta protein; or
- (2) a SID® polynucleotide encoding a SID® polypeptide of SEQ ID Nos. 15 to 215 or a variant or a fragment thereof wherein said polynucleotide is placed under the control of a regulatory sequence which is functional in said mammal; or
- (3) a recombinant expression vector comprising a polynucleotide encoding a SID® polypeptide which binds either to a *Shigella flexneri* protein or to a human placenta protein involved in a protein-protein interaction between a *Shigella flexneri* protein and an human placenta protein.

[0178] In another embodiment the present invention nucleic acids comprising a sequence of SEQ ID Nos. 15 to 215 which encodes the protein of sequence SEQ ID Nos. 216 to 416 and/or functional derivatives thereof are administered to modulate complex (from Table II) function by way of gene therapy. Any of the methodologies relating to gene therapy available within the art may be used in the practice of the present invention such as those described by Goldspiel et al *Clin. Pharm.* **12** pgs. 488-505 (1993).

[0179] Delivery of the therapeutic nucleic acid into a patient may be direct *in vivo* gene therapy (i.e., the patient is directly exposed to the nucleic acid or nucleic acid-containing vector) or indirect *ex vivo* gene therapy (i.e., cells are first transformed with the nucleic acid *in vitro* and then transplanted into the patient).

[0180] For example for *in vivo* gene therapy, an expression vector containing the nucleic acid is administered in such a manner that it becomes intracellular; i.e., by infection using a defective or attenuated retroviral or other viral vectors as described, for example in U.S. Patent 4,980,286 or by Robbins et al, *Pharmacol. Ther.* , **80** No. 1 pgs. 35-47 (1998).

[0181] The various retroviral vectors that are known in the art are such as those described in Miller et al, *Meth. Enzymol.* **217** pgs. 581-599 (1993) which have been modified to delete those retroviral sequences which are not required for packaging of the viral genome and subsequent integration into host cell DNA. Also adenoviral vectors can be used which are advantageous due to their ability to infect non-dividing cells and such high-capacity adenoviral vectors are described in Kochanek, *Human Gene Therapy*, **10**, pgs. 2451-2459 (1999). Chimeric viral vectors that can be used are those described by Reynolds

et al, *Molecular Medicine Today*, pgs. 25 –31 (1999). Hybrid vectors can also be used and are described by Jacoby et al, *Gene Therapy*, **4**, pgs. 1282-1283 (1997).

[0182] Direct injection of naked DNA or through the use of microparticle bombardment (e.g., Gene Gun®; Biolistic, Dupont). or by coating it with lipids can also be used in gene therapy. Cell-surface receptors/transfecting agents or through encapsulation in liposomes, microparticles or microcapsules or by administering the nucleic acid in linkage to a peptide which is known to enter the nucleus or by administering it in linkage to a ligand predisposed to receptor-mediated endocytosis (See, Wu & Wu, J. Biol. Chem., 262 pgs. 4429-4432 (1987)) can be used to target cell types which specifically express the receptors of interest.

[0183] In another embodiment a nucleic acid ligand compound may be produced in which the ligand comprises a fusogenic viral peptide designed so as to disrupt endosomes, thus allowing the nucleic acid to avoid subsequent lysosomal degradation. The nucleic acid may be targeted *in vivo* for cell specific endocytosis and expression by targeting a specific receptor such as that described in WO92/06180, WO93/14188 and WO 93/20221. Alternatively the nucleic acid may be introduced intracellularly and incorporated within the host cell genome for expression by homologous recombination. See, Zijlstra et al, *Nature*, **342**, pgs. 435-428 (1989).

[0184] In *ex vivo* gene a gene is transferred into cells *in vitro* using tissue culture and the cells are delivered to the patient by various methods such as injecting subcutaneously, application of the cells into a skin graft and the intravenous injection of recombinant blood cells such as hematopoietic stem or progenitor cells.

[0185] Cells into which a nucleic acid can be introduced for the purposes of gene therapy include, for example, epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes and blood cells. The blood cells that can be used include, for example, T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes, hematopoietic cells or progenitor cells and the like.

[0186] In yet another embodiment the present invention relates to protein chips or protein microarrays. It is well known in the art that microarrays can contain more than 10,000 spots of a protein that can be robotically deposited on a surface of a glass slide or nylon filter. The proteins attach covalently to the slide surface, yet retain their ability to interact with other proteins or small molecules in solution. In some instances the protein samples can be made to adhere to glass slides by coating the slides with an aldehyde-containing reagent that attaches to primary amines. A process for creating microarrays is described, for example by MacBeath and Schreiber in *Science*, Volume 289, Number 5485, pgs. 1760-1763 (2000) or Service, *Science*, Vol, 289, Number 5485 pg. 1673 (2000). An

apparatus for controlling, dispensing and measuring small quantities of fluid is described, for example, in U.S. Patent No. 6,112,605.

[0187] The present invention also provides a record of protein-protein interactions, PIM®'s, SID®'s and any data encompassed in the following Tables. It will be appreciated that this record can be provided in paper or electronic or digital form.

[0188] In order to fully illustrate the present invention and advantages thereof, the following specific examples are given, it being understood that the same are intended only as illustrative and in no way limitative.

EXAMPLES

EXAMPLE 1: Preparation of a collection of random-primed cDNA fragments

1.A. Collection preparation and transformation in *Escherichia coli*

1.A.1. Random-primed cDNA fragment preparation

[0189] For the human placenta mRNA sample, random-primed cDNA was prepared from 5 µg of polyA+ mRNA using a TimeSaver cDNA Synthesis Kit (Amersham Pharmacia Biotech) and with 5 µg of random N9-mers according to the manufacturer's instructions. Following phenolic extraction, the cDNA was precipitated and resuspended in water. The resuspended cDNA was phosphorylated by incubating in the presence of T4 DNA Kinase (Biolabs) and ATP for 30 minutes at 37°C. The resulting phosphorylated cDNA was then purified over a separation column (Chromaspin TE 400, Clontech), according to the manufacturer's protocol.

1.A.2. Ligation of linkers to blunt-ended cDNA

Oligonucleotide HGX931 (5' end phosphorylated) 1 µg/µl and HGX932 1µg/µl.

Sequence of the oligo HGX931: 5'-GGGCCACGAA-3' (SEQ ID NO. 417)

Sequence of the oligo HGX932 : 5'-TTCGTGGCCCCTG-3' (SEQ ID NO. 418)

[0190] Linkers were preincubated (5 minutes at 95°C, 10 minutes at 68°C, 15 minutes at 42°C) then cooled down at room temperature and ligated with cDNA fragments at 16°C overnight.

[0191] Linkers were removed on a separation column (Chromaspin TE 400, Clontech), according to the manufacturer's protocol.

1.A.3. Vector preparation

[0192] Plasmid pP6 (see Figure 10) was prepared by replacing the *Spell/XhoI* fragment of pGAD3S2X with the double-stranded oligonucleotide:

5'CTAGCCATGGCCGCGAGGGGCCGCGCCGCACTAGTGGGGATCCTTAATTAAGGGC
CACTGGGGCCCCC

GGTACCGGCGTCCCGGCGCGGCGTGATCACCCCTAGGAATTAATTTCCGGTGAC
CCCGGGGGAGCT 3' (SEQ ID NO. 419)

[0193] The pP6 vector was successively digested with *Sfi*I and *Bam*HI restriction enzymes (Biolabs) for 1 hour at 37°C, extracted, precipitated and resuspended in water. Digested plasmid vector backbones were purified on a separation column (Chromaspin TE 400, Clontech), according to the manufacturer's protocol.

1.A.4. Ligation between vector and insert of cDNA

[0194] The prepared vector was ligated overnight at 15°C with the blunt-ended cDNA described in section 2 using T4 DNA ligase (Biolabs). The DNA was then precipitated and resuspended in water.

1.A.5. Library transformation in *Escherichia coli*

[0195] The DNA from section 1.A.4 was transformed into Electromax DH10B electrocompetent cells (Gibco BRL) with a Cell Porator apparatus (Gibco BRL). 1 ml SOC medium was added and the transformed cells were incubated at 37°C for 1 hour. 9 mls of SOC medium per tube was added and the cells were plated on LB+ampicillin medium. The colonies were scraped with liquid LB medium, aliquoted and frozen at -80°C.

[0196] The obtained collection of recombinant cell clones is named HGXBPLARP1.

1.B. Collection transformation in *Saccharomyces cerevisiae*

[0197] The *Saccharomyces cerevisiae* strain (Y187 (MAT α Gal4 Δ Gal80 Δ ade2-101, his3, leu2-3, -112, trp1-901, ura3-52 URA3::UASGAL1-LacZ Met)) was transformed with the cDNA library.

[0198] The plasmid DNA contained in *E. coli* were extracted (Qiagen) from aliquoted *E. coli* frozen cells (1.A.5.). *Saccharomyces cerevisiae* yeast Y187 in YPGlu were grown.

[0199] Yeast transformation was performed according to standard protocol (Giest et al. Yeast, 11, 355-360, 1995) using yeast carrier DNA (Clontech). This experiment leads to 10⁴ to 5 x 10⁴ cells/ μ g DNA. 2 x 10⁴ cells were spread on DO-Leu medium per plate. The cells were aliquoted into vials containing 1 ml of cells and frozen at -80°C.

[0200] The obtained collection of recombinant cell clones is named HGXYPLARP1 (placenta).

1.C. Construction of bait plasmids

[0201] For fusions of the bait protein (listed in Table II) to the DNA-binding domain of the GAL4 protein of *S. cerevisiae*, bait fragments were cloned into plasmid pB6. For fusions of the bait protein to the DNA-binding domain of the LexA protein of *E. coli*, bait fragments were cloned into plasmid pB20.

[0202] Plasmid pB6 (see Figure 3) was prepared by replacing the *Nco*I/*Sal*I polylinker fragment of pAS $\Delta\Delta$ with the double-stranded DNA fragment:

5'

CATGGCCGGACGCGGCCGCGGCCGCACTAGTGGGGATCCTTAATTAAGGGCCACTGG
GGCCCCC 3' (SEQ ID NO. 420)

3'

CGGCCTGCCCGCGCCGCGTGATCACCCCTAGGAATTAATTTCCCGGTGACCCCGG
GGGAGCT 5' (SEQ ID NO. 421)

[0203] Plasmid pB20 (see Figure 6) was prepared by replacing the *EcoRI/PstI* polylinker fragment of pLex10 with the double-stranded DNA fragment:

5'

AATTCGGGGCCGGACGGGCCGCGCCGCACTAGTGGGGATCCTTAATTAAGGGCCAC
TGGGGCCCCTGCACCTGCA 3' (SEQ ID NO. 422)

3'

GCCCCGGCCTGCCCGCGCCGCGTGATCACCCCTAGGAATTAATTTCCCGGTGACCC
CGGGGAGCTGG 5' (SEQ ID NO. 423)

[0204] The amplification of the bait ORF was obtained by PCR using the Pfu proof-reading *Taq* polymerase (Stratagene), 10 pmol of each specific amplification primer and 200 ng of plasmid DNA as template.

[0205] The PCR program was set up as follows :

94° 45"	
94° 45"	
48° 45"	x30 cycles
72° 6'	
72° 10'	
15° ∞	

[0206] The amplification was checked by agarose gel electrophoresis.

[0207] The PCR fragments were purified with Qiaquick column (Qiagen) according to the manufacturer's protocol.

[0208] Purified PCR fragments were digested with adequate restriction enzymes. The PCR fragments were purified with Qiaquick column (Qiagen) according to the manufacturer's protocol.

[0209] The digested PCR fragments were ligated into an adequately digested and dephosphorylated bait vector (pB6 or pB20) according to standard protocol (Sambrook *et al.*) and were transformed into competent bacterial cells. The cells were grown, the DNA extracted and the plasmid was sequenced.

Example 2 : Screening the collection with the two-hybrid in yeast system

2.A. The mating protocol

[0210] The mating two-hybrid in yeast system (as described by Legrain *et al.*, *Nature Genetics*, vol. 16, 277-282 (1997), *Toward a functional analysis of the yeast genome through*

exhaustive two-hybrid screens) was used for its advantages but one could also screen the cDNA collection in classical two-hybrid system as described in Fields *et al.* or in a yeast reverse two-hybrid system.

[0211] The mating procedure allows a direct selection on selective plates because the two fusion proteins are already produced in the parental cells. No replica plating is required.

[0212] This protocol was written for the use of the library transformed into the Y187 strain.

[0213] For bait proteins fused to the DNA-binding domain of GAL4, bait-encoding plasmids were first transformed into *S. cerevisiae* (CG1945 strain (MATa Gal4-542 Gal180-538 ade2-101 his3Δ200, leu2-3,112, trp1-901, ura3-52, lys2-801, URA3::GAL4 17mers (X3)-Cyc1TATA-LacZ, LYS2::GAL1UAS-GAL1TATA-HIS3 CYH^R)) according to step 1.B. and spread on DO-Trp medium.

[0214] For bait proteins fused to the DNA-binding domain of LexA, bait-encoding plasmids were first transformed into *S. cerevisiae* (L40Δgal4 strain (MATa ade2, trp1-901, leu2 3,112, lys2-801, his3Δ200, LYS2::(*lexAop*)₄-HIS3, ura3-52::URA3 (*lexAop*)₈-LacZ, GAL4::Kan^R)) according to step 1.B. and spread on DO-Trp medium.

Day 1, morning : preculture

[0215] The cells carrying the bait plasmid obtained at step 1.C. were precultured in 20 ml DO-Trp medium and grown at 30°C with vigorous agitation.

Day 1, late afternoon : culture

[0216] The OD_{600nm} of the DO-Trp pre-culture of cells carrying the bait plasmid pre-culture was measured. The OD_{600nm} must lie between 0.1 and 0.5 in order to correspond to a linear measurement. 50 ml DO-Trp at OD_{600nm} 0.006/ml was inoculated and grown overnight at 30°C with vigorous agitation.

Day 2 : mating

medium and plates

1 YPGlu 15cm plate

50 ml tube with 13 ml DO-Leu-Trp-His

100 ml flask with 5 ml of YPGlu

8 DO-Leu-Trp-His plates

2 DO-Leu plates

2 DO-Trp plates

2 DO-Leu-Trp plates

[0217] The OD_{600nm} of the DO-Trp culture was measured. It should be around 1.

[0218] For the mating, twice as many bait cells as library cells were used. To get a good mating efficiency, one must collect the cells at 10⁸ cells per cm².

[0219] The amount of bait culture (in ml) that makes up 50 OD_{600nm} units for the mating with the prey library was estimated.

[0220] A vial containing the HGXYCDNA1 library was thawed slowly on ice. 1.0ml of the vial was added to 5 ml YPGlu. Those cells were recovered at 30°C, under gentle agitation for 10 minutes.

Mating

[0221] The 50 OD_{600nm} units of bait culture was placed into a 50 ml falcon tube.

[0222] The HGXYCDNA1 library culture was added to the bait culture, then centrifuged, the supernatant discarded and resuspended in 1.6ml YPGlu medium.

[0223] The cells were distributed onto two 15cm YPGlu plates with glass beads. The cells were spread by shaking the plates. The plate cells-up at 30°C for 4h30min were incubated.

Collection of mated cells

[0224] The plates were washed and rinsed with 6ml and 7ml respectively of DO-Leu-Trp-His. Two parallel serial ten-fold dilutions were performed in 500µl DO-Leu-Trp-His up to 1/10,000. 50µl of each 1/10000 dilution was spread onto DO-Leu and DO-trp plates and 50µl of each 1/1000 dilution onto DO-Leu-Trp plates. 22.4ml of collected cells were spread in 400µl aliquots on DO-Leu-Trp-His+Tet plates.

Day 4

[0225] Clones that were able to grow on DO-Leu-Trp-His+Tetracyclin were then selected. This medium allows one to isolate diploid clones presenting an interaction.

[0226] The His⁺ colonies were counted on control plates.

[0227] The number of His⁺ cell clones will define which protocol is to be processed :

[0228] Upon 60.10⁶ Trp+Leu+ colonies :

- if the number His⁺ cell clones <285 : then use the process luminometry protocol on all colonies

- if the number of His⁺ cell clones > 285 and <5000: then process via overlay and then luminometry protocols on blue colonies (2.B and 2.C).

- if number of His⁺ cell clones >5000 : repeat screen using DO-Leu-Trp-His+Tetracyclin plates containing 3-aminotriazol.

2.B. The X-Gal overlay assay

[0229] The X-Gal overlay assay was performed directly on the selective medium plates after scoring the number of His⁺ colonies.

Materials

[0230] A waterbath was set up. The water temperature should be 50°C.

0.5 M Na₂HPO₄ pH 7.5.

1.2% Bacto-agar.

2% X-Gal in DMF.

Overlay mixture : 0.25 M Na_2HPO_4 pH7.5, 0.5% agar, 0.1% SDS, 7% DMF (LABOSI), 0.04% X-Gal (ICN). For each plate, 10 ml overlay mixture are needed.

DO-Leu-Trp-His plates.

Sterile toothpicks.

Experiment

[02311] The temperature of the overlay mix should be between 45°C and 50°C. The overlay-mix was poured over the plates in portions of 10 ml. When the top layer was settled, they were collected. The plates were incubated overlay-up at 30°C and the time was noted. Blue colonies were checked for regularly. If no blue colony appeared, overnight incubation was performed. Using a pen the number of positives was marked. The positives colonies were streaked on fresh DO-Leu-Trp-His plates with a sterile toothpick.

2.C. The luminometry assay

[0232] His⁺ colonies were grown overnight at 30°C in microtiter plates containing DO-Leu-Trp-His+Tetracyclin medium with shaking. The day after, the overnight culture was diluted 15 times into a new microtiter plate containing the same medium and was incubated for 5 hours at 30°C with shaking. The samples were diluted 5 times and read OD_{600nm}. The samples were diluted again to obtain between 10,000 and 75,000 yeast cells/well in 100 µl final volume.

[0233] Per well, 76 µl of One Step Yeast Lysis Buffer (Tropix) was added, 20 µl SapphireII Enhancer (Tropix), 4 µl Galacton Star (Tropix) and incubated 40 minutes at 30°C. The β-Gal read-out (L) was measured using a Luminometer (Trilux, Wallach). The value of (OD_{600nm} × L) was calculated and interacting preys having the highest values were selected.

[0234] At this step of the protocol, diploid cell clones presenting interaction were isolated. The next step was now to identify polypeptides involved in the selected interactions.
Example 3 : Identification of positive clones

3.A. PCR on yeast colonies

Introduction

[0235] PCR amplification of fragments of plasmid DNA directly on yeast colonies is a quick and efficient procedure to identify sequences cloned into this plasmid. It is directly derived from

[0236] a published protocol (Wang H. et al., *Analytical Biochemistry*, **237**, 145-146, (1996)). However, it is not a standardized protocol and it varies from strain to strain and it is dependent of experimental conditions (number of cells, *Taq* polymerase source, etc). This protocol should be optimized to specific local conditions.

Materials

[0237] For 1 well, PCR mix composition was :

32.5 µl water,

5 µl 10X PCR buffer (Pharmacia),

1 µl dNTP 10 mM,

0.5 µl *Taq* polymerase (5u/µl) (Pharmacia),

0.5 µl oligonucleotide ABS1 10 pmole/µl: 5'-GCGTTTGAATCACTACAGG-3', (SEQ ID NO. 424)

0.5 µl oligonucleotide ABS2 10 pmole/µl: 5'-CACGATGCACGTTGAAGTG-3', (SEQ ID NO. 425)

1 N NaOH.

Experiment

[0238] The positive colonies were grown overnight at 30°C on a 96 well cell culture cluster (Costar), containing 150 µl DO-Leu-Trp-His+Tetracyclin with shaking. The culture was resuspended and 100 µl was transferred immediately on a Thermowell 96 (Costar) and centrifuged for 5 minutes at 4,000 rpm at room temperature. The supernatant was removed. 5 µl NaOH was added to each well and shaken for 1 minute.

[0239] The Thermowell was placed in the thermocycler (GeneAmp 9700, Perkin Elmer) for 5 minutes at 99.9°C and then 10 minutes at 4°C. In each well, the PCR mix was added and shaken well.

[0240] The PCR program was set up as followed :

94°C	3 minutes	}	x 35 cycles
94°C	30 seconds		
53°C	1 minute 30 seconds		
72°C	3 minutes	}	
72°C	5 minutes		
15°C	∞		

[0241] The quality, the quantity and the length of the PCR fragment was checked on an agarose gel. The length of the cloned fragment was the estimated length of the PCR fragment minus 300 base pairs that corresponded to the amplified flanking plasmid sequences.

[0242] 3.B. Plasmids rescue from yeast by electroporation

Introduction

[0243] The previous protocol of PCR on yeast cell may not be successful, in such a case, plasmids from yeast by electroporation can be rescued. This experiment allows the recovery of prey plasmids from yeast cells by transformation of *E. coli* with a yeast cellular extract. The prey plasmid can then be amplified and the cloned fragment can be sequenced.

Materials

[0244] Plasmid rescue

Glass beads 425-600 μm (Sigma) Phenol/chloroform (1/1) premixed with isoamyl alcohol (Amresco)

Extraction buffer : 2% Triton X100, 1% SDS, 100 mM NaCl, 10 mM TrisHCl pH 8.0, 1 mM EDTA pH 8.0.

Mix ethanol/ NH_4Ac : 6 volumes ethanol with 7.5 M NH_4 Acetate, 70% Ethanol and yeast cells in patches on plates.

Electroporation

SOC medium

M9 medium

Selective plates : M9-Leu+Ampicillin

2 mm electroporation cuvettes (Eurogentech)

Experiment

Plasmid rescue

[0245] The cell patch on DO-Leu-Trp-His was prepared with the cell culture of section 2.C. The cell of each patch was scraped into an Eppendorf tube, 300 μl of glass beads was added in each tube, then, 200 μl extraction buffer and 200 μl phenol:chloroform:isoamyl alcohol (25:24:1) was added.

[0246] The tubes were centrifuged for 10 minutes at 15,000 rpm.

[0247] 180 μl supernatant was transferred to a sterile Eppendorf tube and 500 μl each of ethanol/ NH_4Ac was added and the tubes were vortexed. The tubes were centrifuged for 15 minutes at 15,000 rpm at 4°C. The pellet was washed with 200 μl 70% ethanol and the ethanol was removed and the pellet was dried. The pellet was resuspended in 10 μl water. Extracts were stored at -20°C.

Electroporation

Materials :

[0248] Electrocompetent MC1066 cells prepared according to standard protocols (Sambrook et al. *supra*).

1 μl of yeast plasmid DNA-extract was added to a pre-chilled Eppendorf tube, and kept on ice.

1 μl plasmid yeast DNA-extract sample was mixed and 20 μl electrocompetent cells was added and transferred in a cold electroporation cuvette. Set the Biorad electroporator on 200 ohms resistance, 25 μF capacity; 2.5 kV. Place the cuvette in the cuvette holder and electroporate.

1 ml of SOC was added into the cuvette and the cell-mix was transferred into a sterile Eppendorf tube. The cells were recovered for 30 minutes at 37°C, then spun down for

1 minute at 4,000 x g and the supernatant was poured off. About 100 µl medium was kept and used to resuspend the cells and spread them on selective plates (e.g., M9-Leu plates). The plates were then incubated for 36 hours at 37°C.

[0249] One colony was grown and the plasmids were extracted. Check for the presence and size of the insert through enzymatic digestion and agarose gel electrophoresis. The insert was then sequenced.

Example 4 : Protein-protein interaction

[0250] For each bait, the previous protocol leads to the identification of prey polynucleotide sequences. Using a suitable software program (e.g., Blastwun, available on the Internet site of the University of Washington : <http://bioweb.pasteur.fr/seqanal/interfaces/blastwu.html>) the identity of the mRNA transcript that is encoded by the prey fragment may be determined and whether the fusion protein encoded is in the same open reading frame of translation as the predicted protein or not.

[0251] Alternatively, prey nucleotide sequences can be compared with one another and those which share identity over a significant region (60nt) can be grouped together to form a contiguous sequence (Contig) whose identity can be ascertained in the same manner as for individual prey fragments described above.

Example 5 : Identification of SID®

[0252] By comparing and selecting the intersection of all isolated fragments that are included in the same polypeptide, one can define the Selected Interacting Domain (SID®) as illustrated in Figure 15. The SID® is illustrated in Table III .

Example 6 : Identification of PIM®

[0253] The PIM® is then constructed using methods known in the art as exemplified in Figure 16.

Example 7 : Making of polyclonal and monoclonal antibodies

[0254] The protein-protein complex of columns 1 and 3 of Table II was injected into mice and polyclonal and monoclonal antibodies were made following the procedure set forth in Sambrook et al. (*supra*).

[0255] More specifically, mice are immunized with an immunogen comprising Table II complexes conjugated to keyhole limpet hemocyanin using glutaraldehyde or EDC as is well known in the art. The complexes can also be stabilized by crosslinking as described in WO 00/37483. The immunogen is then mixed with an adjuvant. Each mouse receives four injections of 10 µg to 100 µg of immunogen, and after the fourth injection, blood samples are taken from the mice to determine if the serum contains antibodies to the immunogen. Serum titer is determined by ELISA or RIA. Mice with sera indicating the presence of antibody to the immunogen are selected for hybridoma production.

[0256] Spleens are removed from immune mice and single-cell suspension is prepared (Harlow et al 1988). Cell fusions are performed essentially as described by Kohler et al (1976). Briefly, P365.3 myeloma cells (ATTC Rockville, Md) or NS-1 myeloma cells are fused with spleen cells using polyethylene glycol as described by Harlow et al (1989). Cells are plated at a density of 2×10^5 cells/well in 96-well tissue culture plates. Individual wells are examined for growth and the supernatants of wells with growth are tested for the presence of the complex-specific antibodies by ELISA or RIA using one of the proteins set forth in Table II as a target protein. Cells in positive wells are expanded and subcloned to establish and confirm monoclonality.

[0257] Clones with the desired specificities are expanded and grown as ascites in mice or in a hollow fiber system to produce sufficient quantities of antibodies for characterization and assay development. Antibodies are tested for binding to one of the proteins in Table II, to determine which are specific for the Table II complexes as opposed to those that bind to the individual proteins. More specifically, antibodies are tested for binding to bait polypeptide of column 1 of Table II alone or to prey polypeptide of column 3 of Table II alone, to determine which are specific for the protein-protein complex of columns 1 and 3 of Table II as opposed to those that bind to the individual proteins.

[0258] Monoclonal antibodies against each of the complexes set forth in columns 1 and 3 of Table II are prepared in a similar manner by mixing specified proteins together, immunizing an animal, fusing spleen cells with myeloma cells and isolating clones which produce antibodies specific for the protein complex, but not for individual proteins.

Example 8: Modulating compounds/PIM screening

[0259] Each specific protein-protein complex of columns 1 and 3 of Table II may be used to screen for modulating compounds.

[0260] One appropriate construction for this modulating compound screening may be:

- bait polynucleotide inserted in pB6 or pB20;- prey polynucleotide inserted in pP6;
- transformation of these two vectors in a permeable yeast cell;
- growth of the transformed yeast cell on medium containing compound to be tested;
- and observation of the growth of the yeast cells.

[0261] The following results obtained from these Examples, as well as the teachings in the specification are set forth in the Tables below.

[0262] While the invention has been described in terms of the various preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions, omissions and changes may be made without departing from the scope thereof. Accordingly, it is intended that the present invention be limited by the scope of the following claims, including equivalents thereof.

[0263] All patent and non-patent publications cited in this specification, including the websites set forth on pages 8, 13 and 33, are indicative of the level of skill of those skilled in the art to which this invention pertains. All these publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated herein by reference.

10043487.011102

Table I : Bait sequences

1: name	2: Bait name	3: Nucleic acid sequence	4: Nucleic Position	5: Amino acid ID	6: Amino-acid Sequence
Shigella ospB	1	ATGAA TTTAGATGGTTAGACCAC TGTAGAATCATGTAATGAAAGATGAAAGCATATCAGAT ATTGCAATTGCAATATATAAAGAGTTAAATAATGATCTACTACCCAAAAGCAGCATTG GTTTTTTAGGAGAAAGTTTGGTATAGCAATGATGTTCTCTATATATGGGACACAATA CCAAGAGATTATAGACAAGATGATATGATGTTTAAAAATGAAAAGTAGTAAAAATGATT TCTAAAAATGGCTGAATCGCTACACAGAGTGAACCAATAGTAATAAATAAGATGATGAC GCATTGAATCTGCTGCTTATTTCTGTAAAAAAGCGCAATAAAAACATGACCATGATGAT TTAAAGAGTATATAAGTTTATATTTCTGGACGGTAGTCTGGTCTCATCAATATGAGCCGT GGTTCGAAGTATTGATGACAACATCAATTCGAAGATGAAGACGTGTGTATCTTAAATGTG AAGATATCCGTTTTACTTCATCGCTCCGCTGATAAAGTGCGCTCTCTAAAAATTAACAAATG CCCTGCTGAAGATCTTCTGTGATCGCTTACTCTGCTTTTTTTAAGGAAAAAGAACTTTTGCT AGACAGATAAAAAAGCTGAAACGATGAGTCAATGATGATGGTCTTAAATATCCAGCTCAA ATCGATGATGGAGTTCACTAGTGAAGAGCTTTCCCTCACTCACATATATGTTCAAGTCAA TTCTGCTGATCGGAGCATACAGATAAAGAGGCTCTCAGAAAAAGCACTTTTATTTATTAAGA AAGTGGATGATGATAAAATTTTAACTATAG	[1-888]	8	MNLDGVPRPVCRVNNKKNESIS DIAFAHKKRVNNSCTHPKAAAL VFLGKGGSCNDVLSIMGQQ IPRVFKMVL DYVFMKQSK NDFLKMAESWLVPQSEPIVNN DDTDFKAAAYFVYKKAHKTV NDTDLNKKVYVLGHGSPGS HOLGLGSELIDVTLISRMKDC GLWYKDRIPT SCGSAKDVAPK NFNNAPELSLCILNSLPFKFE KESLLQKHLHENDSELSDLG KISGYHGVHYHGOELFPYSH YRSTSPADPEHTVFRSSQKK THINKEDLYKIFNL
Shigella ospD1	2	ATGTCAATAAATACCTTGGATTACATCCAGCAACAACAACAAATATGCACCTAAATATAGGCAGC AATACTGCTAATGAAATTAAGTAATGAAATTAATATCAATTACGTGACAAATATACCGCTATATCC CACGCCATCAATGAAGAAATATCAGGGGGGATATAGGTGTCTTCTTCAGAAAATTTGGCCA AAATACAGAACATATCCATCCGACAGAAATATAGGAGTATAACCGCATATTTGTTTAT TGATTTGGCATGAAATCCGATGCAAGCGGTAAATACAGTAAGTCGTTGGCGACGCGAAT ACCCAGAGGAAAACTAGAACTTCGCGTCCGATTCAGGCTTATGGAGATTTATTAACAACTTTGAT TACGCTTTCAGAAAGGTTCTTCGCTCGGATTCAGGCTTATGGAGATTTATTAACAACTTTGAT TATGACAAAGAAACGATTAACTATTGGATGTAGAGATATAGGGGTTACCGAGGATTTT CTGGCCGAGGGGAAGGGAATATCGAGCTATGATGGCATATAAATATGCCATCATAGTG GGATAAACCTTACAGAAATAGCAGACAGCTTACAAATATGAACAAGACATGTTTATATTTT CTGCAAAATACAGAGTTGTTTAAAGTGTGCTAAATAGCTGCAAGAAATTTGCACTTAG	[1-711]	9	MSNNYGLHPANNKNNHMLJGS TANENKGMKNINVTNTAIS HAINEEKSGGYSGVSRFKLA KIONISPTKNKNYWRHNLFS LWHPNDAARHYSESLAAEI PKKEELVLAARNNAGESALI ALQEGHSAIAQYGDGKTFDL SPKETIKLVDYRNEGILPGFL AAGKGNEAMAYINICHHSGL KLTEADRLNNNEODMFIISD KIQLFVVCIAAKNCT*
Shigella ospC1	3	ATGAATATATCAAGACCTGAAGTCAGCAATACCAATGCAATATAGATTCTATGGTAACAGA TTACATACATTTGTTTCCAAAGTGACATCGTGGCAAGCGGTGCACAAACAACTATGCCAGATGA AAAAATTTAAAAAGTAGTGAATATATTAAGATTTCTTTAGGAAACTATAGCGACAGAG TTATAGTAGAATGTTCTCTCAAGGCTCTCAACTTTAAATCTTTTAAATATAGCAATGATGACCAATCA GACGCTAAAGCCTCATTTAAGGCTATTGACGACCTTGACAGATTATCGGAGATATATATCTGA AATAGGAAAAAATTCATCCTCTTCTGACAGGAGCAATTTGCTTTCGCTAATATTAATTC TGATTTAATCTTCAGACATCAAGTAATTCATGTTTGTCTGTGATAAAATTTTAAACATTAAGTCATTC	[1-1434]	10	MNISELTNSANTQCNDISMDN RLHLTLPKVTYSVRNAQCTWMP DEKNLDKSANIHKDFRKTIAA QSYVRMFSGNSFKNSLIAND APSDAKASFKAIEHDLRLSKHY ISEIRKHLHPLSAEELNLLSUN SOLIFRHOSNDSLSDKLNKRSF

		AGCATTTAGTGAGCAGTGCACACAAGTAGTATAACGGGTATCGGTGCCAAAAAAGCGATTCAG GGATTAGCGCAAAAGGAGCGCTTAAGAAAGAACCTGCCACTGCTCAATCTCTTGAAAAAG GCTTGAGGTTCTAATTAGGGTTAATTAAGAAAGATAGATAACAATATCACTGCCACCAAGCTAA CTATAGCAAAATTTTAGGTAATAATAACTGGCCAGATTAATATCCTGCTGAAGTGAACA TAAAGCTCTTAGTTTCCGGATATTTCTTGAGGATAAATAGACACCCAGAGAAAGCTTA CGAGCTAATACCTCTTGCGCAGCAAAACAAACATTTAGCCGTGCAACAATGGAAGACTCA GCGCTTGCTGATATATTCACATCGAGGCGCTTATGCTGCTGTGGAAGAGAGAAG AACTAATCAGTCAGGCGAGCATTAACAGCAGGAGCAATGCCAAGTCTTAAGAAGAGCATC CCAAAGCACAATAAATTAACAAAAATTAATGAATATTAATTCAGACGATCAACCAATCAAGAA TTGGCAGCGAGTGCAGTTGCTGGTAACTCGAGCTTAA	[1-1022]	13	MLPINNFSLPQNSFYNTISGT YADYFSAWKWQKALP*GEE RDEAVSRKLECLNNSDELRL DRNLSSLPDNLPAQITLLNS YNLTPLEPVTLLKLYSASN KLSLPVLPALLESLOVQHNE LENLPALPDSLLTNINSYNEIV SLPSLPQALKNLATRNRLTEL PAFSEGNPNVREYFFDNQI SHIPESILNLRNIECSHISDNPL SSHALQALORLTTSPDYHGP IYFMSDGOQNTLHRPLADAV TAWFPENKQSDVSQWHAFAE HEEHANTFSADRLSDTVSA RNTSGFREQVAAWLEKLSAS AELRQQQFVAADATCESCDR MKITSTIQITPEPFENNINSHAGI VTEPLHGLQGGQSATFIEDV NDSSALYKYDGLIGNYNEILE MAWQESLFNAFYGDEASVVI QYGGDVLYRMLRVPGTPLSDI DTADIPDNIESLYLQICKNEL SIHYDLNTGNMLYDKESLIF PIHFRNRYAEYAAATKKKEIID RFLQWTRNDTFYSLNHRKYL* YLLML*
Shigella ipaH9.8	6	ATGTTACCGATAAATAAATCAATTTCAATGCCCCAAATCTTTTATAACACTATTCGGGTACAT ATGCTGATTAATCTTTCAGCATGGGATTAATGGGAAACCAAGCGTCCCGGTGAAGAGGTGA TGAGGCTGTCTCGGACTGAAGAGTCTTATCAATAATTCGATGAATCTGACTGCGCGT TAAATCTGCTGCGTACCTGACACTTACCAGCTCAGATACAGCTGCTCAATGTATCATATATC AATAAGTACCTGACTGAGCTGCTGTACGCTTAAAAAATTAATTCGSCCAGCAATAATAT CAGAATTGCCGCTGCTACCTCGCGTGGAGTCACTTCAGGTACACCAATAGCTGCTTACC CTGCGAGCTTTACCGAATCTGTTATTGACTATGAATACAGCTATACAGCAATAGCTGCTTACC ATGCTCCCAAGGCTCTAAAATCTCAGAGCGCCGTAATTTCTCTACTGAGCTACCGAGT TTTCTGAGGAAATTAATCCGCTGTGAGAGATTTTGTAGAGAAATCAGATAAGCTATATCC CGAAAGCAATCTTAATCTGAGGAATGAATGTTCAATACATTAAGTATAACCCATATCATCC ATGCTCTGCAAGCCCTGGAAGATTAACCTCTTCGCGGACTACACGCGCCACGATTTACTT CTCCAATGAGTGAGCGACACAGATAACCTCATGCCCTGCGCTGATGCCGTGACAGCATG GTTCCGGAACAAACAACTGATGATACAGATGCGATGCTTTGAACATGAAGAGCATG CCACACCTTTTCGCGGTTCTTGACCGCTTTTCGATACCGTCTGCGAGCAATACCTCCGG ATTCGTAACAGGTGCGTGCATGCGTGGAAACCTGAGTCCCTCGCGAGGCTTCGACAGCA GTCTTCTGCTGTGCTGATGCCACTGAGAGCTGAGAGCGGTG	[1-612]	14	
Shigella ospG	7	ATGAAATACATCTACCATTAATCAACAGGCTTTTCCATTTGAGATAATAATTCATGCTGGCA TAGTAACGAGCCCATCTCGGTAAATTAATAGTAGTGAAGGCTCGACAGAGAACTCTTTGAAGA TGTAATGATTCGTCTGTATGAAATAGTAATAGTATGATCTTATGGCAACGAGTCAATAGATCT GGAATGGCTTGGCAAGAACTGAGCTTTTAATGCTTTTATGGCATGAAGCATCCGTTGTA TACATGTGGGGAAGATGTACCTCCGATGCGCTGCGCGTCCCTGGAGCTCCCTTAGTGACAT TGATACAGCTGATATCCCTGATTAATAGAGAGCCCTTTATACAGTGTATGTAAATGAATGA GTGAGTATATCAATTCAGATCTTAATACAGGATTAATGCTGTATGATAAAGAAAGTGAAGATT ATTCOAATAGATTTTCGCAATTTATGCTGAAATTAACGTGCAACGCAAAAGATAAGAGAT TATCGACCGACGATACAAATGGTACAAATGATTTTATTCGTTATTAAACAGAGAAATATTTATA GAGCTATTGTTGATGCTATAA			

Table II : Bait-prey interactions

1: Bait name	2: Bait	nucleic	3: Prey name
--------------	---------	---------	--------------

acid	SEQ ID No.	
Shigella osiB	1	prey44074 (JM5; prey44078) hLM5
Shigella osiB	1	prey67804 (LOC91861) hypothetical proteinXP_041083
Shigella osiB	1	prey67806
Shigella osiB	1	prey67810 (FBXO3 FBX3 DKFZp564B092 FBA) hFBXO3
Shigella osiB	1	prey6237 (NONO NR654 NMT55 P54NRB) hNONO
Shigella osiB	1	prey67661 (CAPN2 CANP2 CANPML) hCAPN2
Shigella osiB	1	prey34730 (LMO4; prey34731) hLMO4
Shigella osiB	1	prey33141 (ZIN; prey33142) hZIN
Shigella osiB	1	prey67575 (LOC136773) hsimilar to 3-HYDROXYISOBUTYRATE DEHYDROGENASE, MITOCHONDRIAL PRECURSOR (HIBADH) (H.sapiens)
Shigella osiB	1	prey67608 (MGC4126) hMGC4126
Shigella osiB	1	prey67637 (LOC90706) hypothetical proteinXP_033663
Shigella osiB	1	prey12713 (LMO2 RBTNL1 RHOM2 TTG2 HBTN2; prey12714) hLMO2 hTTG-2a/RBTN-2a
Shigella osiB	1	prey67836 (MYO9a) hMYO9a
Shigella osiB	1	prey700 (RANBP9 RANBPM RANBP9-PENDING; prey701) hRANBP9 hRANBPM
Shigella osiB	1	prey67844
Shigella osiB	1	prey67853
Shigella osiB	1	prey68272 (FLJ20254) hFLJ20254
Shigella osiD1	2	prey700 (RANBP9 RANBPM RANBP9-PENDING; prey701) hRANBP9 hRANBPM
Shigella osiD1	2	prey2492 (FLJ11026; prey2493) hFLJ11026
Shigella osiD1	2	prey67651 putative homolog of prey064241 - Mouse
Shigella osiD1	2	prey67653 putative homolog of prey067652 -
Shigella osiD1	2	prey67667 (PACSIN2) hPACSIN2
Shigella osiD1	2	prey67667 hUnknown (protein fromMGC:16824)
Shigella osiD1	2	prey67501 (LOC51667) hLOC51667
Shigella osiD1	2	prey67678 (LOC90410) hypothetical proteinXP_031534
Shigella osiD1	2	prey67578 (LOC121052) hypothetical proteinXP_035313
Shigella osiD1	2	prey67580 (DKFZp5861021) hDKFZp5861021
Shigella osiD1	2	prey3160 (KIF5B UKHC KNS KNS1 U-KHC KINH; prey3161) hKIF5B hKinesin heavy chain
Shigella osiD1	2	prey50427 (KIAA0419; prey50428) hKIAA0419
Shigella osiD1	2	prey63765 (LIM; prey63767) hLIM
Shigella osiD1	2	prey67623 (LDB2 CLIM1) hLDB2
Shigella osiD1	2	prey7315 (LDB1 CLIM2 NLI; prey7316) hLDB1 hCLIM2
Shigella osiD1	2	prey67601 (ATIP1 KIAA1288 DKFZp586D1519 FLJ14295) hATIP1
Shigella osiD1	2	prey63735 (TLN1 TLN KIAA1027) hTLN1
Shigella osiD1	2	prey67630

Shigella ospD1	2	prey12665 (CREBL1 CREB-RP G13; prey12666) hCREBL1 hG13
Shigella ospD1	2	prey67631 (FLJ21742) hFLJ21742
Shigella ospD1	2	prey20143 (SYNCOILIN; prey20144) hSYNCOILIN
Shigella ospD1	2	prey1418 (hNR1H2 UNR NER NER1 RIP15 LXB-B; prey1419) hNR1H2 hNer-1
Shigella ospD1	2	prey67642 (ALDH3B2 ALDH3B2-PENDING ALDH8) hALDH3B2
Shigella ospD1	2	prey67648 (PON2) hPON2
Shigella ospC1	3	prey67266
Shigella ospC1	3	prey67267
Shigella ospC1	3	prey50590 (TID1; prey48229) hTID1
Shigella ospC1	3	prey9822
Shigella ospC1	3	prey67268
Shigella ospC1	3	prey67270
Shigella ospC1	3	prey67271 (STAT5B STAT5) hSTAT5B
Shigella ospC1	3	prey7007 (RANBP9 RANBP9 RANBP9-PENDING; prey701) hRANBP9 hRanBPM
Shigella ospC1	3	prey3486 (PM5; prey3487) hPM5 hpm5
Shigella ospC1	3	prey14801 (KIAA0321) hKIAA0321
Shigella ospC1	3	prey67279
Shigella ospC1	3	prey67280
Shigella ospC1	3	prey49194 (KIAA0211; prey49195) hKIAA0211
Shigella ospC1	3	prey67287
Shigella ospC1	3	prey19931 (HEF1 CAS-L) hHEF1
Shigella ospC1	3	prey67290
Shigella ospC1	3	prey67291
Shigella ospC1	3	prey67294
Shigella ospC1	3	prey67296
Shigella ospC1	3	prey67299
Shigella ospC1	3	prey4637 (TAF2A BA2R CCG1 CCGS NSQL2 TAF1I250; prey4638; prey4639) hTAF2A
Shigella ospC1	3	prey67316
Shigella ospC1	3	prey67318
Shigella ospC1	3	prey7144 (hMMT P87/89 hMP; prey7145) hMMT hmp87/89
Shigella ospC1	3	prey67328 (TSC22) hTSC22
Shigella ospC1	3	prey37430 (WASL N-WASP; prey37432) hWASL hN-WASP
Shigella ospC1	3	prey67351
Shigella ospC1	3	prey67353
Shigella ospC1	3	prey26185 (HSPC272)
Shigella ospC1	3	prey4411 (ZNF147 EFP TRIM25 Z147) hZNF147
Shigella ospC1	3	prey2686 (VRP AD3; prey2687) hVRP

Shigella ospC1	3	prey67368 (LOC92609) hlypothetical proteinXP_053074
Shigella ospC1	3	prey67371
Shigella ospC1	3	prey4005 (KIAA0141; prey4006; prey6649; prey44107) hKIAA0141
Shigella ospC1	3	prey67380
Shigella ospC1	3	prey67396 (FHO5; prey3297) hFHO5
Shigella ospC1	3	prey2103 (prey2101; prey2102; prey2107; prey2109) hSimilar to COP9 (constitutive photomorphogenic) subunit 5 (Arabidopsis) hSimilar to COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5 (H.sapiens) hCOP55 hSimilar to COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5 (H.sapiens) hCOP55 hSimilar to COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5 (H.sapiens)
Shigella ospC1	3	prey67403
Shigella ospC1	3	prey67405
Shigella ospC1	3	prey14400 (prey14399; prey14401) hprotein phosphatase 5, catalytic subunit hPPP5C hPPP5C
Shigella ospC1	3	prey50029
Shigella ipaD	4	prey67563 (PRSC1) hPRSC1
Shigella ipaD	4	prey2109 (COP55 JABT SGN5 MOV-34; prey2110) hCOP55 r38 kDa Mov34homolog
Shigella ipaD	4	prey25185 hHSPC272
Shigella ipaD	4	prey63990 (TNFRSF1A CD120a TNF-R TNF-R1 TNF-R55 TNFAR TNFR60 TNFR1 p55-R p55) hTNFRSF1A
Shigella ipaD	4	prey8120 (VIM; prey9122) hVIM hvimentin
Shigella ipaD	4	prey67571
Shigella ipaD	4	prey67572
Shigella ipaD	4	prey65696 (KARS KIAA0070; prey65697) hKARS hLysyl tRNA synthetase
Shigella ipaD	4	prey6889 (PLCB3) hPLCB3
Shigella ipaD	4	prey700 (RANBP9 RANBPM RANBP9-PENDING; prey701) hRANBP9 hRanBPM
Shigella ipaD	4	prey2694 (INDO IDO; prey2696; prey2693) hINDO hINDO
Shigella ipaD	4	prey63735 (TLN1 TLN KIAA1027) hTLN1
Shigella ipaD	4	prey67574
Shigella ipaC	5	prey67509 (POLR2A RPO2 POLR2 POLR2A hRPB220 hSRFB1 RPO2 RplL5 RPB1 RPB1) hPOLR2A
Shigella ipaC	5	prey67514
Shigella ipaC	5	prey2926 (FLJ23153; prey2927) hFLJ23153
Shigella ipaC	5	prey4458 (RRBP1 ES130 ES/130; prey4459) hRRBP1 hES/130
Shigella ipaC	5	prey4458 (RRBP1 ES130 ES/130; prey4459) hRRBP1 hES/130
Shigella ipaC	5	prey67522
Shigella ipaC	5	prey627 (CLTC CLTC2 KIAA0034; prey628) hCLTC hKIAA0034
Shigella ipaC	5	prey63735 (TLN1 TLN KIAA1027) hTLN1
Shigella ipaC	5	prey63735 (TLN1 TLN KIAA1027) hTLN1
Shigella ipaC	5	prey67546 (LOC128116) hSimilar to phosphodiesterase 4D interacting protein (myomegalin) (H.sapiens)
Shigella ipaC	5	prey4671 (KIAA0454) hKIAA0454

Shigella	ipaC	5	prey67550 (LOC92689) hihypothetical proteinXP_046663
Shigella	ipaC	5	prey68889 (PLC83) hPLOCB3
Shigella	ipaC	5	prey11375 (HSPBP1; prey1376) hHSPBP1 hHsp70 binding proteinHspBP1
Shigella	ipaC	5	prey67473 (GALE) hGALE
Shigella	ipaC	5	prey6929 (KIAA0728 FLJ21489) hKIAA0728
Shigella	ipaC	5	prey3488 (ACF7 ABP620 KIAA1251 KIAA0485) hACF7
Shigella	ipaC	5	prey3514 (SNX1; prey3515) hSNX1
Shigella	ipaC	5	prey5814 (USP9X DFFRX) hUSP9X
Shigella	ipaC	5	prey5814 (USP9X DFFRX) hUSP9X
Shigella	ipaC	5	prey67479
Shigella	ipaC	5	prey7700 (RANBP9 RANBPM RANBP9-PENDING; prey701) hRANBP9 hRANBPM
Shigella	ipaC	5	prey67481 (GDBP1, GDBP1) hGDBP1
Shigella	ipaC	5	prey67488 (LOC126257) hsimilar to putative (H sapiens)
Shigella	ipaC	5	prey51967 (UBQLN1 DSK2 PLIC-1 DA41 XDRP1) hUBQLN1
Shigella	ipaC	5	prey67481 (KIAA1007 AD-005) hKIAA1007
Shigella	ipaC	5	prey323 (CSH1 CSMT CSA PL; prey324; prey325) hCSH1
Shigella	ipaC	5	prey67495
Shigella	ipaC	5	prey67506 (LOC126083) hdyamin2
Shigella	ipaC	5	prey4578 (PSAP SAP1 GLBA; prey6684) hPSAP hGLBA
Shigella	ipaC	5	prey1135 (PSMD1 P112 S1; prey1136) hPSMD1 hproteasome subunitp112
Shigella	ipaC	5	prey67465 (COL4A2 FLJ22259) hCOL4A2
Shigella	ipaC	5	prey28880 (KPNA4; prey28881) hKPNA4 hQIP1
Shigella	ipaC	5	prey3599 (TRIP12 KIAA0045; prey3600) hTRIP12 hKIAA0045
Shigella	ipaC	5	prey67717
Shigella	ipaH9.8	6	prey700 (RANBP9 RANBPM RANBP9-PENDING; prey701) hRANBP9 hRANBPM
Shigella	ipaH9.8	6	prey67718 (KIAA1715) hKIAA1715
Shigella	ipaH9.8	6	prey2530 harrestin, beta1
Shigella	ipaH9.8	6	prey67731 (LOC126896) hsimilar to Gene 33Mig-5 (H sapiens)
Shigella	ipaH9.8	6	prey7165 (CSH2 CSB) hCSH2
Shigella	ipaH9.8	6	prey1687 (DCTN1) hDCTN1
Shigella	ipaH9.8	6	prey67734 (FLJ10618) hFLJ10618
Shigella	ipaH9.8	6	prey2694 (INDO IDO; prey2695) hINDO hINDO
Shigella	ipaH9.8	6	prey67740
Shigella	ipaH9.8	6	prey67703 (PPP2R4 PTPA) hPPP2R4
Shigella	ipaH9.8	6	prey67741
Shigella	ipaH9.8	6	prey67742 (FLJ20313) hFLJ20313
Shigella	ipaH9.8	6	prey67339 (MMP19 RAS1-1 MMP18) hMMP19

Shigella	ipaH9.8	6	prey67337 (MMP19 RASI-1 MMP18) hMMP19
Shigella	ipaH9.8	6	prey67746 (FBXO25 FBX25) hFBXO25
Shigella	ipaH9.8	6	prey64430 (PSG4 PSG4) hPSG4
Shigella	ipaH9.8	6	prey67749
Shigella	ipaH9.8	6	prey67751
Shigella	ipaH9.8	6	prey67339 (MLL2 ALR; prey6742) hMLL2 hALR
Shigella	ipaH9.8	6	prey18232 (CCT3 TRIC5 COTG; prey18233) hCCT3 hCOTG
Shigella	ipaH9.8	6	prey66739 (EIF2B1 EIF2B EIF-2B) hEIF2B1
Shigella	ipaH9.8	6	prey67769 (PP2135 FLJ00041) hPP2135
Shigella	ipaH9.8	6	prey13613 (KIAA0970) hKIAA0970
Shigella	ipaH9.8	6	prey43337 (LMNA LMN1 EMD2 FPL LFP LDP1 FPLD CMD1A; prey14196) hLMNA
Shigella	ipaH9.8	6	prey67774 (LOC119758) htsmlr to REGULATOR OF PRESYNAPTIC ACTIVITY AEX-3 (H.sapiens)
Shigella	ipaH9.8	6	prey67776
Shigella	ipaH9.8	6	prey4758 (DKFZP761L0424 KIAA1217) hDKFZP761L0424
Shigella	ipaH9.8	6	prey67781 putative homolog of prey046760 - Mouse Fmrl
Shigella	ipaH9.8	6	prey2109 (COPS5 JAB1 SGN5 MOV-34; prey2110) hCOPS5 h38 kDa Mov34homolog
Shigella	ipaH9.8	6	prey4060 (KIAA0155; prey4061; prey4062) hKIAA0155
Shigella	ipaH9.8	6	prey49284 (SLC7A8 LAT2) hSLC7A8
Shigella	ipaH9.8	6	prey67686
Shigella	ipaH9.8	6	prey66872 (MRPS9) hMRPS9
Shigella	ipaH9.8	6	prey67690 (RRP4) hRRP4
Shigella	ipaH9.8	6	prey67695 (ATP6N1B RDRTA2 RTA1C VPP2 RTADR) hATP6N1B
Shigella	ipaH9.8	6	prey67336 (MMP19 RASI-1 MMP18) hMMP19
Shigella	ipaH9.8	6	prey62399 (KIAA0335; prey6300) hKIAA0335
Shigella	ipaH9.8	6	prey6586 (FLNA ABPX A9P-280 FLN FLN1 NHBP; prey6587) hFLNA
Shigella	ipaH9.8	6	prey65789 (ALDH4 P5CDH; prey65791) hALDH4 hP5CDH
Shigella	ipaH9.8	6	prey67711
Shigella	ipaH9.8	6	prey2118 (RNF2 dinG Bao-1; prey2119) hRNF2 hring finger proteinBAP-1
Shigella	ipaH9.8	6	prey65596 (DDX15 HRH2 DRP1; prey3597) hDDX15 hATP-dependent RNA helicase#46
Shigella	ipaH9.8	6	prey666 (RANBP16 KIAA0745; prey667; prey668; prey669; prey670) hRANBP16 hRAN binding protein16 hRANBP16
Shigella	osfG	7	prey3917 (BTBD2 FLJ20386; prey3920; prey3918; prey3922; prey3919) hBTBD2
Shigella	osfG	7	prey63632 (ZNF189; prey63789) hZNF189
Shigella	osfG	7	prey2109 (COPS5 JAB1 SGN5 MOV-34; prey2110) hCOPS5 h38 kDa Mov34homolog
Shigella	osfG	7	prey64201 (UBE2D3 UBCH5C; prey54202) hUBE2D3 hUBCH5C
Shigella	osfG	7	prey1822 (DLST DLTS; prey1923) hDLST h2K
Shigella	osfG	7	prey67418 (UBE2L3 UBCH7) hUBE2L3

Shigella	osrG	7	prey67314 (UBE2L6 UBC48 RIG-B) hUBE2L6
Shigella	osrG	7	prey67435 hUnknown (protein forMGC3432)
Shigella	ospG	7	prey67443 FLJ11807 hFLJ11807
Shigella	osrG	7	prey67317 KIAA1485 hKIAA1485
Shigella	osrG	7	prey67393 UBE2D2 UBC48B UBC4 hUBE2D2
Shigella	osrG	7	prey700 (RANBP9 RANBP9 RANBP9-PENDING; prey701) hRANBP9 hRANBP9
Shigella	osrG	7	prey67411 (UBE2E3 UBC48) hUBE2E3
Shigella	osrG	7	prey67423
Shigella	osrG	7	prey67298
Shigella	osrG	7	prey67464
Shigella	osrG	7	prey67320
Shigella	osrG	7	prey67321
Shigella	osrG	7	prey35777 (PSG2 PSBG2 PSGGB; prey35778) hPSG2 hPSG1
Shigella	osrG	7	prey67327 (AKAP13 HT31 BRX) hAKAP13
Shigella	osrG	7	prey412 (RPN2; prey413) hRPN2 hsignalpeptide
Shigella	osrG	7	prey50598 (PEX10 NALD; prey50599) hPEX10 hperoxisome assembly proteinPEX10
Shigella	osrG	7	prey67364
Shigella	osrG	7	prey67367
Shigella	osrG	7	prey67369
Shigella	osrG	7	prey67372 (CD63 MLA1 ME491) hCD63
Shigella	osrG	7	prey67379
Shigella	osrG	7	prey67381 (LOC131541) hhypothetical proteinXP_059524
Shigella	osrG	7	

ospB	1	gb AB008515 AB008515 Homo sapiens mRNA for RanBPM, complete cds.
ospB	1	gb AC005091 AC005091 Homo sapiens BAC clone GTA-318C11 from 7p14-p15, complete sequence.
ospB	1	gb AF117888 AF117888 Homo sapiens myosin-Xa mRNA, complete cds.
ospB	1	gb AF141347 AF141347 Homo sapiens myo-a-ub2 alpha-tubulin mRNA, complete cds.
ospB	1	gb AF176702 AF176702 Homo sapiens F box protein FBX3 mRNA, partial cds.
ospB	1	gb AF177198 AF177198 Homo sapiens talin mRNA, complete cds.
ospB	1	gb AF212940 AF212940 Homo sapiens zinedin (ZIN) mRNA, complete cds.
ospB	1	gb AF257211 AF257211 Homo sapiens LMO2b splice variant (LMO2) mRNA, complete cds.
ospB	1	gb AJ005897 HSA005897 Homo sapiens mRNA for JM5 protein, complete CDS (clone IMAGE 53337, LLNLC110F1857Q7 (RZPD Berlin) and LLNLC110G0913Q7 (RZPD Berlin)).
ospB	1	gb AK024239 AK024239 Homo sapiens cDNA FLJ14177 fis, clone NT2RP2003161.
ospB	1	gb AL049176 HVS141H5 Human DNA sequence from clone 141H5 on chromosome Xq22.1-23. Contains parts of a novel Chordin LIKE protein with von Willebrand factor type C domains. Contains ESTs, STSs and GSSs, complete sequence.
ospB	1	gb AL122043 HSM801240 Homo sapiens mRNA, cDNA DKFZp566G1424 (from clone DKFZp566G1424).
ospB	1	gb AL442166 HSMX1A Homo sapiens chromosome 21 from 5 PACs and 5 Cosmids map 21q22.2.D21S349-MX1; segment 1/2, complete sequence.
ospB	1	gb AP002026 AP002026 Homo sapiens genomic DNA, chromosome 4q22-q24, clone:429K21, complete sequence.
ospB	1	gb D127260 HUMORFEA Human mRNA for KIAA0034 gene, complete cds.
ospB	1	gb L14599 HUMPSFHOMO Human mRNA, complete cds.
ospB	1	gb L28809 HUMAAE Homo sapiens dbpB-like protein mRNA, complete cds.
ospB	1	gb IM23254 HUMCANP Human Ca2-activated neutral protease large subunit (CANP) mRNA, complete cds.
ospB	1	gb U24576 U24576 Homo sapiens breast tumor autoantigen (LMO4) mRNA, complete cds.
ospB	1	gb X61118 HSTT02 Human TTG-2 mRNA for a cysteine rich protein with LIM motif.
ospD1	2	gb AB007879 AB007879 Homo sapiens KIAA0419 mRNA, complete cds.
ospD1	2	gb AB008515 AB008515 Homo sapiens mRNA for RanBPM, complete cds.
ospD1	2	gb AB016485 AB016485 Homo sapiens mRNA for LIM homeobox protein cofactor (CLIM-2), complete cds.
ospD1	2	gb AB028956 AB028956 Homo sapiens mRNA for KIAA1033 protein, partial cds.
ospD1	2	gb AB033114 AB033114 Homo sapiens mRNA for KIAA1288 protein, partial cds.
ospD1	2	gb AC003108 HUAAC003108 Human Chromosome 16 BAC clone CIT987SK-327024, complete sequence.
ospD1	2	gb AC008764 AC008764 Homo sapiens chromosome 19 clone CTD-322D19, complete sequence.
ospD1	2	gb AF001601 AF001601 Homo sapiens paracoxonase (PON2) mRNA, complete cds.
ospD1	2	gb AF006466 AF006466 Mus musculus lymphocyte specific formin related protein (Frl1) mRNA, complete cds.
ospD1	2	gb AF061258 AF061258 Homo sapiens LIM protein mRNA, complete cds.

ospD1	2	gb AF068651 AF068651 Homo sapiens LIM-domain binding factor CLIM1 (CLIM1) mRNA, complete cds.
ospD1	2	gb AF128536 AF128536 Homo sapiens cytoplasmic phosphoprotein PACSIN2 mRNA, complete cds.
ospD1	2	gb AF155099 AF155099 Homo sapiens NY-REN-18 antigen mRNA, complete cds.
ospD1	2	gb AF177198 AF177198 Homo sapiens talin mRNA, complete cds.
ospD1	2	gb AF265342 AF265342 Homo sapiens chromosome 8 map BAC 2053N22, complete sequence.
ospD1	2	gb AF001888 AF001888 Homo sapiens cDNA FLJ11026 fis, clone PLACE1004104
ospD1	2	gb AL121808 CN501.DS.J Human chromosome 14 DNA sequence *** IN PROGRESS *** BAC C-2313013 of library CalTech-D from chromosome 14 of Homo sapiens (Human), complete sequence.
ospD1	2	gb AQ628981 AQ628981 RPCI-11-469H15.TJ RPCI-11 Homo sapiens genomic clone RPCI-11-469H15, DNA sequence.
ospD1	2	gb B88348 B88348 CIT-HSP-2063N18.TFB CIT-HSP Homo sapiens genomic clone 2063N18, DNA sequence.
ospD1	2	gb M57288 HUMGPC25K Human GTP-binding protein G25K mRNA, complete cds.
ospD1	2	gb M63960 HUMPRPHOS1 Human protein phosphatase-1 catalytic subunit mRNA, complete cds.
ospD1	2	gb U07132 HSU07132 Human steroid hormone receptor Ner-1 mRNA, complete cds.
ospD1	2	gb U31903 HSU31903 Human GREB-RP (creb-rp) mRNA, complete cds.
ospD1	2	gb U37519 HSU37519 Human aldehyde dehydrogenase (ALDH8) mRNA, complete cds.
ospD1	2	gb X65873 HSKHCMR H.sapiens mRNA for kinesin (heavy chain).
ospD1	2	gb X65873 HSKHCMR H.sapiens mRNA for kinesin (heavy chain).
ospD1	2	gb X65873 HSKHCMR H.sapiens mRNA for kinesin (heavy chain).
ipaD	4	gb AB008515 AB008515 Homo sapiens mRNA for kinesin (heavy chain), complete cds.
ipaD	4	gb AF161390 AF161390 Homo sapiens HSPC272 mRNA, partial cds.
ipaD	4	gb AF177198 AF177198 Homo sapiens talin mRNA, complete cds.
ipaD	4	gb D32053 D32053 Homo sapiens mRNA for Lysyl tRNA Synthetase, complete cds.
ipaD	4	gb D55696 D55696 Homo sapiens mRNA for cysteine protease, complete cds.
ipaD	4	gb J4144 HUMVIM Human vimentin gene, complete cds.
ipaD	4	gb M34455 HUMIGLIDO Human interferon-gamma-inducible indoleamine 2,3-dioxygenase (IDO) mRNA, complete cds.
ipaD	4	gb M63121 HUMTNFR3 Human tumor necrosis factor receptor (TNF receptor) mRNA, complete cds.
ipaD	4	gb U070734 HSU070734 Homo sapiens 38 kDa Mov34 homolog mRNA, complete cds.
ipaD	4	gb Z26649 HSPPLC83 H.sapiens mRNA for phospholipase C-b3.
ipaD	4	gb Z26649 HSPPLC83 H.sapiens mRNA for phospholipase C-b3.
ipaC	5	gb AB002366 AB002366 Human mRNA for KIAA0368 gene, partial cds.
ipaC	5	gb AB002533 AB002533 Homo sapiens mRNA for Qip1, complete cds.
ipaC	5	gb AB007923 AB007923 Homo sapiens mRNA for KIAA0454 protein, partial cds.
ipaC	5	gb AB008515 AB008515 Homo sapiens mRNA for RianBPM, complete cds.
ipaC	5	gb AB018271 AB018271 Homo sapiens mRNA for KIAA0728 protein, partial cds.

ipaC	5	gb X05610 HSC4A2 Human mRNA for type IV collagen alpha (2) chain.
ipaC	5	gb X63564 HSRPII.S H.sapiens mRNA for RNA polymerase II largest subunit.
ipaC	5	gb X98296 HSUBIQHYD H.sapiens mRNA for ubiquitin hydrolase.
ipaC	5	gb Z26649 HSPPLCB3 H.sapiens mRNA for ATP-dependent RNA helicase C-b3.
ipaH9.8	6	dbj AB001636.1 AB001636 Homo sapiens mRNA for phospholipase C-b3.
ipaH9.8	6	dbj AB002333.1 AB002333 Human mRNA for KIAA0395 gene, complete cds
ipaH9.8	6	dbj AB000815.1 AB000815 Homo sapiens mRNA for RanBPM, complete cds
ipaH9.8	6	dbj AB023187.1 AB023187 Homo sapiens mRNA for KIAA0970 protein, complete cds
ipaH9.8	6	dbj AB033043.1 AB033043 Homo sapiens mRNA for KIAA1217 protein, partial cds
ipaH9.8	6	dbj AK001451.1 AK001451 Homo sapiens cDNA FLJ10589 fls, clone NT2HP2004-389, weakly similar to PROBABLE MITOCHONDRIAL 40S RIBOSOMAL PROTEIN S9 PRECURSOR
ipaH9.8	6	dbj AK024449.1 AK024449 Homo sapiens mRNA for FLJ00041 protein, partial cds
ipaH9.8	6	dbj D63875.1 D63875 Human mRNA for KIAA0155 gene, complete cds
ipaH9.8	6	emb AL034405.16 HS537K23 Human DNA sequence from clone RP4-537K23 on chromosome Xq25.26.1, complete sequence [Homo sapiens]
ipaH9.8	6	emb AL034417.14 HS215D11 Human DNA sequence from clone 215D11 on chromosome 1p36.12-36.33 Contains a gene for a RNA-binding protein regulatory subunit, a gene similar to rat gene 33, a pseudogene similar to PLA-X, ESTs, STSs, GSSs and CpG islands, complete sequence [Homo sapie]
ipaH9.8	6	emb AL050313.6 HSBK754D9 Human DNA sequence from clone CTA-754D9 on chromosome 22 Contains GSSs, complete sequence [Homo sapiens]
ipaH9.8	6	emb AL117448.1 HSM800958 Homo sapiens mRNA; cDNA DKFZp586B1417 (from clone DKFZp586B1417); partial cds
ipaH9.8	6	emb AL137058.10 AL137068 Human DNA sequence from clone RP11-165P4 on chromosome 9q34.11-34.13, complete sequence [Homo sapiens]
ipaH9.8	6	emb X53416.1 HSABP280 Human mRNA for actin-binding protein (filamin) (ABP-280)
ipaH9.8	6	emb X73478.1 HSPTPAA H.sapiens hPTPA mRNA
ipaH9.8	6	emb X74801.1 HSJUMAPC H.sapiens Ctg mRNA for chaperonin
ipaH9.8	6	emb X95648.1 HSEIF2BAS H.sapiens mRNA for eIF-2B alpha subunit
ipaH9.8	6	gb AC005392.1 AC005392 Homo sapiens chromosome 19, CIT-HSP BAC 490q23 (BC338531), complete sequence
ipaH9.8	6	gb AC005833.1 AC005833 Homo sapiens 12p13.3 BAC RPCH11-234B24 (Roswell Park Cancer Institute Human BAC Library) complete sequence
ipaH9.8	6	gb AC005881.3 AC005881 clib. 79_e_16, complete sequence [Homo sapiens]
ipaH9.8	6	gb AC020663.1 AC020663 Homo sapiens chromosome 16 clone RPCH11_127120, complete sequence
ipaH9.8	6	gb AF006466.1 AF006466 Mus musculus lymphocyte specific formin related protein (Frl) mRNA, complete cds
ipaH9.8	6	gb AF010404.1 AF010404 Homo sapiens ALR mRNA, complete cds

ipah9.8	6	gb AF064729.1 AF064729 Homo sapiens RAN binding protein 16 mRNA, complete cds
ipah9.8	6	gb AF084940.1 AF084940 Homo sapiens beta-arrestin 1B mRNA, complete cds
ipah9.8	6	gb AF135159.1 AF135159 Homo sapiens GMP reductase mRNA, complete cds
ipah9.8	6	gb AF139184.1 AF139184 Homo sapiens Sec31 protein mRNA, complete cds
ipah9.8	6	gb AF141327.1 AF141327 Homo sapiens ring finger protein BAP-1 mRNA, complete cds
ipah9.8	6	gb AF171689.1 AF171689 Homo sapiens glycoprotein-associated amino acid transporter LAT2 (LAT2) mRNA, complete cds
ipah9.8	6	gb AF174605.1 AF174605 Homo sapiens Sec31 protein mRNA, partial cds
ipah9.8	6	gb AF207661.1 AF207661 Homo sapiens S-box protein Fbx25 (FBX25) mRNA, partial cds
ipah9.8	6	gb AF245517.1 AF245517 Homo sapiens sodium bicarbonate cotransporter-like protein mRNA, complete cds, alternatively spliced
ipah9.8	6	gb AF249874.1 AF249874 Homo sapiens vacuolar proton pump 116 kDa accessory subunit gene, exon 3 and 5' untranslated region, partial sequence
ipah9.8	6	gb J00118.1 HUMPLB Human placental lactogen hormone (PL-4) mRNA, complete cds
ipah9.8	6	gb L14283.1 HUMPROKINC Human proteins kinase C zeia mRNA, complete cds
ipah9.8	6	gb L26286.1 HUMCOLXV1 Homo sapiens alpha-1 type XV collagen mRNA, complete cds
ipah9.8	6	gb M13451.1 HUMLAMC Human lamin C mRNA, complete cds
ipah9.8	6	gb M21616.1 HUMPDGFR Human platelet-derived growth factor (PDGF) receptor mRNA, complete cds
ipah9.8	6	gb M32053.1 HUMH19 Human H19 RNA gene, complete cds
ipah9.8	6	gb M34455.1 HUMIGILDO Human Interferon-gamma-inducible indoleamine 2,3-dioxygenase (IDO) mRNA, complete cds
ipah9.8	6	gb M94890.1 HUMPSBG11 Human pregnancy-specific beta-1 glycoprotein 11 (PSG11) mRNA, complete cds
ipah9.8	6	gb M98478.1 HUMTGH1A Human transglutaminase mRNA, complete cds
ipah9.8	6	gb U24267.1 HUSU24267 Human pyrroline-5-carboxylate dehydrogenase (P5CDH) mRNA, short form, complete cds
ipah9.8	6	gb U37791.1 HUSU37791 Homo sapiens clone rasi-1 matrix metalloproteinase RASI-1 mRNA, complete cds
ipah9.8	6	gb U38431.1 HUSU38431 Human clone rasi-8 matrix metalloproteinase RASI-1 mRNA, splice variant, complete cds
ipah9.8	6	gb U65928.1 HUSU65928 Human Jun activation domain binding protein mRNA, complete cds
ipah9.8	6	ref NM_014285.1 Homo sapiens homolog of Yeast RRP4 (ribosomal RNA processing 4), 3'-5'-exoribonuclease (RRP4), mRNA
ipah9.8	6	ref NM_017762.1 Homo sapiens hypothetical protein FLJ20313 (FLJ20313), mRNA
ipah9.8	6	ref NM_018155.1 Homo sapiens hypothetical protein FLJ10618 (FLJ10618), mRNA
ospG	7	gb AB008515 AB008515 Homo sapiens mRNA for RanBPM, complete cds.
ospG	7	gb AB013818 AB013818 Homo sapiens PEX10 mRNA for peroxisome biogenesis factor (peroxin) 10, complete cds.
ospG	7	gb AB033054 AB033054 Homo sapiens mRNA for KIAA1228 protein, partial cds.
ospG	7	gb AB033054 AB033054 Homo sapiens mRNA for KIAA1228 protein, partial cds.
ospG	7	gb AB040918 AB040918 Homo sapiens mRNA for KIAA1485 protein, partial cds.
ospG	7	gb AC005281 AC005281 Homo sapiens PAC clone RP4-722F20 from Tq31.1-q31.3, complete sequence.

ospG	7	gblAE003603 AE003603 Drosophila melanogaster genomic scaffold 142000013386043 section 4 of 8, complete sequence.
ospG	7	gblAF03095 AF03095 Homo sapiens testis enhanced gene transcript protein (TEGT) mRNA, complete cds.
ospG	7	gblAF035121 AF035121 Homo sapiens KDR/ikl-1 protein mRNA, complete cds.
ospG	7	gblAF061736 AF061736 Homo sapiens ubiquitin-conjugating enzyme RIG-B mRNA, complete cds.
ospG	7	gblAF085362 AF085362 Homo sapiens UbcM2 mRNA, complete cds.
ospG	7	gblAF104913 AF104913 Homo sapiens eukaryotic protein synthesis initiation factor mRNA, complete cds.
ospG	7	gblAF155238 AF155238 Homo sapiens BAC 180123 chromosome 8 map 8q24.3 beta-galactoside alpha-2,3-sialyltransferase (SIAT4A) gene, complete sequence.
ospG	7	gblAJ000519 HSUBICONJ Homo sapiens mRNA for ubiquitin-conjugating enzyme UbcH7.
ospG	7	gblAK000393 AK000393 Homo sapiens cDNA FLJ20386 fls, clone KAI4A184.
ospG	7	gblAK001311 AK001311 Homo sapiens cDNA FLJ10449 fls, clone NT2RP1000947, highly similar to Human E2 ubiquitin conjugating enzyme UbcH5B mRNA.
ospG	7	gblAL050321 HSJ171M23 Human DNA sequence from clone RP4-717M23 on chromosome 20, complete sequence.

Table III : SID®

1: Bait name	2: Bait nucleic acid SEQ ID No.	3: Prey name	4: SID nucl eic acid ID No.	5: SID nucleic acid sequence	6: SID amino-acid No.	7: SID amino-acid sequence
Shigella ospB	1	prey44074	15	CTTCAGCCACGACTCCTCCTCTCTGCGCTTCAGTGAT AAGGGTACTGTGTC CATATCTTTGCTCTCAAGATACCCGCTCAACCGCTCGCGCTCGGCTG GCGTGGGCAAGGTGGGCGCTATGATTGGCAGTACGTGACTCTCAGTGA GCTGGCGAGCTTCACTGTGCGCTGTGAGTCAGCTTGATCTGCGCTTGG GTGCAATATTCGAAGACGTCACCTCTGCTCATGCCATCTGCGTATGAG GACCTTCACAATATGCTTCACTCTGATGGAACCTGCAACGAGAGGCT TTGACGCTGACTTGACATGCTGATGATGATGACTTTAA	216	FSHSSFLCASSDKGTVHI FALKDTRLNRSALAVGK VPMIGQVDSQW SLASF TVPAESACIAFGRIKSTN VNSVIAICVDGTHFYKFT DGNMCNREAFDVYLDICDD DF*
Shigella ospB	1	prey67804	16	GACCAACGAGCTTCGAGTACATGGGACAACTTACCACATGGAGAGCT GTTCTGAGCTGAAGGCTCTTCAAGATCGGCAACCACTCAATGACCCAG TGACGCTGTTTCGGAGGAAACGTATGTTGGTCTCAAGACTTGCCCAAT TAACCTGTGCTCCAGCTCTGTTCCAGATCTGCTGCGGGTATGCAG AGGATGGAGAACTGTCATGGAGAACTTCTGATGGTATCTTCCGCGAA CCTGCCAACAGAGAACGAACTTCTACCCGCTCTCAGGCGCAAGATC CACCACCGACAGGCTGAGGTGTGTCGCGCTTCTCGGCGCAAGATC ACCGGGAGCTTATGATTCAGCAAGCATCAGGAACCTTGTGCAATGAAAG TGTCATCAATACCAACACAGCATGCAAGTGTGTGTTTCCAAATGAAAG ACCTATCTCATGCGAGCTGCGCACCACCAACCTCGGGCATTTGGCAATG TGGAGTGTGCTATGCTGTAATGTCAATGTCACCAAGCAAGTGAAGAAAT CCACTGCCCAATCGATACCCCTGCAAGTATCTCAAAAATAGACGGA TGCTGCAAGGTGTGTCAGGTAAAGGAAAGCAAGCTTCAGGCGCAAGCT TGATCAATGAAGCTACTTCTCGGGGAAAGCAAAATAGCACTGGAGCTGA TGATTCATGGAGGATGGGAGACACCAAGCAATAGCACTGGAGCTTCTC GAGCACTCAGTGAAGTCCACCTTTGGACTATTGGAAGGCTTCTC CAGCACTCCATATTGAGAATCTCAAGAGGATGTTTGAAGGCTTCTC ACTTAAGCTGGTACCAAGAACCCCTGAGCGAGTGGGAAGATCTTCCAGCA AGGAGAAGCTCAGATCAGCAGATGTTTCAAGTGTGATGCAAGACAGA GCTTCAGAGATTTAGTCAAGGTTTGTACCTGGAGAGATCTGAAAGGGCCAC TGTTAG	217	TSKCEYNGTITYQHGLFV AEGLFQNRPNQCTOCSC SEGNYCGLKTCPKLTCAF PVSPDSCVRCRGDGL SWEHSDGDIROPANREA RHSHYHRSHYDPPSRQAG GLSRFPGARSHRGLMDS QASGTIVQVINIKHKG QVCVSNKTYSHGESWHP NLRFAFIVECVLCTCNVTK QECKKHCVPCKAKELPK IDGCKKVCPCGAKELPV OSFDNKGVCFGGETMPVY ESVFMEDGETTKIALETE RPPQVEVHWVITRIGILQH FHIEKISRMFEELPHFKLV FRTLLSQWKIFTEGEAQISQ MCSRRVCRTELEDLVKVLV LERSEKHC*
Shigella ospB	1	prey67806	17	NTCNCCCTGNGCGNAGCAGCGCTGGTNNCTAGCNGGANCACNGAGTGT NGTGTANTGTGCTCTGCGCTTGCCATGATGACTTNTGGGAGCTGCANCCG TCGCGTTCCTTNTGNNCGTNGTGTGGTNGCNGCGCTCCNTANGTGTGNNACGA	218	XXLXXTSLVXLPXGTGCXV XVLCACHDDXWELXFSRX XXVVGXXPPXXVVRRLXFA

Shigella ospB	1	prev:67810	18	AGAGTGT TTTTGTGTAAGGACCTGCGNGTNTGCTGCTTCAATNGGNGAGNTT NNTTAGGGGNGNNTATTNCTAAATNTTGGACATCTTTAAGTITTTNGTNG GGTITTTNNGNNAAGA	219	KDLXXAASGXELGGLX LKXWDSVXXVFXKX AAMETETAPLTLESPTDPL LILSFLDYLRLDNCYVSR RLSOLSHDPLWRFRKX YWLISEEEKTKQKNCXSL FIDYSDVGRYDHYAANK AWDDLKYLEPRCPRMVL SLKEGAREEDDAVEAIG KLPDPYRCSYRIHNGKL VWGLGSMALSNHRSDE LVDVDTAAGFGQROGLK YCLPLTFCIHTGLSQYAVE AAEGHNKNEVYQCCDQM ARNPAADIMFIIAGTDFW TSYKNVSGGFIPIRDQIF RYVHDPCEVATTGDTVS STSELPELSVHPHYFTY RIRESKDALPEKACQLDS RYWRITNAKGDVEEVQGP GWGEFIPISGRVYETSC TTFSTTSGYMEGYTFHFL YFKDIFNVAPRHFHMACT FRVSIARLVSV
Shigella ospB	1	prev:5237	19	AGAGTGT TTTTGTGTAAGGACCTGCGNGTNTGCTGCTTCAATNGGNGAGNTT NNTTAGGGGNGNNTATTNCTAAATNTTGGACATCTTTAAGTITTTNGTNG GGTITTTNNGNNAAGA	220	QQQQQPPPPPIANGQQQ SSONEGLTIDLKNFRKPG KTFTQBSRLFYGNLPDITE EEMKQFRLSKYRAGVEVFI KDKGFGFRLRLETLAEIAK VELDNMPLRGKQLRVFA CHSASLTVYRNLPQYVSNEL LEASVTFGGOVERAVIWD DRGHPVSGKGVSEFSKPA RKALDRSCSEGLSLTTFPR PVTVMFDQDLDEEGLPEK LVKNQKQFHKEREQPPFA

Shigella ospB	1	prey67808	24	<p>ATCTTCCCAGCAGATGTTGCTGAAGAAGCTGACAGAATTATTACAATGCTGC CCACAGTATCAATGCAATAGAAGCTTATCCGGAGCAATGGGATCTAA TTTGAAGAAGGCGCTCATTTAATAGATTCCAGACTATTGCTTCAGCAG TTTCAAGAATTTGGCCAAAGATTGAAAAATGGAGCAGTTTCTCATGA TGCCCTGTGTTCTGGTGTAGAGCTGCACGATCTGGGAACCTCAGCTT ATGTTGGGAGGATTGAAGATGAATTTGCTGCTGCCAAGAGTTGCTGGGG TGCTGGGCTCCACGTGGTGTACTGTGAGCTGTTGGAGCTGGGAGCGG CGAAGATCTCGCAACATGCTGTAGCTATTAGTATTGATTAAGACTGCTGA AGCTATGAATCTTGAATCAGTTAGGCTTGACCCAAATCAATGAGCTAAA ATCCTAATATGAGCTCAGGACGGTGTGGTCAAGTGACACTTAACTCTGT ACCTGGAGTGATGAATGGCGTTCCCTCGGCTAATAACTATCAGGTTGATTT GGAAACACTACTGGCTAAGGATCTGGGATTGGCAAGACTCTGCTACCA GCAAGAAGCCCAATCCTCTTGGCAGTCTGGCCCATCAGATCTACAGAT GATGTGTCAAAGGCGCTACTCAAAAGAGCTTCTCATCCGTGTTCCAGTTC CTACGAGAGGAGGAGCCTCTGTA</p>	<p>KADRIITMLPTSINAIEAYSG ANGILKKVKKGSLIDSSIID PAVSKELAEVKMGAVFM DAPVSGGVGAARSNLTF MGVGVDEFAAAQELLGC MGSNNVYCGAVGTGGAOK ICNNMLIAISMGTAEAMNL GIRGLDPLKLLAKILNMSSG RCWSSDTNVPVPMSSDGV PSANNYQCGFGTTLMAKD LGLAADSATSTSPILLGSL AHQIYRIMWCAKGYSKYDF SSVFOFLREETT-</p>
Shigella ospB	1	prey67637	25	<p>ACGAGAGGAAGGAGCGCCGAGGTGAGACAGCCCAAGGGACACAGCCACG CAGCCCTTAGTTACAGTTATGGGATATTGAACAGCGCGAATCTCTCAT GAGGGTTACCAGTAAGCCAGTAGCCATTAGGAGTTTCCAAAACAGAAAG ATATGAGAAGATACCTACATCAAAACAGGGTTCAGCTGAGCCATCTCCCT CCTGTCACTATCAGCACTCAATCAGCTGTGCACACAGACGCTGGAACCT CATCAGAGAAGGAGGAGTTAGTAGCGCCTCGGAGAGAGGCTCAGCTT GCTGCCCTGCAGTATGAGGAGGAGAAATAGGACCAAGCAGATCCAGAGA GATGGTCTGGACTTTGTCAAAACAAAAGCATCACAAAGTCCACAAAAC AGCACCGCTCCTAGATGGCGTAGTGGTGGCTGCCCTTCCCATCCAGAA GGTCTCAGCACACTGATAGTGGCTTGTGCATGGCTGCTCAGGCTGAA TCAAGTGGGCTGTGCTACCTGCCCTTCTCTGCTGCTCAGCGCTT AGAGTGATGACAGACCTAATGCTCTAATAGTTACCTGCGACACAGAAACAG TTCAATCTCCCTGCATATCTTTCTGCTGCTATCCAGAGAAATCAGCCT CAGCGCCCT</p>	<p>AEFEAEVROPKGFDPDSL SSQFMAYEORRISHGSP VKPRAIFEFOKTDMRYL HONRVPAPSSLSLASH NQLSHDLELHQREQLVE RTRREAQLAALYEEKIR TKQIORDAIVLDFVKQASQ SPQKHPLLDGVGOECPP PSRRSHQTHDDSLCMSL GLNQYGCATLPHSSAFT LKSDDRPNALLSPATETV HSPSPAYSPAQRNQPOR P</p>
Shigella ospB	1	prey67637	25	<p>ACTGATACTACAGGTTACCAATTTGGAGGAGCTTCTCTGTGCCCTAATG ACTATGAACAGTGTGTGCTCTTATTGCTGTGCTACTTCTTAAGCTACTAC ATATAACAGCAATAACTCCAGACTGAGCTGAATACGAAGTATGAGGATT ATGTTTCTTCACTGGATACCTCGTCTGGCCCAACATCATTTGATGCTAT TGAGGAGCCCTGATGATTCAITGGCCAGGTGTTTCTTAATCTTCGATCA GCCTCCACAGTCAGGTTTGCACTCTGGGAAGACATTGATAAATAAATTC ATTTCCCAAGCTGGAAGAAGTGAGATGTTAGGAATTCCTCTTCTGCAAGCAT ATACACCCAGGAGCGAAGAAATGGTAATAGCCAGATGCCATCAGTTTC CAAACTAATGGCAGCTGTGTTACTGTGTAAGGATGTTCCAGGAAAGTGGCCATCAGGATA TTTTTTATTCTGTTACTATGTTGGAATGTTCCACAGGAAAGATGGCCATTCAGGTA</p>	<p>MILQELPDLEELFLCLNDYE TVSCPSICHSLLKHTIND NLQDWTIEIRKLVNMFPSLD TLVLANNHNAIEEPDLSLA LIFPNLNSHLSHKSLGQSW EDIDKINSPFKLEEYRLLGI PLLQPYTTEERRKLVIARLP SVSKLNSWTTDGEREDSE REFRIYVVDVPOEVPFRY HELITYKLEPLAEVLRP</p>

Shigella ospB	1	prey/12713	26	<p>TCATGAAGTCTGATCAATATATGGGAAGTTGGAGCCTTTGGCAGAAAGTGGAG CTAAGACCCAGAGCAGTGCAAAAGTGAAGTCCACTTTAAACGATCAGGTGG AAGAAATGAGCAATCGCTGACCAACAGTGCAGCAACTAAGAAACAGATT AAAACTAGTACAACTTACC</p>	<p>QSSAKVEVHFNDQVEEMSII RLDQTVAELKKQLKTLVLQL</p>
Shigella ospB	1	prey/7836	27	<p>CTGTGAAGAGCTGGCAAGTCTGAAGCTTCCAGCAAGTTGCGAAGCAACTT AAAAAGCAAGCAAGCTCTTTAGATGTCGTGGACTCTCGGTCTCCTTTATG TCTGTCTAACCGGCATCATCTCATGGACCAAGAAACTATTTTCAAGATTTAT CCAAATCTCCATCTACCGAGCTGCCTCAGGTAATGAGCGCCTGGGAATGGA AGACCAATGGCCAGCAAAATCTGTGAAGCAAGCCTCAGTTTATCAGC AGAGGAACCTTCAACCCGAAAGGGCAACAAAAATTAAGAAATGTGAAA ACTCACTCAGAAACCAAGAGACCCAGCGGACAGTCATGTCGGCC GCAGAAAACGTGTGACCCAGACTGCACCTCCAAACCAACAGC</p>	<p>VDEVLQIPPSLLTCGGCCQ VSCDGRFLKXIDYVHEDC LSCDLCRCLGEVRRLLYY KLGRKLCRRDYRLFQGD GLASCDKRIRAVEYMTMRV KDKYHLECFKCAACOKHF CVGDRYLLKNSAOCQDIY EWTKYLIMIN*</p>
Shigella ospB	1	prey/700	28	<p>ATGGGAATGGTCTTTCTGCTCAAGGTGTGAACATGAATAGACTACCAAGTT GGTAAGCAATCATATGTTTACCATGGAGTATGACCAATCGTTTGTCTT TCTGGAAGTGGCAACCTTTAGGACCACTTCACTACTGGTGTGTCATTG GCTGTTGTGTTATCTTCAACAACACTGCCTTTACACCAAGAATGGACAT AGTTAGGATATGCTTTCACTGACCTACCCGCAATTTGATCTACTGTGGG GCTTCAACACCGAGGAAGTGGTGGATGCCAATTTGGGCAACATCCTTTC GTGTTGATATAGAAGCATATGCGGGAGTGGAGAACCAAAATCCAGCAC AGATGATGATTTCTTATCGAGATCGAAGGGAATGGCAAGCAATGAT ACAAAATGGTTTCACTCTTATAGTCCACCTGGGTACTGTGCCACAGCAG AGGCTTGGCATCTACACACCAAGCCGTTCTAGAAATTAAGCTTCCAT TAAGATAGACAAGAAATCAGAAATTTGGTATTAGCAGGAAGATGGAGAA GCCATTGAACCAACCAACGATTATCCCAAGTTTACTTTGAAAG TTCATCAGGAAACCCCATCTGAAGTTCACCAATCAAGAACCAAGGTAG ATAAATCCACGAAGTTGAGGAAGAACCGAGTGCAAAAGGCTGAGAAATCCAA GAACAAAGAGGCTCTCTCTCCCAAGAGATCAAACTCTCGCCAGCAAGG GAACAAAACCGAGGAGATGAGTTTATGATGAATTAACAGAAAGTAGGCTTCA GAAGGTGGGTAAATCAAGTAAGCTAAAGGAGCATGTTCTTAACCCCAATGCAA GGAAGTTAAGAACCTTGAAGAAAGGTTATG</p>	<p>LKTAKGSPSSKLRKQLKK QODSLDVVSSSVSLCLSN TASSHGTGTHKLFQYKSPFY RAASGNEALGMEPLGQT KFLEDPQFISRGTFNPEK GKQKLNKNSPQKTETP EGTYMSGRRTKVDPDCTS NQO</p>
Shigella ospB	1	prey/7844	29	<p>FTGTGSEGHQHQRRPKVD KSTLKRKNQCKKAENSK OKGSSPPKDXQNSPAREQ NOMENEFDELTEVGFRRW VITSKLKHEVLTCQKEVKNL EKRL</p>	<p>MGIGLSAQGVNMNRLPGW DKHSYGYHDDGDSHSCSS GTGPQVPTFTTGDWIGCC VNLINNTCFYKNGHSLGIA FTDLPPNLVPTVQLQTPGE VVDANFGGHPFVDEIDYM REWRTKQADRSFPIVH HEWQTMQIKWMSYLVH HGVCATAEAFARSTDQTLV EELASIKNFQRIQKLVLAGR MGEAIETQLYPSLLE</p>

Shigella ospB	1	prey67853	30	GCCTGGACGGTGAAGGTGCGGCGCTCACCTCGAGAGCATGGAAGTACCA GGTTACTTCACATGAGAGACCGTTTCTCTCTTCACGTGCGCTGCGGTG GCATGAAGAATCTTGCTGCTGCACACACAGCAGCATGCTCTGCTGGAA CAGGAGTTGCTGCTGCTCAGTTGATGAGTGCGAGAAATGAGACGATG GGAAGTGTGTGTGGGCCNTTTTNGTGCTGCTNNNGNNNN	231	AVDGEGAGLTSEAWKYQV TSHREDRFLSSRLALAK NLGADRMGRK'DDGKVC GPXFCXGX
Shigella ospB	1	prey66272	31	ATGTGGGCCCTGGGTCAAGCAGTGTGCCACCTCCAGGAGGACTGA GTGTGGCTGGGATCATGCTGCTGCTGCTGGGCGATCAAGTCTGTCTCCC TTTGCCATCACATCTGATGCGGCTCTCTGATCATCCCAAGCTTACCA AGGCTTCGCGATGATGCGCCCAAGACTTCTCCACTTCTGGACTTGC CTATATGCGAACACTCCCTGCACACCCAGCTGCAGAGCAGCTGTGCA CTCTACCCCGACTCAAGTGTCTGGCATTTGGAGCAAGCGGATCTCCAC CTGTACTACTTCTCTCTCTCTGCTGACAGACCCCTAGCTCTGCC CTGTGATAGAAAGAGCTCTGACAGCCTGAGTGCCTGCAAGGCTG GACCCCTCAGTGCAGCGTCTGGAGGAGCTGTACCTTAAGCACTGTCA CAGTCAGCTCTGCTGAGCACTTGTCAAGCTCTGGAGCAGATCTCC AAGAAGTACAGAAGTCTTTGCAAGAACATTCAGTCTCCTCAAGCTTACCA ACAGGAGCTGCTGAGGAAGGTAGCAGTAAACACGAGATGTGTCACCT GTGACATGCGCTGCAAGGCGCTTTCGACAGGTTACAGGCTCTGCGGTG CTGGAGCGGCTCTCTCTGCTGCTGCTGCTGCTGAGGCTTCTGCT GCCATGACCTCCGGTCACACAGCTCTTCCAGGCTCCCTTACTGGCCGCT TGCTGATCATCTGCTCTTACCTGCTAGCCACACAGCGTGTGCCAAGCT CTACTGCTACGCTGCAAGCTACGCTGCTGGGGAGACACTGCCGCT CTGGGCTCCCACTGCTCAGGTGGTGGGCCAGCTTGCAGCTGCGCT GGGCTCACACATGCCAGTCACTTCTCTGCCCCACTGTGCTGCTCA CCTTGGCTGGTTGTCAGCTCTCACCAGCTCTCTCAGAGGCTACAGATC CAGCTCCCGATTCGCTGAATCAGCTACTCCGCTATCTGAGAGGCTGCC CTGCTTCCACCAAGATGCTGCTGCTGCCACTGTGGCACCTCTGCTGAGG CCCTGGCTGGGCCAGGACAGCTGCCATGAGCATGCAAGAGTGAAGGTG ACCTGGAGCTGCAATGAACACAGCTCAGTGAAGCTCTCCACTGGACGCT CTTGGCTACAGGCAATACAGTGGCTTCTTGGAGCTGGGCACTTGGCCCTGA TATCCGACGATG	232	MWALGAGFANLITGKIV WGLMPVLGKLSLSPFAIT LDRLLMHPNLKFGMG KATFFPLDFTYMPNLSLT PSLQELCQLYPRLKVLAF GKPDSTLHTYFPLSHRA TAPSPENMKELLSLSTEC LTVDFLSASWVRQLPKHL SOSLLLEHLHSWEQIPK VOKSLQETQSLKLTNQELL RKGSNNQDVVTCDMAK GLLQVQGFPRLPWTIRLL LLVFAVGFLCHDLRSHSF QASLTGRLLRSSGFLPASQ QACAKLYSYSLQGYSWLQ ETLPLWGSLLTVVRPSLQ LAWAHTNATVSLSAHCA LFWFGDLSLSORLOIQ LPDSVNLRLYRLPLFLH QNVLLPLWHLLEALAWAQ EHCEACGFEVTDCKMT QLSEAVHTWLCQDITVA FLDWALALISQ*
Shigella ospD1	2	prey700	32	ATGGGAATGGCTTCTGCTCAAGGTGTGAACATGAATAGTACCAAGTT GGGATAGCATATATGTTTACCTAGGGATGATGACATCGTITGTCTT TCTGGAACTGGCAACCTTATGACCAACTTTCAGTACTGGTGTGATGCT GCTGTGTGTTAATCTATCAACATACCTGCTTTACACCAAGATGAGCAT AGTTTAGGATGCTTCTCAGCTACCGCCAAATTTGATCACTACTGTGG GCTTCAACACAGGAGAGTGTGATGCCAATTTTGGCACATCCTTTC GTGTTTGATATAGAAGACTATATGGGGAGTGGAGAACCAAAATCAAGCAT AGATAGATCGATTTCTCTATCGAGATGAGGAGAAATGGCAACGAGT	233	MGIGLSAGGVNMRPLPGW DKHSGYGGDDGSHGFCSS GTSGPYGHTTGDVWGCC VNLIINTCFYKNGHSLGIA FDLPLPNLYPTGLTGPGE VIDANFGOHFVFEDIDYM REWRTKQAOIDRPIGDR EGEWQTMQKMWSSVYLH

Shigella ospD1	2	prey2492	33	ACAAAAATGGTTTCATCTTATTATAGTCCACCATGGGTACTGTGCCACAGCAG AGCC	ACCAACCTAAAGACAGGCTTAACAAGAGAGTGAAGGCGAGCGCTGGCCTA TGTGAAGCGCGTCTCAGTACATCTTCGAAGCAGCAGGATGCCCTCTCAGCG ATCCATCAAAACCTAGAAGCAGATGGAACGGAAGAAAGTAGAAGGATCCATGA CGCAGAACTGGAGAAATGTTCTGAACAGAGCAAGTAACTGACAGACATTT GTTTCAAGAAGTATTAGTCTGCAGGAAGCAGGAGTCCACTAGAAATGCA CTCAATGTCTTCAGCATTTAAGTTCTTTTCAACCTCTCTAAATATGTA AGCAATATCAAAAGGGTATTATGATGTGGTATTATGATTATGAAGAGC CAAGTCACTTTTGGGAAACGGAGTGCAGTTTTCAGAAATATTATGCTGT AAGTAGAACAAGGATTGAAGCTTTAAGAGAAATCTTCGTGAATAATGCTT GAGACACATCAACTTACATGACCAAACTTTACATAGGTACCTGCTCTGA CCTTACGCTGTGACCGCTTGGCAATGATTTGAGCCCAACAAGCTCAAG TGATCCTTCAGCTCATGCAGTTTGAAGAGGCTACGTGAAGATCTCTGA AAGTTAAACCGGCCCTGCACAGTCCCATGTTGGATCTTGATATGATACACG TCCTCAGTGTGGCCATCTCAGTCAGACAGCGTCCCTGAAGAGGGGAG CAGCTTTCAGTGTGTCGAGACGACGTCGGATGAGATACAAACTCCCAAC GGTGGCCTTTGTAATAATTGACAAACTCGCTTGAAGCAGCTCCCTGACG TTCTGGAAGCTCTGGATCTCCTCACTTAATGGAAGCCTCTTCAGTGAGACTG CTGAGAGTCAGCCAGATTGAAGATCAAGAAATGTAAAGCAAGACAAACA TGATTTAAGAAATGATTGAGGAATATGCATCCCTGGTGAAGCTTACCC GCGAGCCTCTGCATCCCTCAGCATCGGGATGGGAAGCCCAAGCAGTAC GGAGCTGGAGGTGAAGTGGAGCTCTCCGACAGTGGCTCGCTCAGCCAGC CATCAGACTGAAGACTTACTCATGAATCGTTGAGCGCTTGAATTCCTTA ATGACCTGTTACAGACTATCAGGACTCATCTTGGATCCGAGTACGTTG CGTATGGCCAGCTTGACGACAGCGGAGAAATAAGAGATTAGCTGA AAAGAGACTGGATTGTGACAATGAAGGACTGACTCTCTACCATGTGAG TTTGAACAGTGCATGGTGTGTTCTGCACTCACTGAAGGGGTCTTGAGGT GCAAGCGGGAGAGGTAGTGTCTTCCAACTCAACACAGAGAGGAGG TTGCAGCTTAAGCATCAATATGAGGTTTTATATCTCTGTGGAACAG TTGAGCACCACGCTTGATGACATATAGATACACATCTCTCTGTGATGT TCTTCCCTGACTGTGTTGGAAGTATCCATGAAGACTTCAGCTTGACCTCAG ACAGCGCC	234	HYGATAE TLNKRANKKSEGLAVVK GGLSTFFEAODALS LEADGETKVEGSM VLNRASNTADTLFQ KDKADSTRNALNLQ LFNLPLINERNIQK INDYEKASLFGTEQ KKYAEVETRIEARL KLETPSLTHDQRYR DLHAGSDPAWQCGA WILQMHSCKEGYK NPLGHSPMLDLND LGHLSQTSASLKR RDDTWRYKTPHRVA LTKLSQLPNFWKL VNGLSFSETAEKSG KNVRQRNDFFKM HSLVKLTRGALHPL AKQYGVGWEKCELS AHAQTVRLTHESLT NDLLQTDILDLIRV ATLQTHAEIKRLAE VDNEGLSVLECKP SLOSLKGLVLECKP QOPKTOEEVQQLS FYCLEQLSTKFPD LSVDVSPDLFGSH TSEQR	QYKALEINETNEEKSGTGP ADKAEKRYKYTKLXPVSL YSSREATRYKENGSGRRS EKRT'S'NNRPSFRGKNNKI R'SCMQNLKSLMSXKKSVS DLQQLX
Shigella ospD1	2	prey67651	34	CAGTATTAAGAGCGCCTTAGAGAAATGAACAAATAGAGGAGAAATCTGGCACAC CAGGAGCTGATAAGACAGAAAAAGATATAAGTATACAGTAAAGCTCANCC AGTCTGGTGTACTCTCTAGAGAACTAGAACTAGAAATACAAAGAAATGGTT CTCAAGCTAGGAGCGAGAAAAAGACATGATCCTAGACACACAGGCCAGCTT CAGAGGGAAGAAACAGATCAGATGAACTGATGATGACAAAGCTTGAAGAAGC TTGATGTCTTANAAAAAGAGTGTTCAGACTTACAAACAACATCAGN	235			

Shigella ospD1	2	prey67653	35	CCTCGAATCTGCAAAATGGCTGATTAATTTGGATGAATTTATTGAAGAGGAAA AAGCCAGATTGGCCGAAGCAACAGCAGATTGGAAGATGATCCACCTTACAT GGAATGAAGGAAAGTTGTGAGCGAGCTTCTGAAACAGTAAGATGATCTG ATCTATGGCTAAGGAACATACCACCAATAGTCAACAGCAGCGGTT CCTTAGAATGATTATGGATTAAAGTTTACCCTTGGAAGAGCTATGAACGG AGAAACATAAATTAAGAGAGAGATTGCG	236	PEICKMADNLDEFIEOKAR LAEDKAELESDDPPYMEMK GKLSAKLSNKSILISMAKE NIPPNOSQOTRGLSDYGL SLPLGEDYERKHKLKEEL
Shigella ospD1	2	prey67667	36	CAGCAGGCGCACCCCGATGATGAGAACATGAGCAGGTTGTTTGAGCA GTGCCAGATTGAGGAGCAACAGCGCTTCGCTTCTCGGGGATCTTCGT GGAGTTTCAGAGCAGCTTAACCTGTCCAATGTGGCTGTACAAGCCATT TACCATGACCTGGAGCAGCAGCATCAGAGCAGCTGATGAGTGGAGACCTG AGGTGGTCCGAGCCAATCAGCGCCAGGCAATGGCCATGAACCTGCCGCA GTTTGAGGATGGTCCGAGACCTGATTTCGAACCTTCAGCGGAGAGAA GAAGAAGCCACTGACGGCTTCACCTGACGGGCATCAACGACAGCGCGA CCAGTTTTGCGGAGTAAGCCGACGACGAC	237	DGQTPQYMMENMEQVFEQC QOFEEKRLRFREFVLELVQ KHLNLSNAGYKAYHDL OSIRADAVEDLRFWRANH GRGMAWNPQFEWWSAD LIRTLISREKHKATDGFSLT GINQTGDOFLPSKPS
Shigella ospD1	2	prey67657	37	CGCGCTCGCATGGACTGGATCTCCAGTGCATCTCTACCATGCCCGCA GGCTCTGCTGACCGAGATGATGGAAGGTGTGAAGAACTAGGAACAATGC CTTGCTGTGAAATCTGTGATGTCTGCTTCGCGGCTGAGTTCATCGCAACA AGGCTATGGATTTCATGGCATGATTAAGAGTGTGATGAATCTGGTTCC CAAGCATCTCTTTTTCGATCTCAGGATTAACCTTGGCTTGGCTGATCCTC CTGAGAGTACCGACTCAGATCTCAACGAGCTTGAAGAGTCACTACTAA GCTGAAGAACCACAGGACTACATTAATGTGCCGAAGTGTGGGTGAATAC ACCTGCAAGCATTTACGAAACGAGAGTGAATACCGTTTGGCAGATGTA TCAAGCAGATGACTCGAGATGTCATTTGAAGATTCCTACCCCACTCA GTATAATTAAGAAAGTTATGCCCATCTCCATGACTCTCAGTTCTTTCTC AGTGGAATAATTTCTGCCGTTCTGGACATGTTCCAAAAGAGAGTGTGGCG GTGGAGAAATTCGAATGATCATGAGCGCTTTATCAAGCATCAACAAGGC CCACCAAGGACC	238	PPAMDWIFQCISYHAPAL LTEMMEWCKKLGNALLN SVMSAFRAEFIATRMDFIG MIKCEDSGFPKHLFRSL GUNLALADPPESDRLQINE AWKVITKLNQPDYINCAE VWVEYTCKHFTKREWTVL ADVKHMTDPAFEDSYPO LOLIKKVIAHFHDFSVLFSV EKFLPDLIMFQKESVREY CKCIMDAFIKHQEQPTKD
Shigella ospD1	2	prey67501	38	TTGCGCGTGGAAACAGCTGGAATGCTTTGATGATGCGAGAAAAAATTAAC TTGCGCCAGAAATGCTTTAAAAATTTGACGGAAGAAATCATCAGAGACTGT CCACATTAAGGGAATTTGGGAAGAGAAAGTACTGTTCTTAAGACTCTAC TTACTTCAAGGAGTCCGAACTATCAGTGGAAATGATGATAGAGCTTATG TAGTCTTAACAGGACGCTCAGCTCTTTAAGAGCTATATATGATCCATCAA AAGTGCAATTTGTTCAGTTGGGGTTTACTGCCAGGAAGCAGCGGCTTG GCCTGAGGCGGTGTGATGGAACTGGATCTGCGCCCACTCATATACCA ACCGCAGAGAGAACTGGCCCAATTAAGAAAGGAGGAAAAAGAGAAAAA GACGCGCCTCGAGACATCAGTTTCTGAAAGGGATGGGCTACTCTCAGCGC ACG	239	FRILEQLDDAEKLNLA QKCFKNCYGENHQRVLHIK GNCGEKVLFLRLYLQGI RNYHSGNDVEAYEVLNPH VSSLKSYLIHQHTCCSW GLLPHKHLRLGRACDQHW DHAATHHRLREELAGIRNE EKEKKRRRLRIIFLKGMG YSTH
Shigella ospD1	2	prey67678	39	GAACAAGCTGAGGAGTTGGACCCAGAGATTACCCAGCAGACCATAGAGCT GAAGGAAGAGTGCMAAGTTTGTGGACAAAATTTGGCCAGTTTCAGAAATA	240	NKLRVLDREVTTQOTIELKEE CKDFVDKIGQFKIVGGLE

Shigella ospD1	2	prey3160	42	GTTGGGAAAGCTCTCGGAGGAAGATCGACC GAGAAACTACATGAACCTACCGGTTATGCAAGATAGACGAGAACAAAGCAAGA CAAGACTGAAGGGTTTGGAAAGACAGCTGSCAAAGAACTTCAGACTTTAC ACAACCTGGCAAACTCTTTGTCAGAGCTG	243	RKHLHETVMQDRPREQARQ DKGLEETVAKELOTLHNL RKLFEVDL
Shigella ospD1	2	prey50427	43	ATGGAGGATATGAGAAGTCTTGTAAGAAAAGTCTTGCGAGAAATACAAGAAG CATCACTATCCAGAGAGTCTTCCTCGTCTCAGTCTGAAAGTATCTCACTT ATTGCTTTATCAGAGTGCTTCTCTCTCCACTCTTAACATTTGAAAGAG AAGGAAATGCAACAAGAAAGAGAAAGCACTTGATGTAGAGCAAGCAAGAG CAGGTTACAGCAAGAAAGCTTTACTACTCGTCTCCGAGAGATTTTGACA ATGTCAGGTAGAAAGAGCACTTAATGCCAGTGATTTTGATCAGTGGAGAT GGAACAGTTTACTCTAAATTCAGAAGTCAGAACTTGAATGTCCTGCTACAT TGCAAAATAGCTTTCCAGCCATACGGAACACTCTACTGACGAAAGCTGTGAT AGATAGCTGGGATTTGCCATTGGATTAATGAGGACCAATGAAACTGATG GAATAGACTTAGCTAGAGATTGAGAGGATTTAATCTCCGAAGCAATGTGAT AGTTCCAATATTAGTCAATGAGAAATGAAAGCTTTTCCAAAGACCTCTTCAGC AACCACAGAAACTCTTATTTCTGATGGTCCCTTCTCAGTAAATGAAACAC AGGATCTACCACTTTTGGCAAGTCACTCCAGATCCCTGTAAATGACTCTT CAGAATCTGATGAAAGTCAAGGAATATATGAAAGAGCAACATCTAGAC GCAGCTGAGAGTGTATGAAAGCAATTTGTAATGAGAGTCAATTTAGACAA AGAAATGATGCTTTGAAGTGGCTGACTGTGTAAAGAGAAAGGCCAGTTG ACAGGCAACACTGTGTCTAGTTATTCCTGACAAACCAAGCCTTAATTAATC AAATGTTCTTCCAGGTGCTTCCACTCAAGCAAGCAGCATGATGTGCCA GTTTTAGCTAGCTTTTCCAAAGTGGACATACCTATACGAAGTGGCCATCCCA CTGTTCTAGAGTCTAATGTGATTTTAAAGTTATCCCACTATTGTACCGAAA ATAATGTTATCAAAAGTCTTACAGGTTCAATGCAAAATTAACCTAGTCCAGAG CCAAGTATGAGTCTTAATGCAAGCCAGAGCTT	244	MEEYCKFOEKSRLARIEAS LSTSEFLPAOSESLSIRFH GVAILSPLINEKRKEMQOE KOKALDVEARKQVNRKAL LTRVOEILDNOVVRKAPNA SDFDOWEMETVYSNSEVR NLNIPATFPNSPFTYTHEHS TAALKDXIAGILPLINDEQC KTDGDLARHDESEGFNSPKQ CDSSNISHVENEAFPKTSS ATPQETLSDGSPSNEQOQ DLPLLAEPIDPYMNSLQNL MKKKEYIEREQSSRLRG SMNRVNVNESHLDKEHDVAE VADCKVEKGQLTGKHCVS VIPDKPSLNKSNVLLQGAST QASSMSMPVLVASFSKVDIPI RTGHPTVLNENSDFKVPIPI VTENNIVKSLTSGYAKLPSLP EFSMSPKMHRRR
Shigella ospD1	2	prey63765	44	GGAGGCCAACCTCTGGCAAGCAGGGGTTACCAAGCCTCACACTGGAGC TGCTCTCAAGCCTGTAGATCCACTGCGCTGATGATCAAGTCAACAGCTGGCAA CGGCCAACCAAGGAGTCTTCCACTGGAAGATCTCAACAGCGCTACT ACTCAGGATCAGTGGCCAGCCAACTCAGCTTTGGGCAAACTCCAGCCAA GTACACGAGCACTTATGTCMAAGAGCTGAGCATCTCCAGCAGGAAC GAATCCGATGTGGCCCAATGTACACAGGTCTCAGAGGACCACTTCTAGT GGCACTGGGAAATCTTGGCCACCAAGAAATTCAACTGGCCTCACTGCAA AAATACMATGGCCTACATGGATTTGAGAGAGAAAGAGCCCTGATTTGT GAGCTGTGCTATGAGAAATCTTTGCCCTTGAATGTGCTGATGCCAAGGA AGATCCTTGGAGAGTCAATCGCTTGAATCAAACTTGGCATTTTCTCGTG TTTGTGTGTGTAGCCTGTGGAAAGCCCAATCGGAACTGTTTTCACCTGGA GGATGTTGAACCCCTGTGAGACTGATTTATGCGCTCTTTGGTACTATAT GCCATGATGTGAATTTCCATGAAGCTGGTGACATGTTCTCTGGGAAGCTCT	245	DSPTSGRRPGVTSLTATAAF KPVGSTGKRNPSWQRPN QGVSTPVIKSNISATYSGSV AFANSALGQOTSPQDDTLV OFAEHPAGKRTPMCAHC NQVRHPFLVALGKSWHPE EFNCAHCKNTMAYIGFVEE KGALCYELCYEKFAPCEG RCORILGVEINALQKTWH VSCFVIVACGKPIRNVFHH LEDGEPYCOTDYALFGTI CHGCEPPIEAGDMFLFALG YTWHDTCFVSCVCCESLE

Shigella ospD1	2	prey/67823	45	GGGCTACACTGGCATGCACACTGCTTGTATGCTGAGTGTGTTGAAAGT TTGGAAGGTGACAGACTTTTCTCCAAAGGAGCAAGCCCTGTGTGAAGAAC ATGCTCATCTGTGAATTTTGA ATTTTATGAGGAGCATACGACTGCTCGACAGAGGATAGTGACAACTCTAT GAGATGAACAGAGACTCGACTGCGACAGAGGATAGTGACAACTCTGG ATGAGGAGCCCTTGGCACTAAATTTTGAAGATGACGCCATTAACCTTTT TTTTTGTGGAAGTGAACAAAGCATACACTATCGCAGGACCTCAT CCCGTTACTTGGAGGAGGCTGACGACCTGTTATACA TTCCAACTCGAAGAGTCACTACCAACTCATCCATCACGCTGACGT CGACCACTTACCATGCCCGCAGCGGAGCCCATGTTTACCAGGT ATGACAGAGGAGCTGCTTGGAGTTCACTTTGATGATCTCATGAGA ATCAAAATGCGACTTTACCATTAGACATACCGAGAGTAGTCCGAGAA GCATCTGACCATGATGACAAAGTCTCGAGTCTGATCAGCTGCTCAA AACATACAGGATGGGCTACCAACTTCAACCTCACTACCTCAGGTG TGTGTAATATTGAGCCAAATGCAAGACTGATGCGAGACATAAACTTACA ACCTGATCCCGAGACTGCTGGAAGACTGCTTTTTCAGAACTGGCAGA GGATGCTGGCTCGCCGACGACCAAGCAAGCAACAA	246	QOTFFSKDKPLCKKHAHS VNF* FYRHRTPYMWOPVRIYEM NKRLOSRTSDSNLWDDA FATEFFEDDATTLSFCELD GPKRYTIGRTLPIRYSTVF EGGVTDLYLKHKSHYH NSSTVDDCCTMVTQHGK PNFTKVCTEGRLILETFDD LNRHKTWHFTQVRELVP RSILAHMAHQPOVLDLQSK NITRMGLNFTLNLRLCVI LEPMOELNSRHKTYNLSPR DCLKTCLFKQWORMVAPP AEPTRQP MILDRDVGTPWMPPTYLEP GIGRHTYVGNQDYLRIEFL NKRLONWTECCDNLWWD AFTTEFFEDDAMLITFCE DGPRTYITIGRTLPIRYFHSI FEGGATELWYVYKHPKEAF HSNFVSLDCCDQSGMVTQH GKPMFTQVCEGRYLEF MEDDMRIKTHWHSIROH RELIPSIAMHAQDPQML DQLSKNITRGLNSLNTLYL DCLVILEPMOELMSRHKT S VTASTICEKLEKARNELQT VYAEFVQHQAEKTEREN RKYETREYHEKRLDITVEE AEKYMQLQEOFDNLNAA HETSKLEIAHSHSEKLELLK KAYEASI SEIKKHSEKKS LEDLLSEKQSELEKINDLK SENDALNEKIKSEEQKRRH
Shigella ospD1	2	prey/7315	46	ATGCTGGATAGGATGTGGGCCCACTCCACTGATCGCCCTACATACCTG GAGCCAGGGATTGGAGCGACACACCATATGSCACCAACTGACTACAGA ATATTGAGCTTAAACACGCTTCAGACTGGACAGAGGAGTGTGACATC TCTGTGGGATGATTCAGACTGAGTCTTGGAGTATGATGCGTGTGAC CATCACTTTCTCGGAGGATGACCAAGAGATATACCATTTGGCCGAGC CTGATCCACGCTATCCGACGATCTTTGAGGGGGTGTACGAGACTG TACTATGTTTAAACACCCCAAGGAGCTTCCACAGCACTTTGTGCTCC TCACTGTGACAGGCGACATGTTGACCCAGCATGGCAAGCCCATGTTCA CCAGGTGTGTGGAGGGCGGTTGTACTGGAGTTGATGTTGACGACA TTGTCGGATTAAGACGTGGACITTCAGCATCGGACGACCGAGGCTCA TCCCGCGAGCATCTTGCATGTCGACGCAAGACCCGACATGTTGGATG AGCTTCCAAAACATCACTCGTGTGGGTGTCCAACTCCACTGTCAAAT CCTCCGACTCTGTGTACTCGAGCCCATGCAAGAGCTCATGTGACGCGAC AAGACCTACAGC AGTCACTGCTTCAACCACTGTGAGAAATAGAAAAGCGAGGATGAGTTA CAACAGTGTGAAAGCATCTGTCACGACGACGAGCTGAAAACACAGAAC GAGAGATCGCTTTAAAGATTTTACACAGGGAGTATGAAAAGCTTCGGGA CACTTACATTGAAGAGCAGAGAATACAAATGCAATTTGCAAGAGCAGTTT GACACTAAATGCTGCGCATGAACCTTAAGTTGGAATGAAGCTAGCC ACTCAGAGAACTTGAATGCTAAGAAAGGCTATGAAGCTCCCTTTCAGA AATTAAGAAAGGCCATGAATAGAAAAGAAATGCGTTGGAAGATTACTTCTG AGAAGCAGGAATCGCTAGAGAGCAAAATCAATGATCTGAAAGAGTGAAGTA	247	GIRHTYVGNQDYLRIEFL NKRLONWTECCDNLWWD AFTTEFFEDDAMLITFCE DGPRTYITIGRTLPIRYFHSI FEGGATELWYVYKHPKEAF HSNFVSLDCCDQSGMVTQH GKPMFTQVCEGRYLEF MEDDMRIKTHWHSIROH RELIPSIAMHAQDPQML DQLSKNITRGLNSLNTLYL DCLVILEPMOELMSRHKT S VTASTICEKLEKARNELQT VYAEFVQHQAEKTEREN RKYETREYHEKRLDITVEE AEKYMQLQEOFDNLNAA HETSKLEIAHSHSEKLELLK KAYEASI SEIKKHSEKKS LEDLLSEKQSELEKINDLK SENDALNEKIKSEEQKRRH
Shigella ospD1	2	prey/67601	47	ATGCTGGATAGGATGTGGGCCCACTCCACTGATCGCCCTACATACCTG GAGCCAGGGATTGGAGCGACACACCATATGSCACCAACTGACTACAGA ATATTGAGCTTAAACACGCTTCAGACTGGACAGAGGAGTGTGACATC TCTGTGGGATGATTCAGACTGAGTCTTGGAGTATGATGCGTGTGAC CATCACTTTCTCGGAGGATGACCAAGAGATATACCATTTGGCCGAGC CTGATCCACGCTATCCGACGATCTTTGAGGGGGTGTACGAGACTG TACTATGTTTAAACACCCCAAGGAGCTTCCACAGCACTTTGTGCTCC TCACTGTGACAGGCGACATGTTGACCCAGCATGGCAAGCCCATGTTCA CCAGGTGTGTGGAGGGCGGTTGTACTGGAGTTGATGTTGACGACA TTGTCGGATTAAGACGTGGACITTCAGCATCGGACGACCGAGGCTCA TCCCGCGAGCATCTTGCATGTCGACGCAAGACCCGACATGTTGGATG AGCTTCCAAAACATCACTCGTGTGGGTGTCCAACTCCACTGTCAAAT CCTCCGACTCTGTGTACTCGAGCCCATGCAAGAGCTCATGTGACGCGAC AAGACCTACAGC AGTCACTGCTTCAACCACTGTGAGAAATAGAAAAGCGAGGATGAGTTA CAACAGTGTGAAAGCATCTGTCACGACGACGAGCTGAAAACACAGAAC GAGAGATCGCTTTAAAGATTTTACACAGGGAGTATGAAAAGCTTCGGGA CACTTACATTGAAGAGCAGAGAATACAAATGCAATTTGCAAGAGCAGTTT GACACTAAATGCTGCGCATGAACCTTAAGTTGGAATGAAGCTAGCC ACTCAGAGAACTTGAATGCTAAGAAAGGCTATGAAGCTCCCTTTCAGA AATTAAGAAAGGCCATGAATAGAAAAGAAATGCGTTGGAAGATTACTTCTG AGAAGCAGGAATCGCTAGAGAGCAAAATCAATGATCTGAAAGAGTGAAGTA	248	GIRHTYVGNQDYLRIEFL NKRLONWTECCDNLWWD AFTTEFFEDDAMLITFCE DGPRTYITIGRTLPIRYFHSI FEGGATELWYVYKHPKEAF HSNFVSLDCCDQSGMVTQH GKPMFTQVCEGRYLEF MEDDMRIKTHWHSIROH RELIPSIAMHAQDPQML DQLSKNITRGLNSLNTLYL DCLVILEPMOELMSRHKT S VTASTICEKLEKARNELQT VYAEFVQHQAEKTEREN RKYETREYHEKRLDITVEE AEKYMQLQEOFDNLNAA HETSKLEIAHSHSEKLELLK KAYEASI SEIKKHSEKKS LEDLLSEKQSELEKINDLK SENDALNEKIKSEEQKRRH

Shigella ospD1	2	prey63735	48	<p>TGCTTTAAATGAATAATGAAATCAGAAGAACAAAAAGAGAGCAAGAGAA AAGCAATTTGAAATCTCAGATCATGTATCTAGAACAGGAGTTAGAAAGC CTGAAGAGTGTTAGAGATCAAGATCGAGTGAACAACTGCATCAACAGCATCA AGTTAAGAAATGGAGAACTGGTGACAAACAAACAGCATTTGGTTGACAA ATTGAAGGTTTCCAGCAGGAGATGAAGATTTGAAGCTCGATGGACAG CAGCTGGAATCTCAAGCGACTTTTCCAGGAGCAGGCTGTCTGCAAGAG TGCTGGAGAGAGTGCAAGAGTCAACAGCGACTCTATGGAAGAACAG GACATCTCGGAACTGCAATGGGAGCTGTGAGCCCAAGACTCC CCACATCTCCGCCATCCCTTTGCAGTCAACAGGAATTCGGGCTCCTTC TAGCCCCAGCAATTCACCCAGATGA</p> <p>CTCGCTTCTCTAGCACTGGACATTTCAAGAGCTCAGAGCCGGTTGAAT GAAGCTTGCTGGGCTGAATCAGGCACCAAGCAAGCTTGTGCAAGGCTCT CGGGAAACCCCTCAGCACTGCTGAGCCTCAGCGCATTTGGACAG CTTCAGAGCTTCTGGAAGCTGGTGTGAGATGGCAGCCAGGCTCGAG CCAGGAGCAGGAGCCCAAGTTGTGCCAATCGAAGGCACTCTCCATGTCT TTCAAGCAAGTCTCTGTGCTGCCAAGCCCTCTCCAGGACCCTGCTGCC CCTAACCTCAAGAGTCACTGGCTGCAGCTGCCAGGCGATGACTGACAGC ATCAATCAGCTCATCTATGTSCACCAAGCAGCGACCCGCGCAAGGAG TGTGATAAGCCCTCGGGAATTTGAGACGGTCCGGGAATCTTGAGAAC CCAGTCCAGCCCATCAATGACATGTCTCTTTGGTGGCTGGACAGTGTAA TGAGAGCTCAAGGTGCTGGCGAGGCGCATGACTGGCATCTCCCAAGT CCAGAACGGAAACCTGCCAGATTTGGAGATGCCATTTCCACAGCCTCAAA GGCACTTTGGCTTACCCGAGGAGCTGCACAGCTGCATATCTGTGGT TGCTCTGACCCCAATAGCCAACTGACAGCAAGGCTAGTGAGCGCCAC ACAGTTGCCGCTGCAACACAGCAATTCAGATGGCTGCCAGATTTGGG AGAGCTGGCTGACCAAGCCAGTGCTCTGSCAGCCACCATTTGGG TAAACAGCTCTGCACTGTGAACAGCTGTGCGCTGCTCTGCCGCTACC ACCAATCTACTGCGAAGCGCGAGTTTGTACAGTCAAGCAGGAGGCTGGCG ACAGCAGCACTAATTTGTCAAGACCATCAAGCGCTAGATGGGCGCTCA CAGAGGAACCGTGCCCACTGCCAGCAGCAACAGCCCTCTCGCTGAG GCTGTGCAATCTGAGTGCCCTTTGGCTCAACCCCTGAGTTCTCCAGCATTC CTGCCAGATAGCCCTGAGGGTGGGCTGCCATGGAGCCCATTTGATCT GTGC</p>	<p>REKANLKNPQIMVLEOLE SUKAVLEIKNEKLHQDIDL MKMEKLVNNNTALVDKLR FOQNEELKARMDKHMALS ROLSTEOAVLESLKESK VKNRLSMENEELLWKLHN GDLCSPKRSPSTSAIPLS PRNSGSPSPSPISPR</p> <p>SLPSTGTFOEAOSSLNEA AAGLNQAAATELVQASRGTP ODLARSFRGQDFSTLE AGVENAGAPQSDRAQV VSNLKGISMSSKLLAAKA LSTDPAAPNLKSLAAAAR AVTDSINQLTMTCTQQAAPG QKCEDNALRELTVRLEL NPVQPINDMSYFGCLDSVM ENSKVLGEAMTGISQNAKN GNLPEFGDAISTASKALCG FTEAAAQAAVLGVSDPNS QAGQGLGVPTQFAHANG AIQMACQSLGEPGCTQAO VLSAARTTNAKHTSALCNSCR LASARTTNPHTAKRQFVQSA KEVANSTANLVTIKALDGA FTEENRAACRAATAPLLEA VDNLASFASNPFFSSIPAQI SPEGRAAMEPIVIS</p>
Shigella ospD1	2	prey67630	49	<p>AGAGCAATTTGAAATCTCAGATCATGTATCTAGAACAGGAGTTAGAAAGC CTGAAGAGTGTTAGAGATCAAGATCGAGTGAACAACTGCATCAACAGCATCA AGTTAAGAAATGGAGAACTGGTGACAAACAAACAGCATTTGGTTGACAA ATTGAAGGTTTCCAGCAGGAGATGAAGATTTGAAGCTCGATGGACAG CAGCTGGAATCTCAAGCGACTTTTCCAGGAGCAGGCTGTCTGCAAGAG TGCTGGAGAGAGTGCAAGAGTCAACAGCGACTCTATGGAAGAACAG GACATCTCGGAACTGCAATGGGAGCTGTGAGCCCAAGACTCC CCACATCTCCGCCATCCCTTTGCAGTCAACAGGAATTCGGGCTCCTTC TAGCCCCAGCAATTCACCCAGATGA</p> <p>CTCGCTTCTCTAGCACTGGACATTTCAAGAGCTCAGAGCCGGTTGAAT GAAGCTTGCTGGGCTGAATCAGGCACCAAGCAAGCTTGTGCAAGGCTCT CGGGAAACCCCTCAGCACTGCTGAGCCTCAGCGCATTTGGACAG CTTCAGAGCTTCTGGAAGCTGGTGTGAGATGGCAGCCAGGCTCGAG CCAGGAGCAGGAGCCCAAGTTGTGCCAATCGAAGGCACTCTCCATGTCT TTCAAGCAAGTCTCTGTGCTGCCAAGCCCTCTCCAGGACCCTGCTGCC CCTAACCTCAAGAGTCACTGGCTGCAGCTGCCAGGCGATGACTGACAGC ATCAATCAGCTCATCTATGTSCACCAAGCAGCGACCCGCGCAAGGAG TGTGATAAGCCCTCGGGAATTTGAGACGGTCCGGGAATCTTGAGAAC CCAGTCCAGCCCATCAATGACATGTCTCTTTGGTGGCTGGACAGTGTAA TGAGAGCTCAAGGTGCTGGCGAGGCGCATGACTGGCATCTCCCAAGT CCAGAACGGAAACCTGCCAGATTTGGAGATGCCATTTCCACAGCCTCAAA GGCACTTTGGCTTACCCGAGGAGCTGCACAGCTGCATATCTGTGGT TGCTCTGACCCCAATAGCCAACTGACAGCAAGGCTAGTGAGCGCCAC ACAGTTGCCGCTGCAACACAGCAATTCAGATGGCTGCCAGATTTGGG AGAGCTGGCTGACCAAGCCAGTGCTCTGSCAGCCACCATTTGGG TAAACAGCTCTGCACTGTGAACAGCTGTGCGCTGCTCTGCCGCTACC ACCAATCTACTGCGAAGCGCGAGTTTGTACAGTCAAGCAGGAGGCTGGCG ACAGCAGCACTAATTTGTCAAGACCATCAAGCGCTAGATGGGCGCTCA CAGAGGAACCGTGCCCACTGCCAGCAGCAACAGCCCTCTCGCTGAG GCTGTGCAATCTGAGTGCCCTTTGGCTCAACCCCTGAGTTCTCCAGCATTC CTGCCAGATAGCCCTGAGGGTGGGCTGCCATGGAGCCCATTTGATCT GTGC</p>	<p>EDLQPPSALSAPFTNSLAR SARQSVLYRSTLPGRRALK NSRLVYQKDDVHVHCLCLR AIMVYQYGFNLVMSHPHAV NEALSLNNKINPRTKALVLE LLA</p>

Shigella ospD1	2	prey12665	50	GAAGCGGCACGAGCGGAATGATCAAGAACCGGAGATGACGCTGCCAGTCCCG GGAAGAAGAAAGAGATATCTGAGGAGCTGGAGCTCGGCTCGACGACG TACTGGCTGACAAACAGCAGCTCCGCGAGAGATGCTGCCCTCCGCGGCG GGCTGGAGGCTGCTGCTGGCTGAACAGCGAGCTCAAGTAGGCTCTGGAA ACAGGAAGGTGGTCTGCATCATGCTTCTCTCTCTCAATGGCTTCAACTT GGACCTGTGAGCATGAGTGGCTCTTCACTGCCATCTCTCTCGGATGA ACAAGGGGAGCCTCAACCCGGAGACATCTGCTGGGTTCTCAGAGCAAG AGCCAGTTCAGGAGTTGAACCTCCAGGGTCTCCAGGGCTCCCTAAGG AGCCAGCCAGCCAGCCACAGACCCAGCGATTCAGCAACCTGACAGCT TCCTGTGGGCGCCAGAGGCTACTACTAAGAGACCTAGACCAGCTCTCC TCTCTGTATTGCGGCACTTCAACCGCACTGAGTCCCTGAGGCTTGTGTA CGAGTTGAGTGGTGGTCCAGCGCCACAGAGCGCGGAGGAAGATCC CTCAGAGCGCCAGGAGACAGAGAAGTCTCAGCCACGGAAGAAGTCACTC CAGTTAAGCGATCCCAATCC	251	KHERMIKRNRESACQSHR KKKEYLOGLEARLOAVLAD NOQLRRNALLRRLEALL AENSELKGSGNRKXVCM VFLFIAGFGPVSEPPSA PISPRMNKGPQRRHLGG FSEQGVGVLEPLOGSSQ GPFQPSPTDQPSFNL AFPGKACELLRLDQLFL SSDCRHFNRTESLRIADEL SGWVQFHQGRRKIPQRA QERQSKSPRKXSPVKA PI
Shigella ospD1	2	prey67651	51	TGAGAGCGAGGTCTCGGAGCATCTCAGTCCGAGCTCGGCTCTCGCATCCA CGAGACAGCACTTCCAGCATGCGACCACTCTGAAGCCCCCATGTGAA CACAGTACGTCAGCTTATTCGGAGGATTTTGAAMACTCTCCAGTCTGACA GCATCTGAGCCAAACCGCCATTCGAAGGAGTCTCTTGACAGACACTGGAC GCTTTGTGTAATCTCTTCAAGTGTGAAGACAGACCTTCCACAACACCG AGTCTAGGAAAAGTGGGCGAGCGACGTGACAAGAGTCTTGTGAAGGACA CAGCTGTGCAGACGCCAGTCTGCTTCACTACGAGTGGACCAAGTGG CCAGCATGGACCATGGGCGCTGCCCTGGGAGCGGCTACGTGGACCCG ACACCATGGCCAACTGTTATCAGTGCAGATGCAATGAAGCCCTGACCG CTTACAGCCCGCGGTGGTGGCACTCCATGATGCTGAAGCAGCAGCTGA CTTACAGCAGCATTCATCCAGCGAGCGGCACTGCAACGCTCCCTCC TGCCTGCCCTGGAGCGGACTCTCTTCCACTACCACACCTGGAGGAGCCA AAGAGTACATTAGTGGCCACAGACTGCCCACTGACCATGGAGGATGCC TGAGGAGGTGAACAGGAGCTGTGA	252	ESEYSEHLSSASSAIQOD STSSMQPPSEAPM/NTVS SAYSEDFENSPLTASEPT AHSXESLDRTLDALESSS SVKTDLPQTAEKRKSGRH VTRVLVKDTAVQTPDPFT YEWTKVASMAAMGAPALGG AYVDP/PIANHVISADAEAL TAYSPAQLALHDVLKQDLS LTQQFQASHHLLHSLRSL DADSFHYHTLEEAKYVPC HRPAPLTMEDALEEVNKL
Shigella ospD1	2	prey20143	52	ATGGCAGAGCGCCGACGACCTGGAGAGGAGATGAGCCCTCAGTTCTGT CGCTCTCAGAGAAAGAAAGCTGGGACCAAGCTCTGCAGAGAACCCAG GCTTGAGTACAGGAATGAAGGAGGCTTGAGACCCCTGCAAGCAGAGGCC CGCAGCTCCGCTCGMAACAGGACCTGGAGGACCAAGTGCAGCTTGTG AGGAAAAACAGATGAAGAGTGCAGCAGTGAAGGAGCAACAGCTGGAGAA ATTGGAACACGCCAGAGCGATTGAAGATGGGTTGCAACTCCAGACACAG AAGAACAAAGATGGAACAGCTAAGGCTCAGTCTGCTGAAGAGCTCTCTA CTTATAGGCTATGCTACTACCCAGAGCCGTGGAACAGCGCTGATGCTCCAC TTCACAGCAGGTGGAATTGGAGACACAGTCTCAAGGGCTGTTTAG	253	MAESRODLEEEYEPQFLRL LERKEAGTKALQRTQAEIQ EMKEALRPLOAEARFLQ NRNLEQJALVROKRDVEV QQYRQLEEMERQRLIR NGVQLQQCKNKNQELRL SLAEELSTYKAMLLPKSL QADAPTSAGGAMTQSQG AV
Shigella ospD1	2	prey1418	53	CTGGGTATCCAGATCCGAGACGACCAAGCGGCGCAAGCGAAGAAGG GCCACGCCCCGAAGATGCTGGGCCACAGAGCTTTGGCGTGTCTGTGGGAGC	254	WIPDPDEEPEPRKRGKPA PKMLGHCLRCVCGDKASG

Shigella ospC1	3	prey50590	58	TNNGGNTNGGNTNGGNGCNGTNTGTNTNGNCNNGTGTGTTNGNNNANG GCNGNCGNGCNGNGTGTATTNCCAGGTNTGNGNNGNNGTNGGNGCNCNT GGCNCCTNGCATNIN GTTCGATCAGCTCAGGAATACITTCATGGAGTTGACATTCGAATCAAGCTGCA AGGGGTCAACAGAGGATTCACCGTCAACATCATGGACAGCTGTGAGCGCT GCAACGGCAAGGAGACCGCGCCGACCAAGGTCGACAGTATGCGACTAC TGTGCGGCTCCGGCATGGAACCATCAACACAGGCCCTTTGTGCGCGT TCACGTTGAGAGATGTGTTGCCCGGCTCCATCATCATATGCGCCGT GTGCTCGAGGGAGCAGGACGACCAAGCCAGCAAGAAAGCGAGTGTGATC CTGTGCTCGAGGATCGAGGATGCGAGGTAGCCAGACCGTGTGAGCTGTGGG AAAAAGGAAATTTTCATTACGTTACGGGTGCAAGAAAGCCCTGTGTTCCGG AAGGCGCGACATCCACTCCGCTCTTTATTTCTATAGCTCAGCGTGA TTCTTGGGGAAGCAGCAGCCAGCGCTGTACGACGATCAACGCTGA CGATCCCCCTGGACTCAGACAGACCCAGAGATTCGGATGGGTGGAAAG GCATCCCCGGATTAAAGCTACGGCTACGGAGCAGCACTACATCCACATCAA GATCAGGTTCCAAAGAGGCTAACGAGCGGCGACAGAGCTGATCCTGAG CTACGCGAGGACGACAGATGTGAGGGACGCGTGAACGGCTCACCC TCACAGCTCTGGTGGCAGCACCATGGATAGCTCCGCGAGGAAGCAAGCTA GGCGTGAGGCTGGGAGGACGAGGAGGGATTCCTTCCAAACTTAAGAAA TGTTCACCTCATGA	XXVXXXAXXXXVXDQVW XXWXXAFX	
Shigella ospC1	3	prey9822	59	ATGGCGACCTTGATTCGGCTCCGAAAGCTGTCAAGGGTGCAGCAGCGTCT GAGGGGTGGAGAGTGGCGCTGCTCGGAAATCTCCGCTGAGCTCATTCG CTCGTCAGACAGTGGCAGAGCTGAGGCTGTATACGAAGCGCTCTCGGG CGAGGAAGTGGTGGAGAGAGCTGGATGCTCTTTTGGAAAGCAAGAA CACCATTTGAAGTAAAGTGTCACTCTCCACCGAATGGGTCTTAATCTCGAG CTGATTTGAGGAGATGCAAGAGAGCTGGCTGGAATGATCACTTACCTGCA ACCTGGCTGAGAATGTGTCCAGCAAGTTCGTACGCTTGAACCTGGCCAGAA CCGCTCTATCAGGCCATTCAGAGAGCTGATGACATCTTGACCTCAAGTTC TGATGGATGGAGTTTCAGACTGCTTTAGGAGTGAAGATTATGAGCAGCTG GCACACATTCATCGCTACTTGTCCGCGACAAGTGGCTCATTTGAGCTGCA CCGACAGGCAAGGGGGAGCAGTGAATTGATGCCAAGCTGAATTTGCTGCA GGAAGCTGACCAAGCTCTCAAGCCATTGTGGCAGAGAAGTTTGCCATTGC CACCAAGGAAGTGATTTGCCCGAGGTGGAGGCTTCTTCAAGATCTTCCCA CTCTGGGTTTGCATGAGGAGGATTGAAGAGGTTTCGGAGTACCTTTGCA ACGAGGTGGCCAGTAAAGCTGAGGAGATCTGCTGATGCTGCTGGGACAG ACATGAGTATCGGAGAGCTGCGAGTCACTTTTCAGATACACTACTCTCT GTTTGAAGGATTCGCCCATGTGGAGGCCGCCACCGCAATAGTGGAGAC CTATATGGCGAGGAGAGCTCTATACCCGTGATCAAAATCTCGAGGTGGAA TGTGACAGACAGGTGGAGAAGTGTGTAGACAAGTTTCATCAAGCAAGGAC	259 260	FDOQPEYFMEFLTNOAAK GVNKFTVNMIDTCERNG KGNFTGTVKQHCYCGGS KMEINTGPVMTCTCHRC GGRSINSPVCWRGAGQ AKQKRVMPVAGVEDG QTVRMPVGKREIFTRVQ KSPVRRRGADHSDLESI AQALLGQTRARQAQLEYIN VTIPGTTQTDQKRMGGKI PRINSYGDYHIIKIRVP KRLTSRQOSILLSYAEDET VEGTWNGVTLTSSGSTM DSSAGSKARREAGDEEG FLSKLKMFTS*

Shigella ospC1	3	prey67268	60	<p>TACCACGACGATCCCGCATGTTCCAGAACACCTGATGAGAAATTTCTACAA CAGAAAAATCGAACAGAACTGACGCCCATCTGACTGAGTCAACCT CLLSCTGKQKCLDLKLLNN YLMRETNYKVALDITYEKG QLTSSMDDIVFYVKKCIGR ALSSSSDCLCAMLNATTE LESDFRDLNCLRMGPPA TTFDQIRGVTSANVIMHS SLQCGKFDTKGIESDEAK MSFLVTLNNVFCSENISTL KYLSESDTKVFSQGGGE QQAQKFGCLSDLAASVSK FRDLLQEGELTELNSTAIKPK VOPWINSFFSVSHNIEEEF NDYENDPWVQQFLHLEQ QMAEFKSLSPVYDSLTLG MTSLVAVELKVVLSKTFN RLGGLQFDKELRSIAYLTT VTTWTIRDFKARLSQMATIL NLERVTEILDYVWGPSGL TWRLTPAEVRQVLAIRDIF RSEDIKRLRL*</p>	<p>YLRLKRISSDFEVGDSM ASEEKKQEHQKCLDLKLLNN CLLSCTGKQKCLDLKLLNN YLMRETNYKVALDITYEKG QLTSSMDDIVFYVKKCIGR ALSSSSDCLCAMLNATTE LESDFRDLNCLRMGPPA TTFDQIRGVTSANVIMHS SLQCGKFDTKGIESDEAK MSFLVTLNNVFCSENISTL KYLSESDTKVFSQGGGE QQAQKFGCLSDLAASVSK FRDLLQEGELTELNSTAIKPK VOPWINSFFSVSHNIEEEF NDYENDPWVQQFLHLEQ QMAEFKSLSPVYDSLTLG MTSLVAVELKVVLSKTFN RLGGLQFDKELRSIAYLTT VTTWTIRDFKARLSQMATIL NLERVTEILDYVWGPSGL TWRLTPAEVRQVLAIRDIF RSEDIKRLRL*</p>
Shigella ospC1	3	prey67270	61	<p>TACCACGACGATCCCGCATGTTCCAGAACACCTGATGAGAAATTTCTACAA CAGAAAAATCGAACAGAACTGACGCCCATCTGACTGAGTCAACCT CLLSCTGKQKCLDLKLLNN YLMRETNYKVALDITYEKG QLTSSMDDIVFYVKKCIGR ALSSSSDCLCAMLNATTE LESDFRDLNCLRMGPPA TTFDQIRGVTSANVIMHS SLQCGKFDTKGIESDEAK MSFLVTLNNVFCSENISTL KYLSESDTKVFSQGGGE QQAQKFGCLSDLAASVSK FRDLLQEGELTELNSTAIKPK VOPWINSFFSVSHNIEEEF NDYENDPWVQQFLHLEQ QMAEFKSLSPVYDSLTLG MTSLVAVELKVVLSKTFN RLGGLQFDKELRSIAYLTT VTTWTIRDFKARLSQMATIL NLERVTEILDYVWGPSGL TWRLTPAEVRQVLAIRDIF RSEDIKRLRL*</p>	<p>261</p> <p>PCGLWLIYQGGCLSLCL*LG FTTL*RFKVFYSALIM*IPV HKNTANYIECH*XLPPRHSR VLPVC*THL*WCFYSYLTINV LLLYLTNHL</p>
Shigella ospC1	3	prey67270	61	<p>TACCACGACGATCCCGCATGTTCCAGAACACCTGATGAGAAATTTCTACAA CAGAAAAATCGAACAGAACTGACGCCCATCTGACTGAGTCAACCT CLLSCTGKQKCLDLKLLNN YLMRETNYKVALDITYEKG QLTSSMDDIVFYVKKCIGR ALSSSSDCLCAMLNATTE LESDFRDLNCLRMGPPA TTFDQIRGVTSANVIMHS SLQCGKFDTKGIESDEAK MSFLVTLNNVFCSENISTL KYLSESDTKVFSQGGGE QQAQKFGCLSDLAASVSK FRDLLQEGELTELNSTAIKPK VOPWINSFFSVSHNIEEEF NDYENDPWVQQFLHLEQ QMAEFKSLSPVYDSLTLG MTSLVAVELKVVLSKTFN RLGGLQFDKELRSIAYLTT VTTWTIRDFKARLSQMATIL NLERVTEILDYVWGPSGL TWRLTPAEVRQVLAIRDIF RSEDIKRLRL*</p>	<p>262</p> <p>XGXXRXSXXXPLHXVLLRX DX*CLTFMKFXXSNGXDA* PSPCXXXCTCSXGLXLLXXL XXIRXXXTLXLSLXLPSCX* XICXSHX*SXXXPXIS</p>

Shigella ospC1	3	prey67271	62	<p>GCAGGAGCTGCAGAGAAGCGACAGACACAGGTGGGGGAAGATGGGTTT</p> <p>1263</p> <p>GCAGGAGCTGCAGAGAAGCGACAGACACAGGTGGGGGAAGATGGGTTT</p> <p>TACTGAAGATCAAGCTGGGCACTATGCCACAGCTCCAGAACACGATGA</p> <p>CCGCTGCCCATGGAGCTGGCCGCTGCATCCGCTATTTGTAACATGAA</p> <p>CAGAGTGGTCCGAGAGCCACAAATGGTAGCTCTCCAGCTGAGAGCTT</p> <p>GCTGATGCATGTCCGAGAACACCTCCAGATCAACACAGAGCTTGAGAG</p> <p>CTGCAAGTGGTCAAGCAGACAGAGAAATGAGTTAAAGAGCTGACGAG</p> <p>ACTCAGAGATCTTATCATCCAGTACAGGAGAGCTTGAGGATCCAGCTC</p> <p>AGTTGGCCGCTGGCCAGCTGACCCGACAGAGCTGTCGAGCCGGAG</p> <p>ACGGCTCCGACGAGAGCGGTGTCTCGAGGCTGTTGACGCTGAG</p> <p>GGCAGACACTGACGAGTACCGCTGAGAGCTGCCGAGAGACACAGA</p> <p>AGACCTGGAGTGTGGGGAAGCAGACACCATCATCTCGATGACGAGC</p> <p>TGACAGTGGAGCGGCGAGCTGGCCGGAGACGGCGGCCGCC</p> <p>CGAGGAGCTGGAGTGTACAGTCTGTGTGAGAGTTGGCGAGT</p> <p>CATCTGGCAACCGAGCAGATCCGACGGCTGACGACCTTGCCAGCA</p> <p>GCTGCCATCCCGGCCAGTGGAGAGATGCTGGCGAGGTCAACGCA</p> <p>CCATACGACATTATCTGACGCTGGTACCAGCAGCTTATCATCTGAGAA</p> <p>GCAGCTCTCAGGTCTGAAGACCCAGCAAGTTTGCAGCCACTGTGG</p> <p>CTGTGTGGCGGAAGCTGAACGTGCATGAACCCCGCCAGGTGA</p> <p>AGGCCACCATCATGTAGCAGCAGGCAAGTCTCTGCTCAAGACGGA</p> <p>ACACCGCAATGATACAGTGGCGAGATCTTGAACAGTGTGCGCTGATGA</p> <p>TGACACCAAGCCACGACCCCTTGTGCCCACTTCCAGGATATGTCCTG</p> <p>AAACGAATTAAGAGTCAGACCGCTGTGGCCAGAGTCGGTGACAGAGAA</p> <p>AAATTAACCTCTGTTGAATCCAGTTCAGTGTGGTGGAAATGAGCTGGT</p> <p>TTTTCAAGTCAAGCCCTGCTGCGCAGTGGTGTGATGCTTACGCGAGC</p> <p>CAGGACAAGTGCACAGGCCACTGCTCTGGCAATGCTTTGCCAG</p> <p>CTGCGAGGTCGCAATTCGCGTGTGACAAAGTGTGTGGCCACAGCTG</p> <p>TGTGAGCGCTCACTGAAATCAAGCCGAGTGCAGAGCAACCGGGC</p> <p>CTGACCAAGGAGACTCTGTCTGGCGAGAACTGTTCAACACAGCA</p> <p>GCAGCACCTGGAGACTACAGTGGCTGTGTGTGGTGGTCCGATCA</p> <p>ACAGCGAGAATTAACGAGCAATACATCTTCTGGCAATGTTGACGG</p> <p>TGTGATGGAAGTTTAAAAAACATCTCAAGCTCAATGGAATGATGGGCG</p> <p>ATTTGGGTTTGTAAACAGCAACGCGCATGACTGATTAACAGC</p> <p>CAGATGGGACTTCTCTGAGATTCAGTGAATCAGAAATGGCGGCGATCAC</p> <p>CATTGCTGGAAATTTGATTCAGAAAGATTTTGGAACTGTATGCGCTT</p> <p>TTACCAACAGACTTCTCAGTGGCTGCTGAGCCGACCGCTGGGAGACT</p> <p>GATTACCTTATACGTTTCTGATGGCGCAAAAGTAAAGTATACCTCA</p> <p>AATACTACACAGTATCCCTGCGAGTCTGCTACTGCTAAAGCTTTCATGG</p> <p>ATACGTGAAGCAGCATGACGCAAGTGGTCCCTGAGTTTGTGAACGCACT</p> <p>GCAGATGGCGGGCGCGACGCGCCACGCTACATGACACAGGCGCCCTCCC</p>	<p>QELOKKAEHQVGEQGLLK</p> <p>IKLGHYATQLONTYDRCPM</p> <p>ELVCRHILYNEORLVREA</p> <p>NNGSPAGSLADAMSKQH</p> <p>LQJNTFEELRLVTDENE</p> <p>LKLQOTQEVFIQYQESLR</p> <p>IQAOIPLQALSPQERLSR</p> <p>ATLQOQYVSEALWQRE</p> <p>AEQTLQKXVLEPEKHQTL</p> <p>QLLKQOTILDDELOWKRL</p> <p>ROQLAGNGPPGSLDL</p> <p>QSWCEKLAIEIWNROQIR</p> <p>RAEHLCOOLPIPGVEEML</p> <p>AEVNAITTDIALVTSTFIE</p> <p>KOPPOVLKTQTFAA TVRL</p> <p>LVGGKLVNHPPOVKATII</p> <p>SEQQAKSLKNENTRNDYS</p> <p>GEILNCCVMYEHQATGTL</p> <p>SAHFRNLSKRIKRRDRRG</p> <p>AESVTEKFTILFESQFSVG</p> <p>GNELVFOVKTLSPVWVH</p> <p>GSQDNNAATVLDWNAFA</p> <p>EPGRVPFAVPDKWLPOQL</p> <p>CEALNMKFAEVSQNRGLT</p> <p>KENLVLAQLKFNSSSHL</p> <p>EDYSGLSVSWSQFNRENL</p> <p>PGRNYTFQWDFDQMEVL</p> <p>KKHLKPHWDFDQALGVNFK</p> <p>QQAHDLLINKPDGTLFRFS</p> <p>DSEIGINTAKWFDQSERMF</p> <p>WNLMPTTFDRFSIRSLDR</p> <p>LGDLNLYVFPDRPKDEVY</p> <p>SKYTYTPVPCESATKAVDG</p> <p>VYKFOIKQVVPFVNASAD</p> <p>AGGSGSATYMDQAPSPAVC</p> <p>POAHYNYMPOQNPDSVLOT</p> <p>DGDFDLEDTMDVAFRVEE</p> <p>LLGRPMSQWIPHAQS*</p>
-------------------	---	-----------	----	---	--

Shigella ospC1	3	prey700	63	AGCTGTGTGCCCAAGGCTCACTATAACATGTACCCACAGAACCCCTGACTCA GTCTTGCACCGATGGGACCTCGATCTGGAGGACACATGGACGTGAGCG GCGCGTGTGGAGAGCTCTGGCGCGCCCAATGGACAGTCAGTGGATCCG GCACGACAATCGTGA	284	MGIGLSAQGVNMNRLPGW DKHSYGYHGDGDSHFCSS KGQPYGPTFTIGDVIGGCC VNINNTCFYTKNGHSLGIA FTDLPLNYPTVGLQTGPE VVDANFGQHPFVEDIDYM REWRTKQAQIDRFPIGR EGEWQTMQIKWSSVYLGH HGYCAAEAFARSDQTVL EELASIKINFRQRIKLVLGR MGEAETTTQQLYPSLLERN PNLLFTLKVROFIEMVNGT DSEVRCLGGRSPKSDSY PVSPPRFPSSPMSHGM NIHNLASGKSTAHFSGFE SCSNGSVNKAHOSYCHSN KHQSSNLVPELNSINMSR SQQVNFNTSNDVDMEIDH YSNGVGETSSNGFLNGSS KHDHEDCDTTEMEVDSS QLRRQLCGSQAAIERMIH FQRELOAMSEQLRDRCKG NTANKMKLKDFAFLAYSD PWNPSVGNQLDPIDREPV CSALNSAILETTNLPKQPPL ALAMGOATQOCLGLMARSGL GSCAFATVEDYLYH*
Shigella ospC1	3	prey3486	64	ATGGGAATGGTGCTTTCTGCTCAAGGTGTGAACATGAATAGACTACCAAGTTT GGATGAAGCATTCATATGTTTACCATGGGATGATGAGCAATTCGTTTGTCTT TCGGAAGCTGGACAACTTTCATGACCAACTTTCACACTGGTGATGATCATG GCTGTGTGTTAATCTTACCAATACCTGCTTTTACACAAAGATGGACAT AGTTTGTGATGCTTCTTACTGACCTACCGCCAAATTTGATCTACTGTGGG GCTTCAACACACAGAGAAGTGTGCGATGCCAAATTTTGGGCAACATCCTTTC GTGTTGATATGAAGACTATATGCGGGAGTGGAGAACCAAAATCCAGCAC AGATAGATCGATTCTCTGAGAGTCGAGAGGAGAAATGGCAGACCATGAT ACAAAATGGTTTCTCTATTTAGTCCACCTGGGTACTGTGCCACACGAG AGSCCTTGGCAGATCTACAGCACCGACCGTTCTAGAAGAAATAGCTTCCAT TAAGATAGACAAGAAATCAGAAATTTGTTATGACGAGGAAGATGGGAGAA GCCATTTGAACACACACAGCTTATACCCAGTTTACTTGAAGAAATCCTAA TCTCCTTTTACATTAAGAGCGTGAGTTTATAGAATGGTGAATGGTACAG ATAGTGAAGTACGATGTTGGAGCGGAGTCCAAAGTCTCAAGACAGTTA TCTGTTAGTCTCGACCTTTAGTAGTCCAAGTATGAGCCCGACCGCATGA ATGAATATCCACAATTTAGCATCGGCAAGGAGAACCGCACATTTTTCAG GTTTGAAGTTGTAGTATGGTGAATATCAATTAAGACACATCAATCATATT GCCATGAATTAACACAGTCACTCAACTTGAATGTACAGAACTAAACAGT ATAAATATGTCAAGTACAGCAAGTTAATTAACTTCAAGCAATGATGATGA CATGGAACAGATCACTACTCAATGAGTTGGAGAACTTATCCAAATGGT TTCTTAATGGTAGCTTAACATGACCAAGATGGAAGATTGTGACACCG AAATGAGTTGATTCAGCTGAGACCGCGAGTTGTGAGGAGGATCA GGCGCCATAGAAGAAATGATCCACTTTGGACGAGAGCTGCAAGCAATGAG TGAAACAGTATAGGAGAGACTGTGGGAAGAACACTGCCAAACAAATGTTG AAGAGTGCATTCAGTCTACTAGCATATTAGATCCCTGGAAACGCCAATGTTG GAAATCAGCTTGACCCGATTGAGAGAACCTGTGTCTCAGCTCTTAAACAG TGCATATTAGAACCCACATCTGCCAAAGCAACCTCCACTTGCCCTAGCA ATGGGACAGGCCACACATGCTAGGACTGATGGCTGATCAGGAATTTGGA TCTGCGCATTTTGGCACAGTGGAGAGTACCTTCAATGAT	285	IEIHKGAGLFLGGQHPPELE GVEIVISEKSGASPLITVTD DKGAYSVSGPLHSDLEYTVT SOKEGYLVAVEGTIGDQFK AYALAGVSEFKAEDDOPL PGVLLSLSGGLFHSNLLTQ

Shigella ospC1	3	prey14801	65	<p>TTATCCGCTGAGCGGTGGGCTGTTTCGTTCCAACTCTTGACCCAGGACAAGC GCATCTGACATCTCAAACTGAGCCCTGAGCCAGTATTAATCTCAACCCAT GATGAGGAGTTCCGGTTTGAGCCATCTCAGCATGATCGAGTGCAGGA AGCCAGACCTCGAAGATCACCATCAGCGGTACCGACCGCTTACAGTTG CTATGCACATGCTCTCTTAAACGAGAGCCGAAACAGGGTGGCCAT GGAAGCGGTGGCCAGAACCTGACGATTTACGGAGAGACACACCTGAC AGACGAAGAGGCGAAGTACGATTACGTTGCTGCGGGATGTGTGTGA CCAGCTCAGCTCAAGCGAAGCAACGACATTAAGCGGCGCTCC CCACATAGGGTGTAGGTGGGAATATGACATGATGATGAATACAT ATAGTTTCCGCGCATATCAATTTGATTTAAGTGGAAATGTGATCATCTC CTGGAATACCTTCTCATATTGAGGTCAAGCTTTACAAGGCAAACTCG ACAATCAATCAGACAGTTTCCCTTGGCCAGTCCCTGTTCTTCAATTCGCC CCACTCTCAGACGCGGAGAACTATGTTGCTTCTGGAATCCACACTCC CAGATCCAGTATGACTACATCTTGCTCAAGTTCTTCCACGCGAGTGG CTACCATACACACCCACTTGTATTTTAACTCCAGAGGAAGCTGCGTGA CAGACATGACACAGGATCCTACATGCGCTGCGATGACGCTGCTGGTTG TGCTGCGCGGTACAACTACAAAGCTCATTTCTTGTGCTGCGATGTTGAC AAGCGGCTACAGGAGTCCGCGCTGCGCGAGCGCTCTGACAAATA GCGGCCAGAGATGCAAGAGACAAGCCAGCAAGACAAGAGCGGGA CTTGA</p>
				<p>266</p> <p>LGLHSPIALDVLSEAFESL VARDWSRALQLTEVYGRD VDDLSSIKDAVLSCAVAYD KEGWQYLPFKDASLRSL ALQFVDRWPLESCLEAY CISDTAVOEGKGLQELQRL AELOYVKILGLQSPVWC DWQTLRSCCVDPSTVMN MILEAQEYELCEEWGCLYP IPREHLISHQKHLLER RDHDKALQLLRIPDPTMC LEVTEQSLDQHTSLATSHF LANYLTHFYGQLTAVRHR EQALYVGSKILLTPEOHR ASYVSHSNLPLFMLEQLLM NMKVDWATVAVQLQOLL VGOEIGFTMDEVDSLSRY AEKALDFPYQPOREKRSOV HILQEIWHQAADEPTELPRSP</p>

			<p> OTGGACCTTCCOATACCCCTCAGAGGGAACAGCATCAGATCTGTGATTCACCC TCCAGAAATTTCCACAGGCTGCAGATCCCGAGACCCCTCCCTAGATCAACC ATCAGCAGATTTCTCTGCTCTCTGCTGATCTCCAGTATACATATCCCT CTAGTCTAAGGGAAGGAGTTTCCACCAACCAGCCCTCACAGGAATTTGT GCGCCAGGACACCCCTGCCAGGACACAGTGGTACCGGATGAGACTG AGAGATCTGCATGGTCTGTGCGAGGAGCACTTCCACATGTTTAAAGCGG TCATATTTGCGCGCTGTGCGCGCTAGTGTGAGCTCTGCTGCCTCACTAA GAAATGGTGTGAAGCTGCAGAGAACCCCTGCTGCTGTGTGTGATCA GTGCTATAGTTACTGCAACAAAGATGTACAGAGGAGCTCAGAAACCA GAAGCTTAGACGCTCCAGAGTGAAGCCCTCCATCTGCTTTGGTGA GAGTCCCAAGCAGATGAGGTGGAATGGATTTGGATCTCAAGAGGAGG AAATGAGCTGGTGGGAGTAAATTTACTATGAGCGGCCCCCGCCGCT CCTGTGATTTGCCATCTGTAATCTGCACGGGACAGCATTCCTGTGGTCA CCGTGGATTTGAGCACTGCTGACGCTCTCCAGGCGCTCACCAACCCAGA GGTGATGCGGGCTCTCACGGACATCAAGCAGCTGTGTTTCAAGCGC CAAGATGATGTTGTTCAAGCGGCCAGACCAAGACTGGCTCTTGTGAC AGCTACATCAGCAAGGTAGTGTGCTGAATATTTTGTGCTGCTGCTATC GCCAGTGGCATCTTTGGATCAGATCTTGACCGACCTGCAGTAAACAGGCT AAGAACAGCTTTTGAAGCCGAGTACTACCACTGGCGTTGAGGTCTC CACAGACTGGGCTTGATACCCGGGGCGTGGCATGCTTGGGCGCATGGC CTGCTCAAGCGGGAACCTCACTGCTGCACGGGAGATTCAGTCCGCTG TCTGAAGCCCCATTTGACCTCAATCAGCTGAATCATGCTCAAGGCTGGT CAGGATGTGGTTGAGTACCTAGACGTGCACAGTGAAGCCCTTTGTATCCTTG AAGATGACATTTACTTTGCCACCTGAGGAACTGGAAGCTACCTCTCGGAC GCAGAGCTTTCTTGGCAGTGAATCTGGAAGGAAATCATGAACACACC TACTACCAAGATGCTCTTCTACCTGCACACTATAGCACCACTGGCCA TATCAGCTTCTAGTGAGGCACAGCTGCCTGCGGAGGCTCTTGCACTT TCTCAAGGAGAGTCTCCAGAGTTTATTAAGAAGCATTTTCCACCAA GCTATAAAGTGGAGCTACACATTTGGAGAACTTGTAGATCCATTTGA TCCACCTTTGAGAGCTGGGAAAGTACTGATTTGCTGCCGCCAATTTA CAGCAAGAAGCTACTACCACTTGTATGAGCTGCAGCAGTTATGAAG ACCAAGTTCGGCGCCATGACCTGATTCGTTCTTCACTCAAGCAAGAA GTCATACAGAACTGGAGAGAAGCTCTCATGGCTACTTAAGGCCAAGGAC CAGCTGAAGATCTACCTCCAGAAACATCCCGACCTCTGGAAGGAAGAA CCACATCTTTCAGAAAGATGATGACCTGATGTGCAAGGCACTAGAA CACATTTAGCTGCAGATGGAAGTACCAAGTTCTTGCATCGGTGCGAAGT GCTGGGACCTCTCAATCAGCACTTTCCTCTGCCAACCTGTTTGGAAATA ACCAATGAATGATGTTCCTTGCAGGTGCTGCGGAGGGAAGAAATGT AGAAGATGGTTTGGAAATGCTTTCGTTCTGCAAGGACTTCCAGCTGGAT </p>	<p> SAESPAPPPGSISSHPSL HERSFPPTQPSQSEFVPAT PCRHQWPFDESCIMW CCRHFHTMFINRRHHCHRC GRLVCCSCTCKMVEGC RENPARVCDOCYSYCNKD VPPEPSEKFEALDSKSES PPSYFVVRVPKADVEWIL DKEEENELVRSEFYEQA PSALCIALLNHRDSIACG HOLHECHCRISKGLTNPEV DAGLLTDIMKQLLSAKMM FVKAGQSDALALOCYSISK VDVLNIIWAAVHRVPSLD QILOPAAVTRLNRNLEAEY YOLGVEVSTKGLDITGA WHAWGMACLKAGNLTAAR EKFSRLCKPFDNLQNLNHG SRLVODVWEYLESVTRPFI SLODDDYFATLRELEATLR TOSLSLAVIPEGKIMNTFY QECIFYLHNYSTNLAISEF VRHSCLREALHLLNKESP PEVFIQIFQPSYSGKLHT LENLLESIDPTLESWSGYLI AACQHLQVKNYYHILYEO QFMKQDVRAMTCIRFFSH KAKSYTELKESLWLLKAK DHLKYLQETSRSSGRKKT TFFRKHMTAADVSHMNTLT QLQMEVTHFHLHRCESAGT SQTITLPLTFLFGNNHMKM DVACKMILGKNVEDGFGI SVACKMLQDFDAAMTYCRRA AFRLVKEKYSFQQLLKCC FQSGMAKSGDGTILLNC LEAFKRIPPQLEGLQIAIHN DNMKYRAYLICCKLRSAYLI AVKQEHRSATALVOQVQO </p>
--	--	--	--	--

				GTTGCCATGACCTACTCGAGAGCTGCCGCCAGTTGGTGAGAAAGAAG TACAGTGAGATCCAGCAACTGCTCAATGTGTGAGTGAGTGAGGAGCGAG CCAAAGTCCGGGACACCATCTCTCACTGCTGCGTGAAGCGTTCAAGA GAATTCGCCCCAGGAGCTGGAGGCGCTGATCCAGGCAATACAAATGATG ACAAAGGTTGCGGCGCTACCTGATATGTTGCAACTGCGTTCTGCGCTACT GATTGCTGAAGCAAGAACACTACGGGCCACAGCCCTGTTCACGAGGT GCGAGGCGCTCGCAAGAGCGGGATGCAGTAGTGCAGAGACATCTGTG CCAGTGGCTCTGACAAGCCACCCCGGGGTGCCATGGCCAGGCTCC AGGAAGTGA			AAKSSGDAVVODICAQWLL TSHPRGAHGPGRK*
Shigella ospC1	3	prey67279	66	CTCCCTCTGCTAGCTGGCTTCTGTAAATAATATTGTGTCATAGCTTA CAGCTTTTAAACAATTACATTTATTTATTTCAATTTTACACACAGCC GAAAGTGTTTTTCCACTTTACAAATTAAGATGCAGAGCTCAGCAATANN NN NN TATTAAATGTCTGGGCCAATTACGTAATCAGTAAGC	267	LPLIAGFLI*HICVIAVSFLNI FTFISNFHTS*PEKCFHFT N'DEAGQQXXXXXXX XXXXXXXXXXXXXXX GEAQQY*MSGPIT*SVS	
Shigella ospC1	3	prey67280	67	AATTTCCACCTCCGAAGGAAGTTATGATTTTCTAGGCCCTTTTCTATGT CTTTACATCTGTCTACACACACAGCTATACACACACAGCTTATTTT AATAAATAGGATTAATCCACACACATCTGTCAGCTGCTTTTGTCTTAAGA GTATATCTAAGAAATCCTTTGTGTCAGTGAAGCTGGAGCTACCTCATCTTT TAAGTGGCTGCGTGGGTTCCATGAGTGTCTGTCATCATGTGTTTAGCCGA GTGGATGGATAGTCTGCTGTTTATGTTTNTGC	268	NFHLPREVVVFF*ALFYVFT SLSHTRHTHLSLFLK'DY TTHLSLAFLLKSISKRLICVS EAGATSF*LAARSIKLS SCV*PSGWIVCLFLVX	
Shigella ospC1	3	prey49194	68	CAACCCGTGCCCTCTATGCGCCAATCTAGCCCGCGCTGGCGACAGCAG GATCCACGTGCGCGCACTGGTACTGCTGCGGAGTGGAGACGCAT TGCTTTAGAAAGAGCCTGAGCAGCACTATGGCGGAGCGTCCACAT TGAGTACTGTGCACACTGCTGCCAAGCCTGCTCTTTCACAAAGTGC AGCTGCTCCGGCAGCGGCTGACCAACAGAGCAAGGGCTCGTATGCA GTGTTCCAGCTGCTGGTGAAGCTATCTCTGGGACCAATGTTCGTGTGG GCCCTGTGAACTCAGCCAGCAGCAGCCCGCCCTTCACTCTGCC AAACATGGCTCACTTGGGCGAGTSCCACTGCCCTCTCCAGCCTTGCA CTCTACCAAGACCTGTGAGGCTACCGGTACTCAATCAAGTGTCTTGAAT GTCAAGAGATGCGGAGTACATGGTCTGCGTGACATTTCCAGAGGA CAACAGAGAGACAGAGGGGTGACCTGCCAGGTATGCCAGATGCTGCTGC CTCAACAGTGCAGTTTGTGGCCACACAGCGGATTCATGCAACAGTCCGC CTACTGCTGCCCGAGTGTGGGCTGCTGCGGCTCTGCTACTTCCAGAC CCATGTAAAGAGAATTCGCTACTATGCCGCAAGTGGGCTACAGGTTG CATCCACTGTGGTGTGCTCCACTGACCTTGGCCTTGTGTGAAAGCCACATC CAGAGGCACACTGCCAGTTTTCACAAATGTGCATCTGCCCCATGGCT TCAAGACTGCGCAGGAGCTGCAAGCAGATGCCACCAAGTGCACCCAGCC AGCCCCACAGACCCCTCCAGCTCATTTAAGTGTCTGCTGTGAAATGGTCTT	269	NPVFLYAPNLSPPADSRH VPASGYCCGCGDAFALEK SLSQHYGRSSVHIEVLCTL CSKTLFFNRKCSLLRHARD HKSKGLVMQCSQLLVKPS ADOMEFVSAPVNSTAPAAPA PSSSPKHGLTSGSAPPPP ALPLPYDVLHRLYSIKOLE CHQMDFMYDMAALHFQRT TEETGLTQCVQCMPLPNQ CSFCAHQRIHAHKSPPCCP EGVLCRSAYFQTHKEN CLHYARKVGYRCHIGGVVH LTLALLKSHIOERHOVPHK CAFCPMFATASSTADHSA TQHPTRHPSQLLYKCVS EMVFNKRIHQHQFYQNV KTQGVKFCPEPCLLVQK	

Shigella ospC1	3	prey67287	69	CAACAAGAGAGGACATTGACGAGCATTTTACCAGAAATGTGACGACGAGG CAGGTGGGGTCTTCAAGTGCCTGAGTGCACCTCTTTGTCGAGAGAG CGGAGTGTATGACACCTCAAGACGACCCAGCTTCTCCGGAATAGT GACAGCTGTCAACCTCCAGTCTTACGCGACACATCTCCAGCGCCTCT GGCTCTGAGTTCCACTGACGACCCAGCACTAGTGTGCTGCGAGG AGCTCGTGCCTTCTGGCGCTGGGTAGGCTGAAGCCGACGAGGCT GAAGACGCGCGCGCTGAGGAACACTGGCTGGACCTGCCAGAGTGGC ACGGTGGGATTCAGATCGGAGAGCTACGTGCCACATGAAGAAGAGC ACGCTGGAATTTGAAGCGGTACCCATCGCGCAGTGTGAACAGCTCTCC ACACCCACACAGCCTGCGCAACACATACAGGACACCAATGACACAGTAA GAAGTTTACACCTCGGGTACTGCACAGGACGACCCGACGCTTCTCGT GGCTCCCTCTGAGAGCCACATGAGCTTATGCAATGGCATGACGAACCT GATTTGAGCCAGCTCCAAAGTGAACCTCCGGGTGGACATTCCTCCAG GTGAACATCTGAAGACGACGTGAGTGGGAGCGCTCCAGCGACCC ACCAATGGCGCAAGTCTCTTCCACAAAGGCACAAAGTCCCTTTTTCAGT GCGCAATGTAGTTTGGCACAGCTCGGGGCTCGAGTTTCAGAGCACA TACCTGACAGGTGACAGCTCCACAGCCCAATGTCTCTGTGTGTTT GTGTACACCTCTGCCAGCTCCCTACGCGCCACCTCTCATTTGTCACAG GTGAGACAGGAGGAGGAGGAGGAGGAGGAGGCGCGGACGAGAG TGGAGTGGAGTGGCAGAGCGAGGAGGAGGCTCCGCGAGGAGGTGCT CATGGAGTAGAGAGATGGACTGGAAGATGTCCGCTGAGGCTTTGTC ACGTGCCACAGGCGAGGAGATGCTGGCCCGCGCCCTGAGGACGATG GTGGCCACATGATCAGATCAACACAGGCGCTCTCAGGACGAGCAGCC ACACACTGTCCCTCAGGTGTGA	270	EHSSSLVLMFF-VCL-VGKV DLFGLA-GLNVSSSLGLLIS PSWLGMISLKGQF-SINIL PSNILLTVYVFSSEF-ALSR KSNALAFNQK-KVY
Shigella ospC1	3	prey19931	70	GGTGACCAAGTGACAGATCTTCAGAAATGCCAGCTGTCAAGCGCTCT TTGCTGGAGATGGCAAGCTCTGA	271	VHQVTDLSRNAQLFKRSL EMATF*
Shigella ospC1	3	prey67290	71	GGGGGGTGGGATGGGAGGANNTTATACANNNAATTCCTTTGGTANTNATA CAGGTGGNANTCTNTNNTGAANNITCTATGACANNAATATCTTTT NTCTATCTTCTTNTGCTCTGTGGGAGGCTGCTNTNTNTTANNNG TCTTGNTATTTCTNTATAGCAAGATATCAGGNNTCTNTNCTNCTAT TTTATGANATANNITGCTNTANNCTNTNANAATCTGATTAAATATTATNNACT NTTTTACATCATAGNNAATCTTT	272	GGVGMGR**XXLLLVXIQ GXLY-XXLXTXNIFXS XVFCGRLLXLLXIFXIS RISAXLXLYFXLXXXXX NLINYLXLLHXIF
Shigella	3	prey67291	72	TTTGAAGGGTNTANNAACATAGGANAATGTGGCTATAGTTTGAAGCTNCT	273	FEGXXXT-XNVAVVWNLHLI

ospC1	3	prey67294	73	TACATATTGTGGAATGGCTTTGACANACTTGCATAGTATGATATGAACATTA NINGTCAAGCTGAGGTGCTCAATAGAGATGAGAACTTTGTGGAACT GAAGACAGGTGACTCTTGTATTTTANCCAAGCAAGCTGCTNCTATTG CCTNGCCCTANANATTTNGAACTTTTACNCTGAGANANATGATNCANGAT CTTGGNNGANGANNNTTAAINGNNNTATTNN	274	C*MALTXLXVITLXSKLRW SOMENHLITGEXQVTLV MFXPRIISFCPLCPXXXW NFXXEXDXXSWXXXXXX XXYX QAQVPIQVAKIYSLVFFXK* IKSVHFGLIUFLICLFEVNF FLVLKSSSSSXXC*ENXC SH*XYFGYLX*XXYXXYXV XNXLRLXVAXRRKXXXXXX RE RVGMGWASVVRSPDPHVC CPKPRSLWVYVSVGLG** LDTRLTGLOFTFRLWLW CPGVSN*PGSOGCRLFP GWGAAC*TCQSGFAGLFXI CFR PPPTVHTVSAQCLLFF KXFXXXXXXXXXXXXX FXFXFXFXFX*XXXXKRX KXKXTXGXGLL*NXPLN XPQXXFX*XRFXKXGLG
Shigella ospC1	3	prey67296	74	GCAAGTGGGATGGCTGGGCTCTGTCGTCGTCGACGCCCTCATGTG CTANAAATAGATTAAGTCTGTGATCCATTTGGGTAAITTTCTGTGATGAT AGCTTGTGTGAGGTAAITTTTCTAGTTTAAATTTACTCCAGTTTGTCC ACGTCNCTGTGTGAGAAATTTGTNTCCCATTAANATTTACTTGGATACCT NNGTGANNTATATGNGNCTATANNGTGNGNAGNACNGACGCTGG CAGNGTGGONTANGCTGTAGNNGTNGNAGNAGNAGNCCGNGAGA AGAGTGGGATGGCTGGGCTCTGTCGTCGTCGACGCCCTCATGTG TGCTGCCCAACCTCGCCCTCGCTAGTTTGGTATTCTGTCCGCGCTGG GGTAGTGTGGACACAGACTCAATCTGGGCTCCAGTTCCGACTTTTGG CCTCCTCTGGTCTGCTCGGTGAGTAAACCGGGTCCGACGGGTG TGGTCTTTTCCCTCGGCTGGGCGCTGCCGTGATCATGCCAGGGATCTTT GCAGGGCTCTTTCATCCANAITGCTCAGGG	275	RVGMGWASVVRSPDPHVC CPKPRSLWVYVSVGLG** LDTRLTGLOFTFRLWLW CPGVSN*PGSOGCRLFP GWGAAC*TCQSGFAGLFXI CFR PPPTVHTVSAQCLLFF KXFXXXXXXXXXXXXX FXFXFXFXFX*XXXXKRX KXKXTXGXGLL*NXPLN XPQXXFX*XRFXKXGLG
Shigella ospC1	3	prey67299	75	CCTCGCTCCACACAGCTGCACAGTGTCTGCCCAATGCCATCTTTT TTTTAANGAANNTTANNNGNANTANANNNGNTAAANGNCTNNNC NTNANCCTTTTNNNGTTTTTNNNTTNTTTTTTNGNTAANNANNNGTT TTTNAAGAGGTNNAAAAATNTNACANTTTTNGGGNTAANTTTTAAIT AAACTTNGNCCCTTAAATANCACCNCNCAANTTANCAATTTTNAAGTTT TNAANAANNITGGGA	276	PPPTVHTVSAQCLLFF KXFXXXXXXXXXXXXX FXFXFXFXFX*XXXXKRX KXKXTXGXGLL*NXPLN XPQXXFX*XRFXKXGLG
Shigella ospC1	3	prey4637	76	ACGAGAAGGATGATAAAGCCGACGCGAGTGAAGACAGTGAACAGAA CAGATGACAGCTCGCGCTTTCCCTGAAATGCGAAGCAACTTCTACG TAATTTGGTGCCTGAGGAAGAGATTAAAAATTTGTCGCGTGGGAAGTG ATTGATGGTGGCACAATGTCAACAGAACAGGCTGCTTCTGAGAGGGG CCGATGAGTAAATTTGCCGTGGATCAAGTTTCTGCGTGAAGTCAAG AGCGTTCAAGAGGAATGTACGCGCATTTTGACCTACAGAAACAGGTCT GTCACTCAAGTGTCTTCACTGACACAGACGCTGAGTGAAGT AGTCACTTTGAAGAAATGGGAAGAACATTTGAACAATGTTGACAAAGA AAACAGCTCTCAGCTTTCACTGACGCGGAGAACAGGAGCGGAAGAAC TAGAGGAATGCTAGTGGCAGGCTGAGCAGCATCCGGAACAACTACAA GAGATGATGACAGCTTCCGTGACTGCTTAACTTCTGCCACTGACG CTGTCTGAAGTTTATCGACGTTTCSAGATGAAGGGGGAAGAGTATGT CGCTGTGACACAGTCCGAAACCGCTGTGATGAGTATGCGCATAC GGACTACAAAGATGAGGAATTCATCGAAATTTGCCGTTTTGATGAACA CATCGGAGAGATGCGAAAGAACGCGGAGGATTCAGAGCACTACGAGG CGGCTTAAGAGGAACCGAAAAAGGAGAGCTTAAGGGTCTGCTGAGAAG	277	QKDKPEQPPVKKTVTGTD ADLRSLIKNAKQLRKFG VPKEIKLSRWEDVVRFT MSTEQARSGEGPMKFAF GSHFVAHQERYKEECQ RIFLQNKLSSTEVSLTST DSSAEDSFEEMGNEN MLQNKTSDFLSREEQ ERKELORMLLAAGSAAG NNHRDDTASVTSLSNAT GRLCYHTFRDEEGKEYV RDEYRKPAVIDAYVRIT KDEEFIFALFDEQHREE MKERRIQEQLRLKRN QEKELKGPPEKPKNIKE QERDLKJCGACGAGHMRT

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

			<p> GGCTTGCTGTCGAGAGAGTGGACCTTCAGATGGGGGGTAGACGACG CATAACGGCTTCTGGCAGTAACTGTAGTACTCTCTCCGCTCCGAGGAC GGCTCTCTGGACCAAGCCCTTCTGCTGTGGTCTACTATTTGTG GATGACAAAGCTCAACTACTAGCGTCTACCCGAGTACTGAGAAATCTCT GCTACATGCCAGACCCGCACTGGGTATCCGAGTCTGCTCTCATCTT GAGCGAGCAGTGGAGTGAGTATGCATGTAAACACCCCAAACTACTACAC AGTGGAAAGGCGAAAAGTGGAGCAAGAGCTGTGGTCAAGTAGCCAT GAGAACCTCCCTGCGCTCTACAAAGTAGAGTAGAAGAGCTCCAA CAGCTTCTGCGCTCAGTATCATGATGACGCTAGCGAGCAGTCA ATATATTCAGATCCAGCTTCAGGGGGGCTAAACATACCGAGAAGCATGC AAGCGGTGGCTCCACGCTCCATCATCCCAAGCTGCTCTGTGCTG CAGACAGTGTGGATACACTTCAATTTGGCCAAAGTATTTCCAGCCACT TCCAGCAGCGGCAACAAAGAAACAACTGTGAGAGTGATCGGGAAGGG GCAATAAGCGCTGAGCCGCTCTCCAGCTCTCCAGCTCCGAGTGGCATTTG CACAGACTTCTGGGACTTATGGTAAACTGGACAACTGAATGTCCAGCGG AAGGCAAACTCCGTGAAGTCAAGTCCAGTGAGCGCTGGCGGTGAGCG GGAACCTCTCCATACGCTCGAGGCTCTCCACTGAGCGAGCTCATGAA CATGTTGTACACCGAGTCACCGCGGAGCTCTCTTAACTGAGAACTC CTCAGACTCTTCTCTCATCTCAATTGCTCTCCAGAAACAAAGGTGTGAGA AGCAGAGCTAATCTGGCAGCGGTCTTCTCCACCACTGCACTGCACTC AACCAGCTACCAACCACTGCGGCTCCACCACCGCACACCCGCT TACTGACCCACCTGTCACTCTGCTCAGCGCTGCTGCTGCGCAGCGCT ATTTCACCATTTGTAGTCTCTGACACAGTACTACCCCAAGCTG CTACCACTACTGTTCAATTTCCCACTACTAGGCGCAAACTTCCAGCG AAGTGTAGTGGGCGAGCAGCTACAGACTTAAAGATGTGCTCTCT GGCTCAGTGAACCACTACAGCTCTCTGAGAGGTGTGACTCCCACT CTGTCTGAGAAAGCTTAGAGATGCAGCCAACTACTACTGCACTCTC CGGGGGAGCTTGGACCCCGGAGCTGTCTCAAGCTGCTACTGAATGG AGCCGCACTTGGGTTATCCCTTTGTAACAAATAGGTACCCCTGCTGGCC GAGCTCGGGAATACACCTCGAGCAGCGCGCGCCCAATGTGAAAC CTCTCTCTGAGGCTGCTGAGGAGCAGCCAGCAGCAGCAGCTGAGG GGCAAAATGACAGCAGGTTTACATGGCTGAGATGTGGTAAATTTGGGCT CTCAGAAAGCAGCTTGGGTGGCGGAGCTCCAGTGGCTCTCTATGCCA TGTGTACATCCAGACATCTACCAAGATTCTTGTGAGGCTACTACAGGT CATTCATCCAGCTCGGAGCAGCGCGCGGTAAACAGAAAGCAGGCA GACAGGAGGCTAGGTTCTCGGTTAGGCTGAGCTAGCAGCAGCTCAGAGC AGCTGTTCGCGAGCTGGAGCTGAGCTGATGCCATTACAAATGTAGC TGAGGCTCAAGGGCGGAGACAGCAACAGCAGCACTCGAGGTCTA GCCAGTACAGAGGCGTCTGTCGGGAGGAGGAATCACCCATGATGTGAGC </p>
			<p> PSGNSVDTLLRLRGLLLD HEALSLLVLLVDEPKLNT SRLHRLNLRCHSAOTHR WYRSLLSILORSESELCIE TPKLTSEEKGGKSKSCG SSSHENPLDLHKMESKS SNQLSWLSVMDAALGCR TNIFQIRSGGRRKHTEKHA SGGSTWHHPQAPWVCRH VLDTLQALKVFPSPHTQOR TKETNCCSDRERGNKACS POSSOSSSGICTDFWDL VPLDNMNVSRKGNVSKS KFSVAGGEGETSPYSLEAS PLGQLMNLSPHVRPSSL LTKLRLLSLSIALPENKV SEAOANSOGSGASSTTATS TTSITTTTAAATTPPTPTAP TPVTSAFALVAATTAITWA ASTVTPTTATTTVTSIPT TKGSKSPAKYSDGSGSSST DFKMVSSGLTENQLQLSVE VLTHSROSEEGLEDAANVL LOLSRSDSGTHTDVLKILL NGARHLGYLTKQIGTLTA ELREYNLEQQRACQETLS PDGLPEEQPTTKLKKGM QSRFDMAENVNVASOKRP LGGRELQLPMSMLTSKTS TOKFFLHVLIQLRDDTR RANKKAKOTGRLGSSGLG SASSIOAAVFLTEAADAIL QMVREGORARRQQAAT SESSOSEASVRESPPMD VDOFPSAQDPTOSIASDGT POGEKEETPERPELPLISE QLSLDELWMLGECLEKE ESHDOHAVLLOPAVEAFF LVHATERESKPPVRDITRES </p>

[illegible][illegible]

ospC1	3	prey2686	86	<p>CAGCGAGTGCACTCTGCCACATCTGCTGCTGGAGCATAGAACCTGCTCTCC CGCTCCCTGAGCCAGCCGACCTGCGACCTGGAGCCACCTGAGCACA AAGTAACTGCTACGATCAAGCTGACGCGGCTGCGAGGACCTGGATG ATGTGAGAACAGCAGCAGGATGTGCGGATGACTCGAACACAGAAAGTG AGAGCTACAAGAATACCGMAATGAAGCTCTTGGACGCTCAGA GACCACTCGACAGGAATAAGGAAGAGGAGAGAGGCTCAACAGCAA GTTTGACCACTTTTACGATCTCTCAAGAAAGAGTGAGATCCAGACT TGAGAGGAGATGAACAGAGCTGACCAAGAGGATGAGTTGAGTTCT TGAGAAAGCATCAAACTGCGAGGATCTCAACAAGCAGCTGCTACATCC CGAGTGGAACTGAACCAAGCTGATAAAGGCTCCACAGAGCAGCAT AGACCTCAAAACAGCCTGAAGCAGTGCATCGGCGGCTCCAGAGCTCAC CCCCAGTTGAGGTGAGCTGGAGCATGACCCAGCGTCCACACAAATC CACAGCCCTGTGAAGAAGTCTCAAGAGGAAAGAAATCCAGAAACCT CCCGCTGCTGCTTACCAGCAAGCTCCACAGCTTTGGAGCCCGGAA CAGTTAGTGATTTAAACAAGCTGCTGGAGGCTGCAGCCAAAGCCACCA GCTCACTCCGAACCTCAACATCTCTCAAGGCCAAGGCTGGAGACTTCTCT GGCAAGTCCAGCTGAGCTCTGGAGTATTACATTAAGTCACTCTGGAC TACAACCCGCCACACAAAGTGGCTCTGTCAGAGTGTATACAGTAGCTT CTGTGGCTGAGATGCTCAGAACTACCGCGGCATCCCGAGGTTACAT ACTGCTCAGGTGCTGGCGCTGCATCTACAAAGAGGATCCACTACT GGAGGTGGAGCTGCAGAAACACTCTGTGGGCTAGGCACTGCTACG GAAGCATGAACCGGAGGCGCCGAAAGCAGCTCGGCGCAACAGCGCC TCTGGTGGTGGAGTGTTCAACACCAAGATCTGTGCTTGGCAGCAATACG TGAGAAACCTGCCCTCCACAGGCCACGGGCTGGCGGTGTTCTCA ACTGTGACCACGCTTGTGATCTTCTGAGGCTTGTACCGCAAGGCTCCACT GATGTAAAGTTAGGGTGGACTTTACTGAGGCTTTGTACCGGCTTCTGCTG GTATTTCTGCTGTGCCACACTCTCCATCTGCTCCCAAGTATG</p>	<p>MEQLADVTLRLLDNEVFD LDPLDQFSQTRKLEAR AONEFFRAFLPRKELH AVDCSLWTFPSRCHTAG RMFASDSYICFASREDGCC KIILPLREWYSIEKMDTSL PHIIVSRKSAVOAFIELRD RSLVLEATLARLKQVFNHS PHYOTSDADDMAVSLVHS TSMCSDHFRFGLDLMSSQ NSEESEKESPLMHPDALV TAFQSGSGSDPSDRMSRE</p>
Shigella ospC1	3	prey2686	86	<p>CAGCGAGTGCACTCTGCCACATCTGCTGCTGGAGCATAGAACCTGCTCTCC CGCTCCCTGAGCCAGCCGACCTGCGACCTGGAGCCACCTGAGCACA AAGTAACTGCTACGATCAAGCTGACGCGGCTGCGAGGACCTGGATG ATGTGAGAACAGCAGCAGGATGTGCGGATGACTCGAACACAGAAAGTG AGAGCTACAAGAATACCGMAATGAAGCTCTTGGACGCTCAGA GACCACTCGACAGGAATAAGGAAGAGGAGAGAGGCTCAACAGCAA GTTTGACCACTTTTACGATCTCTCAAGAAAGAGTGAGATCCAGACT TGAGAGGAGATGAACAGAGCTGACCAAGAGGATGAGTTGAGTTCT TGAGAAAGCATCAAACTGCGAGGATCTCAACAAGCAGCTGCTACATCC CGAGTGGAACTGAACCAAGCTGATAAAGGCTCCACAGAGCAGCAT AGACCTCAAAACAGCCTGAAGCAGTGCATCGGCGGCTCCAGAGCTCAC CCCCAGTTGAGGTGAGCTGGAGCATGACCCAGCGTCCACACAAATC CACAGCCCTGTGAAGAAGTCTCAAGAGGAAAGAAATCCAGAAACCT CCCGCTGCTGCTTACCAGCAAGCTCCACAGCTTTGGAGCCCGGAA CAGTTAGTGATTTAAACAAGCTGCTGGAGGCTGCAGCCAAAGCCACCA GCTCACTCCGAACCTCAACATCTCTCAAGGCCAAGGCTGGAGACTTCTCT GGCAAGTCCAGCTGAGCTCTGGAGTATTACATTAAGTCACTCTGGAC TACAACCCGCCACACAAAGTGGCTCTGTCAGAGTGTATACAGTAGCTT CTGTGGCTGAGATGCTCAGAACTACCGCGGCATCCCGAGGTTACAT ACTGCTCAGGTGCTGGCGCTGCATCTACAAAGAGGATCCACTACT GGAGGTGGAGCTGCAGAAACACTCTGTGGGCTAGGCACTGCTACG GAAGCATGAACCGGAGGCGCCGAAAGCAGCTCGGCGCAACAGCGCC TCTGGTGGTGGAGTGTTCAACACCAAGATCTGTGCTTGGCAGCAATACG TGAGAAACCTGCCCTCCACAGGCCACGGGCTGGCGGTGTTCTCA ACTGTGACCACGCTTGTGATCTTCTGAGGCTTGTACCGCAAGGCTCCACT GATGTAAAGTTAGGGTGGACTTTACTGAGGCTTTGTACCGGCTTCTGCTG GTATTTCTGCTGTGCCACACTCTCCATCTGCTCCCAAGTATG</p>	287

Shigella ospC1	3	prey67368	87	CAGTACAATCTCAAAACCTTTTGAAATGAGCCACCAATCAACAATCTGAACCTTAA GCTGAGTAACCTTGATG	288	LPDLQEPYVOPPYTLVLE LTGVLLHPEWSLATGWRFK KRPGETLFLQQLAPLYEIVF TSETGMTAFPLDSDVDPHG FISYLRDRATRYMDGHHV KDLSLNRDPARVWDDK KEAFRLQPYNGVALRPWD GNSDDRLVLDLSAFLKTL NGVEDVRYTLHYALEDDP LAFAKQSRLEQEQQF LAELSKNKONFLGLSLS HLWPRSKQP*
Shigella ospC1	3	prey67371	88	TGGGGGGTGGGGATGGGGTGTGTTNNNNCTNTTTTNTNNNTNNNN ATTGNNNTTNNNTTNTTNTACTATGACNTGANTGATTTTTTTTTTCTTAT NTTNACTTNNNTCTGGNGAGGNTGNAANTATTTTATNTGNNNTTANT CAATTTTTCNAITTAGCCGANANTCNNTATCCTGATACCTCTCATTTGATGA CNTATTGNCITATANTCNTTTTNGAAGCNTGATTANGATTATAAANTNNNTT NCATNCGGATCCANTCN	289	WGYGMGFVXXXXXXX WXXXXLLWT*XIFELFX LXXVGGGKXFXXXXXXFX SRXSXS*YFXIX*XXLXXXXX XDXDL*YFXXGSGX
Shigella ospC1	3	prey4005	89	CTACACAACTCTTTGAGAGAGCTGCTCCTGAGGACCCCTCTGAGGAAGG TCCGGTGATTTTGGCTCTCTGATGCCAGTAGTAGCTGAGTCGAGGCA AAACGACCCAGCTCAGCCACTGTGAAAGGAGCAAGATAAATCAAAA CTCTTCCCTTGAGGAGCTGTGACTTCCATTGACGAGCTTCCAGGCTCAG TGTTCCATGCTTTCAACTCTCGGACAGAGAACATGAAGATGGGCGAC CACAGCGAGCTTTCTTACTCCAGAACGCTGACGCCGCGCTACAGC AAAGCCGAGTACAAATGCGGCTTGTGATGAGCATGCGAGGACGACCCCC AGGACATAGGAGGCGTCTTTTATGATTTGGCTGCGAGCCAGGCG CACAGCTGCTCAGTACCGCTATGCGAGTGCCTACTACGACCCAGCC TCTCTGAGACCCCTGAGCGGAGGCGAGTGTCTGCTGAGGAGCTCTTCC GAGCATGAGCTTGAAGAGGCCAAGCTTCTCTCGGGTGCCTTTTCCACC AAGAGCCCTACCTGATGAGCAGAGCTGTGAATAATCTTGGCTTGAGG CCAAATAGGAGCTACAGAGGATACCACTTGAATTTGCTATGAGAA AGGCTTGTGTGAGAGGAATCTGGGAGGAGCTTGGATGTTACAGCA GTAGCCGCTCTGAGAAATGAGCGCCGAGGAGGCTGCGAGCCCTCT TTTCCATGGGGGCTGAGCCCGGCGGCGGAGCTGACAGTTACAGGA CTGAAGTCTTTCTCAGCCCTACCATGCTGAGCAGCTGAAACCTGCTACGAG GAGCTCAGCCCTACCATGCTGAGCAGGCAAGCTTGGGCTCTCTCT	290	SHNSLRGARPODPSEEGP GDFGLHASSIESEAKPA QPOPTGEKEDKSKTSL EAVTSIQQLFQLSVSIAPNF LGTENMKSGDHTAASFYF OKAAAGYYSKADYNAGLC HEHGRGTPRDJSKAVLYO LAASGSHSLAQRYARCLL RDPASSWNPERQRAVSL KQAAQSGHLREAOAFLGVLF TKPEYLDQRAKYLWLA NINGDSOSRYHLGICVEKLL GVORNLEALRCYQSOAA LGNEAAQTHRALFSMGA AFPGSDLTTLGTLSKFSFSP LCSLNTLLAGTSLRPHASST GNLGLLFRSHGLGASLEAS SRAPHPYPLERSVRLG

Shigella ospC1	3	prey67380	90	<p>GCAGAAAGTGGCATCTCGAGGACGACGCTCGGAAGCCTCCAGCAGGGGTATTC CCCCACCCCTACCCACTCGGAAAGGAGTGTGTAAGACTAGGTTTTGGCTA A</p> <p>NN ATGATCTCTTTAAATGTAAGTTTGTGTTTATAATTTTTCACATCTACTGGA ATTAAATCGAAGCACTGTTTGCAAAATAAATTTTGTCTCCATCTGCTGCC AAAAGTCTCGATGTCACAGTATTTCTCTCAGGACATCTCTATTGCTGCCA AGTTTCAACAGATTTTGGGAGCCAAACCTCAGGATTTACCTCTANATCTGG TTAACTTTTGAANAATACANG</p>	291	<p>XXXXXXXKXXXXXXSLCIF F*V*VLCIFH*YK*SEQ*LC AK*LLSILAKS*MSRMISP GHL*YCSOVSNFLGAKTSG FTLXLVNLKXXY</p>
Shigella ospC1	3	prey3296	91	<p>GGACCGTCTGTCAGTGGACAGCGCGGCGAGTGGACACACCTTTGAGTCTCG TGCCAAAGAGGCTGTGCCCTCCAAAGAGCTGGAGAGCGCGCGGACAAAT GACCACAGTGTGGACGCCACGACGACGCAAGCCCATCAAGATCGGCGTAAC CACACTGCCACTGTGCATGTCTAAGGCTGCTGCTCAACTTTGATGAG TTTGCTGTCAAGAGTGGCATTTGAAGAGTCTGACCACTGATGCCACGG AGGAAGAGCGGACAGATTTAGGAGCGCCAGCTGGCCACACCTGACATAC CCCTGGGCCGCGCAAGATTTCTGATGACTCTTCCCTCCATTGCGCGCC TGCGTCTGCTACACTCTGGGCTTCAAGCTGGACTGATGACAGCATGGA GGGGAAATTTGCTGAGCCACTGTTGACCTGAAATGGGTGATGGAACAGCT GGTAGCAAGATGCCACTTCGCTGCACTGCGTACCTCGCTGACTGTGGG CAACTTCTCATGGCTCCAGACAGCGGCTTTGAGCTGAGCTGACTGTGGA GAAGTGTTCAGATGTGAAGGACACGCTGCTGACAGTCACTGCTACACCA TCTCTGCTCCCTAGTGTCTCGACGCCGCTGAGTCCCTGCTGACCTCTATTCA GAAATCCCTGCGCTGACCGCTGCGCCGAGGTGGACTTTGAACAGCTGACT GAGAACCTGGGCGAGCTGGAGCGCGGCGGCGGAGCGGAGGAAGGCC TGGCGATTTGCTGCGCAAGCATGAGCTGGCCCGACCCCTGCGTGGCCGCTC ACCCACTTCTGGACAGTGTGCGCGCGTGTGCACTGTAAGATAGTGT CACCGCGTGTCTGCATAGTTTCCATGCTTCCCTGCTGCTACCTGGGCTACA CCCGCAGGCGCGGTGAAGTGGCATCATGAGTCTGCTGCCACAGCTGAC GGGAATTTGCGTGTGAGTATGCGATGCTGCGCGGAGCAGGTGTACAGCAGC ATCCAGAGCGGCCACATCTTCGAGTGGCGAAGAACCCGCGGAGCGCATG ATCAGGACAGACAGAAATTTCTAGGTGTGGTGGGAAAGCCCGACCAAC CCCTGTGCCAGTAGCAGTAGCAGCGCGGCGGCGGAGAGTGTCTGA CAGTCACTGCTAGTGAAGAGTGTCTGACACAGAGGCTTGAGGACACAC ACACAATCGCCGACAGGATGTCGACAGCAGCTCCCCAATCATGCC ACAGTGGCGCTCCACTGCACTGCCAGAGAACCCCGAGCTCCAGTTT ACCGATGATACATCAGATGAGTATGAGCTTCTGGTGCAGTCACTGAGCC AAGAGCAGTCTCTGCGCTTAGCTGCTAGGGAACCGCAAGCTTCCCGCGGC AACCAGGACTTTTGAAGAGGACGTTGAAGAGTGGGCTCGGAGATGACCTG GTGCGGCACTGGGACTAAGCAAGGGTCTCGGCTGGAGGTTGTGA</p>	292	<p>DPVSDVTAARLEHLEFESRAK EVLPSKAGGHEHRRMTTTLV DKPRTNAINIGLTTLPVHVI KAALINDEFAYSKDIEKL LTMPTTEERQKIEGAQLA NPDIPLRQENFNLMTLASIG GLAARLQWAFKLDYDSM EREAEPLFDLVKGMEQLV QNATFRCILATLLAVGNFLN GSQSSGFEELSYLEKVDVK DTVRRSHLLHLCSLVLOT RPESDLYSEIPALTROAKY QETENLQGLERRSRA EESLRSIAKHELAPALRA LTHFLDQARRVAMLRIWH HRVNRHMFHLLYGTPTQ AAHVRIMOFCHTLREFAL EYRTCRERVLLQOQKQAT YRERNKTRGRMITETKFS GVAGEAFSNPSVPVAVSS GPGHGDADUHSASMKSGLT SRLLDTTHNRRSRMGVS SSPIMPVTGPTASPEEPP GSSLPSDTSDIEMDLLVOS VTKSSPRALAAERKRSRG NRKSLRLTKSLGDDDLVQ ALGLSKRGPGLGV*</p>

Shigella ospC1	3	prey/2108	92	GCAGGAAGCTCAGAGTATCGATGAAATCTCAAAATACGACAGAAGAACAGCAG CAAGAAATCTCGGCGGAAGCCCTGAGTAAAGATACCATTAATTAAGT GCTCAAAATCTCAGCAATGCTGCTGCTGAGATGGTGATGCATGCCAGT CGGAGCAACTTGGAAATGATGGGTCTGATGCTAGGAAGGTGGATGGTGA AACCATGATCAATATGACAGATTTGCTTTGCTGCTGGAGGCACTGAACGC CGAGTAAATGCTAGGCTGCTGCATATGAATACATAGCTGTCATACATAGAAA ATGCAAAACAGTGTGGCGCTTGAAATGCAATCGGTTGGTATCATAGCCA CCCTGCTGCTGCTGCTTCTGGAGTTGATTTAGTACTCAGATGCTCT AATCAGCAGTTCAGGAACCAATTTGAGCAGTGGTATGATGATCCAAAGAA CAATATCCGAGGGAAGTGAATCTTGGCGCTTAGGACATCCCAATTAATA CTAAACCTCTGATGAAGACCTCTGAGTACCGACTATCCACTTAATA AATAGAAGATTTGGTGTACATCGCAAAATATTAATGCTTAGAAGTCTCA TATTTCAAAATCTCTTTGGATGCAAAATGCTGAGCTGTTGTGGAAATAAAT CTGGGTGAATACGTTGAGTCTGCTGCTGCTTACTAATCAGACATACCA CTGGTCAGTCTTGAATGCTGTAAGAGTTAGAGCAGTACAGAACCCAGCT GGACGAGGGAAGTTTCAATGCTGGGTTTAGAACGCAATGACCGAAATCAGAA GACAACTTGCCAAAGCTACAGAGACAGCTGTAAAACTACCATAGAACGTA TCCATGGATGATGCTCAGGTTATTAAGGATAAACTGTTTAAATCAAAATTAACA TCTCTTAA	293	QEAQSIDEYKYDKKQOQEI LAAPWTXKHHYFKYKIS ALALLKMWHARGGNLEV MGLMLKGVDDGIMIMDSF ALPVEGTETRVNAQAAAYE YMAAYENAKQVGRLENAI GWTYHSHPGVGCWLSDIV STQMLNQOFQEPFVYMD PTRTISAGKWLGAFTYVP KGYKPPDEGSEYQTIPLN KIEDFGVHCKQYVALEVS FKSLIDPKLELLWNKYVW NTLSSSLTNADYTTGQV FDLSEKLEQSEADLGHGSF MLGLETHDRKSEDLAKAT RDSCKTTIEAHGLMSQVIK DKLFNQINIS"
Shigella ospC1	3	pre/67403	93	TTGGGCGATCTGGCAGGAGCTTTGGATTTCTTAGGGAATGGCAATCAGA TGGGCGCAGTGTTTCTGCTGAGGATCAGATGATCCCTCAACAGCAC CTTTGATCTGATCTGCTGAAGATGGTGGTCTCTCTACTTCCCGCAGACC CCGTGCTGTGCCATTTCCATGAAATTTTACAGGGTCAAGACAAAGGTT TAGTCTTGCTTAATGAGACCTCTGACTGGCTCTGGAGTACGACTGAAC TAGTGAATGCAATTTGCTTTCTGGAACTCCN	294	LGLHRSFGFL'GNGNOM GOSVFC'GNQNDPSNTF DL'YSLKMWLPLLPQTVSV PFP'FHQGHRTKVLVFGSN ET'SDALALDDYETSECILF WNP
Shigella ospC1	3	prey/67405	94	GCTAATGGTAGCTATTGAGCTAGTACTGATCAGATCGNNNNNNNN NN NN GCTAGGACTACAGTGGTGAAGCCACCATGCCAGCTAATTTTTTTTTT NNNAAGAGGNNNTNTNTNTGCGCGNNNGNNNTNAACNTCTNNIC CTNAGGNNATNNCCNCCCTNGCNCNCCAAANGGCGGNGANT	295	ANMVAIDSLLCIRSRXXXXX XXXXXXXXXXXXXXXXXX XXXXXXXXXXE'LGLOW'A TWPS'FFFFFXKGGXXXXX PXXVXXXPXGXGPPXPPX GXX
Shigella ospC1	3	prey/14400	95	CGGCGAGGAGCTAGTGTGCTGAGCCCCCGGAGCAAGCCCGCTG ATGAGCTCTGAAGCGGCGAGGAGCTCAAGTCTACAGCCAGTACTACT TCAAGCCCAAGGACTACGAGAACGCCATCAAGTTCTACAGCCAGGCGCTG AGCTGAACCCCAAGTACCATCTACTACTGCAACCCAGCGCTGGCCATC TGCGCATGAGTGTCTATGCTACGCGCTGGAGACGCCACGCGGCCATC GAGTGTGACAAAGAAGTACATCAAGGTTATTACCGCGGCTGCGCAGCAAC ATGCGACTGGGCAAGTTCCGCGCGCTCGGAGACTACGAGAGCTGGT CAAGGTGAAGCCCATGACAGAGATGCCAAATGAATACGAGAGTGCAC	296	GERTCEAPPEHDEPPADG ALKRAEELTQANDYFKAK DYENAIKFSQAIENPSNA IYGNRSILVLRTECYGVA LGDATRAIELDKKYKGYR RAASNMALGKFRALRDYE TVVKVPHDKDAKWKYQE CNKIKVKA'EFERAAGDEH

Shigella ospC1	3	prey50029	96	CAAGTCGTGAAGCAGGAAGGCCTTTGAGGGGCCATCGCGGGCAGCAGC ACAAGCGCTCGGTGGTGAAGCTCGTGGACATCGAGAGCATGACCATTTGAG ATGATCAGCGCCAGCAGCTTGAAGCGCAAGTGAACATCAGTTTCAAT GAAGAGCTCATGAGTGTACAAGACACAGAAGAACTCAACCGAAATG TGCCACAGATCTGTCAGGTCAAGAGGTCTCTCCAAGCTGAGCAAG CTGTGGAAACACACTCAAGAGACAGAGAGATACAGTATGTGGGACA CCATGTGGCCAGTTATGACCTCTCAACATATTCGAGCTCAACGGTTTACC CTTGAGCAACACCCCTATATTTAATGGTGAAGTTGTGGACGAGGCTCC TTCTGTAGAAGTGATCTCAACCTTTTGGCTTCAAGCTCTGTACCCAGA TCACTTTCACTCTTGAAGCAACCCAGACAGACACAACTGAACACAGATC TACGTTTCGAGGGTGAGTGAAGGCCAAGTACACGCCAGATGACGAG TTCTAGCGAGGTGTGAGTGGTCCGCTTGGCCAGTGCATCAACGGC AAAGTGCTGATCATGCACGAGGCGCTTTCAGTGAAGACGGTGTACCGTC GAATGATCCGGAATTTAGCGGATTCAGACACCCAGATTCAGGGCC ATGTGACCTGCTGCTGTCAGATCCACACGACAGACGGCGCTCGATC AGCAAGCGGGCGTGAGCTGTGAGTTGGCGCTGACGTCAACGAGCGCTC TTGGAAGACAACCTGGACTATATCATCCGACGCCAAGTCAAGGCC GAGGGCTACGAGGTGGCTCAGGAGCGCGCTGTGACCGCTCTCTCTGCC CCCACTACTCGACAGATGGGAACAAGCCTCTACATCCACCTCAG GGCTCTGACTACGGCTCAGTTCCACAGTTCAACGAGTGCCTATCCCA AGCTCAAGCCCATGGCCTATGCCAACGCGCTGCTGACGATGGAATGATGT GA	297	LTSEIPQINDWRLSPHSH HCQERLKTSGDHFFSKQFF RWILTLISLRECSGAVSAH YTLPLAPARMYFSFSPCLL CRDHSJCPCHIVGHQSHQ STK'LHOAPMYAQSHPRV PHLPTTEERQLW'E'LLAP VLSLANVRLCTRHLRNF'LLK MKD'T'MVQLKCFKM'FYL K'KMKF'YIHNTPN'KRYA K'NKGDMKQIYDSTVYMS LK'TTT'ROKVDSCG'GLLE GQWRVSV'WVQCHSGCSV YGVGTGLSYFSNKL'AH KEKALEID
Shigella	4	prey67503	97	CGTGTGTGAGAGGCGATGCAGAAGCAGTGAAGGGCATAGGATCGCGCAAA CTCACTAATAAGTCGCTCACACTAAAGAAAGAGCTCTGGAGATTGATAG	298	AVLRGDAEAVKIGSGKVL

ipaD					<p>GTCTGAAGAGTGGCCCGCAGATCAGTGTTCAATTACTTCACTGACCATG GATCTACTGGAATCTGGTTTTTCCCAATGAAGATCTTCAATGAAAGGACCTG AATGAGCATCCATACATGTCACAAACAAATGTACCGAAAGATGGTTGT CTACATGAGCCTTGAGTCTGGCTCAGATGATGAACCATCGCGGATTAAC ATCAATGTTATGCACTACTGCTGCCAACCCAGAGAGTGGTCTACGCCCT GTTACTATGAGAAGAGTCCACGTACTCTGGCGGAGACTGGTACAGGCTCA ACTGGATGGAAGCTCGAGCTGGAAGATCTGGTAAAGAGACCTGCACA AGCAGTACACCTGGTAAATCGCACACCAACACAGCCACCTCATGCAATGA TGGAAACAAACAATCTCCACATGAAGTGAATGATGCTTCCAGGATAGAA CGAAGCCAGTCTCCGCTCCCTACCTCCAGTACACACCTTGACCTCA CCCCAGCCTCATGTCCTCTCACCATCAAGAAAGAACTGACGAACTCA CAATGTTGAGGAGTCCAGAGCTCACGAGGAGATCAGCGGCATCT GATCGCAGACCTCATTTGAGAAGTCAGTGCCTGAAGATCGTCTCTGCTG GCAGCTCGAGGCTGAGTGAGCAGCTCTGTCGAGAGAGCCCGCT CAGGGGCACAGCTGCTACCCAGAGCCCTGCTGCATCTCCGAGCCCACTG CTCAACTGGCACTCCCGCAGTACGAGTATGCGTTGAGACATTTGTACGTG GTGGTCAACCTTTGTGAGAAGCCGATATCCACTTCACAGGATAAATGTCCAT GGACCACTGTGCTTGGTCACTACTGA</p>	98	prey2109	4	<p>TKDHHFYKYKISALLAKM VMHAFSGGNLEVMGLMG KVDTGETMIMDSFALPVEGT ETRVNAQAAAYEYMAAYIE NAKOVGRLENAIGWYHSH PYGOWLSGIDVSTQMLN QQQPEFVAVVIDPHTHTISA CKVNLGAFRTYVPKYKPPD EGPSEYQTPTLNKIDFQVH CKQYVALSVYKXSLLDRK LELLWNKYWNVLSSSL LTNADYTTGQVDFLSEKLE QSEAOGRGSMFLGLETH DRKSDKLAKATRDSCKTT IEAHGLMSQVKKDKLFNQIN IS*</p>
Shigella ipaD					<p>GATCAAGGATCAACCTTACTTTAAGTACTGCAAAAATCTCAGCATTTGGCTCTTC TGAAGATGGTGAATGCATCCAGATCGGAGGCAATTTTGAAGTGAATGGGTC TGATCTAGGAAGGTGATGATGTAACCACTGATCATTTATGACAGTTTTCG TTTGCTGTGGAGGCACTGAACCCGAGTAAATGCTCAGGCTGCTGCATAT GAATACATGGCTGCATACATGAAAAATGCAAAACAGTTTGGCGCCCTTGAA ATGCAATCGGGTGGTATATAGCCACCTGGCTATGGCTGCTGGCTCTTGG GATTGATGTTAGTACTCAGATGCTCAATCAGCAGTTCGAGGAAGTGAATCTTGG CAGTGGTATTGATCCAAAGAAACATCCGAGGGAAGTGAATCTTGG CGCTTTAGGACATACCAGGGCTACAAGCCTCTGATGAAGGACCTTCT GAGTACCGAGCTATCCACTTATATAATAGAAGATTTGGTGTACACTGCA ACAATATATGCCTTAGAAGTCTATTTCAAATCTGTTTGGATCGCAAAAT GCTTGAGCTGTTGGAAATAATCTGGGTGAATACGTTGAGTTCTTCTAGCT TGCTTAACTGACAGCTATACCACTGGTCAGGCTTTGATTTGTCTGAAAG TTAGACAGTGAAGCCCGCTGGAGCAGGGAGTTTCATGTGGGTTA GAAACCATGACCGAAAAATCAGAAGACAACCTTGCCAAAGCTACAAGAGACA GCTGTAAAACTACCAATAGAGCTATCCATGGATTGATGTCACAGTTATTAG GATAAACTGTTTAATCAAAATTAACATCTCTTAA</p>	99	prey21185	4	<p>GNKACPSQSSQSSSGICT GWDLLVKLDNMNYSRK KNSVKSVPVPSAGGEGTS PYSLEASPLGQLMNLMSHP</p>

GAACATGTTGTCAACCCAGTATCGCGCGAGCTCTCTTAAGTACGAGAA CTCCTCAGACCTTTCTCATCTCAATTCCTCCGAGAAACAGAGTGTG AAGCAGAGGTAACTTGGCAGCGTGTCTCTCCACCACTGCCCAC CTACCAACATCAACACCACTGCGCGCTCCACAGCCACACAC CCCTACTGACCCACCTGCTACTCTGCTCAGCGCTGTTGTCGCAC GGCTTTCCACCATTTGCTAGTCTTGACCCACAGTACTACCCACAG ACTCTACCACTACTTTTCAATTTCTCCACTAAGGCGCAAACTCTCC AGCGAAGGTGAGTATGGCGACAGCAGTACAGACTTAAAGTATGTGTC CTCGCCTCACTGAAACAGCTACAGCTCTGTAGAGTGTGTACATCT CACTCTGTCTGAGGAAGGCTAGAGATGACCAAGCTACTGCTACGAC CTCTCGCGGGGACTCTGGACCCGGAGACTGTTCAAGCTGCTACTGA ATGGACCGCCATCTGGGTATACCTTTGTAACAATAGTACCCGTGCT GGCGAGCTCGGGAATACACCTCGAGAGCGGGCGAGCCCAATGTG AAACCTCTCTGATGGCTGCTGAGGAGCAGCCAGCACCAACAGC TGAAGGCAAAATGAGAGCAGTTTACATGGCTGAGAATGTGTAATGT GGCATCTAGAGCGACCTTTGGGTGCGCGGAGCTCGAGCTGCCTTCTAT GTCCATTTGACATCCAAAGACATCTACCAAGAGTTCTCTTGAGGGTACTA CAGGTCATATCCAGCTCCGGAGCAGCAGCGCGGCTAACAGAAAGCC AAGCAGCAGGAGGCTAGTGTCTCCGGTTTAGCTGAGCTGAGCAGTAC CAGCAGCTTTCCGACGTGGAGGCTGAGGCTGATGCCATTATACAAATG GTAGTGAAGGTCAAAGGCGCGGAGACAGCAACAGCAGCAGCTCGGA GTCTAGCGAGTACAGGCGTCTGTCGGAGGAGGAATCACCCATGGATGT GGACGACCATCTCCAGTGTCAAGATACTCAATCCATTGCCCTCGGATGA ACCCACAGGGGAGAGGAAAGAGAAAGAACACACCTGATACCCCTG CTCAGGACAGCTGAGTTTGACAGAGCTGGGACATGCTTGGGAGTGT CTAAGGAACTAGAGGAATCCCATCACCAGCTCGGCTAGTGTGCTACAG CCTGCTGCGAGGCTTCTTCTGTGCTTSCCAGCAGCGGAGCAGCAG CCTCTGTCCGAGACCCGTGAGCCAGCTGGCACACATCAGGACGAG CCTCTGTCCGAGACCCGTGAGCCAGCTGGCACACATCAGGACGAG CCTCTCCTCTCCCTGCCCTTAAACCCAGCGGCTCTCTCCCTGTG ACCATTTCTTCCGAGGAGCTTATGTACACATCTCTCAAGCGTGCC CCCTGACACAGAGTCTTCTGCTTTCAGAGACTCAGCAGCTGTGTA AACCAGATCTACGCGAGTCCACAGCCACTTGTGATGAGCGCAATATTC TCCTGTGAGCTACATGTTGCTCTGAGCTTGTGATGACGCGCAATATTC CGCCAGAGAGCTGGAGCTTTAGATGAGGGCTCCGGAAGAGACATGCT GTGATGTCCTGTGACCATGTTTGAAGACTCCTATGTTGAGCTGCACT GCAATCCCCAGAAATGAAGATCGATTATATAGTATTTGAAGGAGA AGAAGGCGAGGATGCTCGCGGCTCTCGGAGAGTGATATGATCATCT TCGAGAGATGTTTACCCTATGATGCTTGTCCGTAAGCTCAGCTGGTATC GAGTCACTACCATCAATCCATCTTCCACTGCAACCCCAACGACCTCAG	VIRRSLLTEKLRLLSLSIA LPEKNVSEAGANSQSGAS STTTTSTTSTTTTAASTT PTPTAPTPTSPALVAAT AISTVAASTTTVTPTATT TVISPTTKGSKSPAKVSD GSSSTDFKMWSSGLTEN QLQSLVSLTSSCEEGL EDANVLVLTRSGDSGTHD TVKLLNGARHLGYLQK QIGTLAEELRYNLQQR AOCTLSPDGLPEEQPOT KLKGMQSRFMAENVIV ASQKRLPGGRELQLPSMS MLTSKTSQKFFLRVLQVII QLRDDTRFRANKAKQT LGSSGLGSASSIOAAVRQL EAEADAIQMVREGORARR QQQAATSSSQSEASVRR EESPMVDVQDPSASODTQ SIASDGTPOGEKEERPP ELPLLSEQLSLDELWDMLG ECJKELESHDOHAVLVQ PAVEAFFLVHATERESKPP VRDTRFESQLAHKDEFPPL SPAPLTATPSSLDFFSR EPSSMHISSTLPDQTKFL RFAETHRTVLNQLROSTT VLADGPFAVVDYRVLDFD VKHVRHRELRHDEGLRK EDMAVHRHDFGSDSYR ELHRKSPPEEMKNRLYVFE GEEGQDAGGLLRWYMIS REMFPMAVFRTPSGDR VYTYNPSHCNPNHLSYF KVFGRVAKAVYNNRLEEC YFRFSFYKHLGKSVRYTD MESEDFHYFQGLVLLNED VSTLGYDLTFTSFQVEFGV
--	--

Shigella ipaD	4	prey5990	100	<p>CTACTTCAAGTTTGTGGAGCGCATGTGGCCAAAGCTGTATATGACAAACCGT CTTCTGGAGTCTACTTTACTCGATGCTTTTACAAACACATCTTGGCGAGTCT AGTCAGATATACAGATATGAGAGTGAGATACCACTTACCACTTACCAAGCTCTG GTATATGCTGGAAATGATGTCTCCACATAGCTATGACCTCACTTACCACTTAC CACTGAGTCCAGAGTTTGGAGTTTGAAGTTCTGGACCTCAAAACCCAAAT GGGCCAACATCTTGGTACAGAGAGAGATAGAAAGAGATATGTACACCTG GTATCCAGATGAGATGACAGGAGCCATCGCAAGCAGATTGGCGGCTTTC TTAGAAAGCTTATGAGATCATTTCCAAAGCCCTCATTTCCATCTTACGATGA GCAGAGCTTAGAGTCTTATCAGGAGTCCCAACCATTCAGATCATGATCAT CTGAATCCAACTGAATACCAAGTACCACTGCTCACTCTATTCAGATCCA GTGTTCTGGAGAGCATTCGTTCTTTCGATCAAGCTGACCTGGCCCAAGTCT CTCAGTTTGTACGGGTACTTCCAGGTACCCCTGCAAGGCTTTCCTGCGCC TCGAAAGCATGATGGCATTCAGAGTTTTCAGATCCATGAGATGACAGGCT CACAGATCGCTGCTTCCAGCTCACATGTTTAAATCAGCTGAGTCTGCGT GCTATGAGAGCTTGGAGTCCGACATGCTACTGTGGCTATCCAGGA GTCTCTGAGGCTTGGCTGGCTTAAAGGCCCTGCCCACTCCGCTGG GGTTTTTACCATTTGGACCTGGGAGGGGGAGTTAAAGAGAACCC AGAAAGAAATGCAAAACCAATAAATGAATCCCAACTCACCGTGTGTG TCCAGCTGCCCATCTTCCGACGCACTACTTCTCTTCTCATCTCTC CCGCGCGCTTTCCTCACCTTCTCCCTCTTCCATGCCGTCATGATCC CACCCCATGTGTTTAAAGGCGAGTAG</p>	<p>CEVRLKPNGANILVTEEN KKEYVHLVCOMRMGTGAIRK QLAAFLLEGYFIEIPKRLISFT EQELELLISGLPTIDIDLISKT NTEYHYQSNISQIOWFWIR ALRSFDOADRAKLEDFVTG TSKVPLOGFAALGEMNGIQ KFIQHDDRSITDLRPSAHT CFNQLDLPAYSEFEKSATC YCWLSRSALKALGWPNKA LPNSVGFLLPLDLGRGEL KKPERNCKPINEIHQLTV CVPAAPSPHATCSSSHLP PAAOFLTFSPHSMPSMPTP CVLKRPQ*</p>
Shigella ipaD	4	prey9120	101	<p>GTACTTCAAGTTTGTGGAGCGCATGTGGCCAAAGCTGTATATGACAAACCGT CTTCTGGAGTCTACTTTACTCGATGCTTTTACAAACACATCTTGGCGAGTCT AGTCAGATATACAGATATGAGAGTGAGATACCACTTACCACTTACCAAGCTCTG GTATATGCTGGAAATGATGTCTCCACATAGCTATGACCTCACTTACCACTTAC CACTGAGTCCAGAGTTTGGAGTTTGAAGTTCTGGACCTCAAAACCCAAAT GGGCCAACATCTTGGTACAGAGAGAGATAGAAAGAGATATGTACACCTG GTATCCAGATGAGATGACAGGAGCCATCGCAAGCAGATTGGCGGCTTTC TTAGAAAGCTTATGAGATCATTTCCAAAGCCCTCATTTCCATCTTACGATGA GCAGAGCTTAGAGTCTTATCAGGAGTCCCAACCATTCAGATCATGATCAT CTGAATCCAACTGAATACCAAGTACCACTGCTCACTCTATTCAGATCCA GTGTTCTGGAGAGCATTCGTTCTTTCGATCAAGCTGACCTGGCCCAAGTCT CTCAGTTTGTACGGGTACTTCCAGGTACCCCTGCAAGGCTTTCCTGCGCC TCGAAAGCATGATGGCATTCAGAGTTTTCAGATCCATGAGATGACAGGCT CACAGATCGCTGCTTCCAGCTCACATGTTTAAATCAGCTGAGTCTGCGT GCTATGAGAGCTTGGAGTCCGACATGCTACTGTGGCTATCCAGGA GTCTCTGAGGCTTGGCTGGCTTAAAGGCCCTGCCCACTCCGCTGG GGTTTTTACCATTTGGACCTGGGAGGGGGAGTTAAAGAGAACCC AGAAAGAAATGCAAAACCAATAAATGAATCCCAACTCACCGTGTGTG TCCAGCTGCCCATCTTCCGACGCACTACTTCTCTTCTCATCTCTC CCGCGCGCTTTCCTCACCTTCTCCCTCTTCCATGCCGTCATGATCC CACCCCATGTGTTTAAAGGCGAGTAG</p>	<p>TYTPGDCPNFAAPREHRE PYQGADPILATKALSDPIPN PLQKWEDSAHKPQSLDLD DPATLYAVVENVPPLHWKE FVRLGLSDHEIDRLLEQL GRLREAOYVSLATWRRR TPREATLELLGRVLRDMD LLGCEIDIEALCGPAALPP APSLLR*</p>
Shigella ipaD	4	prey9120	101	<p>GTACTTCAAGTTTGTGGAGCGCATGTGGCCAAAGCTGTATATGACAAACCGT CTTCTGGAGTCTACTTTACTCGATGCTTTTACAAACACATCTTGGCGAGTCT AGTCAGATATACAGATATGAGAGTGAGATACCACTTACCACTTACCAAGCTCTG GTATATGCTGGAAATGATGTCTCCACATAGCTATGACCTCACTTACCACTTAC CACTGAGTCCAGAGTTTGGAGTTTGAAGTTCTGGACCTCAAAACCCAAAT GGGCCAACATCTTGGTACAGAGAGAGATAGAAAGAGATATGTACACCTG GTATCCAGATGAGATGACAGGAGCCATCGCAAGCAGATTGGCGGCTTTC TTAGAAAGCTTATGAGATCATTTCCAAAGCCCTCATTTCCATCTTACGATGA GCAGAGCTTAGAGTCTTATCAGGAGTCCCAACCATTCAGATCATGATCAT CTGAATCCAACTGAATACCAAGTACCACTGCTCACTCTATTCAGATCCA GTGTTCTGGAGAGCATTCGTTCTTTCGATCAAGCTGACCTGGCCCAAGTCT CTCAGTTTGTACGGGTACTTCCAGGTACCCCTGCAAGGCTTTCCTGCGCC TCGAAAGCATGATGGCATTCAGAGTTTTCAGATCCATGAGATGACAGGCT CACAGATCGCTGCTTCCAGCTCACATGTTTAAATCAGCTGAGTCTGCGT GCTATGAGAGCTTGGAGTCCGACATGCTACTGTGGCTATCCAGGA GTCTCTGAGGCTTGGCTGGCTTAAAGGCCCTGCCCACTCCGCTGG GGTTTTTACCATTTGGACCTGGGAGGGGGAGTTAAAGAGAACCC AGAAAGAAATGCAAAACCAATAAATGAATCCCAACTCACCGTGTGTG TCCAGCTGCCCATCTTCCGACGCACTACTTCTCTTCTCATCTCTC CCGCGCGCTTTCCTCACCTTCTCCCTCTTCCATGCCGTCATGATCC CACCCCATGTGTTTAAAGGCGAGTAG</p>	<p>ATRSVAHLRSSVPGRVLL QDSVDFSLADAINTEFKNT RTNEKVELQELNDPFAVNI DKVFRLEQNKILLAELEOL KGKGSRLGDLYEEMRE LFRQVDQLTNDKARVEVE RONLAEIMRLREKLQEEEM LOREEAINTLOSFRQDQD</p>

Shigella ipaD	4	prey8889	105	GGTATCGGCAGAGATACCTTGACCTTGATCGTGAATGACCTTTGTGAGGCAGAA ATTTATCATCGCTTAAGATCATACATATATAAGAAGTTCTTAGATGAGCT GGGATCTCGAGATTGAATCCATCCATGAACATCATCCGAGGGGAGC CGTGGCCAGCCCTTTCATCTTATCACACGAGCTGGACATGAACCTATATA TGAGAAATGCTCCGAACTCTATCATAGATGCTTGTGGTGGTGGCATGGA CGGGTTTATGAAATGGACGCCAGTTCGGGAATGAGGGATGATTTGACG CACATCTCGAGTTCCACCATCTGTAGTTTACATGGCTATGACAGACTATC ACAGTCTCATGAAATCACGGAGAAGATGGTTTCAGGGAATGGTGAAGCATAT TAGAGCGATTACAAGTTCACCTACACCCAGATGCCAGAGGGCCGACG CTACGATGTGACTTACCCACCCTTCCGCGAATCAACATGTTAGAGAG CTTGAGAAGCCCTGGGATGAGCTGCCAGAACCAACCTCTTTGAACTG AAGAATCTCGAAATTTTGTATGATATCTGTGGGCAAAAGCTGTTGAATGC CTCCACCTCGACACACAGCGGCTCTTGACAAGCTTGTGGGGAGTTTC CTGGAAGTGAATGCATCAATCTACATCTCTGTGATCAACACAGATAT GAGCCCTTGGCTAATGGCACCGCTCTAAGAGGGTCTGACTGAGCGCTT GAGCTGTTGTGATGAAGAAGATGCAATGCGTATCTGAGCTGAATG ATCCCATGGGAGCGGCGAGCTTTTGAAGAACAGGCCAAGGCCAAGGCTG CAGGTGATGATGAGGCCATGTTATGATGAATGAACCTTCTGACTGCCCTGGA ATATGGGCTGCCGCCACAGCTGGTGGGGCATGGGCATTGATCGAGTCGC CATGTTCTCAGGACTCCAACACATCAAGAAAGTACTTCTGTTCTCGCCA TGAAACCCGAGACGAAGAGGAGATGTAGCAACCACTGATACACTGGAAAG CACACAGTTGGCACTCTGTCTAG	306	RSKIITYBSFDELGLFEIET PMMINIPGGAVAKPITYHN ELDMNLVYRIAPLEYHKML VGGIDRVYIEIGRQFRNEGI DLTHNPEFTTCEFYMAYAD YHDLMEITEKMYQWVWKHI TGSYKVTYHPDPEGGOAY DVDTFPPKRNINVEELEK ALMGKLPETNLFINETFKI LDDICVAKAVEQPPRTTA RLDLKLVEFLVCINPTFI CDHPQMSPLAKVWHSKE GLTERFELFVKKKEICNAVY ELNDPMHROQLFEICQAK KAAQDEAMFIDENFCTAL EYGLPPTGAWGMGIDRVA MFLTDSNNIKVLLFPAMKP EDKKENVAITDLESTTVG TSV
				GGTATCGGCAGAGATACCTTGACCTTGATCGTGAATGACCTTTGTGAGGCAGAA ATTTATCATCGCTTAAGATCATACATATATAAGAAGTTCTTAGATGAGCT GGGATCTCGAGATTGAATCCATCCATGAACATCATCCGAGGGGAGC CGTGGCCAGCCCTTTCATCTTATCACACGAGCTGGACATGAACCTATATA TGAGAAATGCTCCGAACTCTATCATAGATGCTTGTGGTGGTGGCATGGA CGGGTTTATGAAATGGACGCCAGTTCGGGAATGAGGGATGATTTGACG CACATCTCGAGTTCCACCATCTGTAGTTTACATGGCTATGACAGACTATC ACAGTCTCATGAAATCACGGAGAAGATGGTTTCAGGGAATGGTGAAGCATAT TAGAGCGATTACAAGTTCACCTACACCCAGATGCCAGAGGGCCGACG CTACGATGTGACTTACCCACCCTTCCGCGAATCAACATGTTAGAGAG CTTGAGAAGCCCTGGGATGAGCTGCCAGAACCAACCTCTTTGAACTG AAGAATCTCGAAATTTTGTATGATATCTGTGGGCAAAAGCTGTTGAATGC CTCCACCTCGACACACAGCGGCTCTTGACAAGCTTGTGGGGAGTTTC CTGGAAGTGAATGCATCAATCTACATCTCTGTGATCAACACAGATAT GAGCCCTTGGCTAATGGCACCGCTCTAAGAGGGTCTGACTGAGCGCTT GAGCTGTTGTGATGAAGAAGATGCAATGCGTATCTGAGCTGAATG ATCCCATGGGAGCGGCGAGCTTTTGAAGAACAGGCCAAGGCCAAGGCTG CAGGTGATGATGAGGCCATGTTATGATGAATGAACCTTCTGACTGCCCTGGA ATATGGGCTGCCGCCACAGCTGGTGGGGCATGGGCATTGATCGAGTCGC CATGTTCTCAGGACTCCAACACATCAAGAAAGTACTTCTGTTCTCGCCA TGAAACCCGAGACGAAGAGGAGATGTAGCAACCACTGATACACTGGAAAG CACACAGTTGGCACTCTGTCTAG	306	LPKPEMRBPKSFDPPFEV IVDGVANALRVKVISGQFL SDRKVIYIEVDMFGLPVD TRKRYRTRTSQGNFNPV WDEEFPDFPKVLPRLASL RIAAFEFGKFKVGHRLPVS AIRSGYHYVCLRNEANQPL CLPALLIYVTEASDYPDDHQ DYAEALINPKHVSMDORA RQLAALIGESAQAQOETC QDTSOQLGSPSSNPFT SPLDASPRPPGPTTSPAS TSLSPGCRDILIASLSEV APTLDLURGHKALVKLRS RQERDLRELKKHQHRAV TLTRLLDGLQAQAQAEGRG RLRPGALGAADVEDTKE

Shigella ipaD	4	prey/700	108	<p>ACGCTACCCGCCGCGCTGCTGATGCCCTGAGCTCAGGCACAGGCTGAGGG CAGTGCCTGCTGCGCAGGTCCTCTAGTGGGGCGCTGATGTTGGAGG ACAGGAAGGGGGGAGCTGAGGCAAGCGGTATCAGGAGTTCACAGAG AGACAGTGCAGAGCTGCTGAGGCTGCGGGAGCCCGAGGTGCAGCAGA GGCCAGCGAGGCTGGAACACCTGAGACAGGCTCTGACAGCGCTCAGGG AGGTGCTCTTATGCAACACACCTGATTCAGAGGCTGAAAGAGATGAA CGAGAGGAGAGAGAGCTGAGAGAGTCTGGACAGAGAAAGCGCATAA CAGCATCTGGAGCCAGATGAGGACAGCATAAAGAGGAGCGCGAAGCT GACGGAGATTACCGTCCGACATCACTGAGTCAGTCACTCATCCGCTCG CTGAGGAGGCGCCAGACAGCGGCTGACCGCTCTTGGCTGGGAGCG AGAGGCTCTGCAACAGCTGGCAGAGAGAGGCCAGCGCTGCGGCCAG CTGCCACAGGTTGTCAGGACAGCGGCGAGGCTCCCGAGGAGATCCG CGGAGCTGCTGGCGAGATGCGGAGGCTGGGAGCGGCGGCTGTG TGGCCTGTGCCAGCAACGCTACGCACCCGAGGAGCGGCGACCTGTG GGCGCTGACTCGAGAGCCAGGAGAGACACGCGACTCTGA</p>	<p>307</p> <p>MGIGLSAGGVNMNRLPGW DKHSYGYHGGDDGSHFSS GTGQPYGPTTGTGDI/GCC VNLINNTCFYKNGHSLGIA FTDLPLNLYPTVGLQTPGE VDANFGGHPFVDEDIYM REWRITKQIQADRPFGDR EGEYQTMIOKMVSYLVH HGYCATAEAFARSDQTVL EELASIKRQRIQKVLAGR MGEAETTCQLYPSLLERN PNLLFTLKVRQFEMWNGT DSEVRFLTGGRRSPGSDSY PVSPPRFSFSPMSFSGHM NHNLAGKGKSTAHFSGFE SCSNGVSNKKAHOSYCHSN KHQSNLNVPELNSMRSR SOQVNNFTSDND/MEIDH SOQVNGETSSNGFLNGS KHDHEMEDCDTEMEVDS QLRRQLCGSQAIAERMIH FGRELOANSEQLRPDCGK NTANKMKLQDAFSLAYSD PWNSPVGNQDLPIOREPV</p>
------------------	---	----------	-----	---	---

Shigella ipaD	4	prey2694	107	<p>AAGGATGCATTACGCTACTAGCATATTCAGATCCCTGGAACGCCAGTTG GAAATCAGCTTGACCCGATTACAGAGAACCTGTGCTCAGCTCTTAACAG TGCATATTAGAACCCACAATCGCAAGCAACCTCCACTTCCCTTAGCA ATGGACAGGCCACACATGCTAGGACTGATGGCTGGATCAGGAATTGGA TCTGGCAATTGGACAGTGGAGACTACCTACATTAG</p> <p>ATGCAACGCTGATGGAAACCTCTGGACATCAGTAAGAGTAGACCATTTG ATGAAGAGTGGCTTTGCTCGCAATCCAGCAAAATCTACCTGATTT TATAATGACTGGATTGCTTAACATCTGCTGATCTAGAGCTGG CAGCTTCGAGAAAGATTGAGAACTTAACATGCTCAGCATTGATCATCT ACAGACCAAGATCACAGCGCTGCACGCTAGTCTGGGATGCATCACCA TGGCATATGTGGGGCAAGGTCATGGAGATGTCGGTAAGCTTCTGCCAA GAAATATTGCTTCTTACTGCCAATCTCCAGAAACTGGAACTGCTCCT ATTTTGGTTATGAGACTGTCTTGGCAACTGGAGAAAGAGTCTGTA TAAGCCCTGACTTATGAGAACATGGAAGTTTGTCTCTGCTGATGAGG ACTGCAGTAAGGATTCTCTGGTCTCTATGGTGGAAATAGCAGCTGC TTCTGCAATCAAGTAATCTACTGATTCAGGCAATGCAATGCAAGAC GGGACACTTTGTAAAGCGCTGTGGAAATAGCTTCTGCTTGGAGAAAG CCTTCAAGTTTACCAAATCCACGATCATGTGACCCAAAGCATTTTTC GTCTTCTCGCATATTTGTCTGGCTGGAAAGCAACCCAGCTATTACA CGCTGTGCTGATGAAGGTTCTGGAGAACCCAAAGSAGTTTSCAGGGG CAGTGCAGGCCAAAGCAGCGCTTTTACGTGCTTTGACGCTCTGCTGGGCAT CCAGAGACTGCTGGAGGACATGCTGCTAGTTCTCCAGGACATGAG AAGATATATGCCACGCTCACGGAATCTCTGTGCTCATTAGAGTCAAT CCCTCAGTCCGTGAGTTTGTCTTCAAAGGTGATGCTGGCTGCGGAA GCTTATGACCGCTGTGAAAGCTCTGCTCCTCGAGGAGCTACCATCTGC AAATGCTGACTAATACATCTGATTCCTGCAAGCCAGCAGCAAGGAGAA TAAGACTCTGAAGACCCCTCAAACCTGGAGCCAAAGGAACTGGAGGCACT GATTTAATGAATTTCTGGAAGCTGTAGAAGTACAAGTGAAGATCCCTTTT GAAGGAAGTTAA</p>	<p>CSALNSAILETHNLPKQPPL ALAMGQATQCLGLMARSGL GSCAFATVEDYVH*</p>
Shigella ipaD	4	prey53735	108	<p>GGGTGAACACGAAGGTTTCTGTGGATTACCAACAGCTATGGTGGGACA GCCAAGCCATTGCACTGACGCTTCTAGGAGATGGTTACCAAGTCAACACC AGCCAGAGAGCTGGGCCCTCTTGCAACAGCTGACAGTACTATGGC GATCTGGCTGGAGCCAAAGCTGCAAGGCTGGCTGCTGAAATGAAGA CGTGTCCCATATCAACACCGGCTACAGAGCTGGCCATGGCTGTGC CGCTCTGTTACCAAGGAGGCCCTCGCATGCAAGCCAGTGAAGCTCA CACCAAGAGAGCTCATAGATGTGGCCGGAGATCTCTGAGAAGGTTCTC CCAGCTCTGGCTGGCTCAGGCTGGGAATCGTGGCACCCAGGCTGCAT CACAGAGACAGGCTGTGCTGGTATCATTTGCTGACCTGACACCAACCAT ATGTTGGCACTGCTGGCAGCGCTCAATGCTGAGGGTACTGAAACTTTCGCTG</p>	<p>MAHAMENSWTISKEYHIDE EVGFALPNPQENLPDFYND WFIKHLPLIESQLRE RVEKLNLSIDLTHDKSO RLARVLGCTIMAYVWKG HGDVRKVLPRINAVPYCQL SKDVLPIILYADVCLANW KKDPKPLTYENMDVLS FRDGCSKGFFLSVLEIA AASAKVPTVFKAMQOE RDTLLKALLEIASCLEKALQ VFHQIHDHVNPKAFSVLRI YLSGKWGNPLQSDGLVE GFWEDEPKFAGSGAGSS VFQCFDVLGIGQTAGGGH AAQFLDMRRYMPFAHRN AACLESNPSVREFVLSKG DAGLREAYDCAVKALVSLR SYHLQIVKYILIPASQPKR NXTSEDFSKLEAKGTGGTD LWNLKTVRSTTEKSLKE G*</p>
Shigella ipaD	4	prey53735	108	<p>GGGTGAACACGAAGGTTTCTGTGGATTACCAACAGCTATGGTGGGACA GCCAAGCCATTGCACTGACGCTTCTAGGAGATGGTTACCAAGTCAACACC AGCCAGAGAGCTGGGCCCTCTTGCAACAGCTGACAGTACTATGGC GATCTGGCTGGAGCCAAAGCTGCAAGGCTGGCTGCTGAAATGAAGA CGTGTCCCATATCAACACCGGCTACAGAGCTGGCCATGGCTGTGC CGCTCTGTTACCAAGGAGGCCCTCGCATGCAAGCCAGTGAAGCTCA CACCAAGAGAGCTCATAGATGTGGCCGGAGATCTCTGAGAAGGTTCTC CCAGCTCTGGCTGGCTCAGGCTGGGAATCGTGGCACCCAGGCTGCAT CACAGAGACAGGCTGTGCTGGTATCATTTGCTGACCTGACACCAACCAT ATGTTGGCACTGCTGGCAGCGCTCAATGCTGAGGGTACTGAAACTTTCGCTG</p>	<p>GEPEGSFVDYQITWVRFA KAAVTVQEMVTKSNTSP ELGPLANQLTSDYGRASE AKPAARAENEIEGSHIKHR VQELGHGCAALTKAGALQ CSPSDYATFKELIECARV SEKYSHVLAALQAGNRGT OACITAAASVSGIADLDTI MFATAGTLNREGTETFDH REGIGLTKAVLVEDTKVLVQ</p>

					ACACCGGGAGGGCATTCTGGAAGACTGCGAAGGTGCTGCTGGTGAGGACACC AAGGTCCTGGTGCAAAACGCGCTGGGAGCCAGGAGAAITGGCGCAGGC TGCCAGTCTCGCTGGCGACCATCACCGCTCGCTGATGGTGAAGT GGGTGACCGACGCTGGGAGCTGAGGACCTGAGACCCAGGTGGTACTAA TCACGCACTGAAGATGTAGCCAAAGCCCTGGGAGACCTCATCTAGTCAA CGAAGGCTCGAGCTGGCAAAAGTTGGAGATGACCTGCTGTGGCAGCTAA AGAATCTGCCAAGGTGATGGTGACCAATGTGACATCATGCTTAAAGCAGT AAAGCGCTGGAGATGAGGCCCAAGGACCTCGGCCCTGGAGGCAA CCACGAACACATACGGCAGGAGCTGGCGGTTTCTGTTCCCGACAGCCAC CTGCCAAGACCTTACCCGAGACTTCATCCGATGACCAAGGGTATCAC CATGGAACGCCAAGGCGGTTGCTGCTGGCAATTCCTGTGCCGCAAGA TGATCTGCCAGCCAACTGAGCGCGCTGCTATTGCAGATGCTTCGG GCTTGCAAGGAGCAGCTTACACCCAGAAGTGGCCCTGATGTGCGGCTT CGACCCCTGCATATGCGCGGGAGTGGCAATGGCTACCTGGAAGCTGCT GACATGTACTGCTGACCTGCGAAGGAGCAAGCCCAAGAACTGAAGCAGCAG TTGACAGGACATTCAGAGCTGTGGCTGGTTCCGTCACTGAGCTCATCGG CTGCTGAGCGATTGAAGGGAACAAGTGGGTAGACCCAGGAGGCCACAG TCATTTGAGAAATGAGCTCCCTGGGAGCTGAGCGGCCATTGAAGCTGCA CMAAAGCTAGACAGCTGAAGCCCGCGGCCAAACCCAGGAGGAGCATG AGTCTTGAACCTTTGAGGAGCAGATAGAGAGCTGCCAAGTCCATTGACG AGCCACAGTGCATGTTAAAGCTGCGTGGCTGGCCGACAGAGAACTAGT GGCCCAAGGAAGGTGGTGCTTCCTCCAGCCAACTGCACTGGACGATGGCC AGTGCTCCGAGGCGCTATTCTGCTGCCCGGAATGGTGGCTGGCGGCCACCA ACATCTGTGTGAGGAGCAACATGACGCTGTACAAGGCCATGCCAGCCAGG AGAAGCTCATCTTACGCAAGCAGGATGATGCTGCCCTGACAGCCGACCTCC TTGTGGCTGCAAGGTCAAGGCTGACCGAGCTCGGAGGCAATGAACAGCAG TTCAGGCTGCTGGCAACGCGATGAAGCGAGCCTCAGATAATCTGGTGAAG CAGCAGAGAAGCTGACGCTTTGAAGAGCAGGAGATGAGACAGTGGTG TGAAGAAGAATGGTTGGCGGCTTGGCCAGATTCATCGACGACAGGAAG AAATGCTTGGGAAGGAACGAGCTGGAGAGCGCGGAGAACTGGCC CAGATCGGCAGCAGCAGTACAAGTTTCTGCTTCAGAGCTTCGAGATGAG CACTAA	310	XAEXELQXAGDAXLPRXR XTDAXXWVLGXGXTTXXTX VPRXXGXGTXIXIA'XXX MPPHFXGXGIXHXX'FXFX XCOT*REHXXSWELVFX XXXT
Shigella ipaD	4	prey67574	109	INACAGAGAGANTGAGTTGGAANCGGGGTGATGNNNTCTACGNNNGCT GNAAGCAGCAGACGCTNCCTGCTGGGTCTGGGATGCCAACACNANN NCATNTACNTTNGTCTGACAGANNCNTGNGGNTGCACTNCNNNGTCA TTGCTTAACNNACNAGATGCNCNGCTCATTCNAGNCACNCAATCAATACCA CNTGNTGNTGATTTNTTNTTNGANNNGCCAATNTGATGAAGGGGAACATA TNTNTTCATGCCAAGTGGTCTTCTGTTNANNNGTNTNAAC GCTACTCACCCAGCTCTCCAGCTACTGCCCAAGCTCTCCAGCTATTTCGCC	311	YSPTSPSYPTSPSYPTSPS	
Shiella	5	prey67509	110				

Shigella ipaC	5	prey4458	113	GTTTATGAAAGAAAGATAATACATTGTGATGGCTATTTCATTCCAAATCGT ATCTTTCCAATTAACAGCACCTACAGTCTGTTTGGTTTACCTCCCTGGTG TTATTGTGCGCATCTTCAACTGTACCGAGGACAAAATACCGTGATGCCA GACTGGCTTGA	314	QDV/QASQAEADDDQOTRLK ELESQVSGSLERAEIHEAV EOKKYKNDLREKNWKAM EALATQACGKEKLHSLTQ AKESEKQOLCUEAQTMEA LLALFELSVL	ACFGLPWPWCYCHSHTVP RHKIPSPRLA*
Shigella ipaC	5	prey4458	114	CGCGAGAGTCCAGGCGGAGCGGAGGCTGACGAGCAGCAGACTCGGC TCAAGGAGCTGGAGTCCGAGGTGTCCGGTCTGGAGGAAGGAGGCCATCGAG CTCAGGGAGCGCTCGCAGCAGAAAGTGAAGAACATACCTCCGGGA GAAGAAGTGAAGGCCATGGAGCAGCTCGGCCACGCCGAGCGCTCGA AGGAAAGCTGCACCTCCGTGCCAGCGCCAAGGAGGAATCGGAGAAAGCAG CTCTGTCTGATTGAGGCGAGACCATGGAGGCGCTGCTGGCTGCTGCCA GAACTCTGCTCTTGGC	315	AEETOSTLOAECDDYRSIL AETEGMRLDLOKSVEEIE QVWRKAVGAEEELQKSR VTWKHLEIV	AEETOSTLOAECDDYRSIL AETEGMRLDLOKSVEEIE QVWRKAVGAEEELQKSR VTWKHLEIV
Shigella ipaC	5	prey67522	115	GANGAATNCNNTATGCCAAAAGGACAGAGGATATGGTNGCTTANGCTGG CTATGAATACNCTNTTCTGTTTGTGANTCTATTTACACCNCTNGCCAT GGTAGCAANNCCACAGTANATGCCACATCTATGAGGCTGNNGCNGCATA CTCGCGGTGCTANCTACATCCTNGTANNNGTNGGCCGCCNGCGTTC TNCCGATTNTGTCNGNCACAGCTGGTGTNGACANCTCGACCGCGNT NACATNACCTCCTGGAGGACCTACCGAANGCATGCTNACCCCTGGTGGG GAGGCTGGAAAG	316	XXEXMPKGGGGIGLXWL* IXXSCDXLLFTPSGMVWX XHSXGHYEAAXSPCLX TSXLXXARVXPDXVXT AWCXTXRTXTXTSWRTY HEXMLTLVGRLE	XXEXMPKGGGGIGLXWL* IXXSCDXLLFTPSGMVWX XHSXGHYEAAXSPCLX TSXLXXARVXPDXVXT AWCXTXRTXTXTSWRTY HEXMLTLVGRLE
Shigella ipaC	5	prey627	116	CATGACTCGAGACCTTCCTAATGAACCTATTGAACCTGGGAGAAATGTCT CTTGATACTCTGTATTAGTGAACACAGGAATCTGCAAAACCTCTTATCTG CACTGCAATTAAAGCTGACCGTACACGTGTATGGAGTATTAAACCGCTGT GATAATTATGATGCCCGAGATTGCCATATCGCCATCAGCAATGAGCTGT TGAAGAAGCAATTGCCATTTCCGAAATTTGATGCAATCTTACAGACTTC AGGCTTTAATTGAGCATATTGAACTTGGATCGGCTATGAGTTTGTCTGA ACGTTGCAATGAACCTCGGCTCGGATCACTTGCAAAAGCCAGTTGCGAG AAAGGATGGTGAAGAAGCCATTGATCTTATCAAAGCAGATGATCTCTC CTCTACATGAGATTGTTACGGCTGCCATCTAGTGGGAACTGGGAAGAA CTGTGGAAGTCTGCAATGGCCGTGAAGAAGGCTCGAGAGTCTCTATGTG GAGACAGAATGATTCGCTACTGGCTTAAACCAACCGC TGCACTCAAGAGATCTCCCATCTATTGACCGCTGGCCAAATGCTGCCCG GGCTGAAGCTCCACGCTGGACACAAAGGTGTCCAGATGGCGCAGACTT TGAGCCGCTCACCTGGCTGCGAGTGGTGGTCTCCTCCAAGACCTGAGCCA CCGCGACGATGGCACTCTGGACACGACTAAACATTTGGCAGACTCTGCG CTCGAGTTGCTATACACTGCCAAGGAGGCTGGTGGTAACCCAAAGCAGC AGCTCACACCCAGGAAGCCCTGGAGGAGGCTGTGCAGATGATGAACGAGG	317	MTADLPINELIELLEKVLN SVFSEHRLNQLLILTAIKA DRTWMEVYRLNLDYDAPD IANIASELFEEAFNFKF DVNTSAVOVLIEHGLNDRA YEFERONEPAWWSOLAK AQLQKGMKEADYSYKAD DPSSVMEVYQAANTSGNW EELVKYLQMARKKARESIV ETELIFALKTNR	MTADLPINELIELLEKVLN SVFSEHRLNQLLILTAIKA DRTWMEVYRLNLDYDAPD IANIASELFEEAFNFKF DVNTSAVOVLIEHGLNDRA YEFERONEPAWWSOLAK AQLQKGMKEADYSYKAD DPSSVMEVYQAANTSGNW EELVKYLQMARKKARESIV ETELIFALKTNR
Shigella ipaC	5	prey63735	117	TGCACTCAAGAGATCTCCCATCTATTGACCGCTGGCCAAATGCTGCCCG GGCTGAAGCTCCACGCTGGACACAAAGGTGTCCAGATGGCGCAGACTT TGAGCCGCTCACCTGGCTGCGAGTGGTGGTCTCCTCCAAGACCTGAGCCA CCGCGACGATGGCACTCTGGACACGACTAAACATTTGGCAGACTCTGCG CTCGAGTTGCTATACACTGCCAAGGAGGCTGGTGGTAACCCAAAGCAGC AGCTCACACCCAGGAAGCCCTGGAGGAGGCTGTGCAGATGATGAACGAGG	318	AYQESHLEPLANVARAEA SQLGHVQSMAQYFEPLTL AAGVGAASKTLSHPQOMALL DQTKTLAESALQLLYTAE AGNPKMATAHTQEALEEA VQMMTEAVEDLTTLTLEAA	AYQESHLEPLANVARAEA SQLGHVQSMAQYFEPLTL AAGVGAASKTLSHPQOMALL DQTKTLAESALQLLYTAE AGNPKMATAHTQEALEEA VQMMTEAVEDLTTLTLEAA

Shigella ipaC	5	prey63735	118	<p>CCGTAGAGGACCTGACAAACACCCCTCAACGAGGAGCGAGCTGCTGCTGGGG TCGTGGTGGCATGTGGACTCCATCACCGAGGCCATCAACGACTAGATG AGGACCAATGGGTGAACCAAGAGGTCTCTTGTTGATTAACCAAGCAATAT GAGCGACAGCCAGGCCATGCGTACGCTGACCGTTCAGGAGATGGTTACCAA GTCAACACCGCCAGAGGAGCTGGGCCCTCTTCTAACCGCTGACCAG TGACTATGGCGTGTGGCTGGAGGCCAAGCTGCGAGGGTGGCTGCTG AAATTAAGAGATAGTTTCCATATCAACACCGGTACAGAGCTGGGCC ATGGCTTCGCGCTGTGTCACCAAGGAGCGGCCCTCGCATGTGCAAGCC AGTATGCGCTACCAAGAGGAGCTATAGATGTGCCGAGAGATCTCT GAGAAGTCTCCACGCTCTGCTGCGCTCCAGGCTGGGATCTGTGGCAAC CAGGCGTGCATCACAGCAGCCAGCGCTGTGTGTGATCATTTGCTGACCTC GACACCATCATGTTGCGACCTGTGGACGCTCAATGTGGAGGTACT GAACTTTGCTGACCGCGGAGGACATCTGGAAGCTGCGAAGTGTGCTG GTGAGGACACCAAGGCTCTGTTGCAACACGAGCTGGGAGCGACGAGAA GTTGGCGAGGCTGCCAGCTCTCGCTGGCGACCATCACCCGCTCGCTGA TGTGTCAAGCTGGTGCAGCCAGCTGGGAGCTGAGGACCTGAGACCTGAGCC AGGTGATCTAATCAACGAGTGAAGATGTAGCCAAAGCCCTGGGAGACC TCATCAGTGCACGAGGCTGCGCTGGCAAAGTTGGAGATGACCCGTGCTG TGTGGCAGCTAAAGAACTCTGCCAAGGTGTGGTACCAATGTGACATATT GCTTAAGACAGTAAAGCGGTGGAAGATGAGGCCACCAAGGCACTCGGCC CTGAGAGCAACCCAGAACACATACGCGAGGAGCTGGCGGTTTCTGTTC CCAGAGCCACCTGCCAAGACCTCTACCCCAAGAGCTTATCCGAATGAC CAAGGGTATACCATGGCAACCGCAAGCGGTTGCTGTGGCAATCTCTG TCGCCAGGAAGATGTATTGCCACGCAATCTGAGCGCGCTGCTATTGC AGATATGCTTCGGGCTTGCAGGAAGCACTTACCACCAAGATGGCCCG TGATGTGCGGCTTCGAGCCCTGCACATGTGCGCGGAGTGTGCCAATGGCTA CCTGGAACCTGCTGGAC</p>	<p>COBTAGAGGACCTGACAAACACCCCTCAACGAGGAGCGAGCTGCTGCTGGGG TCGTGGTGGCATGTGGACTCCATCACCGAGGCCATCAACGACTAGATG AGGACCAATGGGTGAACCAAGAGGTCTCTTGTTGATTAACCAAGCAATAT GAGCGACAGCCAGGCCATGCGTACGCTGACCGTTCAGGAGATGGTTACCAA GTCAACACCGCCAGAGGAGCTGGGCCCTCTTCTAACCGCTGACCAG TGACTATGGCGTGTGGCTGGAGGCCAAGCTGCGAGGGTGGCTGCTG AAATTAAGAGATAGTTTCCATATCAACACCGGTACAGAGCTGGGCC ATGGCTTCGCGCTGTGTCACCAAGGAGCGGCCCTCGCATGTGCAAGCC AGTATGCGCTACCAAGAGGAGCTATAGATGTGCCGAGAGATCTCT GAGAAGTCTCCACGCTCTGCTGCGCTCCAGGCTGGGATCTGTGGCAAC CAGGCGTGCATCACAGCAGCCAGCGCTGTGTGTGATCATTTGCTGACCTC GACACCATCATGTTGCGACCTGTGGACGCTCAATGTGGAGGTACT GAACTTTGCTGACCGCGGAGGACATCTGGAAGCTGCGAAGTGTGCTG GTGAGGACACCAAGGCTCTGTTGCAACACGAGCTGGGAGCGACGAGAA GTTGGCGAGGCTGCCAGCTCTCGCTGGCGACCATCACCCGCTCGCTGA TGTGTCAAGCTGGTGCAGCCAGCTGGGAGCTGAGGACCTGAGACCTGAGCC AGGTGATCTAATCAACGAGTGAAGATGTAGCCAAAGCCCTGGGAGACC TCATCAGTGCACGAGGCTGCGCTGGCAAAGTTGGAGATGACCCGTGCTG TGTGGCAGCTAAAGAACTCTGCCAAGGTGTGGTACCAATGTGACATATT GCTTAAGACAGTAAAGCGGTGGAAGATGAGGCCACCAAGGCACTCGGCC CTGAGAGCAACCCAGAACACATACGCGAGGAGCTGGCGGTTTCTGTTC CCAGAGCCACCTGCCAAGACCTCTACCCCAAGAGCTTATCCGAATGAC CAAGGGTATACCATGGCAACCGCAAGCGGTTGCTGTGGCAATCTCTG TCGCCAGGAAGATGTATTGCCACGCAATCTGAGCGCGCTGCTATTGC AGATATGCTTCGGGCTTGCAGGAAGCACTTACCACCAAGATGGCCCG TGATGTGCGGCTTCGAGCCCTGCACATGTGCGCGGAGTGTGCCAATGGCTA CCTGGAACCTGCTGGAC</p>	319	<p>SAAGVVGWGVDSITQAINQ LDEGFMGPEGSFYDYQT TMVTRAKIAVTVQEMVTK SNTSPEELPLANQLTSDY GRLASEKPAVAEAENEEL GSHKHVRVQELGHGCAALV TKAGALQCSFSDAYTKKEL ECARVSEKTVSHVLAALQA GNRGTOACTAASVASGIIA DLDTTIMFATAGTLNREGT ETFADHREGILKTAFLVED TKVLQNAAGSQEKLAQAA QSSVATITRLADVYKGAAS LGADEPTQVVLINAVKDV AKALGDLISATKAAAGKYG DDPAVWLKNSAKVMVTN DPAVWLKNSAKVMVTN VTSLTKTVKAVEDEATKGT HALEATTIHIROELAVFOSP EPKATSTPEDFIRMTKGIT MATAKAVAGNSCRQEDVI ATANLSHRAIADMILRACKE AAYHPEVAPDVRILRALHYG RECAANGYLELLD</p>	<p>SDVLDKASSLIEEAKAAG HPGDPESQRLAQVAKAV TOALNRCVYSLPGQRDND NALRAVGDASKRLLSDSL PSTGTQCEAQSRLLNEAAG LNQAATELVQASRGTPDIL ARASRGPDGFSTLEAGV EMAGQSPSEDRQAQVSN LKGISMSKLLKAAKALST DPAAPNLKSQALAAARAVT DSINQLTMCCTQOAPGQKE CONALRELETVRELLENPV</p>
------------------	---	-----------	-----	--	--	-----	--	--

Shigella ipaC	5	prey67546	119	CCAGAAGGAGTGTGATACGCCCTGCGGGAAATTGGAGACGGTCCGGGAACCT CCTGGAGAACCCAGTCAGCCCAATGACATGTCCTACTTTGGTGGCCGTG GACAGTGAATGAGAACTCAAAGCTGCTGGGAGGCCAGTACGTCATCTC TCCAAAATGCCAAGACGAAACCTGCCAGATTTGGAGATGCCATTCCCA CAGCCTCAAAGGCATTTGTGGCTCACCGAGCGACTGCACAGCTGCAT ATCTGTTGGTGTCTGACCCCAATAGCAAGCTGGACAGCAAGGGCTAG TGGAGCCCAACAGTTTCCGGTGGCAACAGGCAATTCAGATGGCTGCC AGATTTGGGAGAGCTGCTGTACCCAGGCCAGTGCTCTCTCGAGCCA CATTGTGGCTAAACACCTGTGCACTGTGTAAAGCTGTGCGCTGGCTTC TSCCGTACCACCAATCTACTGCCAAGCCAGTTGTACAGTCAGCGAAG GAGGTGGCCACACAGCACTAATCTGTCAAGACCATCAAGGCGTGAAT GGGCGCTTCACAGAGGAAACCGTGCCAGTGGCCAGGACCAACAGCCCC TCTGTGGAGGCTGTGGCAATCTGAGTGGCTTTGGCTCCACCTGAGTTC TCCAGCTTCTGCCAGATCAGCCCTGAGGCTGGGCTGCCATCGACGCC ATTGTATCTCTGCCAAGACAATGTTAGAGAGTGGCGGGGACTCATCCAGA CAGCCGGGCCCTCGCAGTCAATCCCGGGAC	320	OPINDMSYFGCLDSVMENS KVLGEAMTGISONAKNGNL PEFGDAISTASKALCGFTEA AAQAAYLVGSDPNSQAG OQGLVEPTOFARANQAIQ MACOSLGPBGCTQAQVLS AATVAKHTSALCNSCLAS ARTTNPATKHOQFVDSAKEV ANSTLANVKTKHIDAFTE ENRAQCRAAATAPLEAVDN LSAFASNPFFSIPAQISPE GRAMEPNWSAKTMLESA GGIQTARALAVNPHD
Shigella ipaC	5	prey4671	120	CCTGGAGAGTCTCATCAGAGAGTATCCAGCTGGAGGCCAGCTCCCAAA AAATGGACTAGAAGAGCTGGCTGAGGAGCTGAGATCAGCCCTGTGGCC TGGAAATATGATTCCTGATCAGGATCAGGATCAGGCCCGGAACTGTCTACCTA CGGAAAATACGAGAGGAGAGGATTTGTTATCTTATCACCCGGATG CAAAAGATACAGTAAATCTTTGAGGATCTCTAAGAGCAATGACATGAC TACTACCTGGAGAGCTTCGGGAGCAACTCCCGAGGAGCAAGCTG ACAGAGGCTCACCAGCAACTCAGCAGCAAGGATCATAAAGTGAGAAA GATCAAGCTGACTTGACCCACTGGCCCTCAGGCTCAGCAGGAGCTCAG GAGAGGAAAGATGATGAAATGCTTCGAGGCCAAGCTGAGTGTCTGGCTG CTCACACCTCAGAGCCATGCCTTTGTGATCCGACCGCTGCTCCAGCA GCACCTTTCTGCTGATGAATGAAGAGCAAGCTCTCCAGTGGACATAGT CAGCAGTACACACTATGAAGAGAAAGCTCTCCAGTCACTCAGAT TCATCCATCATTCAGTCAITCTGCTGTGTGCTCTAAACCATCATCAAC CAGTGATCTCAGGGGCTAGGCCAATCCACAGCAACCCCATCAGCTT GCCAGTCCCGAATACCCCAAGGAGCAACAGGCCCATTTAGGCTT TCATTTTCACTACCAAGCTGCTGAGCTTCTCAGGCCCATTTGCC TCAGCTCACTCAGCTGCTGCTTTTCAGCCCACTGGCCCTCTGCTG GCTGCTGTGAGACCAAGTGTCTCTCTGGCTGAGGCTCAGCAGGAGCTAC AGATGCTGCAAGAGATGGGAGAAAGTGCAGCACTGTTCTGCTGCT CCACAGCTACATTGCTGAGCAAGACTTGGAGCCGACTCTCTCTACTACCT	321	LESLIQRVYSLAEQPKNGL EELKLAELFSAWPQKYDS LIQDOARELSYLROKIPREG GICYLITHAKDVTYKSFEDL LRNSIDYLYGOSFREQLA QGSQTLERLTSKLTSDHK SEKDOAGLEPLRLSLDKH OEKEKVEIYLOAKIDARSLT PSSSHALSDSHRSPSTSF LSDELAACSDMINDSEYTH YEEKKSPSHSDSHSHSH SAVLSKPSSTASQGAKA EENSNPISLTPONTPEKA NOAHSGFHFSIPKLASLP QAPLPSPASF LPFSTGP LLMLGKCTPWSLAEAQOE LLOKQGLGESASTVPAS TATLLSNDLEADSYLYNS AOPHSPPRGITELRIEPLG YLGSSGKVDWMPQKGSV

Shigella ipaC	5	prey67560	121	CAACTCTGCCGAGCCTCACTCTCTCTCCAAAGGGGACCATAGAACTGGGAAG AATCTAGAGCCTGGGTACCTGGGACGAGTGGCAAGTGGGATGTGATGAG CGCTCAGAAAGGAGTGTATCTGGGACCTATCTCAGGCTCTGTGTGTA CGACTTAATCTCAAACCCACAGGGGCTGACCTGCTGGAAGAGCATCTTGG TGAATTCGGAACCTGCGCCAGCGCTGGAGGAGTCCATCTGCATCAATGA CGCCTACGCGGAGCACTCTTGAATACGACACCGGC	322	MLTELFELHVAATPDKLNK AMKRAHDWEEEDQTVSV DVAKVSEETKKEEKES ODPQDKKEETKTIEEV YMSSIESLAEVTRCJOLH KVAEHLHGQEEEPKADQ AKVLKLTATMCNEVASLK KFTNSLTGVSNKKAEVLN PMISSVLLLEG
Shigella ipaC	5	prey8889	122	ATCAGTGTGTTATTGAGGGGTGGA GTTCCAGAACACAGAGGTGCAGAGCTGCTGGAGTGGGAGGGCCAGG TGAGCGACAGGCCACCGAGGCTGGAACACCTGAGACAGGCTCTGCAG CGGCTCAGGAGGTGCTCTTGTATGCAACACAACTCAGTTCAAGAGGCTG AAAGAGATGAACGAGAGGAGAGAGGAGCTGCAGAAAGATCTCTGGAAG AAGGCCATAACAGCATCTCGAGGCCAAGATGAGGGACAGCATAGAAAG GAGGGGAACCTGACGGAGATTAACGTCGGCACATCACTGAGTCAGTCAAC TGATCCGTGGGCTGGAGGGCCAGAGAGCGGCGATGACCCGTCTTGTG GCTGGCCAGCAGCAGGCTCTGCAACAGCTGGCAGAGAGGAGCCCAAGT GCTGGCCAGCTGGCCAGAGGTGTCAGGAGAGCGGGCGAGGCTCGCC AGAGATCCGCGGAGCCTGCTGGCGAGATGCCGAGATGCCGAGGGCTGGGGA GGGCGCTGTGTGGGCTGTGCCAGCAACGTCACGACCCCGGAGAGCGG GGACCTGTGGGCGCTGACTCGGAGAGCGAGGAGAACAGCGAGCTC TGA	323	FQNRQVQSLLELREAOVDA EAQRRLHLEHLOALRLREV VLDANTTQFKRLKEMNERE KKELKILLDRKHNISEAK MRDKHKEAELEINRHIT ESVNSIRLLEEAQKQPHDR LVAGCGQVLQQLAEPEPKL LAQLAQECQEARLPOEI PRSLLEMPGEGLDGDLV ACASNGHAPGSSGHLGSA DSQEOENTQL*
Shigella ipaC	5	prey11375	123	GTCCTGGGCTGGGGCTCGGCGCAATTCGCGGCGCCACCACTCCAG GCTCTGCGATGATGGCATCCGCGGCTCTGAAGACCGACCTCCTC CAGAACCAGTATGAGGAGACCGTCACTGCTGCGAGGAGCATGCTG GCTGCTTCGAGGCGCAGGAGGAGGTGAGGAGATGAGAGCTGCGCT CCGAGTGTCTCAGACCCATGCCCCACTGTGGGAGGCGGAGCAGC CGCCGACAGCAAGAGGAGGCGCTGGAGCTGCTGGCGAGCTG GTGAGACATGGCAATGCCGAGACTCTGCCAGCTGTCTGGCATGCAC CTGCTGGTGGCGGATACCTGGAGGCGGGCTGCGGAGACTGCGGTGAG GGGCGACAGCTCATCGGACGTGCGAGTCAGACACTGGCAGCCATCGG GAGCAGGTGCTGGGCGCTGCGGCTGCGTAAAGTGTGCGGCTGCTGGA	324	SSAGSGNSRPRPNRLQGL LOMAITAGSEEDPPPEPM SEERHROWLEQMSAARFG QREEVQMKSLRVLSPQ MPPTAGEAQRADQERE GALLADIENMNAADF CQLSGMHLVGRYLEAGA AGLRWPAOLQGTCSQNV AICEOVLGLGALKRLILD RDACDVTVRVKALFANSLV

Shigella ipaC	5	prey67473	124	CGCGACGCCCTGCACACGCTCGCGTCAAGGCCCTCTTGGCCATCTCCTG TCTGTCGAGACGAGAGGCTGGCTGCTGCAGTTCTCGCGCTGGACG GCTCTCTGTGTTGATGAGCGCATCGACGACGAGTGCAGAAGCTCAAGG TCAATATCAGCATCTCTGTCAGAACCTGCTGCTGGCGCACCTGAACAAA AGGACCC	325	MAEKVLVTCGAGYGSHTV LELEAGYLPVVDNFHNAF RGGSPLPSLRVQVLELTG RSVEFEEMDILDOGALQRL FKYFSMAVHFAGLKAVG ESVOKPLDYRVNLTGTIQ LLEIMKHAHGVKNLVFSSAT VYGNPQYLPIDEA	REQEAGLLQFLRLDGFSL MFMQOOQVOKLKWSAHL LQNLLVGHPEHKGT
Shigella ipaC	5	prey6929	125	AAAGTGGTTCACGGTTGGTAGAGAGGAAGATCTTGGATGATGCAAGG AAGAGGCCAAGCAGTTCATGAAGCTTGGAGTAACTTATGGAGTGGCTAG AAGAGTCAGAAAAGTCTTGGATCTGAAGCTGGAAATCGAAATGATCGAAT CAAAATAAACACAACTTGCACACATAAGGAGTTTCAAGAAATCACTCGGAG CAAAGCATTTCTGTACGACACCAACAGGAGCTGGAGCTTCTGGAAGGA GAAAGCTCCCTGGCTGATGACAACTGAACTGGATGACATGCTGAGTGAA CTCAGAGCAAAATGGGATACCATATGTGAAATCTGTGGAAGACAAACA AATTGGAGAGCCCTGTTATTTCTGGAATTCACAGATGCCCTACAGGC TCTCATGATTGTTATAGATTGAACCCAGCTGGCAGAAAGACACGCTT GTTCTGAGAGCATTTGTTGATGAATCTGATCGAATACAAAGGCCCT CCAAAAGAGTTGGGAAAGAGGACCGAGTGTGCGAGCCCTGGAAGCCCTC AGCCAGAACTCTAGAGCGAGTCCGGAGTACTCTCTCGGCTCAAGGT CTCAGAGAAATAGACACAGTGGAGACCGTGTGTCACATTTCTATA TCAAAGCAACAGGTTAGAGAGCCCTGGTCAAGGAGAGGAATTCAC TCGGTGTACATGCCCTTGGAGTGGCTGGCTGAGGCGAGCAACCCCTG GTTTCCATGGTGTCCCAAGATGATGAGGATGCTCTCGGAGCTCTCATTTG ATCAGCATAAAGAT	326	KVQRLVERGRSLDARK PAKQFHEAWSKLMWLEE SEKLSLELIANDPKIKT QLAQHKEFKSLGAKHSYV DTTNRFTGKSLKEKTSADD NLKDDMLSELROKWDTC GKSVRONKLEALLFSGQ FTDALQALDWLYRVEPOL AEDQFVHGIDIDLWNLDN HKAFQKELGKRTSSVQALK RSARELIEGSRDSSWVKV OMQELSTFWETVCAISIK QTRLEAALROAREEFSVH ALLWLEAEQTLRFHGLV PDDEALRTLIDQHKHE	LTHTTEELDAQRPISGDPKV IEVELAKHHVLKNIDLAHQ ATVETNKGKNLLESSAG DDASLSLFRLEAMNQWE SVLQKTEEREQQQLQSTLQ AOGFHSIEDFLELTME SOLSASEPGLPETAREQ LDTHMELYSQKAKEETYN
Shigella ipaC	5	prey6488	126	GCTGATCATACCGAAGATGTTTAGATGCTCAGACCACTAAGTGGAGAC CCAAAGTCTTAAAGTTGAGCTCGCAAGACCATGTCTCAAAAATGATG TTTTGGCTCATCAAGCCACAGTGGAAACAGTCAACAGCTGCGCATGAGCT TCTTAATCCAGTGTGGAGATGCGCAGAGCTTAAAGAGCCGTTTGGAA GCCATGAACCATGCTGGAGTCAAGTGTACAGAAAGCAGGAGGAGGAG CAGCAGCTTCAAGTCAACTCTGCAGAGCCAGGCTTCCACAGTGAATT GAAGATTTCTCTTGGAACTACTAGATTGGAGAGCCAGCTTCTGCATCTAA GCCACAGGAGGAGCTTCTCGTGAAGCTGCTAGGAGACGCTTGTATACATATG	327	LTHTTEELDAQRPISGDPKV IEVELAKHHVLKNIDLAHQ ATVETNKGKNLLESSAG DDASLSLFRLEAMNQWE SVLQKTEEREQQQLQSTLQ AOGFHSIEDFLELTME SOLSASEPGLPETAREQ LDTHMELYSQKAKEETYN	LTHTTEELDAQRPISGDPKV IEVELAKHHVLKNIDLAHQ ATVETNKGKNLLESSAG DDASLSLFRLEAMNQWE SVLQKTEEREQQQLQSTLQ AOGFHSIEDFLELTME SOLSASEPGLPETAREQ LDTHMELYSQKAKEETYN

Shigella ipaC	5	prey5814	128	<p>CTTCAAGAACCCACGTGATCAAGTACCTTGAGACACTCCTTTACTCACAGCAG CAGCTGGCAAGTACTGGGAAGCCTTCCTCTGAGGCAAGGCCATCTCC TAA</p> <p>TGATGCCCGCACACAGCTTGAAGATGAGGAACGCTGATTCACACACTGAC TTGGCAAGTTGGATGACATGATCACAGCCCTCGATGGTGCTCCAGTTT TGCCGAAGGGGAATTAAGAGTGCTTTTGAAGCTGCTGATTAATGATCTAGTAA AAGGCGCTTGATTTAAAGTGAAGCATGTCACGCAATTTTCCGTGATGGCC TAAACATATCACTCACTAAATCTTACAGATGAAGCAGTGAGTGGCCGAG TTGAAATCATAGGTCTGCTGGTGAGCTATGTGTGCCAAGTGTCCCAAG ACTGTTTCCACTTTTGAACCTTCTGCCATGGCTTAATCCTCAATGSCAA TTCCATATACAAATGGTACACGTCATGTAATCACTGTTTCTCAAGTGTCA GTTGCTGAAGTAAGCTTTTGTCTGTTCTCCAGATCTCGATCACACAAG GGTGTAGTAGTGATCTTCTCAACAAATTTGGCCTTTAAATGGGTTCCAGT TTGCGATGCTTTTATTAATGATCAGCATTAAGCTTCAATTAATGTCAGC CCTTATTAACCAATTTGGCAGTGCATGTGATTTCTCACTTCTACAGTGA AAAGTACTTCTTCCATATAGAAATGGTCCACAGTTTTAGAAACTTAA CTGATGAAGAACTGAAAAAGAACAAAGATGAAGCCCAAAATGATGCTCT TTCAATGATTAATACTTTGAAGAAATTTAGCTTGAAGGGTTCCAGGACAAG AAGAACTGTTAAACCTTAGAAATTAATAGTTTAAATGATGATAGATTAT TGCAATTTCTTCTTCAATGAAAGATGAATGCACTGAATGAAGTTAATAAG GTGATATAGTGTATCACTACTACATCGACATGGTAATCCTGAGGAGGA AGAGTGCTCAGCATGACCAATGGCAAGATGATACAGCAGCAACATATC TTATCCATGTTTGGAGATGCTTTCATCAGCCACAGATGATGAAGAAAT AGAGAAGATTTCTGTTTGTATCAAGAAAAAGCTGTGACCTTACAGACTC TTGATAATCTCGGCAGCAGCAGCGGAAACATGAAGCCATTGTGAAGAA TGATCATGCTCGCGCAAAATGGCATGGGATTTTCTCTGAAACACTG ATCATCCTTTGATGTTTGAAGCCAGTCGACAAATGGCAGTAAAAAGCA CGTGAAGAGCTACTTGAGCTGATACGTGCTTTCGAGAAGATGATAAGAGT GTGTGAGGCACACAGAGTTTGAAACCTCTTGGAATCTGGCTCAGACTGA TGATGCTCTGATATCATGACCTGGCTCTCAGTGCACAGTAAAAATTA CTGATACAGTTGCTCCAGAGCCGTGATACAAAGATCCAATGGATAG ATCGCTTATAGAAGACTTCGACAAATGACAATGGGTTATTCGCCGACTG AAACAAATTAGAAGATTTGTAGTTTGTGGTGAAGGCCCTCAAAATTTGAG TCAAACTCAGCGAGTCCCACTGTTTATGCGCA</p>	<p>329</p> <p>330</p>	<p>LPEAKAIS'</p> <p>DAPQLEDEEPAPFTDLA KLDIMINRPWVVPVLPKG ELEVLAEADLTKGGLDK SEACQRFDDGLTISFTKL TDEASWGWFKEHRCLVEL CVAKLSQDWFFLELLAMA LNPHCKHYNGTRPCSEV SSVQLPEDELFAKSPDPR SPKGWLDLLKFGTLNGF QILHFRINGSALNVQIAALI KPGOCYEFLTHTVKFYK LPIEMVQFLENLTDDEEL KEAKNEAKNDALSMIKSLK NLASRPVGOETVKNLEIF RLKMLRLQLQISSVNGKMINA LNEVKNVSSVSYTHRRG NPEEEEWLTAERMAEWIQ QNNILSVLRDSLHQPOVVE KLEKILRFVKEKALTLDLD NIWAAQAGKHEAVKNVHD LLAKLAWDFPEQLDHPFD CFKASRTNASKQREKLE LIFRLAEDDKDGVMAHRVL NLLVNLAHSDQVDMIDL ALSAHIKLDVSCQDRDTC KIOWIDFEEELRTNDKWWI PALKOIREICLSGEAPQNL SQTQRSPHFVYR</p>
Shigella ipaC	5	prey5814	129	<p>GCATGCCAACTTGGAGAAAGCAGCTTAGTCACTCTTGACTCACTTTCT TTGGCTCTACAGCTCAAGAGCTATCTAACAGAGTGATGTACGCTTG TTAATGCTGCTGGTGCACCTCTGGCTGATGATTCCTGATTTTCAGTTTCA CTCTTTGAAAGTGGTGGCCTACCCCTGTACGAGTACTGAGTATGCTAACCAAGAT AAGTCTTACCGATGCGATATGAAATGATGAAACCTGAGGGGTGCCTCAATG</p>	<p>330</p>	<p>HAKLGESSLSPSLDSLFFG P'SASOVLYLTVVYALLMP AGAPLADDDSDQFHFLLKS GGPLVLVLSMLTRNNFLPNA DMETRRGAYLNAIKAKILL</p>

			<p> AGCTGGAAGGGGATAATGTAAACCCAGAGAGTACAGTTGATACACACAGAGTGA GCAGTCTGAAAGTGAGACGAGGAGGACACAAATACAGACTTGTGGGTGT GCTGTCACAGTGGTCAAGCGAGTGGGGGCGATTATTTCTTACATCATC CAAGGAATGGTGAGATGGTGAGAGAAATCGCTGTTATAATTTGATGATG GTGATGACAGAAATGTAAATGGATGACGAGAAATGAAAACACAGT TTTTGGTGAGAGTACATGGGAGAGTGTTCATACATGATGAAGCGCTATG TCATACAGCGCCGAAAGGTGGTGAATGCTTATACCTTTTATGAAAC GAATGGACAATAGACCAAGATGATGATTAAGATATATATACAGACTT GCTATCACACAGACCTCATGATTATATGCCATCAGCCATGAGAGAA GTGACGGMAACAGACGTCAACTCATCAACCGAATGCGATACAGTAT GGATATTGAGTTTATGAAAACCTGCTTACATGATGCGGTTACTTAA CCTCTCCGGGCAAGATCACCTTGGCTGGAAGCAGAGAAATCACTATG ATCAGTTTCAACTTGTCTAGTTCCTTTACTACAGGATTTTACACAAA GAAGTAGTCGTGCTGCTGCGAGTATGATGATGATTTGTTTAA CTCGTACACGCAAGAATGTACGTTTTGTTTCTCATACGCTCTTTTAA TGTTCAAATCGCTCTCCGATACCTCTGGAGTGCCTTAGTGCAGAGTG AGGGGTGCGTTTGAACACTTATAGTCTTATGCACATTTTCTTGCACGA TGGCCATGCTCTTACCTTTTGCTCTCTCTGGACCTCTAGTCAGGCTTAT GACACTTAAGCTTGAAGTATCACTTACTAAGACGACTAAATCTCTGAG AAGGAAGTTTACAGCATGGGCGTCTTTACAGCAGTATTTCAACGCTTT GTAATGATGCCAATTTAGTGTGGCAGAGACACACGCTTCTGAAATTGA GTGTAAGTCTACTTTATGCTGTGCTTTAGATGAAGTCCAGGCTCTCCA ATCAATACAGATGCTGAAATAGGCAATTA TACTCAGTATGTCACAGCT GATCGCTGTGTGCAATGCTCTTCAAGAAATGCACTTCAATCAATGGTATC CTCCTCTCCCAATCTTTTGGTATCCTAATTTATCAACCTATATATGCOAA TTCACGAAATGGCAGACATTTATTTGTGAGAACAAAGTTATGTGAAGAAA ATCATGAAGATGACGTAATCAGAGAAACCGCTCAAAATGTCTGCTTTTG CTGCTGGGAAATCTCTAGTCTCTACTGCTCTCTAGTGAACCTCTCTGG CAGTTTGCATTTCTCTATCCCTATGAACCTGGCGCTATT TGGATCTGCTTTT GCAATTTACTGATGAGGACTCTGGCAACTCAGACATCATATGCAC TGAAGGAATTCAGATGACGAGATGGGCTTTGACACAATCCAGCGCT TAAGATCACTATCAAAAAGAGCATACCGATGTATAAATGTATGGTAGCTC TATTAGTAAGTGTCTGTTGCTTACCAATCTCTGACGGCAATGGAGATCTT AAAAGAAATGGACCTGGGAGTGGAAATGGCTTGGAGATGAACCTTGAAGA AGACATATAGTGAACCTCTCAGTACATTTACAAATTTGTTCTCCCCAGT GCAAGCAATGAACCTCCATGGTTATTTCTTGGAGAGATACATATAGTCT AGGATGACATTTGCAAAAGCTTGTGAACCTCTCCAGAGGAGTAAAGAAAG CCACCATGTGACGACATAGAAATGGAAGAGACCAAGACCGCATGAGACC AAGATGCTCCAGATGAACATGAGTGCCTCCACCTGAAGATGCCCATTTGTA </p>	<p> DDDEEMKQCFGGVWG EYFDHMKRMSYRQKR WNNAYPFYEROTIDQDD ELIRYSELATITRPHQIMPS AIEERSVKRONVQMHNRM OYSMEYFQFMKLLTONG VYLNPFGODHLLPEAEIT MISQLAARFLFTGTGTHK VWRGSADWYDALCILLRH SKNRYRWFHNLVFNYSN SFNRYLLECPSEAERGAFA KLIVFAHESLDQGPCPSF ASPGSSQA YDNLSLDHL LRAVLNLLHRESEHGRHL QOYNLFMYANLGVAEKT QLLKSLVPATFMLVSLDEG PGPIKYQVAELGKLYSVW SOLRCNVSRRMQSSING NPQLPNFGDPNLSQNPMP QONVADILFVRTSYKKIE DCNSSEETVKLLRFCCWE NPQFSSTVSELLWQVAYS YPYELRPLDILLIQUILDES WQTHRIHALKGPIDDRDG LFDTHORSKNHYQKRAYQC IKCMVALSNCVAYOILQG NGDLKRKWTWAVEWLDG ELERRPYTGNPQYTYNNW SPVQSNETJNGYFELRSH SARMTLAKACELPREEVK ATSVQOIEEMESKEPDDQD APDEHESPPEDAPLYPHS PGSQYQQNNHNVHGQPYTG PAAHHNNNPORITGQRAQE NYEGSEEVSPPTQKQ* </p>
--	--	--	---	---

Shigella ipaC	5	prey67/479	130	CCCCATTCACTGGATCTCAGTATCAACAGAATAACCATGTGCATGGAAG CCATATACAGGCCCGCAGCACATCAATGAACACCCCTCAGAGAACTGGC CAACGAGCAAGAAATATGAAAGGCAGTGAAGAAGTATCCCCACCTCAAA CCAAGGATCAATGA	CGATGAGCTCATGAGACATCAGCCACCCCTTAAACAGATGAAGCACTGCC ATCTCAAGTTACTTGAAGAAATCTGTAATCTTGAAGGAGCCCAATACAT CTGTGAAGCCCTCATGACGAGCAGATGGCACTGCCACTGCTCTCTCC CCAAAGCTTAATCATCGCCGAGGAAGCCCTCTAGTAGGATGAGGAGGA AGAGAAATACAGCCATCGAGAGCTTAACTCTACCCAGCAAAATGAAC GAGCCTAATCAGCAGGTTGTTGTACAGGAGGAACTATCTTATCCCTCA TGGATTACATCTTAATGATGAATTTGGAACTGATGAGCAACAT ACACAGATGACCATGCCAAGAAATTTGTAATCAGAAGGACTGTTGCCCT TGGTACCAATTTGGGCTCTCCCAATCTGCCATTTGACTTCCCACTGCTGT GCCGTGAGGCTGTTGGAAGTGTCTGCAAAATCCATATTGACACTGTCACTG AACCCAAAGTCTTCAAGAGGCTCTCTCAGTTTGGACTCCATCTCTCTCTC CTGAGGCCCTTACACGCC	331	DELMRHOPLTKTDATIAIK LLEEICNLGRDPKYCKPKS IQKADGTATAPPRSNHAA EEASSEDEEEVOAMGS FNSTQONETEPNQOVWGT EERIPILMDYILNMKFEV SILSNNTDDHCQEFVYNQK GLPLVTILGLPNLPIDPPTS AACQACAGVCKSILTL SHE PKVLQEGLQLDLSLSLEP LHR	MGIGLSAGGVNMNRLPGW DKHSYGYHGGDDGHSFCSS GTGQPYGPTFTTGDVIGCC VNLINNTCTYTKNGHSLGIA FTDLPNLVPTVLQTPGE VVDANFGOHFPVFDIEDYM REWRTKQAQIDRFPIGR EGEWQTMCKMWSYLVH HGVCATAEAFARSTDQTLV EELASIKRQRIQKVLAGR MGEAIETTQQLYPSLLE
Shigella ipaC	5	prey700	131	ATGGGAATTGGTCTTCTGCTCAAGGTGTGAACATGAATAGACTACCAAGTT GGGATGAAGCATTCATATGGTTATCCATGGGATGATGACATTCGTTTGTCT TCTGGAAGTGGCAACCTTATGGACCAACTTTCACACTGGGTGATGATG GCTGTTGTGTTAATCTTACCAATACCTGCTTTTACACAAAGATGACAT AGTTTAGGTATTGCTTCTCAGTACCTACCGCAAAATTTGATCTACTGTGG GCTTCAACACGAGGAAGTGTGCTGATGCCAATTTTGGCAACATCTTCTC GTGTTGATATAGAAGCTATATGGGGAGTGAGAACCAAAATCCAGGCAC AGATAGATCGATTCTATCGGAGATCGAAGAGGAGAAATGGCAGACCATGAT ACAAAATGGTTTCTATTTAGTCCACCTGGGTACTGTGCCACAGCAG AGCGCTTTGCCAGATCTACAGCAGCAGCGTCTAGAAGATTTAGCTTCAT TAAGAAATAGCAAAAGAAATTCAGAAATGGTATTAGCAGGAAGAAATGGGAGAA GCCATTGAACACACACAGCTTATACCCAAAGTTTACTTGAAG	332	MGIGLSAGGVNMNRLPGW DKHSYGYHGGDDGHSFCSS GTGQPYGPTFTTGDVIGCC VNLINNTCTYTKNGHSLGIA FTDLPNLVPTVLQTPGE VVDANFGOHFPVFDIEDYM REWRTKQAQIDRFPIGR EGEWQTMCKMWSYLVH HGVCATAEAFARSTDQTLV EELASIKRQRIQKVLAGR MGEAIETTQQLYPSLLE		
Shigella ipaC	5	prey67/481	132	AAAAACAGACCAAGCTCCAGATAAAGAGCCATCTGCGGGCCACCGC CAACCTGCCCTCTACAACTCCGAGAGATCTGGTGTCTCTCAGCAACATGAG AGACTCCAGACAGAACTCCGAGAGATCTGGTGTCTCTCAGAGGTGGC GCAGAAGCTGTTAGCGCTGAACCCAGATGCGGTGGAATTTGTTAAGAAGC GAATGCAATGCTGGAGAGGAGGAGGATGAGCGTGTGGAGCAGGCTGCC TGCGGAGCTCACGAGATGGGCTTCCGGAGAACAGACGCCAGGCGCC CTTACGCTGAACCATGTGCGTGCCTCAGGCCATGGAGTGGCTTAATTGAAC ACGACAGAAGCCCG	333	KDQKAPKPEKALRATANL PSYNMDRAAVQTNMDFQ TELKILVLSVIAQKLLAN PDVLEFKKANMLDEDED ERVDEALROLTEMGFEN RATKALQLNMVSPQAME WLIHAEEDP		
Shigella ipaC	5	prey67/488	133	CTGTTGATGAAGATGAGCGACACGACCGCGAGGCGACAGCTGGCCACAGCA GAGCAGAGCTACGGGGCTACGAGCGAGCGGAAAGGCTCCCGAGG CCGAGAGCGCGGCCGAGGAGCTCTGGAACAAAGGCCAAGGAGAGCAAG	334	LFMKSRHAAEAAQLATAEQ QLRGLRTAEARARQASR AQEALDKAEKDKKTELKSL		

Shigella ipaC	5	prey51967	134	<p> AAGATCAGAGAACTCCAAAGAAAGTCTTCAATCTTAAGAGGCTTGAAGG AGCAGCGCGCCCTCGCCACCCCTGAGTGGAGGCTCTCGTGACCCAG GTGGAGATTATACAGAGAGCTGCGAGGACCTCCAGTCCAGC GTGGTGGCTTGTACAGAGCCACTCTATATGCCATTGAG </p> <p>335</p> <p> TGACCAACTGTGTGATATTGTCTGGAATAATTTGAAGATCAAGATACCT TGAGTCAGCATGGAATCATGATGGACTACTTGTCCACTGTGATCTAAACA CAAAAAGCGCTCAGGATCATTCAGCTGACGCAACAAATACAGCTGGAAGCA ATGTTTACATCACTCACTCAATGATTAACCTACATCTGTTCTGCTAGTA CGAACCTTTTGGTTAGTGGCTTGGGAGCTTGCAGGTCTGAGTAGCT GGTTTGAATACTACCAACTCTCTGAACTACAGATCAGATGCGAGCGCAAA CTTTGTCTACCCCTGAAATGATGTTGTCAGATCATGGAATAATCCCTTTGCA GAGCATGCTCTAAATCTGACCTGATGACAGATTAATATGGCCAATCCA CAATTCAGCAGCTGATACAGAGAAATCCAGAAATTAGTCATATGTTGAATA TCAGATTAATGAGACAACTGTTGAACCTTCCAGAACTCCAGCAATGATG CAGGAGATGATGAGAACCGAGACCGAGCTTTGAGCACTTAGAAGACATC CAGGGGGATATAATGCTTTAAGCGCATGTACACAGATTAATGCTTCCTTGGT TGCTGAGTGTGCAAGAGCGATTTGGTGGTAAATCCATTTGCTTCCTTGGT GAGCAATACATCTCTGGTGAAGGTAGTCAACCTCCCGTACAGAAATAGA GATCCACTACCAATCCATGGGCTCCACAGACTTCCAGAGTTCATCAGCTT CCAGCGGAC </p>	<p> EVENLKEALKEOPAALATP EVEALRQVKDLQQLQOE AARDHSSWVALYRSHLLYAI Q </p> <p> DQDLVJFAGKILQDQDLSQ HGHDGLTVHLVKTQNRP QDHSAQQTNTAGSNWTTTS STPNSTNSQDTSNPFPL GGLGGAGLSGLNTNF SELSQMRQLNSNPEMM VOIMENPFVOSMLNSPDL RQLMANPQMQLOENPE ISHMNPNDIMRQTLLELAR NPAMMOEMMRNDORALS NLESIPGGYNALRRMYTDI QEPMLSAAQEQFGNPFIA SLVNTSSGEGSOPSTEN RQPLNPWAPQTSUSSA SSG </p>
Shigella ipaC	5	prey67491	135	<p> AAGAAAGATGTCAAGCAGCAGAAAGAACTCCCTCCCATCAACAACCAACA ACTCTACTACACAGCTACCAACACACTTGTACAGCCACGGTTCACACAC AGCCAGATACAGCTACACAGACATCAATGTCTATTCCCTTCGGGGCTTGGC ACCACACTTACTTAATCCAACTTCCCTGTTTTCAGGCCCATCCACAGT TGAAGCAGTGTGTGCTCAGCAATGAAACGGGCTGTCAGGAGCTGCTC ATGCTGTGGTGGATCGATCAATTAAGATTGCCATGACTACTTGTGAGCAATA CTCAGGAGGATTTGGCTGGATTGCGAGGAATCTCGAATGCGAATAGCA GCTCATCATGATGCGTAACTTGCAGCTGGAATGGCTATGATATCATGCA GGAAACCTTTGCTATGAGCATATCTACCAACTTAAACAAAGTTTTGGCTCA GCCCTCTGATGCTTCCCAACAAAGAAATGATGGATCAGGACGCTG CTCAATTAGCTCAGGACAAATTTGAGTTGGCTGCTGTTTATTCAGAAGACT CGAGTAAAAAGCAGGCCCTGAGATGGAAGAGAGATTAGCACTGAAATTTG AGCTGAGAAAACATGCTAGCGAGAGAGGACGAGATCAGCTGTGAAGTTGGT TTTACATCATACGCTGACGGATGCCAGGACAAATCAGGCTGGAAGTTGGT GGTGTGAGCCCAAGCAGTTGGCTGTTTACGAAGATTGGACGCAATGTTG CTGGCTCTTACCTACAAATGACTTAAGTCAGGCCACGGGATTTTAGCCCA GCCCATGAAGCAGCTTGGCAACACATGATGATGCCATCCCACTTTTGGCA TGATTTACGAACCTGGAGCACTATCATGCCATCCCACTTATGAGGCA TGAACCCCTCAAGCTCAGGCTCTTCSAGTCTCTTGGAGGTGTGATTATCT </p> <p>336</p> <p> KKDKVQPEELPIPTTTTST TPATNTTCTATVPQPQYS YHDNVYSLAGLPHITLNP TIPLQAHPLQKOCVHQAE RAVQLHPVWVDRSKIAMT TCEQVRFKDFALDSESRM RIAAHMMRLNLAGAMVIT CREPLLMSTNLKNSFASA LHTASPOREMMDQAAQ LAQDNCELCACFIQTAVE KAGDEMPKLFATEFELRH ARQEGHRYQDPVLLTYQA ERMPEQIRLKVGGVDPKQL AYVEEFARNVPGLPNDL SQTGHLQAQMIKQAWATD DVAQYDKCTIEQHLHAI PPTLAMPNPQALRSLELV VLSFNSRDAIAALGLLCA VEGLDATSGADADLLRY </p>	<p> EVEALRQVKDLQQLQOE AARDHSSWVALYRSHLLYAI Q </p> <p> DQDLVJFAGKILQDQDLSQ HGHDGLTVHLVKTQNRP QDHSAQQTNTAGSNWTTTS STPNSTNSQDTSNPFPL GGLGGAGLSGLNTNF SELSQMRQLNSNPEMM VOIMENPFVOSMLNSPDL RQLMANPQMQLOENPE ISHMNPNDIMRQTLLELAR NPAMMOEMMRNDORALS NLESIPGGYNALRRMYTDI QEPMLSAAQEQFGNPFIA SLVNTSSGEGSOPSTEN RQPLNPWAPQTSUSSA SSG </p>

Shigella ipaC	5	prey1135	140	<p>TCGAGATGATGATGCAATGCAATGCAACCAAGAGAGATCTGTGCGCTGGTGGGTT CTGTGATGAGGTGAAGAGATGCCATGACAGACTCTGTGCGCGCCAAAGT GCCCTCCGAAGATGTCATCCCTGCCGTGGAATCTGTGTGGAGCCATTAAGAA GACCTGAGGTCCAGCAAGCTGATTTTACTGTGAGGTGTGTGATTCCTGTG GTGAAGAGGTGACCAAGCTGATGACCAACCAAGACTGAGAAAGAAATAC TGACGCTTTTGACAAATGCTGCTGAGCTGCCAGTCCCTGTGCGGAAGA GTGCGCAGAGG</p>	<p>CALVGFCDVEMPMQTL VPAKASKNVPALVELPEI KKHEVPAKSDVCEYCEFL VKEVTLIDNNKTEKLEIDA FDKMCCKLPSKSEECQE</p>
Shigella ipaC	5	prey1135	141	<p>TCGCTGATTAAGTGCATCAAGATTTTATCATCTGGGGCTTTTGAGGAG TGCTGAAATATGCTGTGGAGCAGGACCTCTTCAATGTCAATGATAACTC TGAATATGTGMAACTATTATGACAAATGCAATGTGATCATCACCAACAGT GTGGAATAATGCAATTTGCTGCAAGGAGAAACCAATTTGACACAG ATTGGAAGCATGTAATAAATGTTTCAAGGATGCTAGATGATCACAAGT ATAACAGGCTATTGCAATGCTGTGGAGACGAGACTGGACCTGTGTA AAAGCACTACTGGAGTGAATGATGCCAGGAATGTTAGCTATGACCTT AAGCTGCGATGCTTTAATGAGAAATAACAGTTCCGAATAAAGTAACT AGTCTAGTMAATCTACATGAATCTGGAGAACCTGATTTTCATCAATGTT GTCAGTGCTTAATTTCTAGATGATCCTGAGGCTGTGAGTATCTTAGAG AACTGTGTAAGGAGACACCTCCTGATGGCATATCAGATTTGTTTGAAT GTATGAAGTGTAGCCAGCATTTTGTTCATCTGTAATCCAGAACTTGGA CTGTTGGACCCCTATTGCTGCTGCTGGATCCCACTAATACGGTACTGT TCGGGATCAGAGAAGACAGTACTCGATGTAACACAGAAAGAAAGCAAG CAGTGCAATTTGAGAAAGACAC</p>	<p>AALVASKVYVHLGAFESL NYALGARLFLNVNDSEYV ETIIAKCIDIHYTKOVENAD LPESEKKPIDORLEGVWK MFORCLDDHKYKQAGIAL ETIRLDDVFEKTLSENDDPG MLAYSLKLMSLMONKQF RNKVLRLVKYVMNLEKPD FINVCQCLFIDDPQAVSDIL EKLKEDNILLMAVQICFDLY ESASQGFSSVQNLRTVG TPIASVQFSLNTGTVPGSE KDSDSMETEEKTSSAFVGK T</p>
Shigella ipaC	5	prey2880	142	<p>CACGCGCGCTGCCCATGATGCGCGTGGCGGAGACGAGATCAAGCCCTA CATCAGCCGCTGTTCTGTGTGAGGCCCGCGCCATGCCATCGCGTCCA CAGTCAGGATGTCCTCATCCACACTGCCAGCTGGGTGGCGGAGTTGTG GATCGGATTCCTTCCTCGACACACGCGGCGGAGACGAGCTGGTG CCAACTACGTGTGACCGGACGCTGTCTAGAGGACTTCGCGCCACACCC ATTCATGGAATGCAATGAGGCGCGGACCTCGCCTACTACGCCACACA GTACAGCTTCTGGCTGACCACTTCGCGGAGAGACTTCGAGGCTCGCC TCAGGCGCACGCTCAAGCGCGCTCATCCGACACACATCAGCGCGCTG CGAGGTGTCGATGAAGAAGCTGTGA</p>	<p>TARLPMPVIADEIKPYISR CSVCEAPAIAMVHSQDVSI PHCPAAGWRSLWIGVSLFM HTAAGDEGGQSLVSPGS CHDFRATPIECNGBRGST CHYANKVSWLTIPEQOS FQGSFADTLKAGLRTHIS HCGVCMKNL</p>
Shigella ipaC	5	prey3599	143	<p>AGATCAAGTGGCTTACCCTATCCACAAATGTTATGCCACCTTTTGCAAC TTGCTGACTGTAAAGATGCAAGTGTGCAAGTACTCGATGGACTAA GTAATATTAATAATGGCTGAAGATGAGCGAGAACCACTACGCAATCTATA GGAAGATGTGGGGCTGGAGAAATTAACAACCTTCAAAATCTCAAAATG AGACATCTACAAATGGCCTATTGAGATCATGATCAGTTCTTCTCTCAGAT GATATTGATGAAGCCCTAGCCTTGTCCAGAGGCAATTCAGGGCGGACAT TTGTTTCAATTTCACTGCCAATGTACCAACAGAGGGTTCAGTTTATG GGCAGTATTGAGATGCTGCACTTACCTGCTGCGGAAATGAGAGACACTG</p>	<p>DOVAYLIQNVIPFNCNLT VKDAQVQVWLDGLSNLK MAEDEAETIGNIECGGLE KIEQLCNHEDNYKSLAYEII DOFFSSDDIDEDPLVPEAI QGGTGFNFSSANVPTEGF OF</p>
Shigella	5		344	<p>AVIEMCQLLVMGNEETLGG</p>	

ipacC			GGAGGGTTTCTGTCAGAGTGTTGTTCCAGCTTTGATTAGCTTACTTTCAGAT GGAGCAAAATTTGATATATGAACACGCTTGTGAGCCCTTAACATACATGA TSGAAGACTTCTCGATCTGCTGTGTGTATGATAGTACTTCTGCTGT TTAGAAAGCTGCAAGTTATCAGTGATGTCAGAGCAGCGCTGA TTGCACTGGAGATGTTGTCAGGAGACATAGTAAGCCATCTACAGCGCG GGGTTTGGCAGACTGCTTGTCTACCTAGAATTTCTCAGCATAAATGCCGA AAGAAATGCATTAGCAATTCAGCTAATTTGTCGAGAGATACACGCGAT GAATTCATTTGTCGAGATACCTCCCATTTGCTAACCCAGAGCTTAACACA TCAGATAAAAGTCACTAGAAAGCACTTGCCTTTGTTTTCAGCGCTAGTG GACACTCCAGCATGAGGAGATTTACTCAGCAGCTTGTCTTCCAAAGT TGCTTCAAAATGTTCAACAGCTTGTGTAGTGAAGTCTCCACCCATTTAAGTCT GGGATGTTAATGTTGTTGCTGTGATTTCTCTGATGTGTCCTCACTGTCC AAGTGTGCTTCACTTATGAACAAACATTTGCAAAACCTTCACTTCT TCTGTGTTGCTCCAAATGGAAGTTGTCAGGAACAGATGATCTTGTTC ACGAGCCCTCAAGATGTTGATGAAGTGCATCTCTGATTTGTGAAGTATGCG CATGTTTACCAAAAGAGGCAATTTTGCAGTTGATACCTGTTGAAGAAGGGA AATGCAGAGACACATAGGTGCGATATGGCAGTGGCGTGATGATCGGGCG CTCTGCGATCCATATACAGATTTGACGCCGATCAITGAGCAAACTAATG AGGACAGCGGACAGCAGCTGCGATTCAGAGAAACCTAACCGGTTAGCGA ATAGTACACTAGTGGATATTCAGAGTCAAGAGAGGATGATGCTCGAGCACA GCTTATGAAGAGGATCGGAGCTGGCTAAGTCTTATTAAGACATTTATG GTGTTCTTGAAGTGTATGTTCTCAGCAGGACCTGCGGTGACAGATAA GTGCTGTAGCAAAATCTTAGGATAATTTTGGGATGCTGCACTGTGA AGGATGCTGAAAAATCATGCTTTTCAAGTCAATTTCTTCCAGTCTGTCA AGCAAGACTGAAGATAGTAGTGGGACACTCAGATGGCAGAAATTTAA TGCAAGATTTACCTGATATTTTGTGTTTACTTCAAGAGAGAGTGTATG CATCAAGTAAACACTTAGCAGATCAGAGTCTTGTGCAAGTCCACCAA GGCATGTAGCAATGGATGGGATCCATGGATCCACACTTCACTCAGCAG TGGACAGACAGAGCTGCCACTCATGCTGCAGCTGACTTGGGATCACCCAG CTTGACAGCAGCGGAGTATCTTTAGATCTCAGCCCTCAAGGTGCAATTA AGTGTGTTCTTAAGAGAAAGCACTGCCAAACAGGCGCAAGAGGCCA AAGTACTACCTCCAGAGATGATGACAAATAGACAATCAAGCTTAAAGGCC CCACCACTACTCAGTCACTAAATCTTCTTCTGCGCAAGTGAATCAAAA ACATGGGGAAGTTAAGTACAGTCCAAACAGCAACATTAGCGCAGCAC GGAGCTGGGAGTAGTGGCTTCCAGGCGCTGCTTAAAGGATACCATCT CCAAATAGAGAAAAAATTAAGGTTGATTAAGGAGCAGGACATAAATTT GTAGACGTTATTCAGTCTGAGAAATGATGGTGAAGCAACCTGCACTTGA ATGTCTCTCAGAGACTTTGTGCTGCACACCGAACCACTCAACCTCCAGGTGGA TGGTGGAGCTGAGTGGCTTGTAGAAATCGTAGCATAGTCTCAGAGTCAGAT
			FPVKSVPALITLLOMEHNF DIMNHACRALTYMMEALPR SSAVDAIPVLEKLVQIO CIDVAEALTALEMLSRH SKAILQAGGLADCLLYEFF SINAQRNALAANCOSIT PDEFHFVADSLPLTLQRL HODKKSVESTOLCFARLVD NFOHEENLLOQVASKDIT NVQQLVVTPIPLSSGMFIM VVRMSFLMCSNCPITAVQL MKQNAETILHELLCGASNG SCQEQIDLVPSPQELYEL TSCEICLMPCLPKGIFAVD TMLKKGNAQNTDGAIWOW RDDRGLWHPYNRIDRIIE QINEDTGTARAIOKPNPLA NSNTSGYSESKDDARAQ LMKEDPELAKSFIKTLFGVL YEVYSSAGPAVRHKLCRA ILRIYFADAELLKDLVKNHA VSSHASMLSSODLKVVGA LOMAELMOKLPDIESVYFR REGVMHQVYKHAESLIT SPKACTNGSGSMGTS VSSGTATAATHAADLSP SLQHSRDDSLDSPQGRLS DYLKRLPKRGRPRPKYS PRRDDKVDNOKSFSTTT QSPKSFSLASLPKTVGRL STQSNNSIPNATAGGSG LARAASKDTISNNREKING WIKQAHKFRYERYFSENM DGSNPALNVLORLCAATEQ LNLQVDGGAECLEIERSIVS ESDVSSFEIHSFGVSKOLL YLTSKSEKDAV/SREIRLKR LHVFFSP/LPGEIEGRVFP VGNAPLALVHKMNNCLSQ

<p> GTTTCATCATTTGAAATCCAACTAGTGGAATTGTGAAGCAGCTGTTGCTTTA TTTGACATCTAAAGTGAAGGATGCTGTGAGCAGAGATCAGATTAAAG CGATTCTCATGTATTTTGTCTCCACTTCCTGGAGAGGCCAATGG AAGAGTGACCAGTGGGTATGACACTTTGTTGGCAATAGTTCACAAATG ACAAGTCCCTCAGCAGATGGACAAATTTCCAGTCAAGTACATGATTCC CTAGTGAATGGGACAGGAGCAGCTTTCTCTCAACAGAGATCAGAC CTTTAAATTTTCAACACATCAATTAATACCGATTACAAGGATCCA GACTGTCAATGTGAAGCTGAGAGGTGGAGCTGTCAAGATTGACCT TGTGCTTGGTACAAGCTCGAGATACCTTGTCTAGAGGTTGTGAA GAGTAGAGAGATGATGAACAGAGCTGACGATGATGATGATGAGGAA TAGTAGTCTGCTGCTGCTGCTTCTTAATTTGAGGAATGTGAAGACAG GCTGCAGTTTTATTTGGAAGCAATTTGCTGGCTATTAACATGACTGTATC AGCAGTACGGAGTTAGTATACAGGCTGAAGATGAAGAGAAATCCACAGA TGATGAGAGCAATCCTCGCAGAGCTGGTATTTGGACAGAACTACACA ATATGGTAAACCTGTGAGAGAGGATGAAGAAAGTAAAGGATTGTGGT GTGGTAAAGGAGAGCCCAACAGCTCCACAGAACTCCCTCAGTAA TCGAAAGGATGATGAGTTATGGCAGATGGAGTGGCCATCAGTATCA AATCCTTTAGAGTTTACCTATCCACACACCTGAAATATAACATTGAA GACCGTCAATTAGATGATGATCCTTTTAAAGTTTTACATGCTATGCTG ATACTGGTATTACTGTATGATAATGCAATGTGCAAGGAAATATCCAACTA GTGAATTTTACAGTAGTAAAGCAAGCAAGCAATAGGCAACTCAAGAT CCTTAGTATCATGACAGAACTCCCAACATGGCTACTGAGCTAGGAA AAACCTGCCATTTTCTTTGATACCCGGCAATGCTTTTATGTATGTA CTGCTTTGATCGGACGAGCAATGCAAGATTGATACCAACCCAGA AATCAACAGTCTGATCTCAAGTAGAGATTGCACCTAGATTGGATAGA AAAACAGTACTGTAAACGAGGAGCTGCTGAACAGCGCGGAGTCTGTG ATGACGACTCGGAGCTCAGCGGCTGTAGAAATCCAGTATGAAATG AGTGGTACAGGCTTGGCCCTACACTGGATTTAGGCGTGTATCTCA GAACTACAGAGCTGACTGGGCTTTGGAGAGTGGAAGTAACTCT AGCAATCCAAAGGAGCAAGAGGACCAATATATCCAACTCGAAG CGCTGTTGGCTTCCCTTGGTAGGACGCAAGCCAGCTCATATCGAAA GGTTAGATGAAGTTGCGTCTTAGGAAATTAATGCCAAGGCTACTG GATTAGATTGGTGACTTCCCTTGGCTTACCCTTTTAAATGGATGCT ACBGCAAGAACTTCACTGATCAGACATGATTGTTGACATCGACCAAGT GTAGCCAGTACGTTTACCTTAAAGACATTTGTCAGACAGAAAGAGC TTGAACAGATAATCCAGCAAGAGAGTCTACAGTATGCATTAGCAAG CTTGACTGATGAAGCTGCTCAGTTGAAGTCTAGGACTGATTCAGCTG CCAGGGTTTCCCAATCGACTGAAGAGGAGGAGGATACCACTCA CTACACAAATTTAGAGAGTATCTAAGACTGGTTATATCTGGGCCTAAT </p>	<p> MEQPRVKVHDFPSNGTGT GSFSLNRSQALKFFNTHQ LKQQLRHPDOANVKWK GPKYKIDPLALVQAIERYLV VRGYRVREDDEDSDDDG SDEEDESLAQFLNSGNV RHRLQFYKHEHLLPYNMSTV YOAVHPRFISQADERESTD DESNPLFSQAGRWTKTHIW YKPVREDEENKDCVCGK FGRACQTAPTKTSRPNKK HDELWHDGVCPSVSNPLE VYLPTPENITDEPSLDVI LLRLVLAHSRYWYLYDNA MKKEIPTSEFINSKLTAKAN RQLQDPLVMTGNPTWLT ELGKTCPEFFDTRQMLF VYTAFDPRAMQRLDTPN EINQSDQSRSVAFRLDRK KRTVNRHEELLQJAEVWQ DLGSSRAMLEIQYENEVGT GLGPTLEFALYSQELORA DLGLVRGEEVTLNPKGS QEGTKYQNLOGLFALPFG HTAKPAHIAKVMKFRFLG KLMAKMRDLRVLDPGLP FYKWLRLQETSLTSHDLFD IDPVAVRSVYHLEDIVRQKK RLEQDKSOTKESLOYALET LTMNKGSGEDLGLDFTLPG FPNELKKGSGKQIPVTHNLE EYVLRFLVFWALNEGVSROF DSFRDGFSEVFLSHLOYF YPEELDQLLCSKADTWID AKTLMCCRPDNGYTHDS RAVKFLFEILSSFDNEQOHL FLOQVFTGSRPLPVGGFHSL NPPLTVRKRTFTESENPDFF LPSVMTCVNYLKLDPYSSIE </p>
--	--

Shigella ipaH9.8	6	prey67717	144	GAAGGCGTTCTAGGCAATTTGATGGTTCTAGAGATGATTTGAATCAGTCCTT CCCACTCAGTCCTCAGTACTTCTACCGGAGGAACTGGATCAGTCCTT TGTGCGATTAAGACAGACACTTGGAGTGCAGACACTGATGGAATGCTGTGA GGCTCAGTCATGTTATCTCATGACAGTCGGCTGTGAATTTTGTGGA GATCTCAGTAGTTTGAATGAGCAGCAGAGTTATTTCTCCAGTTTGTGA CTTGATGCCAAGATTGCTGTGGAGGATCCGGAGTTTGAATCCACCTTT GCAATGTCCGAAGACGTTTGAATCAACAGAAACCCAGATGACITCTTG CCCTGTGAATGACTGTGGAATCTTAAAGTTGCCGAGTATTAACGACAT TSAGATAATGGGTGAATAACTGTTGATAGCAGCAAGAGAGGACGACAGTC GTTCATCTTCTGTA	345	AGHPVLSRA*DCPROOH NHVQPSVSDALVWOPRE CEPICSWEGHLSWASGEGL LPGALHSLHRSRAPASAA APICANDVWPNRVRPRL PPIQTVGF*ELGAWGLQW GGQEQVGSVSLFPHALT HPNVRTELKATEGGA AHSTWVAHRSALFLPAGS LCRLSL*PSSPPPPSSETE PGPLAAPRPFRSDRGATT PGRGKEGRPKSRGLSW WPWASLELWCHLQKGG KNACVWQLRGYAVKTRNW GRLANNNGSWPGFAAHAC NPSTLGGRRGRTSRGDD DHPG*NGETPSLLKIQKISR A*WRAPVVPATWEAEAGE WCEPGRSRLQ*AEIPLHLS SLGDHARLILKKKKNNNGS NFSADDEEUSWPGRATPTT HPSLYNRRATFSSSEQDRL VAKSRK*GLVPARWLIPVP VLWEAEAGAWIT*GQGF TSPTNNMKRPL*YEYKN*P GVVARACNLSCLGG*GHRH A*TRAEAVVSRDRATTVO PGGSVRLGL
---------------------	---	-----------	-----	--	-----	---

Shigella ipaH9.8	6	prev700	145	AGTTGCAGTGAGCGGAGATCGAGCCACTACTGTCCAGCCCGGGGGCAGT GTGAGCGCTCGGTCTC	ATGGGAATTGGTCTTCTGCTCAAGGTGTGAACATGAATAGACTACCAAGTT GGTGAACCATTCATATGTTACCATGGGAGTATGACATCTGTTTGTGTTCT GGTGAACCTGACCACTTATGACCAACATTCCTACTGATGATGCATG GCTTGTGTTTAACTTATCAACAATACCTGCTTTTACCAAGATGACAT AGTTTAGTATTGTTCTCACTGACCTACCCGCAATTTTATCCTACTGTGG GCTTCAACACCGAGAAGTGTGATGCGCAATTTTGGGCAACATCTCTTC GCTTTGATATGAAGACTATATGCGGAGTGGAGAACCAAAATCCAGGCAC AGATAGATCGATTTCTATCGGAGATCGAAGAGAGATGGCAGACCATGAT ACAAAAATGGTTTCACTTATTTAGTCCACCATGGTACTGTGCCACACGAG AGCG	346	MGIGLSAQGVNMNRLPGW DKHSYG YHGDDGHSFCSS GTGQYGFPTFKDGVIGCC VNLNNTCFYTKNGHSLGIA FTDL PNLVPTVGLOTPGE VVDANGQHPFVDEDIYMI REWRTKIOAGHDFPIGDGR EGEWQTMQIKMVSSYLH HGYCATAE
Shigella ipaH9.8	6	prev6718	146	ATGGGTGGATTAATTTCTCGTGAGGACAAAAACCTTCAACTGTAGAAGTTCT AGAAAGTATAGATAAGAAATTCAGACTGTGGAAGAAATTAGGAAAAAATC AGAGATACAAAAATATGGTTGGAAGATTAATCTGTATTCCTCAGTTCTC TATCTGTTACATGCTTAATGTATATTGTTGGTATCTTCTGATGAATTACG GCAAGACTTGCATGACACTCCCAATTTTGGCTTTCCATGATCATCTGGAG CATAGAACAGTAAATTTCTCTTTTCCAGAGAACGAAAGAAATATAGA AGCATTTGATGATTTAAATCCCGAGAGAAAAAATACITGGAAGAGTCAATG AAAAAGAACTTACAAGAGC	ATGGGTGGATTAATTTCTCGTGAGGACAAAAACCTTCAACTGTAGAAGTTCT AGAAAGTATAGATAAGAAATTCAGACTGTGGAAGAAATTAGGAAAAAATC AGAGATACAAAAATATGGTTGGAAGATTAATCTGTATTCCTCAGTTCTC TATCTGTTACATGCTTAATGTATATTGTTGGTATCTTCTGATGAATTACG GCAAGACTTGCATGACACTCCCAATTTTGGCTTTCCATGATCATCTGGAG CATAGAACAGTAAATTTCTCTTTTCCAGAGAACGAAAGAAATATAGA AGCATTTGATGATTTAAATCCCGAGAGAAAAAATACITGGAAGAGTCAATG AAAAAGAACTTACAAGAGC	347	MGGLSRWRTKPTSTVEVL ESIDKEIQALEEFREKNORL OKLWYGRLLIYSSVL YLFTC LIVLYWLPDEFTARLAMTL PFFAPFLIWSIRTVIFFESK RTERNEALDDLKSQRKKI LEEWKEKETYKT
Shigella ipaH9.8	6	prev2530	147	ATGGGGCAACAAGGACCGAGTGTTCAGAAAGGCCAGTCCCAATGGAAG CTCACCGCTCTACCTGGGAAAGGGAGCTTTGTGGACACATCAACCTCGTG GACCGTGTGGATGGTGTGGCTGTGGATCTGAGTATCTCAAGAGCCGG AGAGCTATGTGACGTGACCTGCGCTTCCGCTATGGCGGGAGGACCTG GATGCTGGGCCGACCTTTCGCAAGGACCTGTTGTGGCCCACTGACAGT CGTCCACCGGCCCGGAGGACAGACAGCCCTGACGCGCTGCGAGAA CGCTCTCAAGAGCTGGCGAGCAGCTTACCCTTTACCTTTGAGATCC CTCAACCTCTCGATGTTGTGACATGAGCGCGGGCGCCGCAAGACAGG GGAAGCTTCGGTGTGGATGATGAAGTCAAGGCTTCTGCGCGGAGAAAT TGAGGAGAGATCCAAAGCGGAACTCTGCTGCTGCTGATCCGGAAGG TTGAGTATGCCAGAGAGCTGCGCCCGCCGACGACGAGACACCA GGAGATCTCTATGAGAACCCCTTGACCTTGAAGCTCTCTGGATTA AACACCAACAGAGCGTGAAGAGATCAAGTCTAGTGGCGCAGTATGCA AGCTGATGACACTGTGGCCCGGCTGACGCTCTGCAAGGCTGACAC TGACCCCTTCTAGCCAAATACCGAGAGAGCGGCGCTCGCTTGAGCG GGAAGCTCAAGCAGAGAGACGAACTTGGCTCTAGACCCCTGTTGAGG AAGTGCCAAACCGTGAGATCCTGGGATGATGTTTCTTCAAGAGTGAAGT	ATGGGGCAACAAGGACCGAGTGTTCAGAAAGGCCAGTCCCAATGGAAG CTCACCGCTCTACCTGGGAAAGGGAGCTTTGTGGACACATCAACCTCGTG GACCGTGTGGATGGTGTGGCTGTGGATCTGAGTATCTCAAGAGCCGG AGAGCTATGTGACGTGACCTGCGCTTCCGCTATGGCGGGAGGACCTG GATGCTGGGCCGACCTTTCGCAAGGACCTGTTGTGGCCCACTGACAGT CGTCCACCGGCCCGGAGGACAGACAGCCCTGACGCGCTGCGAGAA CGCTCTCAAGAGCTGGCGAGCAGCTTACCCTTTACCTTTGAGATCC CTCAACCTCTCGATGTTGTGACATGAGCGCGGGCGCCGCAAGACAGG GGAAGCTTCGGTGTGGATGATGAAGTCAAGGCTTCTGCGCGGAGAAAT TGAGGAGAGATCCAAAGCGGAACTCTGCTGCTGCTGATCCGGAAGG TTGAGTATGCCAGAGAGCTGCGCCCGCCGACGACGAGACACCA GGAGATCTCTATGAGAACCCCTTGACCTTGAAGCTCTCTGGATTA AACACCAACAGAGCGTGAAGAGATCAAGTCTAGTGGCGCAGTATGCA AGCTGATGACACTGTGGCCCGGCTGACGCTCTGCAAGGCTGACAC TGACCCCTTCTAGCCAAATACCGAGAGAGCGGCGCTCGCTTGAGCG GGAAGCTCAAGCAGAGAGACGAACTTGGCTCTAGACCCCTGTTGAGG AAGTGCCAAACCGTGAGATCCTGGGATGATGTTTCTTCAAGAGTGAAGT	348	MGDKGTRVFKKASPNKGL TVYLGKRFVDHIDLVDPV DGWLVDPEYLKERRYVYT LTCAFRYGREDLDVLGLTF RKDLFVANVQSFPPAPEDK KPLTRLQERLUKLGEHAYP FTFEPNPLPCSVTLQPGPE DTGKACGVDEYKAFACE NLEEKHKNSVRLVIRKQV YAPERHPQPTAETITROFL MSDKPLHLEASLDKEYWH GEPISVNVHVNTNITVKY KKISVROYADICLNTAQP KCPVAMEEADDTVAPSTF CKDYTLTLPFLANREKRL ALDKGLHEDTNLASSTLL REGANREILGINVYKWKV LWVSRRGLLDGLASSDVAV ELPFLIMHPKKEPPHRE

Shigella ipaH9.8	6	prey67731	148	GAAGCTGTGTGTGTCGCGGGGGCGCTGTTGGGAGATCTTCATCCACGGA CGTGGCGGTGGAACCTGCCCTTACCCTAATGACCCCAAGCCCAAGAGGA ACCCCGCATCGGGAAGTTCCAGAGAACGAGACGCCAGTAGATACCAATCT CATAGAATCTGACAAATGATGACGACATGTATTTAGGAGATTTGCTCGCC AGAGACTAAAGGCATGAAGCATCAAGGAGGAAGAGGAGGATGTTACCG GCTCTCACAGCTCAACACAGATAG	349	MSIAGVAAQEIIRVPLKTLGFL HNGKRNFLNDIPKITYWYSR SEFKNNFLNDIPKITYWYSR SSAQERIPLGHASKAPM NGHCFEANGPSQSSLPPL LIPPSENLGPHEEDQWCG FKKLTVNGVCASBPPLTPHK NSPLSPFCAPLCERSGRPL PPLPSEALSDDTDCEVEF LTSDDTDFLLEDSTLDFKY DVPGRSRFGCGQINVAVF DTPAVSAADLSYVSDONG GVDPNPPPPQTHRLHR SHSGPAGSFNKPDIRSNC CHRASPSDEDEKPEVPPR VPIPPRPVKPDYRRWSAEV TSSTYSDEDRPPKVPREP LSPNSRTSPSKSLPSYLN GVMPPTQGFAPDPKYVSS KALQRONSEGSAKVPOL PIIENGKVSSTHYLLPER PPYLDKYKFFAEETNG GAQIOLPADCGSSATKPK DSKTQMDLGGHVKRHL YWSP*
Shigella ipaH9.8	6	prey7155	149	GAAGCTGTGTGTGTCGCGGGGGCGCTGTTGGGAGATCTTCATCCACGGA CGTGGCGGTGGAACCTGCCCTTACCCTAATGACCCCAAGCCCAAGAGGA ACCCCGCATCGGGAAGTTCCAGAGAACGAGACGCCAGTAGATACCAATCT CATAGAATCTGACAAATGATGACGACATGTATTTAGGAGATTTGCTCGCC AGAGACTAAAGGCATGAAGCATCAAGGAGGAAGAGGAGGATGTTACCG GCTCTCACAGCTCAACACAGATAG	350	SHTSLLAFALLQLPWLOEA GAQVQTLDRQLPFWLQEA HRAHQIADLYTQEFYIP KDKYSLFHDSQTSFCFSD SIPTSPNMEETQOKSNLEL LRISLLUESWLEPVRFLRS

Shigella ipaH9.8	6	prey1687	150	GCTCATCGAGTCGTGGCTGGAGAGCCGTCGGGTTCTCAGGAGATGATGTTCCG CAACACCTGGTGTATGACACCTCGGACGCGATGACTATCACCTCTCTAAAG GACTGAGGAGGACATCCAAACGCTGATGGGGTGAGGGGTGGCGCCAGG GGTCGCCAATCTGGAACCCCACTGGCTAG	351	MFANNILVYDTSDDYDHLL KDL EEGIQTLMGVRA PGV ANPGTILA* EYDAERPPSKPPVELRAA ALRAEITDAEGLGLKLEDE TVIKELKSLKIKGEELSEA NIVRLSLKRLKLSAOKAD ERIEKYVTRLEETQALRKK EKFEETMDALQADIDQLE AEKAEKORLUNSOKRTIE GLRPPSPSGIATLVSGIAGE GLRPPSPSGIATLVSGIAGE EQQRGAIPQAPGSPVPG EQQRGAIPQAPGSPVPG GLKXDSPLLQOISAMRLHI SOLQCHENSILKGAQMKASL ASL
Shigella ipaH9.8	6	prey67734	151	ATGAGCCAGGAGGACGCTGGTGCACTCTGTTTCGGGAGGAGATGTGGTGGT ACAGTGGGAGCTATTCTGACATGCTCCACTGGAAAGTTGTAAACACGACTGC AGTCATCTTCTGTGACGCTTATTTCTGAAGTTCAAGTGAACACCATGGCT GGAGCCAGTGTCAACCGAGTAGTGCTCCCGGACCTCTTCATTCGCTAAAG GTGATCTTGGAAAAAGAGGGGCTCGTTCCTGTTTAGAGGACTAGGCGCCCA ATTAAGTGGGGGTGACCCCTTCCAGAGCAATACITTTGCTGCTTATTCAAAC TGCAAGAAAAGTTGAATGTGATTTGATCTGATTTACCCAAAGTACAT TGCTTCAGCTCAATCGGAGGTTTACTGCAATCAAGAACCGCGGGAAGG TGCTTTAAGACTCGGTTACAGCTTGATGCAAGAACCGCGGGAAGG CGAATGGGTGCTTTGAATGTTGCTGTAAGTGTATCAGACATGGAATCA AAGATTTTATAGGGCATCTGCTCTCATATGCTGCTGATATCAGAGACTGTT ATCCATTTTGTATTTATGAAAGATATAACAAACAACTAGGAATATAAGACT GTGTTACATGGAATGTGAAGAGTCTGTGAAGAGAGCATCAGATTTTG TGGMATGATGTAGCTGCTGCCACTCAAAACTGTGCCACACATATGAC ATATCCACATGTTGAAGACAGACTAGTGAAGAGGAAACAAATACAGA TCTTTTTTGAGACTCTATCTTTGCTGTTCAGAAAGAGTTATGGGTCTCT TATGCTGTGCTGACAACTCATCTAGTGAGACAGATTCACAAACAGACCATAT GATGGCCACCTGATATGGTGTGTTTACTCACTCAATGGATAG	352	MSQRDILVHLFAGCGGCT VGAILTCPLVVKTRLQSSS VTLYSEVQNTMAGASVN RVSPGLHCLKYLEKEG PRLSFRGLGNLVGVAPSR AYFAAYSNCKEKNDFD POSTOVHMISAAMGFAT TATNPWLKTRQLDARNR GERRMGAFECRVKYQTD GLKGYRGMSAYAGSET VHGFVIESIKOKLEYKTAS TMENGEES/KEASDFVGM MLAAATSKTCAITTAAPHV LRLAREEGTKYRSFFQTL LLVQEEGYGSLYRGLTTHL VRQIPNTAIMMATYELVYL LNG*
Shigella ipaH9.8	6	prey2694	152	ATGGCAGACGCTATGGAAGAACTCTGGACAACTAGTAAAGAGTACCATATG ATGAAGAAGTGGGCTTTCGCTGCGCAATCCAGAGAAATCTACCTGATTT TATAATGACTGGATGTTGATTCGTAACATCTGCCTGATCTCATGATCTGG CCAGCTTCGAGAAAGAGTTGAGAAAGTTAAACATGCTCAGCATTTGATCATCTC	353	MAHAMENSWITSKEYHIDE EYGFALNPQENLPDFYND WMFAKHLPLDSEGLQRE RYEKLNMLSIDHLTDHKSQ

					ACAGACCAAGTCACAGCGCTTGCACGCTAGTCTCTGGGATGCATCAACA TGGCATATGTGTGGGCAAGGTCATGGAGATGTCCGTAAGGCTTGTGCCAA GAATATTGTCTTCCCTACTGCCAATCTCCAGAACTGGAAGTGCCTCT ATTTTGGTTTGGAGACTGTCTTGGCAAGTGGAAAGAAAGGATCCTAA TAAGCCCTGACTTATGAGAACATGGACGTTTTTGTCTCATTTCTGTATGGAG ACTCGAGTAAGGATTTCTCGCTGCTCTATTTGGTGAATAGCAGCTGC TTCTGCAATCAAGTAATCTCTAGTATTCAAGGCAATGCAATGCAAGAAC GGACACTTTGCTAAGCGCTGTGTGGAATAGCTTCTGCTTGGAGAAAGC CCTCAAGTGTTCACCAATCCAGATCATGTGAAC	354	RLARVLGCTMAYVWGKG HGDVRKPLPRNIAPYCOL SKKLEPPLIYADCVLANW KKKDPNKLTYENMDVLES FRDGDCKSGFELVSLVEIA AASAKIVPTFKAMQOE RDTLLKALLEIASCLEKALQ VFHQHDHN
Shigella ipaH9.8	6	prey67740	153	GNATGATACGNCATNTGTAGAAATGGGCACTGNGGACAGAGGGGATG GTTGATCTTCTTAACCTGTGTCACATGTGNAACATNGTCTATACGNAATNG NGTGCACTTTTAAATGAATCCGATTTGTCTGCACNTNNTCNCTGATCTANTG TONTTATGTNGTGCAGCGTTTACNCTACTNCANTCTGANTACTGATCTANTG GTNATCTTCNCTGNTGNGGNTGNGGNGTGTGNTCGCNTTTTTTNTCTGT GTACGNNNGGGGGGNN	355	XXITCXVVEIGHXDKGMVH VSLNCLTXWHXLYVXVHF *NESDLSALXXXXLXXCXC SVYTX*XYLXVIXXXXXX GXGXRXFXLCTXXGG	
Shigella ipaH9.8	6	prey67703	154	GGCATTGAGAACTACTGCGTCTTCTCAACAGCTGGACAGGTGGATTGAT GAGACTCTCCAGTGGACGACGCTCTCGGTTTGGGAATGAAGCATACAGG ACCTGATGTCGCAAACTTGATGAGGAAGCAGAAACTTGGTGGCCACAGTG GTCCGTACCATCTGGAGCTGTCTGCTGAGGTGGCTGTTTACTCTAAG GAGTCAGTGGGAACTCCACGCGCATTGACTACGGCACAGGGCATGGGA GCCCTGCGTCTTCTCTGCTGCTGCAAGATGGGGTGCCTCGGGTG GATGACCAATAGCTATTGTCTCAAGGTGTCTCAATCGGTACCTTGAGGTAT GGGAACTCCAGAAACATACAGGATGGAGCGACGCGGACGCCAGGGAG TGTGGGCTGTGGATGACTTCCAGTTCGACCTTCTGCGGCGATCTCGCA GCTGATAGACCAC	356	AEKLLALLNLTDRWIDETP PVDQSPFGNKAYRTWYA KLDEEAENLVATVPTHLA AANPEVAHYLVKESVGNSTR IDYGTGHEAFAAFLCCLC KIGVLVDDQIAIVFKVFNH YLEVMRKLOKTYRMEFAG SQGVWGLDDFQLPEIWG SSQLDHH	
Shigella ipaH9.8	6	prey67741	155	GACAAGTGGAGCCAGCAAAAGCCTACTGCAACTTGGGCTAGCATTCAAGG CTCTGCTGAATTCAGTAAGCTGGAAGTGTTCANGAAGTACCTACTGTCC TAGCCAGTCTCTGAATTAATTCGACGCTAAATTTTCGAGCCCTAGGAACCT GGCGATATATCTCATGTTAAAAAGATATAAATGTGTGCAATAAAATCTATG ACGCAACACTGGGCTTAGCTCACAGGTAAAGGACAGAGAAGATTAGAAGCA GTGCATATGCAGCCCT	357	DKLSOAKAYCNLGLAFKAL LNFSAKECXYEPTVPSPV SE*FPG*ISSPRKGRYHL* KRYKWCNKIL*AAATGLSSP GKGKIKHSQCICSP	
Shigella ipaH9.8	6	prey67742	156	AGGTAATGAGCTGTGTGGTGGCAGCAGCCAGAAACTCCACTCTTGAAGCT TACTCGATTTGGACAGAGAAATCAAGAGCAGAGTGTCTCCGGTGGAGA GTTTGTCTTATTAACAGAGGTTATCATGATATCCACTTGCCTTCCAGAAATACAT TGTAGTGCCAAAGTCTTTAGCAGACCAAGATCTTAAGATCTTTTCCCATCTT TGTGTGGAGAGGATGCCACTGTGGTGGTGGAGCCACTCTAACGCGCATG CTCTGTGGGAATGGCCCTCATCAAGACGCTGTCCACAGCAGAGAAGTGTG ACGAGAGGATTTGTATGCAATTAACATAAGTACCCACAGAGAAGTGTATG TTACAAATCAGATTGGATAGACCTTGGCTAATATTAAGAAAGTACAAAGCAG		GNGAGGSSGSKQKTLPLFETY SDWDREIKRTGASGWRVC SINEGYMISTCLPEVWPS SLAQDLDKIFSHSFVGRHM PLWCWSHSHSNGSALVRNAL IKDVLQORIKDHCNRNATKS HPORSRVYKSDLDKTLPLNI QEVQAAAFVKLKQLCVNEFP	

Shigella ipaH9.8	6	prey67339	157	CAITTTGTTAAAGTGAAGCAGCTATGCGTATTATGAGCCTTTTGAAGAAAGTGAAGGAGAATGGTTATCTTCACTCGGAAATACTCGATGGTTTGAAGATATGTAGGGCAITTCCTTAGCATTACAGCAGAACTTGATACATGCTGAGGAGCAACATCTCTGTAGCTACAGAGGAGGAGGAGAGACTGTAGCTGTGTGTGAGCTTCTGTGTCAAGTGTACTGATCCCTATTTTAGACAATATCTGAGCAATATCTGATAGACAGATGTGATACAGAGAGATGGGTGATGAGCAAGAGTCCCTTATTTTGTATCTTGTGCAACCTCTAAAGAGTACAGAAAGAGTCCCTTATTTTGTATCTTGTGATCCGCTGGCAGCTGTAGAACATATCTGCGAGCTTTGAGTGTCTCGCAACCTCGGAGTGTGTAGACACCGGATCTCACTGTGTGGCACCTTCTGTTCACTCCCTCACCGAGGTGAAGCAACGCGTTCAGTAGGATAAAAGTGTACAAACACAGATTATTTCTTCACGAGATTGA	358	EEEEIELTVPVPVTEPSPMPDPOSSELDAMMLGPRGKTYAFKGDYVWTVSDSPGGLFRYSALWEGLPGNLDAVYSPRTQWIIHFQGDVWRYNFKMSPFPKLNVRVPEPNDAAALWYPLNQKVELFKGSGWQWDELARTDESSYPKPKGLFTGVPNQP
Shigella ipaH9.8	6	prey67337	158	GGCTCCCTTGACCTTCCAAGAGGTGCGAGCTGTGCGGCTGACATCCGCGCTCTCTCCATGCGCCGAAAGCTCGTACTGTTCCTCAATCTTTGATGGCGCTGGGAGATCTCGGCCATCCGACATCCGAGAGCTGGCGAGTGTGACCTTCGACGAAGACGAGTTCTGGACTGAGGGACCTACCGTGGGTGAACTCGCGCATCTGACGCCCATGAAGTGGGCCATGCTCTGGGGCTGGGCATCTCCGATATCCGAGGCCCTCATGGCCCGAGTCTACGAGGGCTACCGGCCCGCACTTAAGCTGCACCGAGATGATGTGGAGGATCCAGGCTCTATGTGGCAAGAAAGTGCACCGAGTAAAGGATGAGGAAGAGAGACAGAGCTGCCACTGTGCCCGAGTGCACAGAACCGACTCCCATGCCAGCCCTTGCAGTAGTGAACCTGATGCTGGGTGAGGCCCTCCCTCCCGCTGTTGGCAGCGGTGGGGCGAGCTGCTGATCTGAGGCTTGACAAATGGGAGTGACAAGGGAGTATGTGGAGATGGAGGGCCCCGTGGGAAGACCTGCTTTCAGGGAGTATGTGTGAGCTGTATCAGATTGAGACCGGGCCCCCTGTTCCAGTGTCTCGCCCTTGGAGGGGCTCCCGGAAACCTGGATGCTGCTGTCTACTCGSCCTCGAACCAATGATTCATCTTTA	359	APLTQEQVQAGAADIRLSFHQRQSYSCNTDGPGRVLAHADIPELGSHVHDEDEFWTEGTYRGVYNLHIAAHEVGHALGLQHSRYSQALMAPVYGYRPHFKLHPDDVAGIQAALYKSPVRDEEEETELPTVPVTEPSPMPDPCSEELDAMMLGAPPLQAVGRRWGPADPFAWTNGSGDMGLQHEQWHPAWMEDLFOGGLCVDQIRFRFTPLVPVCPPLGAGAPRKPGCCCLASNTMDSLL*
Shigella ipaH9.8	6	prey67746	159	ATGGAGAAATATTCAATATGAAGAGCATGATATGCGATCGAAAAAGGAGAAAGAGACCATTTTGAATATGACACAAATACTTCAAGAGCATTCGATTTGCACTTGGGAGAGGCTTTAATCGGTTAGACTTCCAAAGTGCATTCGAATATCAAGATATCCG	360	MEKYSIMKSMNMHHRKKGKRTILEMTOILKRXHVGCTLGEAFNRLDSSAQDIQRTFNVY

Shigella ipaH9.8	6	prey54430	160	AACGTTCAATTATGTGGTCAAACGTTGCGAGCTAATTGCAAAATCCCAAGTAA CTTCAATTAGTGGCGTGCACAGAAATTAAGTCAACATTTTGGATAAAATC TTCGAAAGGTTCTGATCACCACCAATCTCGCTTAATCAAGATCTCT GCAAGACCTAAGCTCTACCCCTGCACTTATTAGAGGATAGGAAAGTCT GTATTGTGGGAAACATCAATATTGGATTGCGATTCGCAATATTCAGCAATCTCGC CTGGCAACACAGCTACAGGATCTTCAGATGACTAAGCAAGCAATCAATCGC CTCACCTCAGTGACCTTCTGTCACATGCTGAACAACATCTTATACCGGT TCTCAGCGGATGGACATCACTGAGCGAGGTGACCCCAAGTTGT TATGCTTGTAGTGAAGCAGACAGCTGTGGGAAGCTTTGTCAAGTACATTT GCTGAAAGCAGTTTGTAGACATTTGATCTTTCAGAAAGGTCATATGA ATTGGAATTTGATGATCTTTCAGCTTCAGAACATATCCCAAGCAAGGACAG TACGGACACACAGTGCATTTCTGTGGCAGCTGAGCATTTCTTTTGAAGG ACTCAGGACCCCTGACGCGCGCCACCTGACAGCTGCTCAGCGCTG TGCTCCGACGACCTTCATCGACCTCTTCAAGTTTAA	361	LSKTNRTLFIQVTKYIAGP YECERNPVSASRSRDPVTL NILHGPDPSPYSPFTYRBS GENLYLSCHFAESNPRQAQYS WTINGKFQLSGQKLSIPQIT TKHSLGVLKSGVSRNSATGKE SSKSITVKVSDWILP*
Shigella ipaH9.8	6	prey67749	161	AAGAAATTAAGTATATGAGAAATTTGAAAATATGTTAACTTGAAGTACTG AATCTCAGCTATATCTAATAGGGAAGTTGAAAGTTTGGACAAGCTGTTAAA ATTACGTGAACCTCAACTTATCATATACAAATCAGCAAAATTTGAATGAGCAT AAATATGTATCTGCAAAAGCTTAACCTTGCAAGAAATGAAATTTAGCAT AATCAAGTATGTTTGGAGGAAGTAAATCTTTGCGAGTCTCTCA GGAGGACGAGCAAGACATGCTCTTAAAAAGGAAGAAACATCGACAAG AATCTAGTGGAGGAGGAGGACACCTGTTGATGGGTGCAATATGACCA GTCAATGGAGCAGATGTCAGGAAAGGAGGTTGTAGTGCAGGAGGAGCC AGTTTCGAACACCTGCGACGGAAGCAGGCTGTGAGACGCGGCTCTG AGCGGCAACTGAGGAGGAGTGTAGCCTGGGGCTCTCTGGGGGTGCGAGTG TTCCANGTTGGGGGA	362	KFKYIENLEKQWKLVLNL SYNLGKIEKDLKLLKRLNL LSYNKISKIEIENWMLNLOK LNLAGNIEHIPVWLKGLKL SLRVL
Shigella ipaH9.8	6	prey67751	162	GGRAPHLCKKGGKKTROE S'WHEQDHPYMGQ**PSHG AQ*ORKGQCEQCEGFRT TWQKGACENIGSEPEFLR EELSGLSGGAVFXVG	363	KFKYIENLEKQWKLVLNL SYNLGKIEKDLKLLKRLNL LSYNKISKIEIENWMLNLOK LNLAGNIEHIPVWLKGLKL SLRVL
Shigella ipaH9.8	6	prey8739	163	AEPVPSPPLASSPESAR PKWARPPEEGEDTRPRL KKWGVYRWKRLRLLTQIK GSGROEDEREVAFMEQL GTALRPDKVPRDMRRCCF CHEEGDGATDGPRLNL	364	KFKYIENLEKQWKLVLNL SYNLGKIEKDLKLLKRLNL LSYNKISKIEIENWMLNLOK LNLAGNIEHIPVWLKGLKL SLRVL

Shigella ipaH9.8	6	prey/18232	164	<p>ACTGATGGGCGTGGCGTCTGCTGAACTGGAACCTGGACCTGTGGGTGGCAG CTCAACTGTGCCCTTTGGTCCACGAGGTGTATGAGACCCGAGCGCGAGCA CTGATGAATGTGGAGTTGGCTCGACCGAGGAGTCTTAACCAAGTGTCTCC CTGGCCAGCGAAGTGTGGTCCACCGAGAGTCAATCGCATGGTGTGCCCG AATGTCTACCAATTTGGTGTGCCATCGCGCCAAAGTGCATGTTCTTCAAGG ACAAGACCATCTGTGCTCAATGAAGTCAAGGGGCCCTGTGAGCAAG AGCTGAGCTCTTGTGTCTGCGCGGG</p> <p>CAGTATATGCTGGAACATCAACAGCTCTATTACTACCAAGCCATCA GCGGTGTGCTCTTGGCTGTCAACATTCGCCCTGGATGCTGTCAAGATGGT ACAGTTTGGAGAAATGTGCTCGGAAGAGATTGACATATAAAATATGCAAGA GTGGAAGAAGATACCTGGAGGATCATTAAGAGCTCGCTGTGCTTGGTGGAG TCATGTTAAAGAGTGTGACCCATTCAGCAATCGCGCTCTATCAAGAA CCCTCGATTTGTGCTGGATTCTCTGGAATACAAAGAGGAGGAGC CAGACTGATTTGAGTTACAGGAGGAGGACTTCCCGCAATTCGACGA TGAGGAAGAGTACATCCAGAGCTGTGAGGACATTATCCAAGTGAAGCC CGATGTGGTCACTACTGAAAGGGGCTCTCAGATTAGCTCAGCACTACCTT ATCGGGCCCAATATACAGCATCCGAGAGTCCGGAAGACAGACAATAAT CGCATTTGCTAGAGCCTGTGGCGCGGATAGTCAAGCCAGCAGGAAGCTG AGAGAAGATGATTTGGAACAGGAGCGCTTTGGAATCAAGAAATTTG GAGATGAATCTTACTTCTCATCTGACTGCAAGACCCCAAGG</p>	<p>365</p> <p>SSLMNINSSTTKAISRW SSLACNIALDAVMQVQEE NGRKEDIKYVARYKEIPG IIEDSKVLRGVMWKDVTHP RMRRYKINPRVLDDLSLEY KQMSQTDIEITIEDFTFRI LWMEEYIGSLAQHYLMRA DVITEKISDLAQHYLMRA NITAIRRVKTDNNRIARAC GARIVSRPEELREDDVGTG AGLLEKKIGDEYFTHTDCK DPK</p>
Shigella ipaH9.8	6	prey/66739	165	<p>ATGGAGCGACGAGGATTAATGAATCTTAAGTCTCAGATGAAGAAGATCC TGACATGGCCTCAGCAGTGGCTGCGCATCCGAGCTGTGCTGGAGTCTTGAA GAGAGATAAGGGGAGACATCCAGGGTCTGAGGCGAATCTCACCGATCG CATAGAAACCTGTGTGGTGGACTCTGTGGCAGTGTCTCTGTGGCGG GAGCTCTTCTCCGCTTCATCAGTCTGCTCCCTGGAAATCTCCGAGTAC TCCAATGTAAAGATCATGATGAGCGGGAGAACTTTTCTCAGGAGAA TATCATCTCAAGAAACAAATTTGCAATCTGTGCGCATCTTTCATCAAGAT GGAGCGCAATATTGACTCAAGCTCTCAGAGTGGTCTGAGAGCTCTG GAAGAGCGCTGGCGCCAGAGCGAATTTAGTGTATACGTCAAGAGCTCA GACGCTGATTTGTGAGGTGAAGAAATGGCCAAAGCCCTCGCCACCTCAAGC TCCTGTCTAGTGTGTGTGCTGAGAGTGTGTTGAACGGAGGAATATT AGATCTTGTCTAGTGTGTGCTGAGAGTGTGTTGAACGGAGGAATATT ACAAGATTGGAACCAACAGATGGCTGTGTGCGGCTCTTCCACATAAC CTTTCTATGTGGTTGCAAGAGTTCAAGTTTGAAGTAAAGCAGACACTCAAGTGC CGCAGAGCTGCCAGATAAGTTTGAAGTAAAGCAGACACTCAAGTGC CGCAGACTGACAGACCTCAAGAGGAGGAGCTCCCGTGGGTGCACTACACTG CCCTTCTCTTATCACTCTGCTGTTTACAGACTGGG</p>	<p>366</p> <p>MDKLEJFYKQMKEDPD MASAVAAIRTLLEFLKRDKG ETQGLRANLTSAETLGV DSSVAVSSGGKFLRISLA SLEYSYDSKOKKIMIERGEL FLRISLRNKIADLCHTFIK DGATILTHAYSRVWLVRLEA AVAKKRFVSVYTESOPDL SOKMKIAKALCHLNVPTVW LDAVGVIMEKADLVNGAE GVENGGINIKGTNMQAV CAKAKQPFYVVAESFKFV RLFPLNODVPDKFYKAD TLKVAQTGDQLKEHPWV DYTAPSLTLLFTDL</p>
Shigella ipaH9.8	6	prey/67769	166	<p>GCAGCCTTCAAGGTGCGCACCGGCTATTCCCTGTATGCTGTGCCGAGGG CAGAAGCTCACCTCAGCTGCAGGCTCTTGGCGCCTGTGGACAAGGGGAC</p>	<p>367</p> <p>AAFKVATPYSLVYCPGQGN VTLTRLLGPVDKGHDVTF</p>

Shigella ipaH9.8	6	prey/3613	167	<p>GATGTGACCTTCTCAAGAGCGTGGTACCGAGCTCGAGGGGCGAGGTGCAG ACCTGCTCAGAGCGCGCCCATCCGAACTCAGCTTCCAGGACCTTAC GTGACCATCGAGCGCCAGCTGCCAACACACGACGACCTGGCTGCTAG CGCCAGGCTGGAGTGGCGCTCCGACACCATGCAACTTCTCCATCACC ATGGACCTGACCTGCTGGATAGCGGCTCTACTGCTGCTGGTGTTG GAGATCAGGACACACCTCTGGAGCAGAGGTCCATGGTCCGATCGAGCTG CAGGTGCAGACGAGCAAGATGCACCATCCAACTGTGTGGTGTACCCATCC TCTCCAGAGTAGTGAACACTACGCTCGAGCCCTGGCTACGGGTGCC TGCATCTAGGAATCTCTCCCTCCCTCATCTGCTGCTGCTGCTACAAGC AAGCAGCAGCGCTCCAA</p>	<p>YKTWYRSRGVEVOTCSER RPIRNLTFQDLHLHGGHQ AANTSHDLAORHLEASD HHGFNTMRNLTLDDSL YCCLVVIRHHHSEHRCNV AMELOVOTGKDAPNSVW YPSDDSENITAAALATG ACVIGILLPLULLVYKORQ AAS</p>
Shigella ipaH9.8	6	prey/3613	167	<p>GATGTGACCTTCTCAAGAGCGTGGTACCGAGCTCGAGGGGCGAGGTGCAG ACCTGCTCAGAGCGCGCCCATCCGAACTCAGCTTCCAGGACCTTAC GTGACCATCGAGCGCCAGCTGCCAACACACGACGACCTGGCTGCTAG CGCCAGGCTGGAGTGGCGCTCCGACACCATGCAACTTCTCCATCACC ATGGACCTGACCTGCTGGATAGCGGCTCTACTGCTGCTGGTGTTG GAGATCAGGACACACCTCTGGAGCAGAGGTCCATGGTCCGATCGAGCTG CAGGTGCAGACGAGCAAGATGCACCATCCAACTGTGTGGTGTACCCATCC TCTCCAGAGTAGTGAACACTACGCTCGAGCCCTGGCTACGGGTGCC TGCATCTAGGAATCTCTCCCTCCCTCATCTGCTGCTGCTGCTACAAGC AAGCAGCAGCGCTCCAA</p>	<p>LGAGPFSHMIKLTKLPP DPPILECVAFSHONLKLW EDKNGPKTSLSQYHLOW EGKNGFVSLYRPGCHTY KVQRNLESTSYKFCIOACN EAGEGPLSQEYFTPKSV PAALKAPKIEKVNDHCEIT WECLOPKMGDPVYISLOV MLGKDSEFKQYKGPDDSF RYSSLQINCEYRFRVCAIR</p>
Shigella ipaH9.8	6	prey/3337	168	<p>GGCTGGGCTGAAGGACCTGGAGCTCTGCTGAACCTCAAGGAGGCGCGAC TGAGCACTGCTCTCAGTGAAGCGCAGCTGGAGGGCGAGCTGATGATC TGCGGGCGCAGGTGGCCAGCTTGAAGCGACCTGAGTGAGCGCAAGAG CAACTTCAAGATGAGTCTGCGCGGGTGGATGCTGAGAACAGGCTGCGAG ACCATTCAGAGGAGACTGGACTTCCAGAAACATCTACAGTGAAGGCTGG CTGAGACCAAGCGGCTCATGACACCCGACTGGTGGAGATTGACATGGG AAGCAGCTGTGATTTGAGAGCGGCTGGCGGATGCGCTGCGAGCACTGG GGCCAGCATGAGGACCGATGGGACGATTAAGAAAGGACTTGGAAAGA CTTATCTGCCAAGCTGACATGCCAGGACTGCTGCTGAGAGGACCAAGA ACCTGCTGGGGCTGCCACGAGGAGCTGCGACGCTGCGCATCCGCTCGC CAGACGCTCTGCGAGCTCAGCCAGCTCCAGAAAGCACTGGCAGGCGCAAG GAGCGGAAGCTTGGAGCCTGGAGGACTCACTGCGCCCTGAGCGGAGAC CAGCGCGGCTGCTGGCGGAAAGGAGCGGAGATGGCCGAGATGGCG GCAAGATGACGACGAGTGGACGAGTACCGAGCTTCTGGACATCAG CTGGCCCTGACATGGAGATCCACGCTACCGCAAGCTCTGGAGGGCGAG GAGAGAGGCTAGCCTGTCCCCACGCCCTACCTCGACGCGAGCGCTGG CGGCTCTCTCTCACTCATCCGACACAGGCTGGGGGCGAGCGTCAACAA AAGCGCAAACTGGAGTCCACTGAGAGCGCGAGCAGCTTCTCAGCAGCAGC</p>	<p>ARLKOLEALLNSKEAALSTA LSEKRTLEGEHLHDLRGQVA LKEAALGEARKQLODEMLR RVDNAENLQTMKEELDQF KNYISEELRTKRRHETRLV EIDNGQREFESRLADLO ELRAQHEDEVQYKKELEK TYSAKLDNARQSERNSNL VGAACHEELQQSRHIDLSLA QLSQLQKLAKEAKLRLD EDSLAREPDTSRLLAEKE REMAEMRAMQOQDDEY QELDLKALDMEIHAYRKL LEGEERLRSQSPTSORS RGHASSLSQTTGGGGSVT KKRKLSTESRFSFSQHAR TSGRVAVEEDVEEGKFLVRL RNKSNEDOSMGNWQIKRQ</p>

				ACGCACTAGCGGCGCGCTGGCGGTGAGAGAGTGGATGAGGAGGCGCAAGT TTGTCCGCGTGGCAACAAGTCCAATGAGGAGCAGTCCATGGGCAATTTGGC AGATCAAGCGCAGCAAGTGGAGATGATCCCTTGCTGACTTACCGGTTCCACAC AAAGTTCCACCTGAAGGCTGGAGAGGTGGTACGATCTGGCTGCAAGAGC TGGGCGCCACGACGCCCTACCGACCTGGTGTGAAGGACAGCAACAA CCGTGGGCTGGGAGACGCTGGTACGGCTCTCACTCAACTCCACTGGGG AAGAAGTGGCCATGCGAAGCTGGTGGCTGAGTGAAGTGTGGTGGAGGAGC ACGAGATGAGAGATGAGATGACCTGCTCCATCACCACCATGTGAGTGGTA GCGCGCGCTGA			NGDDPILTYRFPKFTLKA QGVYTWAAAGAGATHSPPT DLVWKAQNTVWCGNSLRT ALINSTGEENVAMRKLVRVS TVVDEDEDEDGDDLLHH HVSGSRR*	
Shigella ipaH9.8	6	prey67774	169	CCCACTCTGGCGCGTCTTGAAGTTTTCGGGGTCTATGGGCAATAATC TGCCAGAGACCAAGTACCAATGAGCTTCCCTATTTGACTTCTCGTCAAG AGGTTTTTGAACCTGCTGGGTGGAGATGTGTTTGAAGCTTTTACTGTGC CTCTGGAGTTTCAATCTGCTCTACTACAGCATTACCAGAGCATGATGA CTGTGGGAGACGATACAGCTCTCATGTTCTTCCAGTGGCAGCATGT CTATGCTCTATCTCCAGCTCTCTCTGCAATTTTAGATGCTCTGTTTC CATACCTGATGGTTGTCATTCCAATGGCTGGATGACCGGTCAAGCTGGA GCTGCCCTAAGAGGCTTAACCTCTGTTTGGACATTGACACCACTTCATT GAGTTCGACAGGACTTGCCACAGTTCGCCAACAAATTTGGAGTTTGTCCAGG AAGTCTGTGAGATCTCATGGCATTTTGAATTCCTCCCTGAAGGGAATCTTCAT TGCGACAGAGTGCCTCCAAGCTGAAGGCTGCGGGCTCTGAGCTTGTCTC TGCGACAGAGAAATGGGAACATTGCTGGCTCCCTTGTCAATCTCAAGAGC TTCTTAAGGAGAAATGAACATTATGCCGCTGCAAGCCTTGGTCAAGAGC TGGGGTGAGGCTGGAAGTTGGAAGTGGTGAAGAGCCCGCCAGCAATAA GGATCTCAAGTTTCAGTGTGATGAAGAGAACTACAGGATTTACCAGCTAAAC ATTACAGTCCGGAAGTTTTCGAATCGTTTCACTAGATGTTTGCAGATTA TGAGGTGTTGTGATCCACCGCAGGATAAGGAATCGTGGTTTACCAAC AGGAGCAATGCAAACTTTGATAAGCATCTTTCTGTCAGATCAGCTGAT GCCTACCTGCCCTCTCTCAAGATTCTCGAGACCCAGCATGTTTGCATCT TTATTGACAAACAAATATGTGTCATGATGATGATGATGAAGACCTGTACT CCGGGTATTGATTCGGAGTTGACAAGTACAGGCTTGTTGAATGTTCCGACA CTACTCTCCGATACCATGATACAGAAAGTGTACCACTGTGGATGAAGCAG AGAAAGCAATTGAGCTGGCTGGCAAAATGACCATACTGCAATCCACCC ACATTTACTTGATGAAGATTGGACAGGGAATATGAGCCGCGGCTCTTCTC CTTAAGCTGAGTGTGATGTTTCTTCCACTGGGCGCCAGCCAGCAAGTGA CGAAAGGAATGCCCTGCCAGTGGAGGCGGAAGATCGGCGAGAGAGC CACACAGAACCTCGCTTATGATAATGACGAGGAGGGAAGTACATCCAGG AAGCAGGACTATGGCGAGCACTATCCGCGAG			370	PPGRSLKFGVGVPIQCV RPSTNELPUDFPVKEVFE LGVENFQLTCALEFQIL LYSGHQRLLMYAETIAL MFFQWQHVVYPLPASLL HFLDAPVYPLMGLHNSGLD DRSKLELPOEANLCFVID NHFIELPEDLPQFPNKLEFV QEVSEILMAFGIPPEGNLHC SESASKLRLRLASELSVDK RNGNIAGSPLHSYELLKEN ETIARLQALVKRTGVYLEKL EVREDPSNNKDLKVQODE EELRIYQLNIQIREVFANRFT QMFADYEVYVQPSQDKES WFTNREQMONFDKASFLS DOPEYLPFLSRHLETFMF ASFDNMKMHDDDDKDPV LRVDFSRVDKRLNLNVRTPT LRTSMYKQCTTVEAEKAI ELRLAKIDHTAIHPHLLDMKI GGGKYEPFFPKLQSDVLS TGPASNKWTNRNPAQWR RKDRQKHTEHLRLDNDQ REKYIQEARTMGSTIIRQ
Shigella ipaH9.8	6	prey67776	170	TGGGATCTCAACTAAATTTAGCAAGGCACTACTACAAAGCAATGGTAAATTAGCAC TTGGTGTACTGCTCAAGAAAGAGGCACTTGTGATGATGAACAGACTCAGT		WDSTKISKAYYKANVISTW CYWLKRHLMHETDSRVP		

Shigella ipaH9.8	6	prey4758	171	<p> GTACCTGTGAGTTTATTTTGGATCAAAAGTCCCATTTCAAATCAGCAAGGAA TTGGCCCACTTCTGATTCATTTTGAACACATNAAGTTTGATNCTACNTG ACAAGCTNCTNTAAATGGGTGGAGGTGGATGGNGCATGTGGGTGTNANG CGGTGNGGCGGG </p>	<p> 372 </p> <p> LSALSTVPPSPQPPVGT AHMSLEMRHSVAELRLQ LQMRQLQONQELLFAM MKKAEISLQKMETMKRL EPDVQRORVLVEQORY LHEEEKWKVLCLEDFVED LKDDSTASRLVTLKVED GAFILHVGGEATVLTKEF PTLONKMRAILRIVEAVRF LKEEHPKLDLSLLKVRSM DVLTLMRHVTDGLKLGTD AQAQAQYMAEMEKATAEY LKSOEEAHTSGOPPHSTG APGDAAHVPLSGMMVR HAQSSPVIIQSPQSHVALL NPAQNLPHVASSPAV </p>
Shigella ipaH9.8	6	prey67781	172	<p> CCTGAGGACCAAGCATGGTGGGTGCGAGGAGTTCCCTCAATGAAGAGAA CCGTGCGCTGGATGTGTCTGTGAGTATGCTGGCCTTTGCCAGTGCCTGT CACGATGACATGGAGCAGACAGCAACGGGCTTCCAACTGAGCAAAAA CAAGCCCTGTGAGCAGTCTTGGAGAACCTCAGCAAGGGTCCACCGCTC CGTGCCCAAAAGCGGCCACTGACCATCAAGCTGACCCAGCCACGACGAG GAAGTGGCTCGGG </p>	<p> 373 </p> <p> LRTNHIGWVQEFINEENRG LDVLLEYLFAQCSVTYDM ESTDNGASKEENKPLEQS VEDLSKGPSSVPKSRHLL KLTPAHSRKALR </p>
Shigella ipaH9.8	6	prey2109	173	<p> GACTGAAGTACACCATACTTTAAGTACTGCAAAATCTCAGCATTTGGCTCTC TGAAGATGGTATGCATCGCATCGGAGGCAATTTGGAAGTATGGGTCT TGATGCTAGGAAGGTGGATGTGAAACCATGATCATTTGAGACATTTTGC TTGTGCTGTGGAGGCACTGAACCCGAGTAATGCTCAGGCTGCTGCATAT GAATACATGGCTGCATACATAAGCAAAATGCAAAAGTTGGCCGCTTGAAA ATGCAATCGGTGGTATACATAGCAACCCCTGGCTATGGCTGTGGCTTCTGG GATTGGTTAGTACTCAGATGCTCAATCAGCAGTTCCAGGAACCATTTGTAG CAGTGGTGTATTGATCCACCAAGCAACATATCCGAGGAGAAATGAATCTGG CGGCTTTAGGACATACCCAAAGGGCTACAAAGATATTTGGTGTACAGCTGCA GAGTACACAGCATTCACCATTTAATAATAGAGATTTTGGTGTACAGCTGAA ACAATATATGCTTACGAAGTCTCATATTTCAAATCTCCTTTGGATCGCAATTT </p>	<p> 374 </p> <p> TKDHHFYKCKISALLKLM WHABSGNLEWMLGLK KVDGTMMDSFALPVEGT ETRVNAQAAYEYMAAYIE NAKQVRLERNAAGWYHSH PGYQWLSQIDVSTOMLIN QQVQFVFVVDTPRTTISA GKVNLFAGFYTPKGYKPPD EGPEYQTIPLINKDFGVH CKQYYALEVSPFKSLDRK LLELLWNKYWNTLSSSSL </p>

Shigella ipaH9.8	6	prey4060	174	GCTTACGCTGTTGGAAATAAATCTGGGTGAATACGTTAGCTGATGCTTCTAGCT TGCTTACTAATGC	375	LN
Shigella ipaH9.8	6	prey43284	175	GCATCAACTACGCTGGGCTTCATCAACTACCTGTTCTATGGGGGCAAGGTTG CTGGACAGATAGTCTCGCTCGAAGAAGCCTGATATGCCCCGCCATCAA GTACAGCTGCTTCCTCCATCATCTACTTGCTGTCTGGCCCTCTCGTGTG GTTCCAGCTGTGTGTCAGAGCGGTGTGTGGCATTTGGCTGGCCATC ATGTCAGAGAGTGCTGTCTATTCCTGGGTGTGTACTGTGCAACCAAGC CCAAAGTGTTCAGTGACTTCTAGCTGTCAACCTGTGAGCGAGTGTGAGCGAGAGT GTGTGTGTGTGTGTGACCGAGGTGGAGCGGCTCAGGACAGAGGAGG CTAATGGAGCATGGAGGAGCAGCAGCAGCCATGTACCAACCCATCCCA CGAAGGACAAGACGTGGCGGGGCGACCCAGCCCTGA CTGGGATTAACAGGCATGAGCCAGCAGCATCGTGGTGTGATTTCTTCAGCACCAT TTATTGAATAGACTGTCCCTTCCCTGGTGTGTGTATTGTGATTTCTTCAGGAAATG	376	TAAGCA
Shigella ipaH9.8	6	prey67686	176	CGCAATCACCTTTCTTCAAAAGGATTAAGTAAAGTCCAGCATCTGGCCG TCATCGATTCATATACAGAAGTGAAGCTTTAGCAAGCAGAGCTGCTA TCAGCTGATGATCATTCATGTTTCAGGAAGATATGACCAAGCTTTTTCAGT TTTTCAGGACACACAGTGTGGCTCATCTCTTTTGTGCTCCCATTTTGG GTTTGGCAAAATGATATTTATCGAGGTGACAAAGAAATGCATCTCAGTGG TTTGAAGGTTTGAAGCTTCTCTAATAATACAAATATGAAATTTCTC GGCTCTCTGTTGCTGTGAGATCAGAAACAGAGATATGCAAGTCTC GGCATTTGAAGAGTCCACACAGATATCCCATGATGTGAAGCTGTGAT TGAAATGGCAAAATTTAGAACAGACTGATATACAGGTTGGCCCTTTAGCC TATGGAACAGCACAGCAATCTTTCAGGAGAAATGCGAGGCTTGTCTC CAGAGATTCATAATGTGGTGGCTCCATTTAGACTTTGAAACATAGG GGAGCTTAAGAAATTTTGGCGTCAATGGACCGTCAAGAGCAGAGCG GAACAGATGAGCATTAATACGCCATTCCTGTTACCGTCTATATATCT CGCCGGCTATATGAGCGATGTGTAATCCATCAGCAGCAAGAAACTGAT AAAAACATCTTACGCAACATCCTAATTTATGAGGCTTCAGATTTGTTAAG AGCATGGCTAGATAGGAAGAACTTTATGAGGCTTCAGATTTGTTAAG GAGCTCTCAGATTAATCAGGATCCTCAGATGCTTGGTCTTTGATGGCAA TCTCATTTGCAAAACAGAAATGGGCTCGGGCAGAGAAGTTTGAGAGG ATATTAACACAGCCATCCACAGAGTATACCTATCTATGCTAGCCCTTGG CAACGTGTGGCTCCAACTTTACATCAGCCCCCAGAGATCGAAGAAAGAA AAGCGTCAAGATCGTCTCGGCCATCTACAAACAAGTACTCAGAAATG ATGCAAGAATCTGATGCTGCCAATGGCAGTGGAGCTGTTTGGCCCAAA AGATATTTCTGAAGCTCGTGTATTTGCCCAAGTAAGAGAAGCAACA GCAGATATTAGTGTGTGCTGAACCTTAGCACATCTATGTGGAGCAAA AGCAGTACATCAGCGCGCTTCAATGATATGAATAACTGCTCCGAAAGTTCTA TAAGCA	377	LGLOA*ATAPG*VFSAPFIE* TVLSLVVIAFVENEFTIDV*1

Shigella ipaH9.8	6	prey66872	177	AGTTCAACATAGATGTAGATTAATTTCTGGGTCTCTATCCTGTTCTGTTG GTCTATATGCTGTTTCTACGTGGTACCATGCTGTTTGGTTGTTGTTACACGCTC TGATGATATCTGAAGTCAGGTATGATGATTCCTCCANTTTTGTCTTCTG CTNANG	378	YFWVLVPVLVYMSVFMVLV PCCFGYVGSVV*SEVR*CD SSXFLVSAX
Shigella ipaH9.8	6	prey67690	178	TTTCACTCAAGAGATATTGACAGAGCTATTGCTTACCTTCTTCCCAAGTTGCT TGTTTGAGAACAGCAGCGGCGAGTAAATGAAGCATCTTCAACAGATTTTTC AAGACAAAGCAATCCAGTGGGAGAGTAGCGGCTCCATTTCTACTATCTC TTCTATCTGGCAACAGATCACTATTCAATGATATTACCGACTTTACTTCC CGATCACAGCAGACAGACAGCTGA	379	FTQEDIDRAIAYLFPSPGLE KRARPVMKHQEIQFPQRA IQWGEDGRPHYLYFTGK QSYVSLMITSFTSRSHRTE NS*
Shigella ipaH9.8	6	prey67690	179	ATGGAGATGAGGCTTCCAGTGGCTGCGAAGCTCTTAGCAGAGACTGGCG CGCGACATTAAGAAACATCTAGTGGTCCGCGGGGATCAATCACTACGAC ACAGGATTCATGCGGGCGATGGAACATATATGGGAGAGAGAAGCTCATTT GCTCTGTTGGCTGCTGTGGAGAGTAGAACAAGTTGATCTGTGTGAAG CTTTGAAACCAAGATACATTGTTGAAGTAGGACATGATGGGAGCAAT CACAGAGGAGAGATCTGCAGAGATGAGCTTGAATGAGAGTTTCTTA CAGGAAGGGAGCCTTACGTGCTGAGTCCAGGCGTGTCTCTGACGGA GCTGTCTTTGCACAGAGAGCGCTGAAATATGGAACATAGGTACGAGG GTTTTGGTCCAGGTTTCCCTCTCCCTGGTGAACGCGAGAACGCCACTTTC ATGATTTGCCATGTGGTCTGATCTCGTAAACAGGCTTCAATGTC GATTTACCAACACCTGAGCACAAAGAGGAGCGAGGCGTCTCAATGC AACTGGAGCGCTGCTCTCTGCTGATCGAGAGTGATATCCGCGCTCGG AAGTGCATCTGCTGGTAACTCAGAGATGATGCTGATGATACACGGA TCCGTACTGCTATGAAGCATCCCTCCACATCAGATCAAGACATCTAAAG CCAGAATATGGAGGAGATTGTGATGGAACAGCGCAGAGGCTTTTGGAA AGGAGGGATGA	380	KDLNMNVSQKFKFNEV RFCESERLIRFLEDMQN EIVVLLEKSP*PLPREMI TLETVLEKLEGELEQANON QQALQKSFIELTELKYLKK TODFFETNLADDTFED TSGLLELKVAPYMTGKL FIAGVNRMRMASFERLLW RICGNVYLKFSEMDAPLE DPVKKEIQKNIFLYQGEQ LHQKIKCQGFRTATYPCP EPAVERREMLESVNRLED LITVTQTESHRQLLQEA ANHSWLKVKQMKVYHI

Shigella ipaH9.8	6	prey67336	180	<p>TCACGCGCAGCCCTGCTGCGAGGAGCGGCTGCGCACTGGCACTCTCGGCT CATCAAGTGCAGAGTAAGAGCTGTCTACCACTCTCGCACTGTGCAAC ATGCACTGTCACCGAGCTGTCTATCGCGAGATCTGTTCGCCGTGGCA GATGCCACAGCTATCAAGAGGCGACTGGACCAAGCATGGAATTAAGTGC TCCTCATGGCCGCCCATCATGACCACAGTCAATCTAAACAGACCCCTCCCA CATTTACAGGAC</p> <p>ATGGGAGTGACATGGGACTTCAGCATGAGCAATGAGGGGCCCGCTGGAA GACCTATGCTTTCAGGGGAGCATGTGTGAGCTGTATCAGATTCAGAGCCG GGCCCTGTTCCGAGTCTGCCCTTGGGAGGGCTGCCCGCAACCTCG GAGCTCTGTCTACTCGCTCGACACATGATCTACTTCTTAAGGGAG ACAGGCTGTGGCGCTACATTAATTCAGATGTCTCTCGCTTCCCGCAAA CGAGTAATAGGTAGAACCTTAACCTGTGAGCTCTCTATTGGCCTCTCAAC CAAAAGGTGTTCTCTTAAGGCTCCGGTACTGGCAGTGGGAGAGCTA GCCGAAGTACTTCAGAGCTACCCCAACCACTCAAGGTTTGTTCACGG GAGTGCCAAACGAGCTCGCTGCTATGAGTTGGCAAGTGGCCGAGTCT ACTCTTAAGGGGCAAGTCTACTGCGGCTCAACGAGCTTCGAGTAGA GAAAGCTATCCAGAAATATTTCCACAACTGGATGCACTGTGCTCCCGG ACTATGACACTACCCATCAGGTGGGAATACCACTCCCTCAGGTACGGGCA TAACCTTGGATACCACTCTCTCAGCCACAGAACCACTTGAATCTGA</p>	<p>LNMCNDVTCQCVAIEWFP VADATHIKRALEQGMELSG SSMAPIMITTVQSKTAPTF NR</p>
Shigella ipaH9.8	6	prey6299	181	<p>AGACGAGCCATGTTCTCAAGAGCATTTAAGTGAAGAAAGGATGAAGA CTACACTGTGAGAAATATGATAAGCCCTGAATCAGAGTCAGAGAGCCAA CTCCTCTGCCACTGGCAAGTAAATAGACTGAAGAGGAGCAACAGCTA GTTCAAGTTTCATGAAGCTGCTGTACTAGGACCTACACTGAAAGTGTATG ATGAAATATAAAGTACGATTTCCCTCACTAATATGCTACGTTTATGGG CTTCAAGATGATGATGGAAACAGCATTTGATTAATTTGGTGCTATCA ACAAATGTATGTTACAGAGCTACAGTCAGTGTCTGCAAGGAGCGGTAA TGCTAATGGAGCCGAGCTTTGGACACTATGGAATTTTACAGAGATGAT CAACTGAGTTAATGACACAGTTTATGAAGCAGCTACTCCATTTTCATGT TCATCTTACTTTCAGGAGGCAAGTTCAGAAAAGAAATGACTTTGAT ATCTCAAGAGCAATATGCTTCAACATGGAATATGAGAAAGTGTATCTT CTTGTGAGCAACATGAAATGTTTACAGCATGATGAAATTCAGCACAATA TTTGAACAAGAGATATGTTGACTTCTGGGAAATCATCTCACTCAGAGTCA CCCGAGGTTATAGTACCAACTTAAAGTCCAGATAAAGTCAACTGTGT GCCAACCAATATGATACACAGTGGAGATATGCAATATTTGCATTAATTA TGCAACTGTGAGTTACCTGTTGATCTCCCAACAGGATCATCTTTTC ATAATCTCAAAAGTGAATATTTCTAATAACGCTCGTAGTTTTCAGGAACA GCACTGTATGAACCCCTCAAGAGAAATCTTCAATCCAGCAACAGCTGTC AACACCAATATGATGAATCATTTTATCACTAGTATGATGATGAAGATGGA CCAGATGAGCTATTAGCATCTATTAGCCTTTTAAATGATGAAGATGGAAC</p>	<p>MGVTDWDFSMNSNGGPRGK TYAFKGDYVWTVSDSGRG PLFRFSLWEGLPNLDAA VYSPRTQWIHFFKDKWV RYNFKMSPGFPPKLNVE PNLDAALWPLNKVLEK GSGYWGWDDELARTDFSSY PKPIKGLFTGGVGPQSAAM SWQDGRVYFKGKVVYRL NQOLRVEKGYPRNISHNW MHCPRITDITTPSGGNTTP SGTGILDTLTSATETTFEY*</p>
Shigella ipaH9.8	6	prey6299	181	<p>AGACGAGCCATGTTCTCAAGAGCATTTAAGTGAAGAAAGGATGAAGA CTACACTGTGAGAAATATGATAAGCCCTGAATCAGAGTCAGAGAGCCAA CTCCTCTGCCACTGGCAAGTAAATAGACTGAAGAGGAGCAACAGCTA GTTCAAGTTTCATGAAGCTGCTGTACTAGGACCTACACTGAAAGTGTATG ATGAAATATAAAGTACGATTTCCCTCACTAATATGCTACGTTTATGGG CTTCAAGATGATGATGGAAACAGCATTTGATTAATTTGGTGCTATCA ACAAATGTATGTTACAGAGCTACAGTCAGTGTCTGCAAGGAGCGGTAA TGCTAATGGAGCCGAGCTTTGGACACTATGGAATTTTACAGAGATGAT CAACTGAGTTAATGACACAGTTTATGAAGCAGCTACTCCATTTTCATGT TCATCTTACTTTCAGGAGGCAAGTTCAGAAAAGAAATGACTTTGAT ATCTCAAGAGCAATATGCTTCAACATGGAATATGAGAAAGTGTATCTT CTTGTGAGCAACATGAAATGTTTACAGCATGATGAAATTCAGCACAATA TTTGAACAAGAGATATGTTGACTTCTGGGAAATCATCTCACTCAGAGTCA CCCGAGGTTATAGTACCAACTTAAAGTCCAGATAAAGTCAACTGTGT GCCAACCAATATGATACACAGTGGAGATATGCAATATTTGCATTAATTA TGCAACTGTGAGTTACCTGTTGATCTCCCAACAGGATCATCTTTTC ATAATCTCAAAAGTGAATATTTCTAATAACGCTCGTAGTTTTCAGGAACA GCACTGTATGAACCCCTCAAGAGAAATCTTCAATCCAGCAACAGCTGTC AACACCAATATGATGAATCATTTTATCACTAGTATGATGATGAAGATGGA CCAGATGAGCTATTAGCATCTATTAGCCTTTTAAATGATGAAGATGGAAC</p>	<p>DQSHVWQEHLSSEKDERL HCENNDKAPESISEKPTPL STGCGNRAEEGPNASSGF MKTAVLGP TLKNVMMKN KLA VSPNYNATFMGRKMM DGQSHVLKLVPIKONVCSF GSQSGAAKDGVTANLPQT LDTNGFLTGTTELNDTVY MKAATPFSCSSSILSGKAS SEKEMTLISORNNMLGTMD YKSVSSLSATSELTVASV NLTKTFETRNVDFFWGNHL TOSHPEVLGTTIKSPDKVN CYAKPNA VNSGDMHNYCI NYGNCLEPVSSNGSLPF HNYCNPNRSHRRFSSTGT AYVENPQSSSSKTVWQ QPISFSLVPRQESSKPD SLIASILLNDKQDGLKAKS EIEEQVYLEKQONIDQNL</p>

Shigella ipaH9.8	6	prey6586	182	<p>AAAAAGCAAAATCTGAAATTTGAAGACACAGTATGTTTGTAGAAAAGGACAAACAA TTGATGGACAAACCTGTACAGTAATGAAATCAAAATTTAGAGTGTGGCAGCT GAAAAATCTAAATGGGAAGACTTTCTAATGTGCGATTACCTATGATGCTGAG AATCACATCTGTTTTCTCTCCAGAGCCAAACAGGCATCAGAATTTCTGGCCAC CTGAAGTAACCAATTCCTTCAGAGTATTTGAATTAACCACTGATGTAAAC CAAGACTGTAGTAACCTCCAATTAAGGCTTGGCAGCTTCATCTGACACAGTC TTATCAAAACAGCAGAGAGGCAAAATTTGTTGAATCTTCGAAAGATTTCA AAGTCAAGGCACTCTCCAGTTCGCGTCCAGTGGCAGTGTGGGTATTAATGTGCGC TACAAATGATTTGAATTTGAAATTTGAAAAGAAAACCAAGTGTCTCATCAATC CACAGATGTGAGAGATTCAGAGAGATGCCTAGAAATTCAGGTTTGGACAC ATTAATTAAGCTAGTCAGATGCGATTAATACACAGCAGCTGTAAAGACA AATCTAGAGCCACCAACAAATTTAGTGTCTTTTATATGCAAGTCCACTT TTAAATTCAGACAAAATAAATTAATTTGTTGACAGTCTCAAAGGATCTTTA TACCAATGAACATACTAACAGCCTGGCTACCAAGTATTCTCTGGAAATGCT ACTTCAGTGGTTAATTCAGAGGTATCCCTGCTCTCTTTTGTGTAACAAAGAA ACTCGGATGGTTTAAACCTTAATATGGGAACCTTGAAGTGTTCGCGT GTCAAAACCGAGGGTCCCGAGCTGTGGAACTGTGACTAAGGAGCCTTGC AAAACCTATTTGAAGGTAGAACCAACAAATAATTTGTTACACCTGGACT TTGTTCCAGCATTTGGCAGTTGTTTGAAGCATGAAAGTAGCTCAGAAATACTT TGCCATTAAGAGCCCTTACATTTTGAACCAACGAGTTCTGTGAAAGCTGTT CTTATCTAACATGCTATCTGAGCAGACAGCAAGTAAAGTTGAATATCTCGGA TTGATTAACAGAGAAATGAGATTTTCCAAACACCTCTTTATACCTTCTT GCGTGTAGGCAACCAAGCTGTTTTTTAAAGTGTGTGATGCGCAATAAACACTG AGCTGTTAAGCCCAATATGTTCCAAATAGTACTTATCAAAATATACAGCCA AAGAACCTGTAAGGACACCAACAAAGAATATGCTGAAATTTTAAACCTGT TTTAAATGTGACTGCTGCTAATATCTGTGAGTAAGCAAACTCTGATCCTCAT TGCAAAAGACAACTGACCATCTATCATGATATAGGAGGAGAGCAGAAAGA GCGAGAATCTAGAGATGCTTACCTCTTACTAGATGACTTAAATGCCAGAA ATGAAATTTGTAATCTTACTGCAACATGCCAGAACTCTCTGAGGAAACCA ATATGTGTCAGTACTGTTTCAGATCCAGGTATTAAGGTGTAAACAAATTTG TAGAATTCAGAGCACTTCAATAGAAAAGAGACTTCCAAAAAATTTTTTTCAA AACAAAACTCATGGAAGTAA</p>	<p>YSENONLCEKATEKSKWE DFSNVDSMPMHPITSVFSL OSQQAQSEFLPPEVNLQLOD VLKIPDFVKDSSNPNKG LPLHCDQSFQKHEREGKIV ESSKDFKVOGJFVPVPGSV GINVPTNDLNLKFGKEKOV SSPQDQSDAIKMPHRISGF GTLTKTQSDAITQQLVKDK LRATTQNLGFSYMQSPLNL SEQKKTIIVOTSKGFIPLNI TNKFGPLVPIGNALPLVNS QGIPASLVNKKFGPMLVTL NNGLEGVSAVKTEGAPA RGTVTKPEKCTPIKLKVEPN NNCLTPGLCQSSIGSCLSMK SSSENTLPULKGPYLKPTSS VKAVLPNMLSEQQSTKLN SDSVKQQNEIFPKPLYTFL PDGQAQVFLKVMFNPKTEL LKPKLVQNSITYQNIQPKPL EGTPTQRILLKIFNPVLNVT ANNLSVNSASLLOKDNVP SNQIGEGKEKPESDALP FLDDLMPANEVITSTATC PESSEEPICVSDCESRYL RCKTNCRIERNRKRKTSK KNFFKNKNSWK*</p>
			383	<p>APWKIQONTFTRWQNEH LKCVSKFIANLQTLDSGL RLIALLEVLSOKNMHRKHN QRHPTFRQMLENVSVALEF LDRESIKLVSDSKAVDGNL KULGLWTLIHLYSISPMWV DEEEDAAKQGTPTKQRLLG</p>	

			AGGCGCGCGCGAAGCTGACATCGACTTCGACATCATCGCAATGACAATGA CACTTACCGGTCAAGTACAGCCCGCGGGGCTGGAGCTACACCATTA GGTCTCTTCTCAGCAGCAGCCAGCCACCGCCCATCCGAGTCAAGGT GAGCCCTCATGACGCCAGTAAGGTGAGGCGAGGCGCGCTGCCTCA GTGCGCTGGTGTGAGCTTGGCAAGCCACCACCTTACAGTAAATGCCA AAGTGTCTGGAAAGGCAAGCTGGACGTCCAGTCTGACACCCATGACAACTACA GGGATCGAGTGGGAGATGTGACATCATCGACCCATGAGCTCAATGTCACTTA CAGTCAAGTACAGCCCTGTCCAGAGCGCTTCCAGTGGCAGTATCTCCAAAG TGGAGGATCCCATCCCTAAGAGCCCTTCTCAGTGGCAGTATCTCCAAAG CTGACCTCAGCAAGATCAAGTGTCTGGCTGGGAGAGAGGTGGACGTT GGAAAGACCGAGGATTCACAGTCAATCAAGGGTGTCTGGTGCAGGCG AAGTGGCATCCAGATTGTGGCCCTCGGGTGAAGCGTGCCTGTGCAAG GTGAGCGAGCCCTGGGGCTGACACAGTGTGTGGCTTCTCTGCCCG TGAGGAAGGCCCTATGAGTGGAGGTGACCTGTGACGGCGTGCCTGTC CTGGAGCCCTTCTCTGGAAGCTGTGGGCCCCACACGCTAGCAAG TGAGCGCTTGGCGGGGCTGCAGGCGAGCGAGTGGCGCTCCCGCGC CGCTTACCATCGACACAGGGCGCGGACAGGTGGCTGGCGCTGAC GGTGAAGGCCCTGTGAGCGCAGCTCGAGTGTGGACAATGGGATG GCACATGTCCTGTCTACGTGCCACGAGCGCGGAGCTACAACTCA ACATCTCTCGCTGACACCACATCCCTGGCTCCCATTCAGGCGCCAGCT GGTCCCTGCTTGACGATCCAAAGTCAAGTGTGAGGCGCGCGGCTGGA CGGCGCACCGCTGGGAGGTGGCCATTCAGTGGAGTGTCTCGAGCG CGGCGACGCGGAGCTGACCATTGAGATGTCTCGGAGCGCGGCTCCG GCGAGGTGTACATCAGGACCGGTGATGGCACGACACCATTAACATC ATTCGCTCTGCGCGGCGCTACCGTCAACATCAAGTACGGCGCGCAG CCGCTGCCAAGCTCCGACAGGCTGCAAGTGGAGCTGCGGTGGACCT TCGGTGTCCAGTGTCTGCGGCTGGATTCAGGCGCGGCTCTGACACAGCG GAGGCCACCTGATGTTAGTGTGAGCGCGCGGCTCGACCACTGACCG AGGCGCCAGCTCAAGCCCGTGTGGCCACCCTCAGGCACTGACCG AGACTCGTTCAGGACCTGGCGATGGCATGCAAGTGGAGTACACCG CTTACGAGGAGGAGCTGCATCGCTGGAGTGCATACGAGGAGTCCCG TGCCAGCAGCCCTTCCAGTGTGCGCTGACCGAGGCTGCGACCCCTCC CGGTCGTGTCCAGCGCGCAGGACCTCAAGTGGCAGCGCGGCTGGCC CAACAAGTTACTGTGGAGACAGGGAGCTGGCAGCGCGGCTGGCC TGGCTGAGAGGCGCCCTCCGAGCGAAGATGTCTGCAATGGATCAAGG AGGCGACTGCTCGTGGTGGATACATCCCTTATGAGGCTGCGACCTACAGC TCAAGCTCACTATGTTGGCCATCAAGTGGCAGGCGCTCTTCAAGGCTCC TGTGCAATGATGACAGATGCTCAAGGTCAAGTGTCTTGGCGCGGCT GAGCCGAGGCAATGGTGTGGTGGCAACCTCCCTCAGTCTTCCAGGTGGACAG
			GRKLDVQFESGLTKGDVARD VDIHDHNTYTKYTPVQQ GFVGVWVYTGDPKPSPF SVAYSPSLDKSKIVSGLGE KVDVKGDEFTVAKSGAG GOGKVASKIVGPSGAAPC KVEPGLGADNSVWRFLPRE EGPVEVITYDGVVPGRS PFPLEAVAPTKPVKFAFG PGLQSGSASPTAFIDTK GAGTGGGLTVVEGPCEAQ LECLDNGDGTCSVYVTE PQDYNILFADTHIPSPF KAHVVPDASKVKCSGP GLERATAGEVGOFOVDS SAGSALTEICSEAGLPAE VYQDHGDGTHITYPLCP GAYTVTKYGGOPVNFPS KLQPEAVDITSGVOCYGP GIEGOGFREATETFSVDA RALTOTGPHVKARVAP SGNLTEYVODRGDMYK VEYTPYEGLHSVDVTDG SPVSPSQFQVPTGCDPS RVRVHGGIQSGITNKPKN FTVETRGAGTGLGLAVEG PSEAKMSMDNKGSCSV EYVPEAGTYSNLVYGGH QVPSFPKVPVHDVTDASK VKCSFGPLSPGMVRANLP QSFVDITSKAGVAPLQVKV QGFPLGVDPVDVNDAG TQTVNVPSRFGPYISVL YGDVEVPSPKPKVLPTH DASKVKASGPGNITGVPA SLPTEITDAKDAEGGLAV QITDPGKPKTHIQDNHD GTYVYVYVPDITGRYTLIK YGGDEIPFSPVYRAVPTG

Shigella ipaH9.8	6	prey66789	183	<p>GGCCGGGTGAAGAGAGGATCACCGCAGGGGCTGGGCTCTCTCAAGTGGC CAACGTTGTAGTATCTTGAACCTCAGCCTGAATACTTGAATAGCATC CAGGATACAGCCAGGTACAGCCATCGGCAGCAAGCCATCAGTCCGCT GAGATGTGAAGGGGAGCAACACCTACTGATCGCTTGTTCGCGCT GAGATGGGACACACAGCTCAGCTCAAGTACAGGGCCAGCACGCTCC GAGGCGCCCTCCAGTTACCGTGGGCGCTAGAGAGCTGAAGTGAAGTGC CAAGCTCGAGCTGGGCGCTGGCTGGAGAGCTGGCTGGAGCGCTGGCA TTGCTGTGAGGGCCAGCAAGGCTGAGATCTCTTTGAGGACCCAGCA ACGGCTCTGTGTGTGCTTATGTGTCAGGAGCCAGCTGACTACGAAG TCTCAGTCAAGTCAAGAGGACACATCCGACAGCCCTCTGTGTGGCT TGTGGCTTCTCGCTGGGAGCGCGCGCTCAGTCTTCTAGCTCTCA GGATCAGGGCTAAAGTCAACAGCAGCGCTCTTTGAGATCAGCTGAA GGGCGCAAGGGCGATCGATGCCAAGGTGCACAGCCCTCAGAGCC TGGAGAGTGTATGTACAGAAATTGACCAAGATAAGTATGCTGTGCGCTT CATCCCTGGGAATGGCGTTTACCTGATTGACGTCAAGTTCAACGGTACG CACATCCCTGGAAGCCCTTCAAGATCCGAGTTGGGAGCCTGGGCAATGA GGGAGCCAGGCTTGGTGTCTTACGGAGCAGGTCTGGAAGGCGGTGT CACAGGAACCCAGCTGAGTTCTGCTGAACAGCAAGTGGGAGCTGG TSCCTGTGCGTGACCATGACGGCCCTCCAAGGTGAAGTGAATGTGCCA GGAGTCCCTGAGGCTACCGCTCACCTATACCCCATGGCACCTGGCAG CTACCTATCTCCATCAAGTACGGCGCCCTTACCACATTGGGGCGCCG CTTCAAGCCAAAGTCAGGCGCCGCTGTGTGACGACCAACACAGCTCCA CGAGCATCATCAGTGTGTAGACTCTGACCAAGCCACCTGTGGCCCC CAGCATGGGCGCCGCTGTGGCGCTGTGAGCCAGCAAGTGGGTGGC CAAGGCTGTGGCTGAGCAAGCTACGTAGGCGCAAGAGCAGCTTCA CAGTACCTGACGCAAGCAGCAACATGCTGCTGGTGGGGTTCATG GCCAAGACCCCTGCGAGGAGATCCTGGTGAAGACGTGGGAGCCGG CTCTACAGCTGTCTCTACCTGCTCAAGGACAGGGGAGTACACACTGGTG GTCAATGGGGCGCAGCAGCACATCCAGGCGACCCCTACCGCGTGTGGTG CCCTGA</p>	<p>PNIOFVPAADGPFLEGT VTS SEHLGGINFTGSPVTFKHL WKVOAQNIDRFHTFPLA GEOGKNFHFVHRSDVE SVSGDTLRSFAFEGGQK SACSRLYVPHSLWPQIKGR LLEEHSRIKVGDAEDFGT FFSAVIDAKSFARIKKVLEH</p>
---------------------	---	-----------	-----	---	---

Shigella ipaH9.8	6	prey67711	184	GATTGATGCCAAGTCTCTTTTCCGGTATCAAGAAGTGGCTGGAGCAGCGCGG CTCTCGCCAGCCTACCACTCGCTGGGCGAAGTGTGATGACTCGGT GGGCTATTTGGAGCCTCGATCGTGGAGCAAGACCTCAGGAGCG CATATGAAGGAGGATCTCGGCGCTGACTGTCTGTACGTCTACCGG GACACAAGTACAGGAGAGCTGCGTGTGTACAGCAGCCACGACTAT GGCTCAGGGGGGAGTGTCTCCGAGTATAGGAGCTGTCGAGAGCG CACAAAGTGCTGAGGAATGCTCGGGCACTTCTACATCAACGACAAGTCC ACTGCTGATAGTGGCCAGCGCTTTGGGGGGCCGAGCGCTGTGG AACCAATGACAGCCAGGCGCCACATCATCTCGCTGGAGCTGCGC GCAGGTCTCAAGGAGACATAAGCCCTGGGGGACTGGAGCTACGCGTA CATGAGTGA	385	ARRSPSLTILAGKGDSDV GYVFCVSKDQPEIM KEELQVLSVYVDDKY KETLQLVDSITSYLIGAV FSQDKVWQEAATKVLNAA GNFYNDKSTGSGVQQPF GGFASGTNDKPGPHYL RWTSPQVINKTHPLGDW SYA YMQ*
Shigella ipaH9.8	6	prey2118	185	ATGTCAGGCTGTGCGACAAACGGAACTCAACCAATTAAGCAAAACATGGG AACTCAGTTTATATGATTTACACGAACCTCAGGAGGCAATACAGATGG CTTAGAANTTGGTTTACCTCGAAGTCTACAGATGAATTAATGTGCCAA TTTGTGGATATGTTGAAGCAACCATGACTACAAAGAGTGTTCATCGT TTTGTGAGACTGCTATCATACAGCCCTTGAAGTGGCAACAAAGATGTC CATTCTGCGGAAAACATGTTTCCAAAGATCACTAGGCCAGACCCAAA CTTTGATGCACTCATCGCAAAATTTCCAAAGTCGTGATGAGTATGAGCTC ATCAAGAGGAGTATTAGCCAGGATCAACAGCAATTAATCAGCAGCAT CAGTCACAGATTGAGGAAGGATGAAGTACAGCCATGAACAGATGTC GCGAGCAGAACACAGATTGAAATGGTAGGAGCAGAGATTAATGG TGACAGTTCACACTGCAGTATGATCCACATAGCAATCAGGAAGCAGCG CTAGTAAACAAACGCAACCAATCTGATGATCTGGCTAGAGCTTGATA ATCAAGATGCAAGTGAATGATCCAGTATGATGATGGTGGTCTAGTGAAT TGAATTAGTATTACGCTCTCCCACTTATGAAAAGATGAGCAGTATCCAA CAGCAGGATACATAAGACTTCTGGTACGCCAGTGTGATGACTATCCAA GTATCTGGCTGAGGTTAGCTTTAGGAAGACTTCGAAGCAAGGTATATAG AACAGATGAACCTTGATACAGCAGTGAAGAGCAGTATACATTAATAG CAACAGCCAGTGGCCAGTTCTGATTAATGAGCTCTTTTCTTGGAAATG TCAGTGGAGAAATCTGGAATGGAACCAACCCATGGAAGCTTATAGCGAC CTACAAGGAGCACAAATGA	386	MSQAVQTNGTQPLSKTWE LSLYELORTQEAITDGLI VSPRSLHSELMCPICLDM LKNMTTKECLHRCADCI TALRSGNKECTORKLVS KRSLRPDPNFALUSKIYPS RDEYEAHQEIVLARINKHN NOQALSISIEEGLKQAWN RLQHGKQOJENSGAED NGDSKCSNASTHNGEA GFSNKRKTSDSGLELDN NNAAMIDPVMGDASEIEL VFRPHPTLMKDDSAOTRY IKTSGNATVDHLSKYAVRL ALEELRSGESNMWLDTA SEKQYTIATASGQFTVLN GFSFLSELVSEKYWKVNP MELYAPTEKH*
Shigella ipaH9.8	6	prey3596	186	ATGTCCAGCGGACCGGTGGACCTAGGGGAGGATTACCCCTCTGGCAAG AAGCTGTGGGGGCCGATGGAGAGGATCGAGATCGAGACCGGGAGCTGA AGATCGGTCTAAGGATCGAGACCGGAGAACGATGATAGAGGATAGAGCGG	387	MSKRRHRLDLGEDYPSGKK RAGTDGKHDRDRDREDR SKDRDRDRDGRDRERE

Shigella ipaH9.8	6	prey666	187	<p>AGAGAGGAGAAAGAAAGGAGAAAGGAGTTGCGAGCTTCAACAAATGCTAT GCTATCAGTGTGCTGATTACACCCCTGAAAGCTTCCCATTCAGCTCACTCA ACCCATCAGACACATCAACGCATCTACACATCTGCTCATTCACAGCAACG CGACATCAGGTACACGTCATCTCCACAGTGCATTATCGTTACCAAC TTACCCCATCTCTCGATCTATGATATTTCTAAAGAACGTTCTCAGTCCC TGTTTGGGATACAGGATAGTTTACAGATATCTGGTACAGATCACTGCT TTGATCTGTTGTTGAGACTGGTCTGTTAAACAAACAAATCCACACG GTGTGGAGTACATCGCATTCATACAGACCCAGAGAGAGTTGGCTG TACCAACCCAGAGAGTGGCTGCATGAGTGGCTCAGAGAGTTGCTGA TGATGAGTGTGATGTTGGCCAGGAAGTTGTTACTCCATCGATTGAA GACTGAGTAGTGAACAAATTTTTATGTATGATGACTGATGGGATTTACT TGTGAAGCTATGAATGATCCCTCTGGAGCGTTATGGTGTAAATTTCTG ATGAGGCTATGAGAGACATGGCTACAGATATCTAATGGTGTCTGAA GGAAGTTGAAGACAGATCAGATTTAAAGGTTATAGTTATGAGCGCTACT CTAGATGACGG</p>	<p>KEKEKELRASTNAMLSAGL PPLKSHSAHSTHSAHSTH STHSAHSTHAGHSTSLP OCINPTNLPHTPRYDILK KRLOLPWEYKDRFTDILK PHQSLVGETGSGKTTQI PHRCVEYMRSLPGPKRGV ACTOPRIRVAAMSVQARVA DEMOMVLQGEVGSIRFE DCSSAKTFFMYMDGMLL REANMDPLERFYGWILDEA HERTLATDILMGLVKEVR QRSOLKVVMSATLDA</p>
Shigella ipaH9.8	6	prey666	187	<p>CATCATCCCGGTTGGAAATCTGTCACATCATCTGAGAGATGCCTGGAA GATCCCTGGAGATACGGGCTGTCACGACGAGTTGGACCCAGCTGTC ACATTTGGCGGTTGTGAATATGAGAGACGTGTGCATCTCTCGTGAGTTGT TTGACAGTGGCCCGAGTGTACAGAGAGCTGTACAGAGCCGACGCGCAA GCCAATGGACATTGACGTGAGGAGGAGGCTGACATGGCTGTTTACA TTATTTGAGCAGTGTGCTGGCGCGGTTCTTTGCCAGCACTGATGACCT AGAAGCATGGATGTGAGTGTGCTGCTGGGTGCTCCAGCTGATGACCT AACAGATTCGTGTTGGCCAGCGGGTATGAGAGCTAGAGTTGGCCAT GCTGAGCTTTTGAACAGCTTTGCTAAGATCTACATTGGGACCAAGTGAG AAATCCTCTAAGCTGTACCGCGGAC</p>	<p>ITSRLSVHILRDGLDPLE DTGLVQQLDQLSTIGRCE YEKTLVQLFDQSAQSY OELLQASAPVMDIAQVGG RLTWLVYIGAVGGRVYFA STDEQDAMDGLVQVRVQ LMLNLSRLAQAGNEKLEL AMLSFEQFKRYGQDVQV KSSKLHYR</p>
Shigella ospG	7	prey3917	188	<p>GATGACACGCTATACACCGCGAAGAACTACGCGGTGCCAGCGCTCAGGC CCATTGCGTGGAGTTCTGAAAGAAAGCTTCGAGCCGACACACCCCTTCAT GCTGCTCAGCGAGCGCACTCTTCGATGAACCGAGCTGGCCGAGCGTGTG CTTGAGAACATCGACAAAACCTCGACAGCCCATCACCGGAGCGGCTT CACGCATTTGACCTGGACACGCTGTGCTGCTGCGAGCGCACACCT GGCATCTGAGTGGCGGTGTTCAATSCCGCTTTCGCTGCTCGCGAGG CGAGTGTGAGCGGACGAGCTGAGGTGAGCCAGACAGACAGCGCAGG TTTGCGGAAGCCCTGGGCTCATTGCTTCCGCTCTGACCATCGACCTGAGG ATGTCCTCGAGTCCGACAGTGGGATCTGCTGCTGGACCGCGAGGTG CTGAGCTCTTCTGCACTTCCGCTGCGGAAAGAGTGCAGCATCAACCGCT TTGACCGCCCGCTCTGCTGCTGCGGAAAGAGTGCAGCATCAACCGCT TCAGCAGGTGGAGAGTCTGGGCTACAGCGGACCGAGTACCGCATC AGGTTCTCAGTCAACAGGCACTCTGCTGGGATGAGTTGGGCTGTATGAT CCATCCACGCGCCACCGCATACCAAGTGAACATCCAGTTATTTCACCGGA</p>	<p>MTLLTYARKYVPALEAHC VEFLKLRADNAFMLTQ ARLDEPQLASLLENIDKN TADATAEQGTDDLDTLVA VLERDTLGIREFVRFNWVR WSEACQROQLOVTPENR RKVLGKALGILRPLMTIE FAAGPAGSGILVDREVSL FLHFTVNPKRVEIDRRP CCLRKECSINRQQQVESR WGYVSGTSDRIRFSVKNRIF VWGFGLYGSIHGPTDYQVN IQIHTNSTVILGONDYGF CDGSASTFRVMFKPEVIL</p>

Shigella ospG	7	prey63632	189	TAGCAACACCGCTCTGGGCGGAGAACACACGCGCTTCAAGCTGGAGCGCTC AGCCAGCACCTTCGCGCTCATGTTCAAGGAGCGGTGGAGGTGCTGCGCCAA CGTCAACTACACGCGCTGCGCGCTCAAGCGCCGAGCTCCACTGACGG CACAAAGGCTCGCGAAGGTGACACAGAGTCCGCCACCGCGCGCCCA AGACCTGCTTCACTTTTCTAGCGCGCGGGAACAACATGGACATCCGT GAGGAGCGCGAGATCCCGAGTATCTCTCAACCTAG	390	CGKAFSWKSHLIEHQRHTHT GKPYHCTKCKKFSRNSL LVEHQRIHTGHPHKCGEC GKAFRLSTYLQHKHITGE KPELCIEGCKFSRHSFLIE HQRHTGHPYCKEGCK SFSQNLNLRHQRHTGDK PHKOECCGKAFSSSLQIK HQRHTREKTYPNYKES FDPNCSLVIQOEVPKES YKDECGKTFESVAHLVQH QRHTOEKPYLCTVCGKSF SRSSFLIEHQRIHTGHPYL CRQCGKFSQNLNLRHQ VHTGNPKHKDECGKAFS RNSGLHQRIHTGKPYK CEKDKSFSOORSLVNHQ MIHAEVKTOETHCEDACGE AFNCRISLIQHOKLHTANW Q*
Shigella ospG	7	prey2108	190	TAGCAACACCGCTCTGGGCGGAGAACACACGCGCTTCAAGCTGGAGCGCTC AGCCAGCACCTTCGCGCTCATGTTCAAGGAGCGGTGGAGGTGCTGCGCCAA CGTCAACTACACGCGCTGCGCGCTCAAGCGCCGAGCTCCACTGACGG CACAAAGGCTCGCGAAGGTGACACAGAGTCCGCCACCGCGCGCCCA AGACCTGCTTCACTTTTCTAGCGCGCGGGAACAACATGGACATCCGT GAGGAGCGCGAGATCCCGAGTATCTCTCAACCTAG	391	TKDHHTFKYKISALALLKM VMHARSNGNLEWMLGLG KVDGETMIMDSFALPVEGT ETRYNQAQAAEYVMAAYIE NAKQVGRLENAIGWYHSH PGYGWLVSQIDVSTWMLN QQQFEPFVAVVIDPRTISA GKVNLAGRTYPIKGYKPPD EPSEYQITPLNIKEDFGVH CKQYVALEVSFYKSSLDK LLE

Shigella ospG	7	prey6/4201	191	ACGGATTAATAAGAACTTAGTGATTTGGCCGGTGACCTCCAGCACAATGT TCTGCAGTCCAGTTGGGATGATATGTTTCAITGGCAAGCCACAATATGG GACCTATGACAGCCCATCAAGCGGTGATTTCTTTTGACAATCATTT CCTACAGTACCCCTCAACACCCTAAGTTCATTTTACAACAAGATTTA TCATCCAAATTAACAGTAATGGCAGCATTTGTCGATATTTAGCATCAG AGTGGTGGCTGCTTTAAACAAATGCTTAAAGTCTTTTATCCATTTGCTACTGC TATGTGATCCAAACCCAGATGACCCCTAGTCCAGAGATGTCACGGATCTA TAAACACAGACAGAGTAAGTAAACAAGAAATATCGGGAATGGACTCAGAG TATGCATGTGA	392	RINKELSLADRPDPAQCSA GPVGGDDMFHWQATIMGN DSPYGVGGVFFLTHFPIDY PRKPKVAFTHFTHFPHNNS NGSLCIDLRSQWSPALTIS KVLISICSLCDPNDPDLV PEARIKYTDKDKYNRISRE WTQKYAM*
Shigella ospG	7	prey1922	192	AACTGGTGGTCTGCTGCTAAGGCCAAGCGGCTGAAGCTGCTGCTGCTC AGCCCAAAAGAGAACTACAGCAGCGCGCTCTCCCTCGCAGCACAC CATACCCATGAGATGCCAGCGGTCCGCTCGCCCTCACAGCCTCTCTG CAACCTGTGTCAGTAAACCCCACTGTGCGCCACCACTAGCTGAGCCA GGAGCTGGCAAGTCTCGTITCAGAACATCGGGAGAAATGAACAGATG CGCAGCGCATTTGCTCAGCGTCTGAAGGAGGCCCAAGATCATGTGCAATG CTGACAACCTTTAATGAGATGACATGAAGTAAACATCAGGAGATGAGGGCTC GGCAAGAAGGGCTTTTGAAGAACATAACCTCAACTAGGCTTCACTGTC GGCATTTGTGAAGCGCTAGCCTTTGCCITTCAGGAACAGCCGTGTTGAAT GCAGTATTTAGCAGCACAAAGAGGTGTGTATAGGATTTATTTAGCA TCAGTTTGACGTGGCCACCCACGGGTGTGTTGTTCCAGTCAAGGA ATGCGAAGCTATGAATTTGCGATATTGAACGGACCATCACTGAATCGG AGAGAAGCCCGAAGAATGAATTCGATTCGATTAAGATGGATGGCGGTAC TTTACCACTTAGCAATGAGGCGTTTGGCTCGCTCTTTGGAACACCCATT ATCAACCCCTCAGTCTGCCATCTGGGATGCATGGCATCTTTGACAGGC CAGTGCTATAGGAGCAAGTGAAGTGGCGCCCATGATACGTGGCAC TGACCTATGATCAGCGCTGATTTGATGGCAGAGGCTGTGACTTCTCGC CAAAATCAAGGACGGTAGAGGATCCAGAGTCTCTCTCGGACTTATG GGCGGACGAGGAGGCTGATGAAGGAGCTTGAAGAAATCCGCAATGTGG GATGAACAACTTCGTAACATCAAGATGATGAAGCTATTTATTTGACTTGGC AAGGCTATTTGCTCGACACCCCTCATATGATGAAGGAGCTTCAGAA CGAATCAAGTTTCCAGAGTACCCATCAACCCACGAGATCAACATTA AACAAAGATCTACCCAAACATCGACGAAGGGCAGGCTGTCTGCGC AGTAATTAGTGGCGAAACTGGAAGCCAAACCAACCAACCAAGTAATC CAGTCCCTCATGACACTGATGAACCCCGAGCTGAGCAGCCGCTCGG GCTGACCTAGCTGAAGAATACTCTAAGGACCCGTAAATAATCTGTGAAGAATG CTGAAGAGTTTACAAGAAATATGGGGAAGCGACTGTGGAATAA	393	TGAAPAKAKPAEAPAAAA KAEPTAAAAPPAPAPPTQ MPVPSPSPSPGKPKVSA VKPT/APLAEPAGAGKGLR SEHKMNRMFORIAQRL KEAQNTCAMLTTFNEDMS NICEMRARKHEAFKKHNL KLGMSAFYKASAFALQEO PVNAVIDDTKEVYRDYQ DISVAIVPRGLVPVIRNV EAMFAIEDRTITELGEKAR KNELAIEDMDGGTFTSNG GVGSLFGTPIINPQSAAIL GMHGFDPVAVGKGVKVEPR PMYVYALTYDHLRDGREA VTLRKIKAAVEDPRVLLLD L*
Shigella ospG	7	prey6/418	193	GGCGGACGAGGAGGCTGATGAAGGAGCTTGAAGAAATCCGCAATGTGG GATGAACAACTTCGTAACATCAAGATGATGAAGCTATTTATTTGACTTGGC AAGGCTATTTGCTCGACACCCCTCATATGATGAAGGAGCTTCAGAA CGAATCAAGTTTCCAGAGTACCCATCAACCCACGAGATCAACATTA AACAAAGATCTACCCAAACATCGACGAAGGGCAGGCTGTCTGCGC AGTAATTAGTGGCGAAACTGGAAGCCAAACCAACCAACCAAGTAATC CAGTCCCTCATGACACTGATGAACCCCGAGCTGAGCAGCCGCTCGG GCTGACCTAGCTGAAGAATACTCTAAGGACCCGTAAATAATCTGTGAAGAATG CTGAAGAGTTTACAAGAAATATGGGGAAGCGACTGTGGAATAA	394	AASRLMKLEELIRKCGMK NFRNIQVDEANILLTWQGL VPDNPYPDKGAFRIENFPA EYFPKPTFKTKIYHPND EKGQVCLPVSIAENWKPA KTDQVQSLALVNDPQPEH PLRADIAEEVSKDRKKFCK NAEETKYKGEKRPVD*
Shigella ospG	7	prey6/314	194	ATGATGGCGGAGTGGAGTGTGAAGGAGCTGGAGGATCTTCAGAAGAG CTGCCCCCACTCGCGAAGCTGTCCAGCGATGATGCCATGTCTGGTG TGGCAGGCTCTCTCTACCCGACCAAGCTCCCTCACACCTGAAAGCCTTCA	395	MMASMRVKEDELLOKHP PPYLRNLSSDDANLVWHA LLLPDQPPYHLKAFNLRISF

Shigella ospG	7	prey67435	195	ACGTGGCATTGAGCTTCCCGCGAGATATCCGTTCAAGCTCCCATGATCAA ATTACAAACAGATATCAACCCAGCTGGAGAGAACGGACAGATTTGCG CTGCCATCATCAGCTGAGAGCTTGGAGAGCTTGCACCAAGATTGCCAA GTCCGAGGCCCTCAATGCTGCTGATGAGTACAGCAATATCAGGAGCC CTCGGATGGACCTGCTGAGCTGCTACACAGAATCCGAGCGTTTCAGA AAGAAATCCGAAGAGTTACCTCCATCCGATCCGAGTGGACCGCCCTCTAA ATTGACGTTGGGCAAGGACCGAGAGAGCAAGATTCATCAAAACCAAT GAACCTGTGGAGAGAAATCTACATTTCTTCATTCAATCCCAAGCGCC AGGACCTTGAATGTAGCTCAGACAGAGACGACCAATGTTCCCTGGGA ACCTGAAGTCCCTCAGCAGCTGCTACCAAGTGGAGACATGACGTGTA GCCAGCGCTTCAGGTGATGATCGGGTCCAAACAGACCAATCAAGATGA AGATTGCCCTGCGGGTCTCCATCTCGAAAGCGAGAGCGCTCCAGACC CTGGGATCGCTCAAGGCTGCGGCTATGCTGTAAGCCAGCGACGACGA GCTGGCCAGGCTCCTGAGTGGAGAGCAGATCACTCCCTGCCTCATGAC CCTCTGTAATGCTACGATGAGCTGGSCATCGCTACCAAGTCCCATCTAC TGCGTGTACCGCGGTGAACCTGCTGCTGGAGCACACGAGGAGGAGAG CCTGGAGCCCGAGCGCTCCACAGCGTGGCGCTGAGTCCCGCTGA AGGTGCGCTGTCCAGCGGCAAGACGTGAGCTCAGCGCCAGCGTGGCC GACACAGTGGGCGCTCAAGAGCGCTGACGCCAGGAGGATGGA GCATCTGGGCGAGCGTGTCTCTCGGGAAGCTGCTCACAGCCGAC ACGGCTCCAGGAGACCAAGATCCAGAAAGATTTGTATCCAGGTCATCATC AAC	396	MSVGHKAQESKIRYKTNEP VEVNEFTFTHHPKRDQLE VEVRDEHQCSLGNLKVPL SQLLTSEDMTYSQRFLSN SGPNSTKMKIALRVLHLEK REPPD
Shigella ospG	7	prey67443	196	CTGGATCGCTCAAGGCTGCGGCTATGCTGTAAGCCAGCGACGACGA GCTGGCCAGGCTCCTGAGTGGAGAGCAGATCACTCCCTGCCTCATGAC CCTCTGTAATGCTACGATGAGCTGGSCATCGCTACCAAGTCCCATCTAC TGCGTGTACCGCGGTGAACCTGCTGCTGGAGCACACGAGGAGGAGAG CCTGGAGCCCGAGCGCTCCACAGCGTGGCGCTGAGTCCCGCTGA AGGTGCGCTGTCCAGCGGCAAGACGTGAGCTCAGCGCCAGCGTGGCC GACACAGTGGGCGCTCAAGAGCGCTGACGCCAGGAGGATGGA GCATCTGGGCGAGCGTGTCTCTCGGGAAGCTGCTCACAGCCGAC ACGGCTCCAGGAGACCAAGATCCAGAAAGATTTGTATCCAGGTCATCATC AAC	397	WDALAAAYAAEANDHCLA QAILDGASITLPHGLCECY DELGNRYQLPYICLSPPN LLEHTEESLEPPPPSV RRFPLKVLRLTGKDVRLS ASLPDVTGQLKQLHAQE GIEPSWORWFFSGKLLTDR TRLQETKIQKQFVQIIN
Shigella ospG	7	prey67317	197	CGTGTGTGCGCTCTGCCGCAAGAAGTTGTCAGCTCCATCAGGCTGGCAG CCACATCAAGAGGTGACGGGGTGGCCAGAGGCGCTTGGTCTTACACAG TTCCATCAACAGAGCTTCTGCTCCTGGAACCTGGTGGGAGCATCCAGCA GAAGCTCTGGGGAGCAGCTACAGCTGCTGGAAGAGGAGTTTGCCCTCCAG GGCGTGA	398	SVPSAARSSAPSGCAPTS KRCITGLPHRRWSSPVPST RASASWNLVGTSSKLLWG TSYSWWKFLSPSA*
Shigella ospG	7	prey67393	198	GAGAATCCACAGGAATTTGAATGATCTGGCAGGGAGCCCTCAGACAGTG TTACAGCGCTCTGTGGAGATGATTTGTCATTGGCAAGCTACAAATATG GGCCAAATGACAGTCCCTATCAGGCTGGAGTATTTTCTTGCAAAATCATTT CCACAGATACCCCTTCAACCCCTAAGGTTCATTTACACAAAGAAATTT ATCATCAAAATATTAACAGTAATGCGAGATTTGCTTGATTTCTACGATCA CAGTGGTCTCAGCAGCACTAATTTTCAAAAGTACTTTGTGCCATCTGTTCTCT GTTGTGTGATCCCAATCCAGATGATCCTTAGTGCCTGAGATTTGCTCGGCT TACAAACAGATAGAAAAAGTACAAAGAAATAGCTCGGGAATGGAATCAGA AGTATGCGATGTAA	399	RIHKELNDLRDPPAQCSA GPHVDDMFHWQATIMGPN DSPYGGGVFLTIHPHTDY PFKPKVAFTHRYHPNINS NGSICLDILRSQWSPALTS KVLLSICSLCDPNPDPLV PEIARYKTDREKNRIARE WTKYAM*
Shigella ospG	7	prey700	199	ATGGGAAATTTGTTCTTCTGCTCAAGGTGTGAACATGAATAGACTACCAAGTTT GGATAGAGCATTCATATGTTTACCATGGGATGATGACCAATTCGTTTGTCT TCTGGAACTGGACAACCTTATGGACCAACATTTTACATCTGTTGATCTGTTG	400	MGIGLSAQGVNMNRLPGW DKHSYGVYHGDGSHGFCSS GTGQPYGPTFTTGTGDVIGCC

135

Shigella ospG	7	prey67327	207	CTCCGCTTTGAACCTTTACCCGCTTTCTTTGACCGAGTCAAGCCACCCCATCTGCGG GATGTAAATCCCTTGATAAGAAAGTTGGTGGCTGAGATTTGATGACCTGGAAGT TGCCACCGAGTGGAAATGATGATATTTGCTGCGCGCTGGAGCTGCTGAGTGT GCCCGGAGAGACATTTGATGATATTTGCTGCGCGCTGGAGCTGCTGAGTGT TGAGGTGTTCTGTTGCGAACGAGTGGCGGCGCGAGAGCTCTGAGTATCC ACAACAGAAAGGCGACGCTGAGCTGGCTTGGCTTGGAGCGAGGCTAT CACAAGCTGACCAAGCTTTACCGAGGAGAAATGCTGGAGAACCAAGCTCC TGAGCAGTTATCTATGAATACCGTATGGAGACTGCTGCTGAGGAGCAT TGGAGAGTGGACATCTATACATTAACCTCTGAGCTGATCCACATCATGAA CACCATTTCTGGAGACGTTGACCTGGACCAATTTAACTATGAACT CCACAGCACTAATGAACAAACCTCAAGCAATGGACAGTCTATGCCC TTATGATGACGACAGGATCTTCCAGTCCCGCAGAGACAGATGGCGAGT TTTCTCCGTGACCGAGCGCCAGGACCTCAGCGACTTCTCTCTGCA AGAGCTGAGACACTGAGTCTGCTGCCAGGAGCGCC	408	QALNFRFLDQSGPPSGDV NSLDDKLVIARFHLKLPT WNVLGTDSDLDAGPRET LMHFVRLGLRLTWFLQ KPGRRALSHNQEGATPV SLALRGYHLHLIIEEN AGERDWSLSYIEPYGDC SVRHHRELDITLPSGDS HHEHPFGDGTGPIKLM NQOQLMKNLQOMDSL PLMCAADPPSAPETDGO FLMCAPEPTDQRLSSSE TESTQCQCPGS
Shigella ospG	7	prey412	208	GAGCATTGACCCAAAATACCGGGTGACATACCCAGCCAAAGCCAGGG CACATTATCGACAGACCCACAGAACTTGGCTTGTCTTCCAGCTGGTA GATGAACACTGGTGGTGAACCTCACTCTCCACAGACATTTGCCAGCTCC ATACCAAGACTGGCAGGAGTGGTGTGTTGCCAGCGACGACAA AGAACGTACAAATTTGAACCTGATACCTCTGAAGAAAGATTGAATTTGAC TCTGCTCTGGACCTACACTCTCTACTTAACTTGAAGATGCCACTTTGAA GAACCAATCTCTGGAATGTGGCTGATGTGGTCACTCAAGTCTCCCTGAGGAA GAAGCTCCTGCACTGTCTGTCCGAGAACCTTTTCACTCCAAACAGGAAA TTGACACCTGTTCCGCGAGCTGAGAAGAGCGCCCGCCACCG	409	SIAPKTRVITYPAKAKGTFI ADSHQNFALFQLVDMNT CAELTPHQITVRLHNQKTG QEVVFAEPDNKNVYKFEL DTSERKIEFDSAGTYTLYL IGDATALKNPILWADVVIK FPEEAPSTVLSQNLFTPK QEIOHLEFREKRPPT
Shigella ospG	7	prey50598	209	CCTCGTGTCCGAGCTGCGCGAGAGACCTGAGTGGCGCGCTGTTAGCT ACAGGCTGTGGGGTCACTCACTGTGTCACCTGAGTGTCTGCTGAGCGGC TGAGCTGTACGGTTT CAGGAGCGCGACCGAGCGAGGAGTGGAG CTGACCGCGGCTGTCTACCGCAGGCGCTCTTGGAGGAGAGAGCCGT TTCCAGAACCCCTGTCAACCTGTGCTGAGGAGCGGAGGACCGAAC AGCCACGCTCGCGCACCTGTTCTGCTGGAGTGCATCCCGCTGGTG CAGCAGCAGCGGAGTGTCCCTCTGCGGGAGAGATTCCTCCCGCAGAA GCTCATCTACCTTGGGCACTACCGTGA	410	LRVSLPGEDLRAVSYRL LGVSLHLVLSMGLQLYGF RQQRARKWRHLRHLGSLH PRASLEERAVSRNPLCTLC LEERHPATPCGHLFCW EITAWOSSKAECHCREK FPPOKILRHYR*
Shigella ospG	7	prey67364	210	TATTAAATGAACACAGTGGAAATATAGCGAGACCTGACTACCTTGCTG TATTCTTGTAGCAGGAAATACAGAGCATCAAGATCTGTTAGAGGG CCGCTCTGCTGTTAAACATACAGCAGAGCTCCCGAGCGGAGC CACAGCTTTAAGATGGGTGAAGCCTTGATAGAAGGAGAAACAGAGCTG CCGACTGCTTACTTGAAGTGGAGAACATGGAATCTGTTATTATTATGT TGACTGCGANCCTTACNTTTTNTTAAACC	411	LLNETVEI*PDLTNLACIFI* AGENORHODI VEGPVCCL THTSQVPRGHRHRLP'G EALIEGETAAHCLYLEVEN MXFCIYLC*LXFTFXN
Shigella	7	prey67367	211	ATCCAGCAAAACCGCTGCTGCTAAATTTGCAACTAGTGCTAAAGAAATTCAGAG	412	SSKTAALKSTSAKRIQKELA

ospG				GAACITGCGAAATACATTGACCTCTCCCACTGTAGTGTGGACCA AAGGACACACATTTATGAATGGAGGTCAACTATATGGGACCCAGGATC TGCTATTGAAGGAGGGTGTCTTCTTGACATACCTTTACCCAGCATC CGTTTAAACCCGCTAAGTTTACCTTCGGAACAAGATCTATCACTGTAAAT AACAGCCAGGTGTGATCTGTCTGGACATTTAAAGGACAACTGGAGTCCGG TTTAACTATTTCTAAAGTCTCCTCTCCATCTGCTCACTTTACAGATTGCA ACCTGTGACCTCTGTGGGAGCATCGCCACAGCATGATGACCAACA GAGCAGAGCATGACCGGATGGCCAGACATGTGACCAAGCGGTACGCCACA TAG	413	VAMSRDGAATHVYETHPWVW NFFQMCCLNLRWSKHSI FKSTLYSIRKLKLLAYISIK CKPAMLANLNLVIRLLR TSMNW*KEKIVETXLN
Shigella ospG	7	prey67369	212	GTGCAATGAGCCGAGATGGTGGCACTCATGTATGAACCTCATCCATCGT GGAACITTTTTCAGATGTGAGCTCTGTAACCTTTTAAGCTCTGGAAACAT AGTATTTTTAAAGTACACTGTATATCTATCAGGAAATTAATAATTTAGCT TATATCTACATTTCAATAAATGTAAAGCTGTGTCTATGTTGATAGCAAACTG TTAACTTACTGGCTATTAGGCTGTACGTACGTCAATGAAGTGGTGAAGGA GAAAATTTGAAACATANCTCAAC	414	DKVMSEFNINFRQWENY PKNHTASILDRMQDFKC CGAANYTDWIEKPSMSKN RVPDSCCNVTVGCGINFN EKAIHKEGCEVKGWGLHK NLVWVAALGIAFVEVLGI VFAACLKVSIRSGYEM*
Shigella ospG	7	prey67372	213	GAGATAAGGTGATGTCAAGTTTATAACAACITTCGGCAGCAGATGGAGAA TTACCCGAAAAACACACACTGCTTCGATCCTGGACAGGATGCAGGCAGAT TTTAAGTGTCTGGGGCTGCTAACTACAGATTTGGGAGAAATCCCTTCCA TGTGGAAGAACCGAGTCCCGACTGCTGCTGATTAATGTTACTGTGGGCTG TGGAATTAATTTCAACGAGAGCGGATCCATGAAGGAGGCTGTGGAGAA GATTGGGGCTGGCTGAGGAAAAATGCTGCTGGTGTAGCTGCAGCAGCCCT TGGAATTCGTTTTTGTGAGGTTTTGGGAATGTCTTTCGCTGCTGCTGCTG AAGAGTTCAAGAGTGGCTACAGGTGATGATG	415	XXXLNRHLLXXTKTXLX XXATXGXYXXXXYXWLLA HVKGXTVSLX*EXFLCX* STFHXYSDVXYXNXXX* XHDHXSXCICHELXXTCR NEN
Shigella ospG	7	prey67379	214	NAANINCNTTATTCGCACTACTCTCONNNCACATGTAAACATANTT GNTGTNNGGCCACNNGGCTGTNANTAGCTTNTNANNTNNTATTGG NNNCTNCGATGTTAAAGNNNCAGATTTCTGNACTGCTAGGAGANATCT TGNCCTGTAGNGTAAAGTACTTTTCACTNGATAGCTATGNTGACGTNCT TATNAGAACGNWNNTANTGNTGANTGATGATNTCCATTCATNATGTATTG CCATGAGNNGCTAATNNCAAGCTGCTGATGAGAATAA	416	MTVQALVEEVPMEINVKF SKNQENKFSRPRHREKY PAKPLNLCQLVLKFERNL OKSHWTLPTVLDPKRTT FMINGGQLYMDQDLSMKE GCSFLTTPHOTIRLNLRL PSEQSITVILTAKV*
Shigella ospG	7	prey67381	215	ATGACAGTCCAGCACTAGTGGAGGAAGTTCGGATGGAGTCAACGTGAAA GTGTTACGACACAGCAAGAGAACAGTTCAGCCCAAGAAAGAGG GAAAATATCAGCAAAACCGCTGCTAAATGTCACTAGTGTCAAGAAAT CAGAGGAATTCGAGAAATACATATGGACCGTCTCCCACTGTAGTGTG GACCAAGAGAGACAACTTATGAATGGAGGCTCAACTATATGGGACCC AGGATCTGTCTATGAAGGAGGGTGTCTTCTTGACATTAACCTTTACCAAG ACTATCCGTTTTAAACCCCTAAGGTACCTTCGAGCAAGAAATCTATCACTGT AATATTACAGCCAGGTGTA		